



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**


(86) Date de dépôt PCT/PCT Filing Date: 2020/08/14
(87) Date publication PCT/PCT Publication Date: 2021/02/18
(85) Entrée phase nationale/National Entry: 2022/02/10
(86) N° demande PCT/PCT Application No.: US 2020/046425
(87) N° publication PCT/PCT Publication No.: 2021/030711
(30) Priorités/Priorities: 2019/08/15 (US62/887,392);
2020/08/13 (US63/065,028)

(51) Cl.Int./Int.Cl. *C07D 401/06* (2006.01),
A61K 31/517 (2006.01), *A61K 31/5377* (2006.01),
A61K 31/5386 (2006.01), *A61P 35/00* (2006.01),
C07D 401/14 (2006.01), *C07D 403/06* (2006.01),
C07D 405/06 (2006.01), *C07D 405/14* (2006.01),
C07D 413/06 (2006.01), *C07D 453/02* (2006.01),
C07D 471/04 (2006.01), *C07D 491/10* (2006.01),
C07D 498/08 (2006.01)

(71) Demandeur/Applicant:
BLACK DIAMOND THERAPEUTICS, INC., US

(72) Inventeurs/Inventors:
LUCAS, MATTHEW C., US;
PADILLA, FERNANDO, US; ...

(54) Titre : COMPOSES D'ALCYNYLE QUINAZOLINE
(54) Title: ALKYNYL QUINAZOLINE COMPOUNDS



(I')

(57) Abrégé/Abstract:

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

(72) **Inventeurs(suite)/Inventors(continued):** FLOHR, ALEXANDER, CH; ARISTA, LUCA, CH; BUCK, ELIZABETH, US

(74) **Agent:** RIDOUT & MAYBEE LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

18 February 2021 (18.02.2021)



(10) International Publication Number

WO 2021/030711 A1

(51) International Patent Classification:

C07D 401/06 (2006.01) C07D 471/08 (2006.01)
 C07D 401/14 (2006.01) C07D 487/08 (2006.01)
 C07D 403/06 (2006.01) C07D 491/10 (2006.01)
 C07D 405/06 (2006.01) C07D 498/08 (2006.01)
 C07D 405/14 (2006.01) A61K 31/5377 (2006.01)
 C07D 413/06 (2006.01) A61K 31/517 (2006.01)
 C07D 413/14 (2006.01) A61P 35/00 (2006.01)
 C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2020/046425

(22) International Filing Date:

14 August 2020 (14.08.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/887,392 15 August 2019 (15.08.2019) US
 63/065,028 13 August 2020 (13.08.2020) US

(71) Applicant: **BLACK DIAMOND THERAPEUTICS, INC.** [US/US]; 139 Main Street, Suite 301, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(71) Applicants: **LUCAS, Matthew C.** [US/US]; 48 Parker Street, Lexington, Massachusetts 02421 (US). **PADILLA, Fernando** [US/US]; 27 Davis Ave, Arlington, Massachusetts 02474 (US).

(72) Inventors: **FLOHR, Alexander**; Aeschenvorstadt 36, 4051 Basel (CH). **ARISTA, Luca**; Schutzenrainweg 10, 4125 Riehen (CH). **BUCK, Elizabeth**; 77 Sammis Street, Huntington, New York 11734 (US).

(74) Agent: **ERLACHER, Heidi** et al.; 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: ALKYNYL QUINAZOLINE COMPOUNDS



(57) Abstract: The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.



WO 2021/030711 A1

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 338

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 338

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHIER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

ALKYNYL QUINAZOLINE COMPOUNDS

RELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of, U.S. Application Nos. 63/065,028, filed August 13, 2020, and 62/887,392, filed August 15, 2019, the entire contents of each of which are incorporated herein by reference.

FIELD OF DISCLOSURE


[0002] The present disclosure relates to new compounds as inhibitors of receptor tyrosine kinases (RTK), in particular oncogenic mutants of ErbB-receptors. The disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

BACKGROUND

[0003] Mutations affecting either the intracellular catalytic domain or extracellular ligand binding domain of an ErbB receptor can generate oncogenic activity (the ErbB protein family consists of 4 members including ErbB-1, also named epidermal growth factor receptor (EGFR) and Erb-2, also named HER2 in humans). ErbB inhibitors are a known treatment for a number of cancers. However, not every patient is responsive satisfactorily to this treatment. Thus, there is a long-felt need in the art for new therapies that are able to address the variable responsiveness of cancer patients to known therapies. The present disclosure provides compositions and methods for preventing or treating cancer in patients with these oncogenic mutations without the variable responsiveness observed when patients having these ErbB mutants are treated using the existing standard of care.

SUMMARY OF DISCLOSURE

[0004] In some aspects, the present disclosure provides a compound of Formula (I):



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za} ;

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ;

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2; and

Ar¹ is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, -CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl.

[0006] In some embodiments, when X¹ is -NR³-, R² is not hydrogen.

[0007] In some embodiments, when X¹ is -NR³-, R² is C₁₋₄ alkyl, or is -(CH₂)_q- which forms a ring with R³ or with one of R^a.

[0008] In some embodiments, X¹ is -NR³-, and R² is not hydrogen.

[0009] In some embodiments, X¹ is -NR³-, and R² is C₁₋₄ alkyl, or is -(CH₂)_q- which forms a ring with R³ or with one of R^a.

[0010] In some embodiments, X¹ is NR³ or O and wherein R³ is methyl, ethyl, n-propyl or n-butyl-.

[0011] In some embodiments, R¹ is hydrogen.


[0012] In some embodiments, R² is methyl, ethyl, n-propyl or n-butyl-, preferably methyl or R² is -(CH₂)- or -(CH₂)₂- which forms a ring with R³, or R² is -(CH₂)- or -(CH₂)₂- which forms a ring with one of R^a.

[0013] In some embodiments in which one of R^a forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0014] In some embodiments in which one of R^a forms a ring with R³, the ring formed is a 3, 4, 5, or 6-membered ring.

[0015] In some embodiments in which one of R² forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0016] In some embodiments, Ar¹ is of formula i or pharmaceutically acceptable salts or stereoisomers thereof



wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;


R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0017] In some embodiments, R^1 is hydrogen.

[0018] In some embodiments, R^c and R^d are hydrogen. In some embodiments, R^b , R^c and R^d are hydrogen.

[0019] In some embodiments, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

[0020] In some embodiments, Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe;

X^3 is CH or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.


[0021] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0022] In some embodiments, R^1 is hydrogen.

[0023] In some embodiments, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

[0024] In some embodiments, R^c and R^d are hydrogen. In some embodiments, R^b , R^c and R^d are hydrogen.

[0025] In some embodiments, Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^3 is CH or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.


[0026] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0027] In some embodiments, R^1 is hydrogen.

[0028] In some embodiments, R^c and R^d are hydrogen. In some embodiments, R^b , R^c and R^d are hydrogen.

[0029] In some embodiments, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

[0030] In some embodiments, Ar¹ is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X³ is C or N, preferably N;

o is 0 or 1;

R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.


[0031] In some embodiments, R⁵ is F and/or wherein R⁶ is F or Cl.

[0032] In some embodiments, R¹ is hydrogen.


[0033] In some embodiments, R^c and R^d are hydrogen. In some embodiments, R^b, R^c and R^d are hydrogen.

[0034] In some embodiments, R² is methyl or R² is -(CH₂)– or -(CH₂)₂– which forms a ring with R³, or R² is -(CH₂)– or -(CH₂)₂– which forms a ring with one of R^a.


[0035] In some embodiments, Ar¹ is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9 or pharmaceutically acceptable salts or stereoisomers thereof




iv-1




iv-2




iv-3




iv-4




iv-5




iv-6



iv-7



iv-8



iv-9

wherein

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.



[0036] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0037] In some embodiments, R^1 is hydrogen.

[0038] In some embodiments, R^c and R^d are hydrogen. In some embodiments, R^b , R^c and R^d are hydrogen.

[0039] In some embodiments, R^2 is methyl or R^2 is $-(\text{CH}_2)-$ or $-(\text{CH}_2)_2-$ which forms a ring with R^3 , or R^2 is $-(\text{CH}_2)-$ or $-(\text{CH}_2)_2-$ which forms a ring with one of R^a . In some embodiments R^7 is F.

[0040] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IIa or IIb



wherein

X^1 is $-O-$ or $-NR^3-$;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, preferably methyl or is $-(CH_2)_q-$ which forms a ring with R^3 ;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $-(CH_2)_p-$ which forms a ring with R^2 ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;

s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxy-carbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

[0041] In some embodiments, R^1 is hydrogen.

[0042] In some embodiments, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 .

[0043] In some embodiments, when X^1 is $-NR^3-$, R^2 is not hydrogen.


[0044] In some embodiments, when X^1 is $-NR^3-$, R^2 is C_{1-4} alkyl, or is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .

[0045] In some embodiments, X^1 is $-NR^3-$, and R^2 is not hydrogen.

[0046] In some embodiments, X^1 is $-NR^3-$, and R^2 is C_{1-4} alkyl, or is $-(CH_2)_q-$ which forms a ring

with R³ or with one of R^a.

[0047] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula III




wherein

R¹ is H or F;


Ar¹ is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, -CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, or C₆ aryl; and

Z is selected from



[0048] In some embodiments, R¹ is hydrogen.

[0049] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IV



IV


wherein

R^1 is H or F;

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl or C_6 aryl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl; and





Z is selected from



[0050] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0051] In some embodiments, R^1 is hydrogen.

[0052] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-1, V-2, V-3 or V-4

**V-1****V-2****V-3****V-4**

wherein

X^2 is O, NH or NMe;

X^3 is C or N;

R^1 is H or F;


R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

o is 0 or 1;

R^7 is hydrogen or halogen, preferably F; and


Z is selected from




[0053] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0054] In some embodiments, R^1 is hydrogen.


[0055] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-1, VI-2, VI-3 or VI-4




VI-1



VI-2



VI-3



VI-4

wherein

X^2 is O, NH or NMe;

X^3 is C or N;

R^1 is H or F;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F; and


Z is selected from




[0056] In some embodiments, R^5 is F and/or R^6 is F or Cl.

[0057] In some embodiments, R^1 is hydrogen.


[0058] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VII-1, VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9




VII-1




VII-2




VII-3




VII-4




VII-5




VII-6



VII-7



VII-8



VII-9

wherein

R¹ is H or F;


o is 0 or 1;

R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F;

Z is selected from



[0059] In some embodiments, R⁵ is F and/or R⁶ is F or Cl.

[0060] In some embodiments, R¹ is hydrogen. In certain embodiments, R⁷ is F.

[0061] In some aspects, the present disclosure is directed to a composition comprising a compound according to any of the embodiments described herein or pharmaceutically acceptable salts or stereoisomers thereof.

[0062] In some embodiments, the composition comprises a pharmaceutically acceptable carrier.

[0063] In some embodiments, the composition comprises a second therapeutically active agent.

[0064] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR), comprising administering the subject in need thereof a therapeutically effective amount of a compound described herein.

[0065] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR), comprising administering the subject in need thereof a composition described herein.

[0066] In some aspects, the present disclosure is directed to a method of preventing or treating cancer, comprising administering the subject in need thereof a therapeutically effective amount of a compound described herein.

[0067] In some aspects, the present disclosure is directed to a method of preventing or treating cancer, comprising administering the subject in need thereof a composition described herein.

[0068] In some aspects, the present disclosure is directed to a compound described herein for use in the inhibition of an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an

EGFR).

[0069] In some aspects, the present disclosure is directed to a compound described herein for use in the prevention or treatment of cancer.

[0070] In some aspects, the present disclosure is directed to a composition described herein for use in the inhibition of an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR).

[0071] In some aspects, the present disclosure is directed to a composition described herein for use in the prevention or treatment of cancer.

[0072] In some aspects, the present disclosure is directed to use of a compound described herein in the manufacture of a medicament for inhibiting an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR).

[0073] In some aspects, the present disclosure is directed to use of a compound described herein in the manufacture of a medicament for preventing or treating cancer.

[0074] In some embodiments, the cancer is glioblastoma.

[0075] In some aspects, the present disclosure is directed to a method of preventing or treating glioblastoma, comprising administering the subject in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein.

[0076] In some aspects, the present disclosure is directed to a compound according to any of the embodiments described herein for use in the prevention or treatment of glioblastoma.

[0077] In some aspects, the present disclosure is directed to a method of preventing or treating glioblastoma, comprising administering the subject in need thereof a composition according to any of the embodiments described herein.

[0078] In some aspects, the present disclosure is directed to a composition according to any of the embodiments described herein for use in the prevention or treatment of glioblastoma.

DETAILED DESCRIPTION

[0079] The present disclosure relates to compounds useful as inhibitors of receptor tyrosine kinases (RTK), in particular oncogenic mutants of ErbB-receptors. In some embodiments of the invention, oncogenic mutants of ErbB-receptors are also allosteric mutants of ErbB-receptors. In some embodiments, allosteric mutants may comprise or consist of an ErbB receptor variant having a mutation in a sequence outside of an ATP-binding site. In some embodiments, allosteric mutants

may comprise or consist of an ErbB receptor variant having a mutation in a sequence within one or more of exon 19, exon 20 or a C1-C2 extracellular dimerization interface.

[0080] Mutations affecting either the intracellular catalytic domain or extracellular ligand binding domain of an ErbB receptor can generate oncogenic activity (the ErbB protein family consists of 4 members including ErbB-1, also named epidermal growth factor receptor (EGFR) and Erb-2, also named HER2 in humans). Extracellular mutants of ErbB receptors in cancer, including EGFR-Viii (also EGFR-V3) and HER2-S310F, are constitutively activated in the absence of ligand, exhibit sustained signaling that is resistant to downregulation, and are both transforming and tumorigenic (Nishikawa, Ji et al. 1994, 2013, Francis, Zhang et al. 2014). Their expression is associated with metastasis and with poor long term overall survival.

[0081] In glioblastoma (also glioblastoma multiforma or GBM), EGFR-Viii is expressed by 20% of tumors (Sugawa, Ekstrand et al. 1990, Brennan, Verhaak et al. 2013). Expression of EGFR-Viii in GBM tends to be mutually exclusive with expression of other RTK oncogenes, which are co-expressed with EGFR variants in only 7% of GBM tumors (Furnari, Cloughesy et al. 2015). These data demonstrate how EGFR-Viii in GBM has a dominant and mutually exclusive expression pattern compared with other oncogenic drivers. EGFR-Viii is also expressed by approximately 30% of SCCHN tumors (Sok, Coppelli et al. 2006, Keller, Shroyer et al. 2010, Wheeler, Suzuki et al. 2010, Tinhofer, Klinghammer et al. 2011, Wheeler, Egloff et al. 2015) and 10% of squamous NSCLC (Ji, Zhao et al. 2006, Sasaki, Kawano et al. 2007), and is associated with resistance to current therapeutics including the anti-EGFR antibody cetuximab (Sok, Coppelli et al. 2006, Tinhofer, Klinghammer et al. 2011). Normal tissues do not express this oncogenic receptor variants.

[0082] RNA sequencing data has revealed that EGFR-Viii is just one of several aberrantly spliced variants of EGFR expressed in GBM tumors. Two others result in truncation of exons 12-13 (EGFR-Vvi) and 14-15 (EGFR-Vii). Like EGFR-Viii, EGFR-Vii is both transforming and tumorigenic. In addition to splice variants, GBM tumors also express a collection of EGFR point mutations including C620Y, A289V and G598V, which are transforming and tumorigenic.

[0083] HER2-S310F is the most common mutation of HER2 expressed in human tumors, expressed by approximately 0.5% of all tumors. HER2-S310F expression is mutually exclusive with expression of HER2 amplification. HER2-S310F is highly oncogenic, transforming BaF3 cells (a murine interleukin-3 (IL-3) dependent pro-B cell line) to IL-3 independence and promoting

tumor growth in vivo.

[0084] Short insertions of within Exon 20 of EGFR and HER2 are expressed by lung adenocarcinoma tumors and other tumor groups. ErbB Exon 20 insertion mutants are expressed by 4-5% of lung adenocarcinoma tumors. Examples include HER2-YVMA, EGFR-SVD, and EGFR-NPH. These ErbB Exon 20 insertion mutants are highly oncogenic, transforming BaF3 cells to IL-3 independence and promoting tumor growth in vivo.

[0085] ErbB inhibitors are a known treatment for a number of cancers. However, not every patient is responsive satisfactorily to this treatment. Thus, there is a long-felt need in the art for new therapies that are able to address the variable responsiveness of cancer patients to known therapies. The present invention is able to overcome some of these drawbacks of the standard of care, as it existed prior to the development of the compositions and methods disclosed herein.

Paradoxic ErbB Receptor Activation

[0086] Although the mechanisms described herein apply to any form of cancer in which these EGFR variants of the disclosure are expressed, the prevalence of these variants in glioblastoma (GBM) are provide by way of example. Other cancers expressing the EGFR variants of the disclosure include, but are not limited to, solid cancers, epithelial cancers and/or cancers of epithelial origin, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma (GBM), head and neck cancer, lung cancer, and non-small cell lung cancer (NSCLC).

[0087] In GBM tumors EGFR is frequently the target of genomic mutations and alternative splicing events that result in alteration of the extracellular dimer interface. Many tumors express more than one aberrant isoform. The disclosure provides the mechanism of activation for the most commonly occurring variants, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-G598V and EGFR-A289V. Although each isoform/point mutant is the result of a distinct ectodomain alteration, all are activated by a common mechanism involving covalent ligand-independent dimerization.

[0088] AMG-595 (Amgen) is an EGFR-Viii isoform selective antibody that has no activity against wild type EGFR or other splice-activated variants. Rindopepimut (Celldex) is a vaccine the produces an immunological response selectively against tumor cells expressing EGFR-Viii but not wild type EGFR or other splice-activated isoforms. Other EGFR isoforms expressed in GBM tumors (EGFR-Vii and EGFR-Vvi) are constitutively active covalent receptors and their

expression may limit the breadth and duration of treatment benefit for an ErbB inhibitor that is selective only for EGFR-Viii. Therefore, it may be useful to exclude patients whose tumors express EGFR-Vii, EGFR-Vvi, or EGFR ectodomain point mutants from treatment with an EGFR-Viii selective therapy.

[0089] The heterogenous expression pattern for multiple ectodomain variants of ErbB receptors in tumors indicates that a small molecule inhibitor that inhibits all variants is preferred. The family of covalently-activated EGFR isoforms responds very differently to small molecule ErbB inhibitors compared to EGFR catalytic domain mutations observed in NSCLC. Importantly, Type I inhibitors, including erlotinib, all induce the formation of covalent EGFR dimers and increase EGFR phosphorylation at sub-saturating concentrations, an activity that is further enhanced when ErbB inhibitor is washed away. This manifests in paradoxical activation of proliferation at sub-saturating concentrations.

[0090] The discovery of paradoxical activation of proliferation at sub-saturating concentrations of Type I ErbB inhibitors is further demonstrated for a series of extracellular variants of HER2, prevalent in a number of cancers including breast and bladder. All variants existed as covalently activated receptors, and levels of covalent dimers increased following treatment with Type I inhibitors including sapitinib and afatinib. As with covalently-activated EGFR variants, sub-saturating doses of Type I inhibitors paradoxically increased phosphorylation of HER2 variants, increasing the proliferation of cells expressing them.

[0091] In contrast to Type I inhibitors, the disclosure demonstrates that Non-Type I (e.g. Type II) inhibitors including neratinib are devoid of paradoxical activation for cells expressing ErbB ectodomain variants. Neratinib is found to exemplify a preferred molecule that is both potent and selective for each member of the covalently-activated EGFR family versus wild type EGFR.

[0092] Collectively, the disclosure provides a structure/functional relationship for predicting how structural variations affecting receptor regions distal to the active site can confer dramatically different responses to small molecule active site inhibitors. The discovery described herein of paradoxical activation of covalently-activated ErbB receptor variants by Type I inhibitors has important clinical implications. The data of the disclosure provide a mechanistic explanation for the failed clinical studies for Type I inhibitors in tumor types where expression of covalently-activated ErbB receptors is prevalent. This includes erlotinib and gefitinib in GBM tumors, erlotinib in SCCHN tumors, and sapitinib in breast tumors.

Glioblastoma

[0093] Glioblastoma (GBM), grade IV astrocytoma, is the most common form of brain cancer. The outcome for this disease is dismal. Surgery followed by a therapeutic regimen of radiation and temozolomide is standard of care, however this produces a median overall survival (OS) of only 14.6 months and few patients survive for five years. There has been little progress made in extending survival for GBM patients over the past decade. Although bevacizumab showed an improved progression free survival benefit in the recurrent setting, the addition of bevacizumab to standard of care therapy in the front-line setting did not result in an OS benefit.

[0094] EGFR is the most frequently altered oncogene in GBM. In addition to EGFR gene amplification, many tumors express variants generated by aberrant splicing or genomic mutation. The first recognized variant is EGFR-Viii, resulting from truncation of exons 2-7 and expressed by approximately 20% of GBM tumors. EGFR-Viii is oncogenic. EGFR-Viii is constitutively activated in the absence of EGF ligand, exhibiting sustained signaling that is resistant to downregulation. Therefore, EGFR-Viii is both transforming and tumorigenic. Expression of EGFR-Viii is associated with poor long term overall survival in GBM.

[0095] RNA sequencing data has revealed that EGFR-Viii is just one of several aberrantly spliced variants of EGFR expressed in GBM tumors. Two others result in truncation of exons 12-13 (EGFR-Vvi and 14-15 (EGFR-Vii). Like EGFR-Viii, EGFR-Vii is both transforming and tumorigenic. In addition to splice variants, GBM tumors also express a collection of EGFR point mutations including C620Y, A289V and G598V, which are transforming and tumorigenic. The complex landscape of EGFR alterations in GBM is further compounded by the observation that many tumors express more than one receptor variant.

[0096] Because the expression of multiple EGFR variants in GBM gives rise to transforming and tumorigenic activity and because EGFR is the most frequently altered oncogene present in GBM tumors, EGFR is an especially attractive target for small molecule ErbB inhibitors. Following the success for small molecule EGFR therapeutics against NSCLC tumors harboring activating mutations in EGFR (erlotinib, gefitinib, and afatinib), these drugs were tested in GBM. Despite intense clinical investigation of this group of ErbB inhibitors in GBM, involving >30 clinical trials and >1500 patients, all failed to produce any benefit, even for those tumors that expressed EGFR-Viii. Strikingly, some evidence suggests that erlotinib promoted disease progression. A phase 2

study evaluating erlotinib in combination with radiation and temozolomide showed median PFS (mPFS) and median OS (mOS) of 2.8 months and 8.6 months, as compared to 6.9 months and 14.6 months for patients receiving radiation and temozolomide alone. Another randomized phase II trial with erlotinib showed that patients who received erlotinib, including those whose tumors expressed EGFR-Viii, progressed more poorly as compared to those patients who received standard of care therapy. The clinical failures for ErbB inhibitors such as erlotinib in GBM tumors has cast doubt on the role of EGFR as a driver of tumor growth in GBM and led to inquiry as to why ErbB inhibitors that were so effective in treating EGFR mutations in lung cancer were so ineffective in treating EGFR variants in GBM.

[0097] A distinctive feature for the EGFR variants expressed in GBM is their location within the extracellular domain. This is in contrast to activating mutations of EGFR found in lung cancer, which often reside in the intracellular catalytic domain. EGFR is composed of four extracellular domains (two ligand binding domains and two cysteine rich regions), a transmembrane domain, and an intracellular catalytic domain. Ligand binding promotes dimerization of the extracellular cysteine rich domains (CR1 and CR2), an event that confers dimerization of the intracellular domain and activation of receptor catalytic activity. Nearly all EGFR splicing events and mutations in GBM affect the extracellular region, specifically two cysteine rich regions (CR1 and CR2) that form the extracellular dimer interface. The CR regions contain >40 cysteine residues, all of which form intramolecular disulfide bonds. In EGFR-Viii, truncation of exons 2-7 results in partial loss of sequence encoding the CR1 region. A consequence is loss of one cysteine from the Cys295-Cys307 pair, leaving Cys307 as a free unpaired cysteine. For EGFR-Viii, this cysteine can form an intermolecular disulfide bond with another EGFR monomer to drive a covalently dimerized and constitutively activated receptor. Mutation of Cysteine 307 to a Serine (C307S) prevents the formation of covalently dimerized EGFR-Viii and is inactive.

[0098] Although several recent preclinical studies have suggested that EGFR kinase inhibitors such as erlotinib are quite ineffective at inhibiting EGFR-Viii, there has been no mechanism proposed for this effect. There is also a lack in current understanding for the mechanism responsible for activation of other ectodomain variants in GBM, including EGFR-Vii and EGFR-A289V. The disclosure provides a mechanism of receptor activation and impact on ErbB inhibitor activity for a group of four of the most common ectodomain variants in GBM, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-G598V and EGFR-A289V.

[0099] The disclosure demonstrates that like EGFR-Viii, an additional group of commonly occurring EGFR variants in GBM (EGFR-Vii, EGFR-Vvi, EGFR-G598V and EGFR-A289V) all exist as constitutively active covalent dimers and together form a family of EGFR isoforms that are activated by this common mechanism. Furthermore, the disclosure shows that the propensity of these variants to covalently dimerize is coupled to the conformation of the intracellular catalytic site, conferring distinct activity for classes of small molecules inhibitors binding to this distal site. Inhibitors that stabilize the active conformation of the kinase (Type I inhibitors, including erlotinib) induce the formation of covalent dimers for all covalently-activated EGFR isoforms. This is associated with the propensity of Type I inhibitors to increase EGFR phosphorylation at sub-saturating concentrations and to paradoxically stimulate the proliferation of cells expressing covalently-activated EGFR isoforms.

[0100] Neither enhanced dimerization nor paradoxical activation of EGFR is seen with small molecule inhibitors that stabilize the inactive kinase conformation (Type II inhibitors, including lapatinib and neratinib). Examples of Type II inhibitors were identified that were potent inhibitors of covalently-activated EGFR isoforms and which were selective for this family compared to WT-EGFR.

[0101] Similar to the mutations identified for EGFR, the disclosure identifies a group of splice events and mutations affecting the CR domains of HER2 and HER4. The disclosure demonstrates that this group of splice events and mutations affecting the CR domains of HER2 and HER4 exists as covalent dimers and are paradoxically activated by agents with a Type I binding mode. These data provide a mechanistic explanation for the failure of multiple clinical trials involving Type I inhibitors, including >30 clinical trials of Type I ErbB inhibitors in GBM. Collectively these data indicate that tumors expressing covalently-activated EGFR isoforms should be excluded from treatment with Type I ErbB inhibitors such as erlotinib because of paradoxical activation. These data further demonstrate the utility for optimizing Type II ErbB inhibitors against the covalently-activated ErbB family.

Definitions

[0102] Unless specified otherwise the following general definitions apply to all compounds of the disclosure according to the description.

[0103] The term "compound of the disclosure," as used herein, refers to compounds represented

by any of the formulae described herein (e.g. Formulae (I')-(IV') and (I) to (VII)) and any of the specific examples disclosed herein.

[0104] It will be understood that while compounds disclosed herein may be presented in one particular configuration. Such particular configuration is not to be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers or stereoisomers. In some embodiments, the presentation of a compound herein in a particular configuration intends to encompass, and to refer to, each of the available isomers, tautomers, regioisomers, and stereoisomers of the compound, or any mixture thereof; while the presentation further intends to refer to the specific configuration of the compound.

[0105] Further, it will be understood that while compounds disclosed herein may be presented without specified configuration (e.g., without specified stereochemistry). Such presentation intends to encompass all available isomers, tautomers, regioisomers, and stereoisomers of the compound. In some embodiments, the presentation of a compound herein without specified configuration intends to refer to each of the available isomers, tautomers, regioisomers, and stereoisomers of the compound, or any mixture thereof.

[0106] As used herein, the term “isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.”

[0107] As used herein, the term “chiral centre” refers to a carbon atom bonded to four nonidentical substituents.

[0108] As used herein, the term “chiral isomer” means a compound with at least one chiral centre. Compounds with more than one chiral centre may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.” When one chiral centre is present, a stereoisomer may be characterised by the absolute configuration (R or S) of that chiral centre. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral centre. The substituents attached to the chiral centre under consideration are ranked in accordance

with the *Sequence Rule* of Cahn, Ingold and Prelog. (Cahn *et al.*, *Angew. Chem. Inter. Edit.* 1966, 5, 385; errata 511; Cahn *et al.*, *Angew. Chem.* 1966, 78, 413; Cahn and Ingold, *J. Chem. Soc.* 1951 (London), 612; Cahn *et al.*, *Experientia* 1956, 12, 81; Cahn, *J. Chem. Educ.* 1964, 41, 116).

[0109] As used herein, the term “geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are differentiated in their names by the prefixes *cis* and *trans*, or *Z* and *E*, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

[0110] It is understood that “independently of each other” means that when a group is occurring more than one time in any compound, its definition on each occurrence is independent from any other occurrence.

[0111] It is further understood that a dashed line (or a wave being transverse to a bond) depicts the site of attachment of a residue (i.e. a partial formula).

[0112] The term “halogen” or “hal” as used herein may be fluoro, chloro, bromo or iodo preferably fluoro, chloro.

[0113] As used herein, “alkyl”, “C₁, C₂, C₃, C₄, C₅ or C₆ alkyl” or “C₁-C₆ alkyl” is intended to include C₁, C₂, C₃, C₄, C₅ or C₆ straight chain (linear) saturated aliphatic hydrocarbon groups and C₃, C₄, C₅ or C₆ branched saturated aliphatic hydrocarbon groups. For example, C₁-C₆ alkyl is intended to include C₁, C₂, C₃, C₄, C₅ and C₆ alkyl groups. Examples of alkyl include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *s*-butyl, *t*-butyl, *n*-pentyl, *i*-pentyl or *n*-hexyl. In some embodiments, a straight chain or branched alkyl has six or fewer carbon atoms (e.g., C₁-C₆ for straight chain, C₃-C₆ for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms. In some embodiments, the term “alkyl” as used herein refers to a fully saturated branched or unbranched hydrocarbon moiety. The term “C₁₋₄alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety having 1, 2, 3 or 4 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl.

[0114] As used herein, the term “optionally substituted alkyl” refers to unsubstituted alkyl or alkyl having designated substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl, alkenyl, alkynyl,

halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulphhydryl, alkylthio, arylthio, thiocarboxylate, sulphates, alkylsulphinyl, sulphonato, sulphamoyl, sulphonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0115] As used herein, the term “alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term “alkenyl” includes straight chain alkenyl groups (*e.g.*, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), and branched alkenyl groups. In certain embodiments, a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (*e.g.*, C₂-C₆ for straight chain, C₃-C₆ for branched chain). The term “C₂-C₆” includes alkenyl groups containing two to six carbon atoms. The term “C₃-C₆” includes alkenyl groups containing three to six carbon atoms.

[0116] As used herein, the term “optionally substituted alkenyl” refers to unsubstituted alkenyl or alkenyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulphhydryl, alkylthio, arylthio, thiocarboxylate, sulphates, alkylsulphinyl, sulphonato, sulphamoyl, sulphonamido, nitro, trifluoromethyl, cyano, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0117] As used herein, the term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, “alkynyl” includes straight chain alkynyl groups (*e.g.*, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), and branched alkynyl groups.

In certain embodiments, a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (*e.g.*, C₂-C₆ for straight chain, C₃-C₆ for branched chain). The term “C₂-C₆” includes alkynyl groups containing two to six carbon atoms. The term “C₃-C₆” includes alkynyl groups containing three to six carbon atoms. As used herein, “C₂-C₆ alkenylene linker” or “C₂-C₆ alkynylene linker” is intended to include C₂, C₃, C₄, C₅ or C₆ chain (linear or branched) divalent unsaturated aliphatic hydrocarbon groups. For example, C₂-C₆ alkenylene linker is intended to include C₂, C₃, C₄, C₅ and C₆ alkenylene linker groups.

[0118] As used herein, the term “optionally substituted alkynyl” refers to unsubstituted alkynyl or alkynyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulphhydryl, alkylthio, arylthio, thiocarboxylate, sulphates, alkylsulphinyl, sulphonate, sulphonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0119] Other optionally substituted moieties (such as optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl) include both the unsubstituted moieties and the moieties having one or more of the designated substituents. For example, substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.

[0120] The term “alkoxy” or “alkoxyl” as used herein includes substituted and unsubstituted alkyl groups covalently linked to an oxygen atom. Examples of alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropoxy, propoxy, butoxy and pentoxy groups.

[0121] The term “cycloalkyl” as used herein refers to a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (*e.g.*, fused, bridged, or spiro rings) system having 3 to 30 carbon atoms (*e.g.*, C₃-C₁₂, C₃-C₁₀, or C₃-C₈). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,

cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, adamantly, hexahydroindacenyl. It is understood that for polycyclic (e.g., fused, bridged, or spiro rings) system, only one of the rings therein needs to be non-aromatic.

[0122] The term “aryl” as used herein refers to groups with aromaticity, including “conjugated,” or multicyclic systems with one or more aromatic rings and do not contain any heteroatom in the ring structure. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In some embodiments, the aryl is phenyl.

[0123] As used herein, the term “heterocycloalkyl” refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spiro rings), or 11-14 membered tricyclic ring system (fused, bridged, or spiro rings) having one or more heteroatoms (such as O, N, S, P, or Se), e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or *e.g.*, 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulphur, unless specified otherwise. Examples of heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidiny, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranly, morpholinyl, tetrahydrothiopyranly, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1-oxaspiro[4.5]decanyl, 1-azaspiro[4.5]decanyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl, 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridin]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridin]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptanyl, 2-methyl-2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxa-azaspiro[3.4]octanyl, 2-oxa-azaspiro[3.4]octan-6-yl, and the like. In the case of multicyclic heterocycloalkyl, only one of the rings in the heterocycloalkyl needs to be non-aromatic. In some embodiments, the heterocycloalkyl is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-

azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl.

[0124] As used herein, the term “heteroaryl” is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, *e.g.*, 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or *e.g.*, 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulphur. The nitrogen atom may be substituted or unsubstituted (*i.e.*, N or NR wherein R is H or other substituents, as defined). The nitrogen and sulphur heteroatoms may optionally be oxidised (*i.e.*, N→O and S(O)_p, where p = 1 or 2). It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1. In some embodiments, the term “heteroaryl”, refers to a (fully) aromatic ring system having 3, 4, 5, or 6 ring atoms, preferably 6 ring atoms, selected from C, N, O, or S, preferably C, N, or O, more preferably C, N, with the number of N atoms preferably being 0, 1, 2 or 3 and the number of O and S atoms each being 0, 1 or 2. Examples of “heteroaryl” include furyl, imidazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl (pyrazyl), pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl, thienyl, and the like. Preferred examples of “heteroaryl” include pyridinyl.

[0125] In some embodiments, the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is substituted at one or more ring positions (*e.g.*, the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. In some embodiments, the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is substituted with halogen (*e.g.*, F or Cl).

[0126] As used herein, the term “substituted,” means that any one or more hydrogen atoms on the

designated atom is replaced with a selection from the indicated groups, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is oxo or keto (*i.e.*, =O), then 2 hydrogen atoms on the atom are replaced. Keto substituents are not present on aromatic moieties. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (*e.g.*, C=C, C=N or N=N).

[0127] The terms “nucleic acid” and “polynucleotide” are used interchangeably herein to refer to single- or double-stranded RNA, DNA, or mixed polymers. Polynucleotides may include genomic sequences, extra-genomic and plasmid sequences, and smaller engineered gene segments that express, or may be adapted to express polypeptides.

[0128] An “isolated nucleic acid” is a nucleic acid that is substantially separated from other genome DNA sequences as well as proteins or complexes such as ribosomes and polymerases, which naturally accompany a native sequence. The term embraces a nucleic acid sequence that has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems. A substantially pure nucleic acid includes isolated forms of the nucleic acid. Of course, this refers to the nucleic acid as originally isolated and does not exclude genes or sequences later added to the isolated nucleic acid by the hand of man.

[0129] The term “polypeptide” is used in its conventional meaning, *i.e.*, as a sequence of amino acids. The polypeptides are not limited to a specific length of the product. Peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof.

[0130] An “isolated polypeptide” is one that has been identified and separated and/or recovered from a component of its natural environment. In preferred embodiments, the isolated polypeptide will be purified (1) to greater than 95% by weight of polypeptide as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or

(3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes the polypeptide *in situ* within recombinant cells since at least one component of the polypeptide's natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

[0131] A “native sequence” polynucleotide is one that has the same nucleotide sequence as a polynucleotide derived from nature. A “native sequence” polypeptide is one that has the same amino acid sequence as a polypeptide (e.g. EGFR) derived from nature (*e.g.*, from any species). Such native sequence polynucleotides and polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

[0132] A polynucleotide “variant,” as the term is used herein, is a polynucleotide that typically differs from a polynucleotide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions.

[0133] A polypeptide “variant,” as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions, or inversions. Such variants may be naturally occurring, non-naturally occurring, or may be synthetically generated.

[0134] EGFR mutations (or variants) of the disclosure may comprise one or more substitutions, deletions, additions and/or insertions, or inversions of the amino acid sequence that alter the function of the resultant protein. Mutations may be detected, for example, by comparison or alignment of a nucleic or amino acid sequence with a wild type sequence.

[0135] When comparing polynucleotide and polypeptide sequences, two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[0136] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using

default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

[0137] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

[0138] One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

[0139] In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST

algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

[0140] For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

[0141] In one approach, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residues occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[0142] A wild type EGFR sequence of the disclosure may comprise or consist of the amino acid sequence of:

```

1 mrpsgtagaa llallaalcp asraleekkv cqgtsnkltq lgtfedhfls lqrmfnncev
61 vlgneleityv qrnyslflk tiqevagyvl ialntverip lenlqiirgn myensyala
121 vlsnydankt glkelpmrnl qeilhgvrf snnpalcnve siqwrdivss dflsnmsmdf
181 qnhlgscqkc dpscpngscw gageencqkl tkiicaqqcs grcrgkspds cchnqcaagc
241 tgpresdclv crkfrdeatc kdtcpplmly npttyqmdvn pegkysfgat cvkkcprnyv
301 vtdhgscvra cgadsyemee dgvrkcckce gpcrkvcngi gigeftkdsls inatnikhfk
361 nctsisgdlh ilpvafrgds fthtppldpq eldilkvtke itgflliqaw penrtdlhaf
421 enleiirgrt kqhggfslav vslnitslgl rslkeisdgd viisgnknlc yantinwkk1
481 fgtsggqtki isnrgensck atgqvchalc spegcwgppep rdcvscrnvs rgrecvdckk
541 llegeprefv enseciqchp eclpqamnit ctgrgpdnci qcahyidgph cvktcpagvm
601 genntlvwky adaghvchlc hpnctygctg pglegcptng pkipsiatgm vgalllllvv
661 algiglfmrr rhivrkrtrl rllqerelve pltpsgeapn gallrilket efkkikvlgs
721 gafgtvykgl wipegekvki pvaikelrea tspkankeil deayvmasvd nphvcrl1gi

```

781 cltstsvqlit qlmpfgclld yvrehkdniq sqyllnwcvq iakgmnyled rrlvhrdlaa
 841 rnvlvktpqh vkitdfglak llgaekeyh aeggkvpikw malesilhri ythqsdvwsy
 901 gvtvwelmtf gskpydgipa seissilekg erlpqppict idvymimvkc wmidadsrpk
 961 freliiefsk mardpqrylv iqqdermhlp sptdsnfyra lmdeedmddv vdadeylipq
 1021 qgffsspsts rtpllsslsa tsnnstvaci drnglqscpi kedsflqrys sdptgalted
 1081 siddtflpvp eyinqsvpkr pagsvqnpvy hnqplnpaps rdphyqdphs tavgnpeyln
 1141 tvqptcvnst fdspahwaqk gshqisldnp dyqqdfffpe akpngifkgs taenaeylrsv
 1201 apqssefiga (SEQ ID NO: 1, corresponding to epidermal growth factor receptor [Homo sapiens] and Genbank Accession No. CAA25240).

[0143] A wild type HER2 Receptor sequence of the disclosure may comprise or consist of the amino acid sequence of:

1 melaalcwrg lllallppga astqvctgtd mklrlpaspe thldmlrhly qgcqvvggnl
 61 eltylptnas lsflqdiqev qgyvliahnq vrqvplqrlr ivrgtqlfed nyalavldng
 121 dplnnttpvt gaspgglrel qlrslteilk ggvliqrnpq lcyqdtilwk difhknnqla
 181 ltlidtnrsr achpcspmck gsrcwgesse dcqsltrtvc aggcarckgp lptdccheqc
 241 aagctgpkhs dclaclhfnh sgicelhcpa lvtyntdtfe smpnpegryt fgascvtacp
 301 ynylstdvgs ctlvcpnlhq evtaedgtqr cekcskpcar vcyglgmehl revravtsan
 361 iqefagckki fgslafipes fdgdpasnta plqpeqlqv etleeitgyl yisawpdsip
 421 dlsvfqnlqv irgrilhnga ysitlqglgi swlglrslre lgsglalihh nthlcfvhtv
 481 pwdqlfrnph qallhtanrp edecvgegla chqlcarghc wpggptqcvn csqflrgqec
 541 veecrvlqgl preyvnrhc lpchpecqpq ngsvtcfge adqcvacahy kdppfcvarc
 601 psgvkdpsly mpiwkfpdee gacqpcpinc thscvdlldk gcpaeqrasp ltsiisavvg
 661 illvvvlqgv fgilikrrqk kirkytmrrl lqetelvepl tpsgampnqa qmrilketel
 721 rkvvklgsga fgtvykigi pdgenkipv aikvlrents pkankeilde ayvmagvgsp
 781 yvsrllgicl tstvqlvtql mpygcldhv renrglgsq dllnwcmqia kgmsyledvr
 841 lvhrdlaarn vlvkspnhvk itdfglarll dideteyhad ggvkvpikwma lesilrrrft
 901 hqsdvwsygv tvwelmtfga kpydgipare ipdllekger lpqppictid ymimvkcwm
 961 idsecrprfr elvsefsrma rdpqrfvviq nedlpgaspl dstfyrslle dddmgdlvda
 1021 eeylvppqgf fcpdpapag gmvhhrhrss strsgggdlt lglepseee prsplapseg
 1081 agsdvfdgdl gmgaakglqs lpthdpsplq rysedptvpl psetdgyvap ltcsppqeyv
 1141 nqpdvrrpqp spregplpaa rpagatlerp ktlspgkngv vkdvfafgga venpeyltpq
 1201 ggaapqphpp pafspafdnl yywdqdppe gapstfkgp ptaenpeylg ldvpv (SEQ ID NO: 2, corresponding to receptor tyrosine-protein kinase erbB-2 isoform a precursor [Homo sapiens] and GenBank Accession No. NP_004439).

[0144] A wild type HER2 Receptor sequence of the disclosure may comprise or consist of the amino acid sequence of:

1 mklrlpaspe thldmlrhly qgcqvvggnl eltylptnas lsflqdiqev qgyvliahnq
 61 vrqvplqrlr ivrgtqlfed nyalavldng dplnnttpvt gaspgglrel qlrslteilk
 121 ggvliqrnpq lcyqdtilwk difhknnqla ltlidtnrsr achpcspmck gsrcwgesse
 181 dcqsltrtvc aggcarckgp lptdccheqc aagctgpkhs dclaclhfnh sgicelhcpa
 241 lvtyntdtfe smpnpegryt fgascvtacp ynylstdvgs ctlvcpnlhq evtaedgtqr
 301 cekcskpcar vcyglgmehl revravtsan iqefagckki fgslafipes fdgdpasnta
 361 plqpeqlqv etleeitgyl yisawpdsip dlsvfqnlqv irgrilhnga ysitlqglgi
 421 swlglrslre lgsglalihh nthlcfvhtv pwdqlfrnph qallhtanrp edecvgegla
 481 chqlcarghc wpggptqcvn csqflrgqec veecrvlqgl preyvnrhc lpchpecqpq

541 ngsvtcfge adqcvacahy kdppfcvarc psgvkdlsy mpiwkfpdee gacqpcpinc
 601 thscvdlddk gcpaeqrasp ltsiisavvg illvvvlgvv fgilikrrqq kirkytmrrl
 661 lqetelvelpl tpsgampnqa qmrilketel rkvvklgsga fgtvykigiwi pdgenvkipv
 721 aikvlrents pkankeilde ayvmagvgsp yvsrllgicl tstvqlvtql mpygclddhv
 781 renrgrlgsq dllnwcmlia kgmsyledvr lvhrdlaarn vlvkspnhvk itdfglarl1
 841 dideteyhad ggkvpikwma lesilrrrft hqsdvwsygv tvwelmtfga kpydgipare
 901 ipdllekger lpqppictid vymimvkcwm idsecrprfr elvsefsrma rdpqrfvviq
 961 nedlgpaspl dstfyrslle dddmgdlvda eeylvppqgf fcpdpapagag gmvhhrhrss
 1021 strsgggdlt lglepseeee prsplapseg agsdvfdgdl gmgaakglqs lpthdpsplq
 1081 rysedptvpl psetdgyvap ltcsppqeyv nqpdvrrppp spregplpaa rpagatlerp
 1141 ktlsppgkngv vkdvfafgga venpeyltpq ggaapqphpp pafspafdn1 yywdqdppe
 1201 gappstfkgp ptaenpeylg ldvpv (SEQ ID NO: 3, corresponding to receptor
 tyrosine-protein kinase erbB-2 isoform b [Homo sapiens] and GenBank Accession No.
 NP_001005862).

[0145] A wild type HER2 Receptor sequence of the disclosure may comprise or consist of the amino acid sequence of:

1 mprgswkpqv ctgtmdklrl paspethldm lrlhlyggcqv vqgnleltyl ptnaslsflq
 61 diqevqgyvl iahnqvrqvp lqrlrivrgt qlfednyala vldngdplnn ttpvtgaspg
 121 glrelqlrsl teilkggvli qrnplqcyqd tilwkdfhk nnqlaltlid tnrsrachpc
 181 spmckgsrcw gessedcql trtvcaggca rckgplptdc cheqcaagct gpkhsdclac
 241 lhfhnsgice lhcpalvtyn tdtfesmpnp egrytfgasc vtacpynyls tdvgsctlv
 301 plhnqevtae dgtqrcekcs kpcarvcygl gmehlrevra vtsanigefa gckkifgsla
 361 flpesfdgdp asntaplqpe qlqvftlee itgylisaw pdsldpdlsvf qnlqvgrgri
 421 lhnqaysltl qglgiswlg1 rslrelgsgl alihhnthlc fvhtvpwdql frnphqallh
 481 tanrpedecv geglachqlc arghcwpggp tqcvncsqfl rgqecveecr vlqglpreyv
 541 narhclpchp ecqpqngsvt cfpgeadqcv acahykdpvf cvarcpsgvk pdslympiwk
 601 fpdeegacqp cpincthscv dlddkgcpar graspltsii savvgillvv vlgvvggili
 661 krrqqkirky tmrrllqete lvepltpsga mpnqamril ketelrkvvk lgsgafgtvy
 721 kgiwipdgen vkipvaikvl rentsplank eildeayvma gvgspyvsrl lgicltstvt
 781 lvtqlmpygc lldhvrenrg rlgsqdllnw cmqiakgmsy ledvrlvhrd laarnvlvks
 841 pnhvkitdfg larlldidet eyhadggkvp ikwmalesil rrrfthqsdv wsygtvwel
 901 mtfgakpydg ipareipdll ekgerlpqpp ictidvymim vkcmidsec rprfrelvse
 961 fsmardpqr fvviqnedlg paspldstfy rslldeeddmg dlvdadeeylv pqqgffcpdp
 1021 apgaggmvhh rhrssstrsg ggdltlglep seeeaprspl apsegagsdv fdgdlgmga
 1081 kglqslpthd psplqrysed ptvplpsetd gyvapltcsp qpeyvnpdv rpqppspreg
 1141 plpaarpaga tlerpklsp gkngvvkdvf afggavenpe yltppggaap qphppafsp
 1201 afdnlyywdq dpperpapps tfkgtpaen peylgldvpv (SEQ ID NO: 4,
 corresponding to receptor tyrosine-protein kinase erbB-2 isoform c [Homo sapiens] and
 GenBank Accession No. NP_001276865).

[0146] A wild type HER2 Receptor sequence of the disclosure may comprise or consist of the amino acid sequence of:

1 melaalcwrg lllallppga astqvctgt mklrlpaspe thldmlrlhly qgcqvvggnl
 61 eltylptnas lsflqdiqev qgyvliahnq vrqvpqlrlr ivrgtqlfed nyalavldng
 121 dplnnttpvt gaspgglrel qlrslteilk ggvligrnpq lcyqdtlwk difhknq1
 181 ltldtnrsr achpcspmk gsrcwgesse dcqsltrtvc aggcrcckgp lptdccheq

241 aagctgpkhs dclaclhfnh sgicelhcpa lvtyntdtfe smpnpegryt fgascvtacp
 301 ynylstdivgs ctlvcpnlhnq evtaedgtqr cekcskpcar vcyglgmehl revravtsan
 361 iqefagckki fgslafllpes fdgdpasnta plqpeqlqv etleeitgyl yisawpdsip
 421 dlsvfqnlqv irgrilhnga yslltqlglgi swlglrlslre lgsglalihh nthlcfvhtv
 481 pwdqlfrnph qallhtanrp edecvgegla chqlcarghc wpggptqcvn csqflrgqec
 541 veecrvlqgl preyvvarhc lpchpecqpq ngsvtcfge adqcvacahy kdpvfvarc
 601 psgvkpdlsy mpiwkfpdee gacqpcpinc thscvdlldk gcpaeqrasp ltsiisavvg
 661 illvvvlgvv fgilikkrrq kirkytmrrl lqetelvepl tpsgampnqa qmrilketel
 721 rkvvklgsa fgtvykigi pdgenkipv aikvlrents pkankeilde ayvmagvgsp
 781 yvsrllgicl tstvqlvtql mpygcldhv renrglgsq dllnwcmla kgmsyledvr
 841 lvhrdlaarn vlvkspnhvk itdfglarll dideteyhad ggkvpikwma lesilrrrft
 901 hqsdvwsygv tvwelmtfga kpydgipare ipdllekger lpqpictid vymimvkcwm
 961 idsecrprfr elvsefsrma rdpqrfvviq nedlgpaspl dstfyrslle dddmgdlvda
 1021 eeylvppqgf fcpdpapag gmvhhrhrss strnm (SEQ ID NO: 5, corresponding to
 receptor tyrosine-protein kinase erbB-2 isoform d precursor [Homo sapiens] and GenBank
 Accession No. NP_001276866).


[0147] A wild type HER2 Receptor sequence of the disclosure may comprise or consist of the amino acid sequence of:

1 mklrlpaspe thldmlrhly qgcqvvggnl eltylptnas lsflqdiqev qgyvliahnq
 61 vrqvplqlrl ivrgtqlfed nyalavldng dplnnttpvt gaspgglrel qlrslteilk
 121 ggqliqrnpq lcyqdtllwk difhknnqla ltldtnrsr achpcspmck gsrcwgesse
 181 dcqsltrtvc aggcarrckgp lptdccheqc aagctgpkhs dclaclhfnh sgicelhcpa
 241 lvtyntdtfe smpnpegryt fgascvtacp ynylstdivgs ctlvcpnlhnq evtaedgtqr
 301 cekcskpcar vcyglgmehl revravtsan iqefagckki fgslafllpes fdgdpasnta
 361 plqpeqlqv etleeitgyl yisawpdsip dlsvfqnlqv irgrilhnga yslltqlglgi
 421 swlglrlslre lgsglalihh nthlcfvhtv pwdqlfrnph qallhtanrp edecvgegla
 481 chqlcarghc wpggptqcvn csqflrgqec veecrvlqgl preyvvarhc lpchpecqpq
 541 ngsvtcfge adqcvacahy kdpvfvarc psgvkpdlsy mpiwkfpdee gacqpcpinc
 601 ths (SEQ ID NO: 6, corresponding to receptor tyrosine-protein kinase erbB-2 isoform e
 [Homo sapiens] and GenBank Accession No. NP_001276867).

[0148] Based on the definitions given throughout the application the skilled person knows which combinations are synthetically feasible and realistic, e.g. typically combinations of groups leading to heteroatoms directly linked to each other are not contemplated.

Compounds of the Present Disclosure

[0149] In some aspects, the present disclosure provides a compound of Formula (I'):



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za} ;

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ;

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂.

[0150] In some aspects, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3 or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆

alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};


each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂;



or more halogen.

[0151] In some aspects, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3 or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{T} ;

each R^{T} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ;


each R^{Ta} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is $\text{C}_6\text{-C}_{10} \text{ aryl}$ optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{OR}^{\text{A1a}}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{A1b} ; and

each R^{A1b} independently is halogen, CN, $-\text{OH}$, or $-\text{NH}_2$;



or more halogen.

[0152] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^{Z} ;

each R^Z independently is halogen, $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$; wherein the $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ;

each R^T independently is halogen, $-OH$, $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-C(=O)OH$;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, $-OR^{A1a}$, or $-O-(C_1-C_6 \text{ alkyl})$ optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

[0153] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$; wherein the $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ;

each R^T independently is halogen, $-OH$, $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more $-C(=O)OH$;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, $-OR^{A1a}$, or $-O-(C_1-C_6 \text{ alkyl})$ optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

[0154] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;


T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;



or more halogen.

[0155] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;


T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{T} ;

each R^{T} independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$;

Ar^1 is $\text{C}_6\text{-C}_{10}$ aryl optionally substituted with one or more $\text{R}^{\text{A}1}$;

each $\text{R}^{\text{A}1}$ independently is halogen, $-\text{OR}^{\text{A}1\text{a}}$, or $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ optionally substituted with one or more $\text{R}^{\text{A}1\text{a}}$; and

each $\text{R}^{\text{A}1\text{a}}$ independently is $\text{C}_6\text{-C}_{10}$ aryl or 5- to 10-membered heteroaryl; wherein the $\text{C}_6\text{-C}_{10}$ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;



or more halogen.

[0156] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH ;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^{Z} ;

each R^{Z} independently is halogen, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or $\text{C}_1\text{-C}_6 \text{ alkyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ or $\text{C}_1\text{-C}_6 \text{ alkyl}$ is optionally substituted with one or more halogen;

T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{T} ;

each R^{T} independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$;

Ar^1 is $\text{C}_6\text{-C}_{10}$ aryl optionally substituted with one or more halogen.

[0157] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH ;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;
 each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;
 wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

[0158] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C₁-C₆ alkyl;

T is C₂-C₆ alkenyl optionally substituted with one or more 6-membered heterocycloalkyl;
 and

Ar¹ is C₆ aryl optionally substituted with one or more halogen.

[0159] In some embodiments, the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C₁-C₆ alkyl;

T is C₂-C₆ alkenyl optionally substituted with one or more 6-membered monocyclic heterocycloalkyl; and

Ar¹ is C₆ aryl optionally substituted with one or more halogen.

Variable W

[0160] In some embodiments, W is CH.

[0161] In some embodiments, W is N.

Variables Z, R^Z , and R^{Za}

[0162] In some embodiments, Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ; and


each R^Z independently is halogen, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen.





[0163] In some embodiments, Z is 3- to 12-membered heterocycloalkyl.


[0164] In some embodiments, Z is 3- to 12-membered heterocycloalkyl substituted with one or more R^Z .

[0165] In some embodiments, Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .


[0166] In some embodiments, Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .











[0172] In some embodiments, Z is



[0173] In some embodiments, Z is




[0174] In some embodiments, Z is




[0175] In some embodiments, Z is




[0176] In some embodiments, Z is



[0177] In some embodiments, Z is



[0178] In some embodiments, Z is



- [0179] In some embodiments, at least one R^Z is halogen.
- [0180] In some embodiments, at least one R^Z is F or Cl.
- [0181] In some embodiments, at least one R^Z is F.
- [0182] In some embodiments, at least one R^Z is Cl.
- [0183] In some embodiments, at least one R^Z is F, and at least one R^Z is Cl.
- [0184] In some embodiments, at least one R^Z is CN, -OH, or -NH₂.
- [0185] In some embodiments, at least one R^Z is -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za} .
- [0186] In some embodiments, at least one R^Z is -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{Za} .
- [0187] In some embodiments, at least one R^Z is -O-(C₁-C₆ alkyl).
- [0188] In some embodiments, at least one R^Z is -OCH₃.
- [0189] In some embodiments, at least one R^Z is -O-(C₁-C₆ alkyl) substituted with one or more R^{Za} .
- [0190] In some embodiments, at least one R^Z is -O-(C₁-C₆ alkyl) substituted with one or more halogen (e.g., F or Cl).
- [0191] In some embodiments, at least one R^Z is -NH(C₁-C₆ alkyl) or -N(C₁-C₆ alkyl)₂, wherein the -NH(C₁-C₆ alkyl) or -N(C₁-C₆ alkyl)₂ is optionally substituted with one or more R^{Za} .
- [0192] In some embodiments, at least one R^Z is C₁-C₆ alkyl optionally substituted with one or more R^{Za} .
- [0193] In some embodiments, at least one R^Z is C₁-C₆ alkyl.
- [0194] In some embodiments, at least one R^Z is methyl, ethyl, or propyl (e.g., i-propyl).
- [0195] In some embodiments, at least one R^Z is C₁-C₆ alkyl substituted with one or more R^{Za} .
- [0196] In some embodiments, at least one R^Z is C₁-C₆ alkyl substituted with one or more halogen (e.g., F or Cl).
- [0197] In some embodiments, at least one R^Z is C₁-C₆ alkyl substituted with one or more F.
- [0198] In some embodiments, at least one R^Z is CF₃.
- [0199] In some embodiments, at least one R^Z is C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein the C₂-

C₆ alkenyl or C₂-C₆ alkynyl is optionally substituted with one or more R^{Za}.

[0200] In some embodiments, at least one R^Z is C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za}.

[0201] In some embodiments, at least one R^Z is C₃-C₁₀ cycloalkyl optionally substituted with one or more R^{Za}.

[0202] In some embodiments, at least one R^Z is C₆-C₁₀ aryl optionally substituted with one or more R^{Za}.

[0203] In some embodiments, at least one R^Z is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Za}.

[0204] In some embodiments, at least one R^Z is 4-membered heterocycloalkyl optionally substituted with one or more R^{Za}.

[0205] In some embodiments, at least one R^Z is 4-membered heterocycloalkyl.

[0206] In some embodiments, at least one R^Z is oxetanyl.

[0207] In some embodiments, at least one R^Z is 5- to 10-membered heteroaryl optionally substituted with one or more R^{Za}.

[0208] In some embodiments, at least one R^{Za} is halogen.

[0209] In some embodiments, at least one R^{Za} is F or Cl.

[0210] In some embodiments, at least one R^{Za} is F.

[0211] In some embodiments, at least one R^{Za} is Cl.

[0212] In some embodiments, at least one R^{Za} is CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Variables T, R^T, and R^{Ta}

[0213] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5-

to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}; and

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

[0214] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}, and

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

[0215] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

[0216] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

[0217] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆

alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

[0218] In some embodiments, T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

[0219] In some embodiments, T is -O-(C₁-C₆ alkyl) optionally substituted with one or more R^T.

[0220] In some embodiments, T is -O-(C₁-C₆ alkyl).

[0221] In some embodiments, T is -OCH₃.

[0222] In some embodiments, T is -NH-(C₁-C₆ alkyl) optionally substituted with one or more R^T.

[0223] In some embodiments, T is -NH-(C₁-C₆ alkyl).

[0224] In some embodiments, T is -NHCH₃.

[0225] In some embodiments, T is C₁-C₆ alkyl optionally substituted with one or more R^T.

[0226] In some embodiments, T is C₁-C₆ alkyl.

[0227] In some embodiments, T is methyl or ethyl.

[0228] In some embodiments, T is methyl.

[0229] In some embodiments, T is ethyl.

[0230] In some embodiments, T is C₁-C₆ alkyl substituted with one or more R^T.

[0231] In some embodiments, T is C₁-C₆ alkyl substituted with one or more halogen (e.g., F or Cl).

[0232] In some embodiments, T is methyl substituted with one or more halogen (e.g., F or Cl).

[0233] In some embodiments, T is -CHFCl.

[0234] In some embodiments, T is C₁-C₆ alkyl substituted with one or more CN.

[0235] In some embodiments, T is -CH₂CN.






[0236] In some embodiments, T is C₂-C₆ alkenyl optionally substituted with one or more R^T.

[0237] In some embodiments, T is C₂-C₆ alkenyl.

- [0238] In some embodiments, T is ethenyl (*i.e.*, -CH=CH₂).
- [0239] In some embodiments, T is propenyl (e.g., -C(CH₃)=CH₂ or -CH=CH-CH₃).
- [0240] In some embodiments, T is pentenyl (e.g., -CH=CH-C(CH₃)₂).
- [0241] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more R^T.
- [0242] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.
- [0243] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -OH
- [0244] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -O-(C₁-C₆ alkyl).
- [0245] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -OCH₃.
- [0246] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -N(C₁-C₆ alkyl)₂.
- [0247] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more -N(CH₃)₂.
- [0248] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 10-membered heterocycloalkyl.
- [0249] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.
- [0250] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered heterocycloalkyl.
- [0251] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered heterocycloalkyl; wherein the 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.
- [0252] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered heterocycloalkyl.
- [0253] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered monocyclic heterocycloalkyl.
- [0254] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered monocyclic heterocycloalkyl; wherein the 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH.
- [0255] In some embodiments, T is C₂-C₆ alkenyl substituted with one or more 3- to 7-membered monocyclic heterocycloalkyl.

[0269] In some embodiments, T is propynyl substituted with one or more 3- to 7-membered heterocycloalkyl.





[0291] In some embodiments, at least one R^T is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Ta} .

[0292] In some embodiments, at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more R^{Ta} .

[0293] In some embodiments, at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more $C(=O)OH$.

[0294] In some embodiments, at least one R^T is 3- to 7-membered heterocycloalkyl optionally substituted with one or more R^{Ta} .

[0295] In some embodiments, at least one R^T is 3- to 7-membered heterocycloalkyl.

[0296] In some embodiments, at least one R^T is 3- to 7-membered heterocycloalkyl substituted with one or more R^{Ta} .

[0297] In some embodiments, at least one R^T is 3- to 7-membered heterocycloalkyl substituted with one or more $C(=O)OH$.

[0298] In some embodiments, at least one R^T is 6-membered heterocycloalkyl optionally substituted with one or more R^{Ta} .

[0299] In some embodiments, at least one R^T is 6-membered heterocycloalkyl.

[0300] In some embodiments, at least one R^T is 6-membered heterocycloalkyl substituted with one or more R^{Ta} .

[0301] In some embodiments, at least one R^T is 6-membered heterocycloalkyl substituted with one or more $C(=O)OH$.

[0302] In some embodiments, at least one R^T is 3- to 7-membered monocyclic heterocycloalkyl optionally substituted with one or more R^{Ta} .

[0303] In some embodiments, at least one R^T is 3- to 7-membered monocyclic heterocycloalkyl.

[0304] In some embodiments, at least one R^T is 3- to 7-membered monocyclic heterocycloalkyl substituted with one or more R^{Ta} .

[0305] In some embodiments, at least one R^T is 3- to 7-membered monocyclic heterocycloalkyl substituted with one or more $C(=O)OH$.

[0306] In some embodiments, at least one R^T is 6-membered monocyclic heterocycloalkyl optionally substituted with one or more R^{Ta} .

[0307] In some embodiments, at least one R^T is 6-membered monocyclic heterocycloalkyl.

[0308] In some embodiments, at least one R^T is 6-membered monocyclic heterocycloalkyl

substituted with one or more R^{Ta} .

[0309] In some embodiments, at least one R^T is 6-membered monocyclic heterocycloalkyl substituted with one or more $C(=O)OH$.

[0310] In some embodiments, at least one R^{Ta} is $C(=O)OH$.

[0311] In some embodiments, at least one R^{Ta} is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Variables Ar^1 , R^{A1} , R^{A1a} , and R^{A1b}

[0312] In some embodiments, Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a} ;

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b} ; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂.

[0313] In some embodiments, Ar^1 is C₆-C₁₀ aryl.

[0314] In some embodiments, Ar^1 is C₆-C₁₀ aryl substituted with one or more R^{A1} .

[0315] In some embodiments, Ar^1 is phenyl substituted with one or more R^{A1} .

[0316] In some embodiments, Ar^1 is phenyl substituted with one or more halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl); wherein the -O-(C₁-C₆ alkyl) is optionally substituted with one or more R^{A1a} ; and each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

[0317] In some embodiments, Ar^1 is phenyl substituted with one or more halogen

[0318] In some embodiments, Ar^1 is phenyl substituted with one or more F or Cl.

[0319] In some embodiments, Ar^1 is phenyl substituted with one F and one Cl.


[0320] In some embodiments, Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered


heteroaryl); wherein the $-O-(C_6-C_{10} \text{ aryl})$ or $-O-(5- \text{ to } 10\text{-membered heteroaryl})$ is optionally substituted with one or more halogen.


[0321] In some embodiments, Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with $-O$ -phenyl or $-O$ -pyridinyl; wherein the $-O$ -phenyl or $-O$ -pyridinyl is optionally substituted with one or more halogen.


[0322] In some embodiments, Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with $-O$ -phenyl; wherein the $-O$ -phenyl is optionally substituted with one or more halogen.


[0323] In some embodiments, Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with $-O$ -pyridinyl; wherein the $-O$ -pyridinyl is optionally substituted with one or more halogen.


[0324] In some embodiments, Ar^1 is .










or .


[0325] In some embodiments, Ar^1 is .

[0326] In some embodiments, Ar^1 is .

[0327] In some embodiments, Ar^1 is .

[0328] In some embodiments, Ar^1 is .





[0337] In some embodiments, Ar¹ is

[0338] In some embodiments, at least one R^{A1} is halogen (e.g., F or Cl).

[0339] In some embodiments, at least one R^{A1} is F.

[0340] In some embodiments, at least one R^{A1} is Cl.

[0341] In some embodiments, at least one R^{A1} is F, and at least one R^{A1} is Cl.

[0342] In some embodiments, at least one R^{A1} is CN, -OH, or -NH₂.

[0343] In some embodiments, at least one R^{A1} is -OR^{A1a}.

[0344] In some embodiments, at least one R^{A1} is -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more R^{A1b}.

[0345] In some embodiments, at least one R^{A1} is -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.

[0346] In some embodiments, at least one R^{A1} is -O-phenyl or -O-pyridinyl; wherein the -O-phenyl or -O-pyridinyl is optionally substituted with one or more halogen.

[0347] In some embodiments, at least one R^{A1} is -O-phenyl optionally substituted with one or more halogen.

[0348] In some embodiments, at least one R^{A1} is -O-pyridinyl optionally substituted with one or more halogen.

[0349] In some embodiments, at least one R^{A1} is -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl, wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a}.

[0350] In some embodiments, at least one R^{A1} is -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{A1a}.

[0351] In some embodiments, at least one R^{A1} is -O-(C₁-C₆ alkyl) substituted with one or more R^{A1a}.

[0352] In some embodiments, at least one R^{A1} is -O-(C₁-C₆ alkyl) substituted with one or more C₆-C₁₀ aryl or 5- to 10-membered heteroaryl, wherein the C₆-C₁₀ aryl or 5- to 10-membered

heteroaryl is optionally substituted with one or more halogen.

[0353] In some embodiments, at least one R^{A1} is $-O-CH_2-R^{A1a}$.

[0354] In some embodiments, at least one R^{A1} is $-O-CH_2-(C_6-C_{10} \text{ aryl})$ or $-O-CH_2-(5- \text{ to } 10\text{-membered heteroaryl})$, wherein the $-O-CH_2-(C_6-C_{10} \text{ aryl})$ or $-O-CH_2-(5- \text{ to } 10\text{-membered heteroaryl})$ is optionally substituted with one or more halogen.

[0355] In some embodiments, at least one R^{A1} is $-O-CH_2\text{-phenyl}$ or $-O-CH_2\text{-pyridinyl}$, wherein the $-O-CH_2\text{-phenyl}$ or $-O-CH_2\text{-pyridinyl}$ is optionally substituted with one or more halogen.

[0356] In some embodiments, at least one R^{A1} is $-O-CH_2\text{-phenyl}$ optionally substituted with one or more halogen.

[0357] In some embodiments, at least one R^{A1} is $-O-CH_2\text{-pyridinyl}$ optionally substituted with one or more halogen.

[0358] In some embodiments, at least one R^{A1} is C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a} .

[0359] In some embodiments, at least one R^{A1a} is halogen, CN, $-OH$, $-NH_2$, $-O-(C_1-C_6 \text{ alkyl})$, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl, wherein the $-O-(C_1-C_6 \text{ alkyl})$, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1b} .

[0360] In some embodiments, at least one R^{A1a} is C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b} .

[0361] In some embodiments, at least one R^{A1a} is C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

[0362] In some embodiments, at least one R^{A1a} is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

[0363] In some embodiments, at least one R^{A1a} is phenyl or pyridinyl; wherein the phenyl or

pyridinyl is optionally substituted with one or more halogen.

[0364] In some embodiments, at least one R^{A1a} is phenyl optionally substituted with one or more halogen.

[0365] In some embodiments, at least one R^{A1a} is pyridinyl optionally substituted with one or more halogen.

[0366] In some embodiments, at least one R^{A1b} is halogen.


[0367] In some embodiments, at least one R^{A1b} is F.

[0368] In some embodiments, at least one R^{A1b} is Cl.

[0369] In some embodiments, at least one R^{A1b} is F, and at least one R^{A1b} is Cl.

[0370] In some embodiments, at least one R^{A1b} is CN, -OH, or -NH₂.



Exemplary Embodiments of the Compounds


[0371] In some embodiments, when Z is , then

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ; and wherein the C₂-C₆ alkenyl is substituted with one or more R^T


each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ; and


each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.


[0372] In some embodiments, when Z is , then T is not  or .

[0373] In some embodiments, when Z is , then Ar¹ is C₆-C₁₀ aryl optionally substituted


with one or more halogen.

[0374] In some embodiments, Z is not .

[0375] In some embodiments, Z is not , or


[0376] In some embodiments, T is not .

[0377] In some embodiments, the compound is of formula (II'):




or a pharmaceutically acceptable salt or stereoisomer thereof.


[0378] In some embodiments, the compound is of formula (II'):



or a pharmaceutically acceptable salt or stereoisomer thereof.



[0379] In some embodiments, the compound is of formula (III') or (III'-a):






or a pharmaceutically acceptable salt or stereoisomer thereof.

[0380] In some embodiments, the compound is of formula (IV') or (IV'-a):



or a pharmaceutically acceptable salt or stereoisomer thereof.

[0381] In some aspects, the disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I



wherein

W is CH or N, preferably CH;

X¹ is -O-, -S-, -NR³-;

R^a , R^b are independently of each other hydrogen or C_{1-4} alkyl or one of R^a is $-(CH_2)_p-$ which forms a ring with X^1 if X^1 is NR^3 or one of R^a is $-(CH_2)_p-$ which forms a ring with R^2 ;

R^c , R^d are independently of each other hydrogen or C_{1-4} alkyl;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, or is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a ;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $-(CH_2)_p-$ which forms a ring with R^2 ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxy carbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

[0382] In some embodiments of a compound of formula I, W is CH.

[0383] In some embodiments, when n is 0, R^2 is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .

[0384] In some embodiments, when n is 0, R^2 is $-(CH_2)_q-$ which forms a ring with R^3 .

[0385] In some embodiments, n is 0, and R^2 is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .

[0386] In some embodiments, n is 0, and R^2 is $-(CH_2)_q-$ which forms a ring with R^3 .

[0387] In some embodiments of a compound of formula I, X^1 is $-O-$ or $-NR^3-$, more preferably $-NR^3-$.

[0388] In some embodiments of a compound of formula I, R^b is always hydrogen, such that only R^a may be not hydrogen. For example, R^b may be hydrogen and R^a may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl, or $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^2 . Preferably, R^b may be hydrogen and R^a may be methyl or $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^2 . Furthermore, both R^a and R^b may be hydrogen.

[0389] In some embodiments the ring of which X^1 is part of is a monocycle or bicycle.

[0390] In some embodiments of a compound of formula I, R^c is always hydrogen, such that only R^d may be not hydrogen. For example, R^c may be hydrogen and R^d may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. Preferably, R^c may be hydrogen and R^d may be methyl. Furthermore, both R^c and R^d may be hydrogen.

[0391] In some embodiments of a compound of formula I, R^1 is hydrogen.

[0392] In some embodiments of a compound of formula I, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, R^b , R^c and R^d are hydrogen. In some embodiments of a compound of formula I, R^1 , R^b , R^c and R^d are hydrogen.

[0393] In some embodiments of a compound of formula I in which one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0394] In some embodiments of a compound of formula I in which one of R^a forms a ring with R^3 , the ring formed is a 3, 4, 5, or 6-membered ring.

[0395] In some embodiments of a compound of formula I in which one of R^2 forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

In some embodiments of a compound of formula I, R^2 is C_{1-4} alkyl, or is $-(CH_2)_q-$ which forms a ring with R^3 or R^a . For example, R^2 may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a . Preferably, R^2 may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl or i-butyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a . More preferably, R^2 may be methyl.


[0396] In some embodiments of a compound of formula I, R^3 is hydrogen or methyl or R^3 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^2 .

[0397] In some embodiments of a compound of formula I, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0398] In some embodiments of a compound of formula I, X^1 may form a heterocycle with the carbon to which R^2 is directly bound. For example, X^1 may form a 4, 5, 6 or 7 membered heterocycle. In some embodiments of a compound of formula I, X^1 may form a substituted or unsubstituted oxetanyl, thiatanyl, azetidiny, pyrrolidinyl, tetrahydrofuranyl,

tetrahydrothiopyranyl, dihydropyranyl, tetrahydropyranyl, piperidiny, oxepanyl, thiepanyl, azepanyl, azabicyclo[2.2.1]heptane or azabicyclo[2.2.2]octane, preferably azetidiny, pyrrolidiny, tetrahydrofuranyl, piperidiny, more preferably azetidiny, pyrrolidiny or piperidiny.

[0399] In some embodiments of a compound of formula I, Ar¹ is of formula i or pharmaceutically acceptable salts or stereoisomers thereof



wherein

R⁴ hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, -CF₃ or halogen, preferably F, Cl.

[0400] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R⁴ is hydrogen, fluoro, chloro, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₆ aryl, C₁₋₄ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₄ alkylamino, C₁₋₄ aminoalkyl-C₆ aryl, C₁₋₄ aminoalkyl-C₆ heteroaryl, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkoxyaminocarbonyl or C₆ aryl.

[0401] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R⁴ is hydrogen, fluoro, chloro, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₆ aryl, C₁₋₄ alkoxy-C₅₋₆ heteroaryl or C₆ aryl.

[0402] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R⁴ is in general hydrogen, fluoro, chloro, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, n-hexyl, i-hexyl, methoxy, ethoxy, n-propoxy, i-propoxy, n-propoxy, n-butoxy, i-butoxy, n-pentoxyl, i-pentoxyl, n-hexoxyl, i-hexoxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, hydroxy methyl, hydroxy ethyl, hydroxyl propyl, hydroxyl butyl, hydroxyl pentyl, methoxy methyl, methoxy ethyl, methoxy propyl, methoxy butyl, methoxy pentyl,

methoxy hexyl, ethoxy methyl, ethoxy ethyl, ethoxy propyl, ethoxy butyl, ethoxy pentyl, ethoxy hexyl, propoxy methyl, propoxy ethyl, propoxy propyl, propoxy butyl, propoxy pentyl, propoxy hexyl, butoxy methyl, butoxy ethyl, butoxy propyl, butoxy butyl, butoxy pentyl, butoxy hexyl, pentoxy methyl, pentoxy ethyl, pentoxy propyl, pentoxy butyl, pentoxy pentyl, pentoxy hexyl, hexoxy methyl, hexoxy ethyl, hexoxy propyl, hexoxy butyl, hexoxy pentyl, hexoxy hexyl, amino methyl, amino ethyl, amino propyl, amino butyl, amino pentyl, amino hexyl, methylamino ethylamino, propylamino, butylamino, pentylamino, hexylamino, methoxy carbonyl, ethoxy carbonyl, propoxy carbonyl, butoxy carbonyl, pentoxy carbonyl, hexoxy carbonyl, methoxyamino carbonyl, ethoxyamino carbonyl, propoxyamino carbonyl, butoxyamino carbonyl, pentoxyamino carbonyl, hexoxyamino carbonyl, phenyl methoxy, phenyl ethoxy, phenyl propoxy, phenyl butoxy, phenyl pentoxy, phenyl hexoxy, m-fluorophenyl methoxy, m-fluorophenylphenyl ethoxy, m-fluorophenylphenyl propoxy, m-fluorophenylphenyl butoxy, m-fluorophenylphenyl pentoxy, m-fluorophenylphenyl hexoxy, pyridinyl methoxy, pyridinyl ethoxy, pyridinyl propoxy, pyridinyl butoxy, pyridinyl pentoxy, pyridinyl hexoxy, phenyl, pyridinyl or naphthyl.

In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl.

[0403] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, fluoro, chloro, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₆ aryl, C₁₋₄ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₄ alkylamino, C₁₋₄ aminoalkyl-C₆ aryl, C₁₋₄ aminoalkyl-C₆ heteroaryl, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkoxyaminocarbonyl or C₆ aryl.

[0404] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, Ar¹ comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R⁴, R⁵, R^{5'}, R⁶ or R^{6'} may be hydrogen.

[0405] In some embodiments of a compound of formula I, wherein Ar¹ is of formula i, R¹ may be hydrogen and/or R² may be methyl or R² is -(CH₂)- or -(CH₂)₂- which forms a ring with R³, or

R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .


[0406] In some embodiments of a compound of formula I, wherein Ar^1 is of formula i, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar^1 is of formula I, R^b , R^c and R^d are hydrogen.

[0407] In some embodiments compound of formula I wherein Ar^1 is of formula i, in which with one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0408] In some embodiments compound of formula I wherein Ar^1 is of formula i, in which with one of R^a forms a ring with R^3 , the ring formed is a 3, 4, 5, or 6-membered ring.

[0409] In some embodiments compound of formula I wherein Ar^1 is of formula i, in which one of R^2 forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0410] In some embodiments of a compound of formula I, Ar^1 is of formula ii-1 or pharmaceutically acceptable salts or stereoisomers thereof






wherein

R^4 is hydrogen, F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0411] In some embodiments of a compound of formula I, Ar^1 is of formula ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe;

X^3 is CH or N;

o is 0 or 1;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0412] The skilled person understands that if X^3 stands for CH, R^7 may in general also be bound to this carbon, such that X^3 may be CR^7 . Preferably, the corresponding aryl or heteroaryl is substituted only with a single R^7 . Furthermore, it is understood that when X^3 is N, R^7 can in general not be bound to N.

[0413] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0414] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.

[0415] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, o is 1.

[0416] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^5 is F and/or R^6 is F or Cl.

[0417] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^b , R^c and R^d are hydrogen.


[0418] In some embodiments compound of formula I wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, in which with one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0419] In some embodiments compound of formula I wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, in which with one of R^a forms a ring with R^3 , the ring formed is a 3, 4, 5, or 6-membered ring.

[0420] In some embodiments compound of formula I wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, in which one of R^2 forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0421] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1, ii-2, ii-3 or ii-4, R² is methyl or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R³, or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a.

[0422] In some embodiments, X² is O, such that Ar¹ is of formula ii-1a or pharmaceutically acceptable salts or stereoisomers thereof






wherein

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0423] In some embodiments, X² is O, such that Ar¹ is of formula ii-2a, ii-3a or ii-4a or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X³ is CH or N, preferably N;

o is 0 or 1;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.

[0424] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R⁵ and R⁶ are independently of each other hydrogen, $-CF_3$, F or Cl and R^{5'} and R^{6'} are hydrogen.

[0425] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a,

ii-3a or ii-4a, o is 1.

[0426] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R⁵ is F and/or R⁶ is F or Cl.

[0427] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R⁷ is hydrogen if X³ is N and/or R⁷ is F if X³ is CH.

[0428] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R² is methyl or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R³, or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a.


[0429] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^b, R^c and R^d are hydrogen.

[0430] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, in which with one of R^a forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0431] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, in which with one of R^a forms a ring with R³, the ring formed is a 3, 4, 5, or 6-membered ring.

[0432] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1a, ii-2a, ii-3a or ii-4a, in which one of R² forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0433] In some embodiments, X³ is N, such that Ar¹ is of formula ii-1b or pharmaceutically acceptable salts or stereoisomers thereof




wherein

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, -CF₃ or halogen, preferably F, Cl.

[0434] In some embodiments, X^3 is N, such that Ar^1 is of formula ii-2b, ii-3b, ii-4b, ii-5b or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe, preferably O;

o is 0 or 1;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl

R^7 is hydrogen or halogen, preferably F.

[0435] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0436] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, o is 1.

[0437] In some of a compound of formula I, wherein Ar^1 is of ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^5 is F and/or R^6 is F or Cl.

[0438] In some of a compound of formula I, wherein Ar^1 is ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^7 is F.

[0439] In some of a compound of formula I, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .


[0440] In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b or ii-4b, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b or ii-4b, R^b , R^c and R^d are hydrogen.

[0441] In some embodiments compound of formula I wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b or ii-4b, in which one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0442] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1b, ii-2b, ii-3b or ii-4b, in which one of R^a forms a ring with R³, the ring formed is a 3, 4, 5, or 6-membered ring.

[0443] In some embodiments compound of formula I wherein Ar¹ is of ii-1b, ii-2b, ii-3b or ii-4b, in which one of R² forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0444] In some embodiments, X² is O and X³ is N, such that Ar¹ is of formula ii-1c or pharmaceutically acceptable salts or stereoisomers thereof







wherein

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, -CF₃ or halogen, preferably F, Cl.

[0445] In some embodiments, X² is O and X³ is N, such that Ar¹ is of formula ii-2c, ii-3c, ii-4c, ii-5c or pharmaceutically acceptable salts or stereoisomers thereof



wherein

o is 0 or 1;

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.

[0446] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen.

[0447] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, o is 1.

[0448] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R⁵ is F and/or R⁶ is F or Cl.

[0449] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R⁷ is F.

[0450] In some embodiments of a compound of formula I, wherein Ar¹ is of ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R² is methyl or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R³, or R² is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a.


[0451] In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c or ii-4c, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c or ii-4c, R^b, R^c and R^d are hydrogen.

[0452] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c or ii-4c, in which one of R^a forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0453] In some embodiments compound of formula I wherein Ar¹ is of formula ii-1c, ii-2c, ii-3c or ii-4c, in which one of R^a forms a ring with R³, the ring formed is a 3, 4, 5, or 6-membered ring.

[0454] In some embodiments compound of formula I wherein Ar¹ is of ii-1c, ii-2c, ii-3c or ii-4c, in which one of R² forms a ring with R³, the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0455] In some embodiments of a compound of formula I, Ar¹ is of formula iii-1 or pharmaceutically acceptable salts or stereoisomers thereof



iii-1


wherein

R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R⁶ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0456] In some embodiments of a compound of formula I, Ar¹ is of formula iii-2, iii-3 or iii-4, iii-

5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^3 is CH or N, preferably N;

o is 0 or 1;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0457] In some embodiments a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0458] In some embodiments a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, o is 1.

[0459] In some embodiments a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^5 is F and/or R^6 is F or Cl.

[0460] In some embodiments of a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.

[0461] In some embodiments a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

[0462] In some embodiments of a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^b , R^c and R^d are


hydrogen.

[0463] In some embodiments compound of formula I wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, in which one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0464] In some embodiments compound of formula I wherein Ar^1 is of iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, in which one of R^a forms a ring with R^3 , the ring formed is a 3, 4, 5, or 6-membered ring.

[0465] In some embodiments compound of formula I wherein Ar^1 is of iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, in which one of R^2 forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0466] In some embodiments, X^3 is N, such that Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6 or iv-7, or X^3 is C such that Ar^1 is of formula iv-8 or iv-9



wherein

o is 0 or 1;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0467] In some embodiments of a compound of formula I, wherein Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^5 and R^6 are independently of each other hydrogen, $-\text{CF}_3$, F or Cl and R^5 and R^6 are hydrogen.

[0468] In some embodiments of a compound of formula I, wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, o is 1.

[0469] In some embodiments of a compound of formula I, wherein Ar^1 is of formula iv-2, iv-3 or

iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^5 is F and/or R^6 is F or Cl.

[0470] In some embodiments of a compound of formula I, wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^7 is F.

[0471] In some embodiments of a compound of formula I, wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^2 is methyl or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .



[0472] In some embodiments of a compound of formula I, wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^c and R^d are hydrogen. In some embodiments of a compound of formula I, wherein Ar^1 is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^b , R^c and R^d are hydrogen.

[0473] In some embodiments compound of formula I wherein Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, in which one of R^a forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring, or a 5 or 6 membered ring, or a 5 membered ring.

[0474] In some embodiments compound of formula I wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, in which one of R^a forms a ring with R^3 , the ring formed is a 3, 4, 5, or 6-membered ring.

[0475] In some embodiments compound of formula I wherein Ar^1 is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, in which one of R^2 forms a ring with R^3 , the ring formed is a 4, 5, or 6-membered ring or a 5 or 6 membered ring, or a 6 membered ring.

[0476] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IIa or IIb



wherein

X^1 is $-O-$, $-NR^3-$;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, preferably methyl or is $-(CH_2)_q-$ which forms a ring with R^3 ;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $-(CH_2)_p-$ which forms a ring with R^2 ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;

s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

[0477] In some embodiments of a compound of formula IIa or IIb, X^1 is $-NR^3-$.

[0478] In some embodiments of a compound of formula IIa or IIb, R^1 is hydrogen.

[0479] In some embodiments of a compound of formula IIa or IIb, R^2 is C_{1-4} alkyl or is $-(CH_2)_q-$ which forms a ring with R^3 . For example, R^2 may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 . Preferably, R^2 may be selected from methyl, ethyl, n-propyl, i-propyl, n-butyl or i-butyl. R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 . More preferably, R^2 may be methyl. R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 .

[0480] In some embodiments of a compound of formula IIa or IIb, R^3 is hydrogen or methyl or is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^2 .


[0481] In some embodiments of a compound of formula IIa or IIb, X^1 is NR^3 .

[0482] In some embodiments of a compound of formula IIa, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0483] In some embodiments of a compound of formula IIb, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0484] In some embodiments of a compound of formula IIa or IIb, X^1 may form a heterocycle with the carbon to which R^2 is directly bound. For example, X^1 may form a 4, 5, 6 or 7 membered heterocycle or a heterobicycle. In some embodiments of a compound of formula I, X^1 may form a substituted or unsubstituted oxetanyl, thiatanyl, azetidiny, pyrrolidiny, tetrahydrofuranyl, tetrahydrothiopyranyl, dihydropyranyl, tetrahydropyranyl, piperidiny, oxepanyl, thiepanyl, azepanyl, azabicyclo[2.2.1]heptane or azabicyclo[2.2.2]octane, preferably azetidiny, pyrrolidiny, tetrahydrofuranyl, piperidiny, more preferably azetidiny, pyrrolidiny or piperidiny.

[0485] In some embodiments of a compound of formula IIa or IIb, Ar^1 is of formula i or pharmaceutically acceptable salts or stereoisomers thereof



wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxy carbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0486] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula i, R^4 is hydrogen, fluoro, chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-4} alkoxy- C_{1-4} alkyl, C_{1-4} alkoxy- C_6 aryl, C_{1-4} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-4} alkylamino, C_{1-4} aminoalkyl- C_6 aryl, C_{1-4} aminoalkyl- C_6 heteroaryl, C_{1-4} alkoxy carbonyl, C_{1-4} alkoxyaminocarbonyl or C_6 aryl.

[0487] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula i, R^4 is hydrogen, fluoro, chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, C_{1-4} alkoxy- C_{1-4} alkyl, C_{1-4} alkoxy- C_6 aryl, C_{1-4} alkoxy- C_{5-6} heteroaryl or C_6 aryl.

[0488] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula i, R^4 is in general hydrogen, fluoro, chloro, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl,

n-pentyl, i-pentyl, n-hexyl, i-hexyl, methoxy, ethoxy, n-propoxy, i-propoxy, n-propoxy, n-butoxy, i-butoxy, n-pentoxo, i-pentoxo, n-hexoxo, i-hexoxo, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, hydroxy methyl, hydroxy ethyl, hydroxyl propyl, hydroxyl butyl, hydroxyl pentyl, methoxy methyl, methoxy ethyl, methoxy propyl, methoxy butyl, methoxy pentyl, methoxy hexyl, ethoxy methyl, ethoxy ethyl, ethoxy propyl, ethoxy butyl, ethoxy pentyl, ethoxy hexyl, propoxy methyl, propoxy ethyl, propoxy propyl, propoxy butyl, propoxy pentyl, propoxy hexyl, butoxy methyl, butoxy ethyl, butoxy propyl, butoxy butyl, butoxy pentyl, butoxy hexyl, pentoxo methyl, pentoxo ethyl, pentoxo propyl, pentoxo butyl, pentoxo pentyl, pentoxo hexyl, hexoxo methyl, hexoxo ethyl, hexoxo propyl, hexoxo butyl, hexoxo pentyl, hexoxo hexyl, amino methyl, amino ethyl, amino propyl, amino butyl, amino pentyl, amino hexyl, methylamino ethylamino, propylamino, butylamino, pentylamino, hexylamino, methoxy carbonyl, ethoxy carbonyl, propoxy carbonyl, butoxy carbonyl, pentoxo carbonyl, hexoxo carbonyl, methoxyamino carbonyl, ethoxyamino carbonyl, propoxyamino carbonyl, butoxyamino carbonyl, pentoxoamino carbonyl, hexoxoamino carbonyl, phenyl methoxy, phenyl ethoxy, phenyl propoxy, phenyl butoxy, phenyl pentoxo, phenyl hexoxo, m-fluorophenyl methoxy, m-fluorophenylphenyl ethoxy, m-fluorophenylphenyl propoxy, m-fluorophenylphenyl butoxy, m-fluorophenylphenyl pentoxo, m-fluorophenylphenyl hexoxo, pyridinyl methoxy, pyridinyl ethoxy, pyridinyl propoxy, pyridinyl butoxy, pyridinyl pentoxo, pyridinyl hexoxo, phenyl, pyridinyl or naphthyl.

[0489] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula i, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl.


[0490] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula i, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, fluoro, chloro, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₆ aryl, C₁₋₄ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₄ alkylamino, C₁₋₄ aminoalkyl-C₆ aryl, C₁₋₄ aminoalkyl-C₆ heteroaryl, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkoxyaminocarbonyl or C₆ aryl.

[0491] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula i,

Ar¹ comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R⁴, R⁵, R^{5'}, R⁶ or R^{6'} may be hydrogen.

[0492] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula i, R¹ may be hydrogen and/or R² may be methyl or may be $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R³.

[0493] In some embodiments of a compound of formula IIa or IIb, Ar¹ is of formula ii-1 or pharmaceutically acceptable salts or stereoisomers thereof






wherein

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0494] In some embodiments of a compound of formula IIa or IIb, Ar¹ is of formula ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X² is O, NH or NMe;

X³ is C or N;

o is 0 or 1;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.

[0495] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula ii-1,

ii-2, ii-3 or ii-4, R^5 and R^6 are independently of each other hydrogen, $-\text{CF}_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0496] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, o is 1.

[0497] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^5 is F and/or R^6 is F or Cl.


[0498] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^2 is methyl or is $-(\text{CH}_2)-$ or $-(\text{CH}_2)_2-$ which forms a ring with R^3 .

[0499] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.

[0500] In some embodiments of a compound of formula IIa, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0501] In some embodiments of a compound of formula IIb, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0502] In some embodiments, X^2 is O, such that Ar^1 is of formula ii-1a or pharmaceutically acceptable salts or stereoisomers thereof




ii-1a

wherein

R^4 is hydrogen, F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F, Cl.

[0503] In some embodiments, X^2 is O, such that Ar^1 is of formula ii-2a, ii-3a or ii-4a or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^3 is CH or N, preferably N;

o is 0 or 1;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0504] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0505] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, o is 1.

[0506] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^5 is F and/or R^6 is F or Cl.

[0507] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.


[0508] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, R^2 is methyl or is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 .

[0509] In some embodiments of a compound of formula IIa, wherein Ar^1 is of formula ii-a-1, ii-2a, ii-3a or ii-4a, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0510] In some embodiments of a compound of formula IIb, wherein Ar^1 is of formula ii-1a, ii-2a, ii-3a or ii-4a, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0511] In some embodiments of a compound of formula IIa or IIb, X^3 is N, such that Ar^1 is of

formula ii-1b or pharmaceutically acceptable salts or stereoisomers thereof




wherein

R^4 is hydrogen, F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0512] In some embodiments of a compound of formula IIa or IIb, X^3 is N, such that Ar^1 is of formula ii-2b, ii-3b, ii-4b, ii-5b or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe, preferably O;

o is 0 or 1;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0513] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0514] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, o is 1.

[0515] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^5 is F and/or R^6 is F or Cl.


[0516] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R^7 is F.

[0517] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula ii-1b, ii-2b, ii-3b, ii-4b or ii-5b, R² is methyl or is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R³.

[0518] In some embodiments of a compound of formula IIa, wherein Ar¹ is of formula ii-1b, ii-2b, ii-3b or ii-4b, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0519] In some embodiments of a compound of formula IIb, wherein Ar¹ is of formula ii-1b, ii-2b, ii-3b or ii-4b, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0520] In some embodiments of a compound of formula IIa or IIb Ar¹ is of formula ii-1c or pharmaceutically acceptable salts or stereoisomers thereof







wherein

R⁴ is hydrogen, F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, $-CF_3$ or halogen, preferably F, Cl.

[0521] In some embodiments of a compound of formula IIa or IIb, X² is O and X³ is N, such that Ar¹ is of formula ii-2c, ii-3c, ii-4c, ii-5c or pharmaceutically acceptable salts or stereoisomers thereof



wherein

o is 0 or 1;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0522] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0523] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, o is 1.

[0524] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R^5 is F and/or R^6 is F or Cl.


[0525] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R^7 is F.

[0526] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c, ii-4c or ii-5c, R^2 is methyl or is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 .

[0527] In some embodiments of a compound of formula IIa, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c or ii-4c, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0528] In some embodiments of a compound of formula IIb, wherein Ar^1 is of formula ii-1c, ii-2c, ii-3c or ii-4c, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0529] In some embodiments of a compound of formula IIa or IIb, Ar^1 is of formula iii-1 or pharmaceutically acceptable salts or stereoisomers thereof




iii-1

wherein

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F, Cl.

[0530] In some embodiments of a compound of formula IIa or IIb, Ar^1 is of formula iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^3 is CH or N, preferably N;

o is 0 or 1;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

[0531] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^5 and R^6 are independently of each other hydrogen, $-\text{CF}_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

[0532] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, o is 1.

[0533] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^5 is F and/or R^6 is F or Cl.

[0534] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.


[0535] In some embodiments a compound of formula IIa or IIb, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7, R^2 is methyl or is $-(\text{CH}_2)-$ or $-(\text{CH}_2)_2-$ which forms a ring with R^3 .

[0536] In some embodiments of a compound of formula IIa, wherein Ar^1 is of formula iii-1, iii-2,

ii-3 or iii-4, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0537] In some embodiments of a compound of formula IIb, wherein Ar¹ is of formula iii-1, iii-2, iii-3 or iii-4, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0538] In some embodiments, X³ is N, such that Ar¹ is of formula iv-2, iv-3 or iv-4, iv-5, iv-6 or iv-7, or X³ is C such that Ar¹ is of formula iv-8 or iv-9



wherein

o is 0 or 1;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.

[0539] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen.

[0540] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, o is 1.

[0541] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R⁵ is F and/or R⁶ is F or Cl.


[0542] In some embodiments of a compound of formula IIa or IIb, wherein Ar¹ is of iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R⁷ is F.

[0543] In some embodiments of a compound of formula IIa or IIb, wherein Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, R^2 is methyl or is $-(\text{CH}_2)-$ or $-(\text{CH}_2)_2-$ which forms a ring with R^3 .

[0544] In some embodiments of a compound of formula IIa, wherein Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, n is 0 and m is 1, 2 or 3; or n is 0 and m is 1 or 2; or n is 1 and m is 1, 2 or 3; or n is 1 and m is 1 or 2; or n is 2 and m is 1, 2, or 3; or n is 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1 or 2; or n is 0, 1 or 2 and m is 1; or n is 1 or 2 and m is 1, 2 or 3; or n is 1 or 2 and m is 1 or 2; or n is 1 or 2 and m is 1 or 3; or n is 1 or 2 and m is 2 or 3.

[0545] In some embodiments of a compound of formula IIb, wherein Ar^1 is of formula iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9, r is 0 and s is 1 or 2, or r is 1 and s is 1 or 2, or r is 0 or 1 and s is 1, or r is 0 or 1 and s is 2.

[0546] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula III




wherein

R^1 is H or F;


Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-\text{CF}_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

Z is selected from



[0547] In some embodiments of a compound of formula III, R^1 is hydrogen.

[0548] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IV



IV


wherein

R^1 is H or F;

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

Z is selected from



[0549] In some embodiments of a compound of formula IV, R^4 is hydrogen, fluoro, chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-4} alkoxy- C_{1-4} alkyl, C_{1-4} alkoxy- C_6 aryl, C_{1-4} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-4} alkylamino, C_{1-4} aminoalkyl- C_6 aryl, C_{1-4} aminoalkyl- C_6 heteroaryl, C_{1-4} alkoxy carbonyl, C_{1-4} alkoxyaminocarbonyl or C_6 aryl.

[0550] In some embodiments of a compound of formula VI, R^4 is hydrogen, fluoro, chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, C_{1-4} alkoxy- C_{1-4} alkyl, C_{1-4} alkoxy- C_6 aryl, C_{1-4} alkoxy- C_{5-6} heteroaryl or C_6 aryl.

[0551] In some embodiments of a compound of formula IV, R^4 is in general hydrogen, fluoro, chloro, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, n-hexyl, i-hexyl, methoxy, ethoxy, n-propoxy, i-propoxy, n-propoxy, n-butoxy, i-butoxy, n-pentoxyl, i-pentoxyl, n-hexoxyl, i-hexoxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, hydroxy methyl, hydroxy ethyl, hydroxyl propyl, hydroxyl butyl, hydroxyl pentyl, methoxy methyl, methoxy ethyl, methoxy propyl, methoxy butyl, methoxy pentyl, methoxy hexyl, ethoxy methyl, ethoxy ethyl, ethoxy propyl, ethoxy butyl, ethoxy pentyl, ethoxy hexyl, propoxy methyl, propoxy ethyl, propoxy propyl, propoxy butyl, propoxy pentyl, propoxy hexyl, butoxy methyl, butoxy ethyl, butoxy propyl, butoxy butyl, butoxy pentyl, butoxy hexyl, pentoxyl methyl, pentoxyl ethyl, pentoxyl propyl, pentoxyl butyl, pentoxyl pentyl, pentoxyl hexyl, hexoxyl methyl, hexoxyl ethyl, hexoxyl propyl, hexoxyl butyl, hexoxyl pentyl, hexoxyl hexyl, amino methyl, amino ethyl, amino propyl, amino butyl, amino pentyl, amino hexyl, methylamino ethylamino, propylamino, butylamino, pentylamino, hexylamino, methoxy carbonyl, ethoxy carbonyl, propoxy carbonyl, butoxy carbonyl, pentoxyl carbonyl, hexoxyl carbonyl, methoxyamino carbonyl, ethoxyamino carbonyl, propoxyamino carbonyl, butoxyamino carbonyl, pentoxylamino carbonyl, hexoxylamino carbonyl, phenyl methoxy, phenyl ethoxy, phenyl propoxy, phenyl butoxy, phenyl pentoxyl, phenyl hexoxyl, m-fluorophenyl methoxy, m-fluorophenylphenyl ethoxy, m-fluorophenylphenyl propoxy, m-fluorophenylphenyl butoxy, m-fluorophenylphenyl pentoxyl, m-fluorophenylphenyl hexoxyl, pyridinyl methoxy, pyridinyl ethoxy, pyridinyl propoxy, pyridinyl butoxy, pyridinyl pentoxyl, pyridinyl hexoxyl, phenyl, pyridinyl or naphthyl.

[0552] In some embodiments of a compound of formula IV, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen. Preferably, R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6


aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl.

[0553] In some embodiments of a compound of formula IV, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, fluoro, chloro, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₆ aryl, C₁₋₄ alkoxy-C₅₋₆ heteroaryl, amino C₁₋₄ alkyl, C₁₋₄ alkylamino, C₁₋₄ aminoalkyl-C₆ aryl, C₁₋₄ aminoalkyl-C₆ heteroaryl, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkoxyaminocarbonyl or C₆ aryl.

[0554] In some embodiments of a compound of formula IV, Ar¹ comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R⁴, R⁵, R^{5'}, R⁶ or R^{6'} may be hydrogen.

[0555] In some embodiments of a compound of formula IV, R¹ may be hydrogen.

[0556] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-1



V-1


wherein

R¹ is H or F;


R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R^{5'}, R⁶, R^{6'} are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

Z is selected from



[0557] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-2, V-3 or V-4



wherein

X^2 is O or NH or NMe;

X^3 is CH or N;


R^1 is H or F;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

o is 0 or 1;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



[0558] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, R^4 is hydrogen, chloro or fluoro.

[0559] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, R^5 and R^6 are independently of each other hydrogen, $-\text{CF}_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen. Preferably, R^4 is hydrogen, chloro or fluoro.

[0560] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, R^5 and R^6 are independently of each other hydrogen, $-\text{CF}_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen. Preferably, R^4 is hydrogen, chloro or fluoro.




[0561] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, Ar^1 comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R^4 , R^5 , $R^{5'}$, R^6 or $R^{6'}$ may be hydrogen.

[0562] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.

[0563] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, o is 1.

[0564] In some embodiments of a compound of formula V-1, V-2, V-3 or V-4, R^1 may be hydrogen.

[0565] In some embodiments of a compound of formula V-2, V-3 or V-4, X^2 is O, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-2a, V-3a or V-4a

**V-2a****V-3a****V-4a**

wherein

X^3 is CH or N;


R^1 is H or F;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

o is 0 or 1;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



[0566] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, R^4 is

hydrogen, fluoro or chloro.

[0567] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, chloro or fluoro.

[0568] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, R⁵ and R⁶ are independently of each other hydrogen, -CF₃, F or Cl and R^{5'} and R^{6'} are hydrogen. Preferably, R⁴ is hydrogen, chloro or fluoro.





[0569] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, Ar¹ comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R⁴, R⁵, R^{5'}, R⁶ or R^{6'} may be hydrogen.

[0570] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, R⁷ is hydrogen if X³ is N and/or R⁷ is F if X³ is CH.

[0571] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, o is 1.

[0572] In some embodiments of a compound of formula V-1, V-2a, V-3a or V-4a, R¹ may be hydrogen.

[0573] In some embodiments of a compound of formula V-2, V-3 or V-4, X³ is N, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-2b, V-3b, V-4b or X³ is C, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V-5b

**V-2b****V-3b****V-4b****V-5b**

wherein

X^2 is O, NH or NMe


R^1 is H or F;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

o is 0 or 1;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



[0574] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, R^4 is

hydrogen, fluoro, chloro.

[0575] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

Preferably, R^4 is hydrogen, chloro or fluoro.

[0576] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, R^5 and R^6 are independently of each other hydrogen, $-CF_3$, F or Cl and $R^{5'}$ and $R^{6'}$ are hydrogen.

Preferably, R^4 is hydrogen, fluoro, chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-4} alkoxy- C_{1-4} alkyl, amino C_{1-4} alkyl, C_{1-4} alkylamino, C_{1-4} alkoxycarbonyl, C_{1-4} alkoxyaminocarbonyl, aryl C_{1-4} alkoxy, heteroaryl C_{1-4} alkoxy or aryl.


[0577] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, Ar^1 comprises only 1, 2 or 3 substituents which are not hydrogen. Thus, at least two of R^4 , R^5 , $R^{5'}$, R^6 or $R^{6'}$ may be hydrogen.

[0578] In some embodiments V-2b, V-3b, V-4b or V-5b, o is 1.

[0579] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, R^7 is F.

[0580] In some embodiments of a compound of formula V-1, V-2b, V-3b, V-4b or V-5b, R^1 may be hydrogen.

[0581] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-1



VI-1

wherein


R^1 is H or F;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;


Z is selected from




[0582] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-2, VI-3 or VI-4



VI-2



VI-3



VI-4

wherein

X^2 is O, NH or NMe;

X^3 is CH or N;


R^1 is H or F;

o is 0 or 1;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



[0583] In some embodiments of a compound of formula VI-1, VI-2, VI-3 or VI-4, R^4 is hydrogen, chloro or fluoro.


[0584] In some embodiments of a compound of formula VI-1, VI-2, VI-3 or VI-4, o is 1.

[0585] In some embodiments of a compound of formula VI-1, VI-2, VI-3 or VI-4, R^5 is F and/or R^6 is F or Cl.


[0586] In some embodiments of a compound of formula VI-1, VI-2, VI-3 or VI-4, R^7 is hydrogen if X^3 is N and/or R^7 is F if X^3 is CH.

[0587] In some embodiments of a compound of formula VI-1, VI-2, VI-3 or VI-4, R^1 may be hydrogen.


[0588] In some embodiments of a compound of formula VI-2, VI-3 or VI-4, X^2 is O, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-2a, VI-3a or VI-4a



VI-2a



VI-3a



VI-4a

wherein

X^3 is CH or N;


R^1 is H or F;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

o is 0 or 1;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



[0589] In some embodiments of a compound of formula VI-1, VI-2a, VI-3a or VI-4a, R^4 is hydrogen, fluoro or chloro.


[0590] In some embodiments of a compound of formula VI-1, VI-2a, VI-3a or VI-4a, o is 1.

[0591] In some embodiments of a compound of formula VI-1, VI-2a, VI-3a or VI-4a, R⁵ is F and/or R⁶ is F or Cl.


[0592] In some embodiments of a compound of formula VI-1, VI-2a, VI-3a or VI-4a, R⁷ is hydrogen if X³ is N and/or R⁷ is F if X³ is CH.

[0593] In some embodiments of a compound of formula VI-1, VI-2a, VI-3a or VI-4a, R¹ may be hydrogen.


[0594] In some embodiments of a compound of formula VI-2, VI-3 or VI-4, X³ is N, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-2b, VI-3b or VI-4b or X³ is C, resulting in a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI-5b




VI-2b



VI-3b



VI-4b



VI-5b

wherein

X² is O, NH or NMe


R¹ is H or F;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

o is 0 or 1;

R⁷ is hydrogen or halogen, preferably F;

Z is selected from



[0595] In some embodiments of a compound of formula VI-1, VI-2b, VI-3b, VI-4b or VI-5b, R^4 is hydrogen, fluoro or chloro.


[0596] In some embodiments of a compound of formula VI-1, VI-2b, VI-3b, VI-4b or VI-5b, o is 1.

[0597] In some embodiments of a compound of formula VI-1b, VI-2b, VI-3b, VI-4b or VI-5b, R^5 is F and/or R^6 is F or Cl.

[0598] In some embodiments of a compound of formula VI-1, VI-2b, VI-3b, VI-4b or VI-5b, R^7 is F.

[0599] In some embodiments of a compound of formula VI-1, VI-2b, VI-3b, VI-4b or VI-5b, R^1 may be hydrogen.

[0600] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VII-1




wherein

R^1 is H or F, preferably H;









R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

Z is selected from



[0601] In some embodiments, the present disclosure provides a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9



wherein

R^1 is H or F, preferably H;

o is 0 or 1;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;




R^7 is hydrogen or halogen, preferably F;





Z is selected from





2 and pharmaceutically acceptable salts thereof.

[0615] In some embodiments, the compound is selected from the compounds described in Table 2.

Table 1

Compound No.	Structure
1	
2	
3	

Compound No.	Structure
4	
5	
6	
7	

Compound No.	Structure
8	
10	
11	
12	













Compound No.	Structure
13	
14	
16	
17	





Table 2




Compound No.	Structure
18	
19	
20	





Compound No.	Structure
21	
22	
23	
24	





Compound No.	Structure
25	
26	
27	
28	




Compound No.	Structure
29	
30	
31	
32	




Compound No.	Structure
33	
34	
35	
36	

Compound No.	Structure
37	 Chemical structure of compound 37: A quinazoline core substituted at position 2 with a 2-chloro-3-fluorophenylamino group, at position 4 with a (E)-3-(2-morpholinoethyl)acrylamide group, and at position 6 with a 1-methyl-2-((E)-3-(2-morpholinoethyl)acryloyl)pyrrolidine-1-yl group.
37A	 Chemical structure of compound 37A: A quinazoline core substituted at position 2 with a 2-chloro-3-fluorophenylamino group, at position 4 with a (E)-3-(2-morpholinoethyl)acrylamide group, and at position 6 with a 1-methyl-2-((E)-3-(2-morpholinoethyl)acryloyl)pyrrolidine-1-yl group. The stereochemistry at the chiral center is (1R,2R).
37B	 Chemical structure of compound 37B: A quinazoline core substituted at position 2 with a 2-chloro-3-fluorophenylamino group, at position 4 with a (E)-3-(2-morpholinoethyl)acrylamide group, and at position 6 with a 1-methyl-2-((E)-3-(2-morpholinoethyl)acryloyl)pyrrolidine-1-yl group. The stereochemistry at the chiral center is (1R,2S).




Compound No.	Structure
38	
39	
40	
41	





Compound No.	Structure
42	
43	
44	
45	





Compound No.	Structure
46	
47	
48	




Compound No.	Structure
49	
50	
51	

Compound No.	Structure
52	
53	
54	
55	





Compound No.	Structure
56	
57	
58	





Compound No.	Structure
59	
60	
61	
62	




Compound No.	Structure
63	
64	
65	
66	

Compound No.	Structure
67	
68	
69	

Compound No.	Structure
70	
71	
72	
73	

Compound No.	Structure
74	
75	
76	
77	

Compound No.	Structure
78	
79	
80	
81	

Compound No.	Structure
82	
83	
84	

[0616] In some aspects, the present disclosure provides a compound being an isotopic derivative (e.g., isotopically labeled compound) of any one of the compounds of the Formulae disclosed herein.

[0617] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

[0618] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

[0619] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Tables 1 and 2.

[0620] It is understood that the isotopic derivative can be prepared using any of a variety of art-

recognised techniques. For example, the isotopic derivative can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0621] In some embodiments, the isotopic derivative is a deuterium labeled compound.

[0622] In some embodiments, the isotopic derivative is a deuterium labeled compound of any one of the compounds of the Formulae disclosed herein.

[0623] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

[0624] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.


[0625] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Tables 1 and 2.

[0626] In some embodiments, the compound is selected from the compound described Table 3, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

[0627] In some embodiments, the compound is selected from the compound described Table 3 and pharmaceutically acceptable salts thereof.

[0628] In some embodiments, the compound is the compound described Table 3.

Table 3

Compound No.	Structure
D-1	

[0629] It is understood that the deuterium labeled compound comprises a deuterium atom having an abundance of deuterium that is substantially greater than the natural abundance of deuterium, which is 0.015%.

[0630] In some embodiments, the deuterium labeled compound has a deuterium enrichment factor for each deuterium atom of at least 3500 (52.5% deuterium incorporation at each deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). As used herein, the term “deuterium enrichment factor” means the ratio between the deuterium abundance and the natural abundance of a deuterium.

[0631] It is understood that the deuterium labeled compound can be prepared using any of a variety of art-recognised techniques. For example, the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting a deuterium labeled reagent for a non-deuterium labeled reagent.

[0632] A compound of the invention or a pharmaceutically acceptable salt or solvate thereof that contains the aforementioned deuterium atom(s) is within the scope of the invention. Further, substitution with deuterium (*i.e.*, ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability, *e.g.*, increased *in vivo* half-life or reduced dosage requirements.

[0633] The compounds of the disclosure can contain one or more asymmetric centers in the molecule. A compound without designation of the stereochemistry is to be understood to include all the optical isomers (*e.g.*, diastereomers, enantiomers, etc) in pure or substantially pure form, as well as mixtures thereof (*e.g.* a racemic mixture, or an enantiomerically enriched mixture). It is well known in the art how to prepare such optically active forms (*e.g.* by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by chromatographic separation using a chiral stationary phase, and other methods).

[0634] The compounds can be isotopically-labeled compounds, for example, compounds including various isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, or chlorine. The disclosed compounds may exist in tautomeric forms and mixtures and separate individual tautomers are contemplated. In addition, some compounds may exhibit polymorphism.

[0635] The compounds of the disclosure include the free form as well as the pharmaceutically acceptable salts and stereoisomers thereof. The pharmaceutically acceptable salts include all the typical pharmaceutically acceptable salts. The pharmaceutically acceptable salts of the present compounds can be synthesized from the compounds of this disclosure which contain a basic or

acidic moiety by conventional chemical methods, see e.g. Berge et al, "Pharmaceutical Salts," J. Pharm. Sci., 1977:66:1-19.

[0636] For example, conventional pharmaceutically acceptable salts for a basic compound include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like. Conventional pharmaceutically acceptable salts for an acidic compound include those derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.

[0637] The compounds of the disclosure may exist in solid, i.e. crystalline or noncrystalline form (optionally as solvates) or liquid form. In the solid state, it may exist in, or as a mixture thereof. In crystalline solvates, solvent molecules are incorporated into the crystalline lattice during crystallization. The formation of solvates may include non-aqueous solvents such as, but not limited to, ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or aqueous solvents such as water (also called "hydrates"). It is common knowledge that crystalline forms (and solvates thereof) may exhibit polymorphism, i.e. exist in different crystalline structures known as "polymorphs", that have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties, and may display different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. Such

different polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, during preparation of the compound of the disclosure.

[0638] In some aspects, the disclosure also provides methods of preparation of the compounds of the disclosure. Typically they are prepared according to the syntheses shown in the experimental section.

[0639] It is to be understood that the synthetic processes of the disclosure can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt thereof.

[0640] It is to be understood that compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition, John Wiley & Sons: New York, 2001; Greene, T.W., Wuts, P.G. M., *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons: New York, 1999; R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995), incorporated by reference herein, are useful and recognised reference textbooks of organic synthesis known to those in the art

[0641] One of ordinary skill in the art will note that, during the reaction sequences and synthetic schemes described herein, the order of certain steps may be changed, such as the introduction and removal of protecting groups. One of ordinary skill in the art will recognise that certain groups may require protection from the reaction conditions via the use of protecting groups. Protecting groups may also be used to differentiate similar functional groups in molecules. A list of protecting groups and how to introduce and remove these groups can be found in Greene, T.W., Wuts, P.G.

M., *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons: New York, 1999.

Biological Assays

[0642] Compounds designed, selected and/or optimised by methods described herein, once produced, can be characterised using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, the molecules can be characterised by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.

[0643] Furthermore, high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) *High Throughput Screening*, Marcel Dekker; and U.S. Patent No. 5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.

[0644] Various *in vitro* or *in vivo* biological assays are may be suitable for detecting the effect of the compounds of the present disclosure. These *in vitro* or *in vivo* biological assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, *in vitro* cell viability assays, and the assays described herein.

Pharmaceutical Compositions

[0645] In some aspects, the disclosure further provides a pharmaceutical composition comprising a therapeutically-effective amount of one or more of the compounds of the disclosure or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or excipients (also referred to as diluents). The excipients are acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof (i.e., the patient). The term "therapeutically-effective amount" as used herein refers to the amount of a compound (as such or in form of a pharmaceutical composition) of the present disclosure which is effective for producing some desired therapeutic effect.

[0646] Pharmaceutical compositions may be in unit dose form containing a predetermined amount of a compound of the disclosure per unit dose. Such a unit may contain a therapeutically effective dose of a compound of the disclosure or salt thereof or a fraction of a therapeutically effective dose

such that multiple unit dosage forms might be administered at a given time to achieve the desired therapeutically effective dose. Preferred unit dosage formulations are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of a compound of the disclosure or salt thereof.

[0647] The compounds of the disclosure may be administered by any acceptable means in solid or liquid form, including (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) nasally; (9) pulmonary; or (10) intrathecally.

[0648] The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; and (22) other non-toxic compatible substances employed in pharmaceutical compositions.

[0649] Such compositions may contain further components conventional in pharmaceutical

preparations, e.g. wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants, pH modifiers, bulking agents, and further active agents. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0650] Such compositions may be prepared by any method known in the art, for example, by bringing into association the active ingredient with one or more carriers and/or excipients. Different compositions and examples of carriers and/or excipients are well known to the skilled person and are described in detail in, e.g., Remington: The Science and Practice of Pharmacy. Pharmaceutical Press, 2013; Rowe, Sheskey, Quinn: Handbook of Pharmaceutical Excipients. Pharmaceutical Press, 2009. Excipients that may be used in the preparation of the pharmaceutical compositions may include one or more of buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide a composition suitable for an administration of choice.

[0651] As indicated above, the compounds of the present disclosure may be in solid or liquid form and administered by various routes in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.

[0652] In solid dosage forms of the disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), a compound is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates,

and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets, and other solid dosage forms of the pharmaceutical compositions of the present disclosure, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

[0653] Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. An oral composition can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0654] In form of suspensions, a compound may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0655] Dosage forms for rectal or vaginal administration of a compound of the disclosure include a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. Other suitable forms include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

[0656] Dosage forms for the topical or transdermal administration of a compound of the disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required. Such ointments, pastes, creams and gels may contain, in addition to a compound of the disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0657] Dosage forms such as powders and sprays for administration of a compound of the disclosure, may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons,

such as butane and propane.

[0658] Dosage forms such as transdermal patches for administration of a compound of the disclosure may include absorption enhancers or retarders to increase or decrease the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel. Other dosage forms contemplated include ophthalmic formulations, eye ointments, powders, solutions and the like. It is understood that all contemplated compositions must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[0659] The dosage levels of a compound of the disclosure in the pharmaceutical compositions of the disclosure may be adjusted in order to obtain an amount of a compound of the disclosure which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being deleterious to the patient. The dosage of choice will depend upon a variety of factors including the nature of the particular compound of the present disclosure used, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound used, the rate and extent of absorption, the duration of the prevention or treatment, other drugs, compounds and/or materials used in combination with the particular compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. A medical practitioner having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.

[0660] Typically, a suitable daily dose of a compound of the disclosure will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this disclosure for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg, more usual 0.1 to 100 mg/kg per kilogram of body weight of recipient (patient, mammal) per day. Acceptable daily dosages may be from about 1 to about 1000 mg/day, and for example, from about 1 to about 100 mg/day.

[0661] The effective dose of a compound of the disclosure may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout a

specified period (per day or per week or per month), optionally, in unit dosage forms. Preferred dosing also depends on factors as indicated above, e.g. on the administration, and can be readily arrived at by one skilled in medicine or the pharmacy art.

Uses of the Compounds and Compositions

[0662] The compounds of the disclosure inhibit or modulate the activity of a receptor tyrosine kinase, in particular extracellular mutants of ErbB-receptors, such as, but not limited to, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-A289V and EGFR-G598V and HER2-S310F. Thus, the compounds and compositions of the disclosure can be useful as a medicament, i.e. as a medicament in therapy, more specifically for the prevention or treatment of cancer, as detailed below. Therefore, in a further aspect, the present disclosure provides a method of prevention or treatment of a mammal, for example, a human, suffering from cancer, as detailed below.

[0663] The term "prevention" or "preventing" refers to reducing or eliminating the onset of the symptoms or complications of a disease (e.g., cancer). Such prevention comprises the step of administering a therapeutically effective amount of a compound of Formula I or salt thereof (or of a pharmaceutical composition containing a compound of Formula I or salt thereof) to said mammal, for example, a human.

[0664] The term "treatment" or "treating" is intended to encompass therapy and cure. Such treatment comprises the step of administering a therapeutically effective amount of a compound of Formula I or salt thereof (or of a pharmaceutical composition containing a compound of Formula I or salt thereof) to said mammal, for example, a human.

[0665] Thus, the disclosure provides the use of the compounds of the disclosure or pharmaceutically acceptable salts or stereoisomers thereof or a pharmaceutical composition thereof for the prevention or treatment of cancer, as detailed below, in a mammal, for example a human.

[0666] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (e.g., an oncogenic variant of an EGFR), comprising administering the subject in need thereof a therapeutically effective amount of a compound described herein.

[0667] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (e.g., an oncogenic variant of an EGFR), comprising administering the subject in need thereof a composition described herein.

[0668] In some aspects, the present disclosure is directed to a method of preventing or treating cancer, comprising administering the subject in need thereof a therapeutically effective amount of a compound described herein.

[0669] In some aspects, the present disclosure is directed to a method of preventing or treating cancer, comprising administering the subject in need thereof a composition described herein.

[0670] In some aspects, the present disclosure is directed to a compound described herein for use in the inhibition of an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR).

[0671] In some aspects, the present disclosure is directed to a compound described herein for use in the prevention or treatment of cancer.

[0672] In some aspects, the present disclosure is directed to a composition described herein for use in the inhibition of an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR).

[0673] In some aspects, the present disclosure is directed to a composition described herein for use in the prevention or treatment of cancer.

[0674] In some aspects, the present disclosure is directed to use of a compound described herein in the manufacture of a medicament for inhibiting an oncogenic variant of an ErbB receptor (*e.g.*, an oncogenic variant of an EGFR).

[0675] In some aspects, the present disclosure is directed to use of a compound described herein in the manufacture of a medicament for preventing or treating cancer.

[0676] In some embodiments, the compound is selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

[0677] In some embodiments, the compound is selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

[0678] In some embodiments, the compound is selected from the compounds described in Tables 1 and 2.

[0679] In some embodiments, cancer is a solid tumor.

[0680] In some embodiments, the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

[0681] In some embodiments, the cancer is glioblastoma (GBM) or any subtype thereof.

[0682] In some embodiments, the cancer is glioblastoma.

[0683] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an ErbB receptor.

[0684] In some embodiments, the oncogenic variant of the ErbB receptor comprises an allosteric mutation.

[0685] In some embodiments, the oncogenic variant of an ErbB receptor is an allosteric variant of the ErbB receptor.

[0686] In some embodiments, the ErbB receptor is an epidermal growth factor receptor (EGFR) or a human epidermal growth factor receptor 2 (HER2) receptor.

[0687] In some embodiments, the ErbB receptor is an epidermal growth factor receptor (EGFR).

[0688] In some embodiments, the ErbB receptor is a HER2 receptor.

[0689] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an epidermal growth factor receptor (EGFR).

[0690] In some embodiments, the oncogenic variant of EGFR is an allosteric variant of EGFR.

[0691] In some embodiments, the oncogenic variant of EGFR comprises an allosteric mutation.

[0692] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER2 receptor.

[0693] In some embodiments, the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor.

[0694] In some embodiments, the oncogenic variant of the HER2 receptor comprises an allosteric mutation.

[0695] In some embodiments, the oncogenic variant of an EGFR comprises an EGFR variant III (EGFR-Viii) mutation.

[0696] In some embodiments, the oncogenic variant of EGFR comprises an EGFR variant II (EGFR-Vii) mutation.

[0697] In some embodiments, the oncogenic variant of EGFR comprises an EGFR variant VI (EGFR-Vvi) mutation.

[0698] In some embodiments, the oncogenic variant of an EGFR comprises a substitution of a valine (V) for an alanine (A) at position 289 of SEQ ID NO: 1.

[0699] In some embodiments, the oncogenic variant of EGFR comprises a substitution of a valine (V) for a glycine (G) at position 598 of SEQ ID NO: 1.

[0700] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an EGFR and wherein the oncogenic variant of EGFR is an allosteric variant of EGFR, the oncogenic variant of an EGFR comprises a modification of a structure of the EGFR, wherein the oncogenic variant of an EGFR is a capable of forming a covalently linked dimer, wherein the covalently linked dimer is constitutively active and wherein the covalently linked dimer enhances an activity of EGFR when contacted to a Type I ErbB inhibitor. In some embodiments, the modification of the structure of the EGFR comprises a modification of one or more of a nucleic acid sequence, an amino acid sequence, a secondary structure, a tertiary structure, and a quaternary structure. In some embodiments, the oncogenic variant comprises a mutation, a splicing event, a post-translational process, a conformational change or any combination thereof. In some embodiments, the modification of the structure of the EGFR occurs within a first cysteine rich (CR1) and/or second cysteine rich (CR2) region of EGFR. In some embodiments, the first cysteine rich (CR1) and/or second cysteine rich (CR2) region of EGFR comprises amino acid residues T211-R334 and/or C526-S645 of SEQ ID NO: 1, respectively. In some embodiments, the oncogenic variant of an EGFR generates a physical barrier to formation of a disulfide bond within the CR1 and/or the CR2 region. In some embodiments, the oncogenic variant of an EGFR removes a physical barrier to formation of a disulfide bond within the CR1 and/or the CR2 region. In some embodiments, the oncogenic variant of an EGFR comprises one or more free or unpaired Cysteine (C) residues located at a dimer interface of the EGFR. In some embodiments, the oncogenic variant of an EGFR comprises one or more free or unpaired Cysteine (C) residues at a site selected from the group consisting of C190-C199, C194-C207, C215-C223, C219-C231, C232-C240, C236-C248, C251-C260, C264-C291, C295-C307, C311-C326, C329-C333, C506-C515, C510-C523, C526-C535, C539-C555, C558-C571, C562-C579, C582-C591, C595-C617, C620-C628 and C624-C636 according to SEQ ID NO: 1. In some embodiments, the modification occurs within 10 angstroms or less of an intramolecular disulfide bond at a site selected from the group consisting of C190-C199, C194-C207, C215-C223, C219-C231, C232-C240, C236-C248, C251-C260, C264-C291, C295-C307, C311-C326, C329-C333, C506-C515, C510-C523, C526-C535, C539-C555, C558-C571, C562-C579, C582-C591, C595-C617, C620-C628 and C624-C636 according to SEQ ID NO: 1.

[0701] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of EGFR and the oncogenic variant of EGFR is a mutation of EGFR, a nucleotide sequence

encoding the oncogenic variant of an EGFR comprises a deletion or the substitution comprises one or more amino acids that encode an adenosine triphosphate (ATP) binding site. In some embodiments, the ATP binding site comprises amino acids E746 to A750 of SEQ ID NO: 1. In some embodiments, the ATP binding site or the deletion or substitution thereof comprises K858 of SEQ ID NO: 1. In some embodiments, the deletion comprises K858 of SEQ ID NO: 1. In some embodiments, an arginine (R) is substituted for the lysine (K) at position 858 (K858R) of SEQ ID NO: 1.

[0702] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an EGFR and wherein the oncogenic variant of EGFR is an allosteric variant of EGFR, a nucleotide sequence encoding the oncogenic variant of an EGFR comprises an insertion within a sequence encoding exon 20 or a portion thereof. In some embodiments, the sequence encoding exon 20 or a portion thereof comprises a sequence encoding KEILDEAYVMASVDNPHVCAR (SEQ ID NO: 7). In some embodiments, the sequence encoding exon 20 or a portion thereof comprises a sequence encoding a C-helix, a terminal end of the C-helix or a loop following the C-helix. In some embodiments, the insertion comprises the amino acid sequence of ASV, SVD, NPH, or FQEA. In some embodiments, the sequence encoding exon 20 or a portion thereof comprises one or more of: (a) an insertion of the amino acid sequence ASV between positions V769 and D770 of SEQ ID NO: 1; (b) an insertion of the amino acid sequence SVD between positions D770 and N771 of SEQ ID NO: 1; (c) an insertion of the amino acid sequence NPH between positions H773 and V774 of SEQ ID NO: 1; (d) an insertion of the amino acid sequence FQEA between positions A763 and Y764 of SEQ ID NO: 1; (e) an insertion of the amino acid sequence PH between positions H773 and V774 of SEQ ID NO: 1; (f) an insertion of the amino acid G between positions D770 and N771 of SEQ ID NO: 1; (g) an insertion of the amino acid H between positions H773 and V774 of SEQ ID NO: 1; (h) an insertion of the amino acid sequence HV between positions V774 and C775 of SEQ ID NO: 1; (i) an insertion of the amino acid sequence AH between positions H773 and V774 of SEQ ID NO: 1; (j) an insertion of the amino acid sequence SVA between positions A767 and S768 of SEQ ID NO: 1; (k) a substitution of the amino acid sequence GYN for the DN between positions 770 and 771 of SEQ ID NO: 1; (l) an insertion of the amino acid H between positions N771 and P772 of SEQ ID NO: 1; (m) an insertion of the amino acid Y between positions H773 and V774 of SEQ ID NO: 1; (n) an insertion of the amino acid sequence PHVC between positions C775 and R776 of SEQ ID NO: 1; (o) a substitution of

the amino acid sequence YNPY for the H at position 773 of SEQ ID NO: 1; (p) an insertion of the amino acid sequence DNP between positions P772 and H773 of SEQ ID NO: 1; (q) an insertion of the amino acid sequence VDS between positions S768 and V769 of SEQ ID NO: 1; (r) an insertion of the amino acid H between positions D770 and N771 of SEQ ID NO: 1; (s) an insertion of the amino acid N between positions N771 and P772 of SEQ ID NO: 1; (t) an insertion of the amino acid sequence PNP between positions P772 and H773 of SEQ ID NO: 1; (u) a substitution of the amino acid sequence GSVDN for the DN between positions 770 and 771 of SEQ ID NO: 1; (v) a substitution of the amino acid sequence GYP for the NP between positions 771 and 772 of SEQ ID NO: 1; (w) an insertion of the amino acid G between positions N771 and P772 of SEQ ID NO: 1; (x) an insertion of the amino acid sequence GNP between positions P772 and H773 of SEQ ID NO: 1; (y) an insertion of the amino acid sequence GSV between positions V769 and D770 of SEQ ID NO: 1; (z) a substitution of the amino acid sequence GNPHVC for the VC between positions 774 and 775 of SEQ ID NO: 1; (aa) an insertion of the amino acid sequence LQEA between positions A763 and Y764 of SEQ ID NO: 1; (bb) an insertion of the amino acid sequence GL between positions D770 and N771 of SEQ ID NO: 1; (cc) an insertion of the amino acid Y between positions D770 and N771 of SEQ ID NO: 1; (dd) an insertion of the amino acid sequence NPY between positions H773 and V774 of SEQ ID NO: 1; (ee) an insertion of the amino acid sequence TH between positions H773 and V774 of SEQ ID NO: 1; (ff) a substitution of the amino acid sequence KGP for the NP between positions 771 and 772 of SEQ ID NO: 1; (gg) a substitution of the amino acid sequence SVDNP for the NP between positions 771 and 772 of SEQ ID NO: 1; (hh) an insertion of the amino acid sequence NN between positions N771 and P772 of SEQ ID NO: 1; (ii) an insertion of the amino acid T between positions N771 and P772 of SEQ ID NO: 1; and (jj) a substitution of the amino acid sequence STLASV for the SV between positions 768 and 769 of SEQ ID NO: 1.

[0703] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an EGFR and wherein the oncogenic variant of EGFR is an allosteric variant of EGFR, the oncogenic variant of an EGFR comprises EGFR-Vii, EGFR-Vvi, EGFR-R222C, EGFR-R252C, EGFR-R252P, EGFR-R256Y, EGFR-T263P, EGFR-Y270C, EGFR-A289T, EGFR-A289V, EGFR-A289D, EGFR-H304Y, EGFR-G331R, EGFR-P596S, EGFR-P596L, EGFR-P596R, EGFR-G598V, EGFR-G598A, EGFR-G614D, EGFR-C620Y, EGFR-C614W, EGFR-C628F, EGFR-C628Y, EGFR-C636Y, EGFR-G645C, EGFR-Δ660, EGFR-Δ768 or any

combination thereof.

[0704] In some embodiments, the cancer, or a tumor or a cell thereof, expresses one or more of:
(a) a wild type human epidermal growth factor receptor 2 (HER2) receptor or an oncogenic variant of a HER-2 receptor.

[0705] In some embodiments, the cancer, or a tumor or a cell thereof, expresses a wild type HER-2 receptor, the wild type HER2 receptor comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, or 6.

[0706] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor, the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor.

[0707] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a phenylalanine (F) for a serine (S) at position 310 of SEQ ID NO: 2 or 5.

[0708] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a tyrosine (Y) for a serine (S) at position 310 of SEQ ID NO: 2 or 5.

[0709] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a glutamine (Q) for an arginine (R) at position 678 of SEQ ID NO: 2 or 5.

[0710] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a leucine (L) for a valine (V) at position 777 of SEQ ID NO: 2 or 5.

[0711] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a methionine (M) for a valine (V) at position 777 of SEQ ID NO: 2 or 5.

[0712] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic

variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of an isoleucine (I) for a valine (V) at position 842 of SEQ ID NO: 2 or 5.

[0713] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of an alanine (A) for a leucine (L) at position 755 of SEQ ID NO: 2 or 5.

[0714] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a proline (P) for a leucine (L) at position 755 of SEQ ID NO: 2 or 5.

[0715] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises a substitution of a serine (S) for a leucine (L) at position 755 of SEQ ID NO: 2 or 5.

[0716] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, a nucleotide sequence encoding the oncogenic variant of a HER2 receptor comprises an insertion within a sequence encoding exon 20 or a portion thereof. In some embodiments, the sequence encoding exon 20 or a portion thereof comprises a sequence encoding KEILDEAYVMAGVGSPYVSR (SEQ ID NO: 8). In some embodiments, the sequence encoding exon 20 or a portion thereof comprises a sequence encoding a C-helix, a terminal end of the C-helix or a loop following the C-helix. In some embodiments, the insertion comprises the amino acid sequence of GSP or YVMA. In some embodiments, the sequence encoding exon 20 or a portion thereof comprises one or more of: (a) an insertion of the amino acid sequence YVMA between positions A775 and G776 of SEQ ID NO: 2; (b) an insertion of the amino acid sequence GSP between positions P780 and Y781 of SEQ ID NO: 2; (c) an insertion of the amino acid sequence YVMA between positions A771 and Y772 of SEQ ID NO: 2; (d) an insertion of the amino acid sequence YVMA between positions A775 and G776 of SEQ ID NO: 2; (e) an insertion of the amino acid V between positions V777 and G778 of SEQ ID NO: 2; (f) an insertion of the amino acid V between positions V777 and G778 of SEQ ID NO: 2; (g) a substitution of the amino

acid sequence AVGCV for the GV between positions 776 and 777 of SEQ ID NO: 2; (h) a substitution of the amino acid sequence LC for the G between position 776 of SEQ ID NO: 2; (i) a substitution of the amino acid sequence LCV for the G between position 776 of SEQ ID NO: 2; (j) an insertion of the amino acid sequence GSP between positions V777 and G778 of SEQ ID NO: 2; (k) a substitution of the amino acid sequence PS for the LRE between positions 755 and 757 of SEQ ID NO: 2; (l) a substitution of the amino acid sequence CPGSP for the SP between positions 779 and 780 of SEQ ID NO: 2; (m) an insertion of the amino acid C between positions V777 and G778 of SEQ ID NO: 2; (n) a substitution of the amino acid sequence VVMA for the AG between positions 775 and 776 of SEQ ID NO: 2; (o) a substitution of the amino acid sequence VV for the G at position 776 of SEQ ID NO: 2; (p) a substitution of the amino acid sequence AVCV for the GV between positions 776 and 777 of SEQ ID NO: 2; (q) a substitution of the amino acid sequence VCV for the GV between positions 776 and 777 of SEQ ID NO: 2; (r) an insertion of the amino acid G between positions G778 and S779 of SEQ ID NO: 2; (s) a substitution of the amino acid sequence PK for the LRE between positions 755 and 757 of SEQ ID NO: 2; (t) an insertion of the amino acid V between positions A775 and G776 of SEQ ID NO: 2; (u) an insertion of the amino acid sequence YAMA between positions A775 and G776 of SEQ ID NO: 2; (v) a substitution of the amino acid sequence CV for the G at position 776 of SEQ ID NO: 2; (w) a substitution of the amino acid sequence AVCGG for the GVG between positions 776 and 778 of SEQ ID NO: 2; (x) a substitution of the amino acid sequence CVCG for the GVG between positions 776 and 778 of SEQ ID NO: 2; (y) a substitution of the amino acid sequence VVVG for the GVG between positions 776 and 778 of SEQ ID NO: 2; (z) a substitution of the amino acid sequence SVGG for the GVGS between positions 776 and 779 of SEQ ID NO: 2; (aa) a substitution of the amino acid sequence VVGES for the GVGS between positions 776 and 779 of SEQ ID NO: 2; (bb) a substitution of the amino acid sequence AVGSGV for the GV between positions 776 and 777 of SEQ ID NO: 2; (cc) a substitution of the amino acid sequence CVC for the GV between positions 776 and 777 of SEQ ID NO: 2; (dd) a substitution of the amino acid sequence HVC for the GV between positions 776 and 777 of SEQ ID NO: 2; (ee) a substitution of the amino acid sequence VAAGV for the GV between positions 776 and 777 of SEQ ID NO: 2; (ff) a substitution of the amino acid sequence VAGV for the GV between positions 776 and 777 of SEQ ID NO: 2; (gg) a substitution of the amino acid sequence VVV for the GV between positions 776 and 777 of SEQ ID NO: 2; (hh) an insertion of the amino acid sequence FPG between

positions G778 and S779 of SEQ ID NO: 2; (ii) an insertion of the amino acid sequence GS between positions S779 and P780 of SEQ ID NO: 2; (jj) a substitution of the amino acid sequence VPS for the VLRE between positions 754 and 757 of SEQ ID NO: 2; (kk) an insertion of the amino acid E between positions V777 and G778 of SEQ ID NO: 2; (ll) an insertion of the amino acid sequence MAGV between positions V777 and G778 of SEQ ID NO: 2; (mm) an insertion of the amino acid S between positions V777 and G778 of SEQ ID NO: 2; (nn) an insertion of the amino acid sequence SCV between positions V777 and G778 of SEQ ID NO: 2; and (oo) an insertion of the amino acid sequence LMAY between positions Y772 and V773 of SEQ ID NO: 2.

[0717] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-2 receptor and wherein the oncogenic variant of a HER2 receptor is an allosteric variant of the HER2 receptor, the oncogenic variant of a HER2 receptor comprises HER2-Δ16, HER2-C311R, HER2-S310F, p95-HER2-M611 or any combination thereof.

[0718] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a HER-4 receptor. In some embodiments, the oncogenic variant of the HER-4 receptor is an allosteric variant of the HER4 receptor. In some embodiments, the oncogenic variant of a HER4 receptor comprises deletion of exon 16 (HER4-Δ16).

[0719] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an EGFR, wherein the sequence encoding the oncogenic variant of the EGFR comprises a deletion of exon 20 or a portion thereof and wherein the the cancer, the tumor or the cell thereof does not comprise a second oncogenic variation in a sequence other than exon 20 of EGFR. In some embodiments, the second oncogenic variation comprises a sequence encoding one or more of an EGFR kinase domain (KD), BRAF, NTRK, and KRAS.

[0720] In some embodiments, the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an EGFR, wherein the sequence encoding the oncogenic variant of the EGFR comprises a deletion of exon 20 or a portion thereof and wherein the the cancer, the tumor or the cell thereof does not comprise a marker indicating responsiveness to immunotherapy.

[0721] In some embodiments, the oncogenic variant (e.g., allosteric variant) or the oncogenic mutation (e.g., allosteric mutation) is detected by a Food and Drug Administration (FDA)-approved diagnosis.

[0722] In some embodiments, prior to the treatment with the compound of the present disclosure, the subject is treated with a therapeutic agent different from the compound of the present

disclosure.

[0723] In some embodiments, the cancer, or a tumor or a cell thereof, is insensitive or resistant to treatment with a therapeutic agent different from the compound of the present disclosure. In some embodiments, the cancer, or a tumor or a cell thereof, is insensitive or resistant to treatment with a Type I inhibitor. In some embodiments, the cancer, or a tumor or a cell thereof, is insensitive or resistant to treatment with one or more of gefinitinib, erlotinib, afatinib, osimertinib, necitunumab, crizotinib, alectinib, ceritinib, dabrafenib, trametinib, afatinib, sapitinib, dacomitinib, canertinib, pelitinib, WZ4002, WZ8040, WZ3146, CO-1686 and AZD9291.

[0724] In some embodiments, the subject has an adverse reaction to treatment with a therapeutic agent different from the compound of the present disclosure. In some embodiments, the subject has an adverse reaction to treatment with a Type I inhibitor. In some embodiments, the subject has an adverse reaction to treatment with one or more of gefinitinib, erlotinib, afatinib, osimertinib, necitunumab, crizotinib, alectinib, ceritinib, dabrafenib, trametinib, afatinib, sapitinib, dacomitinib, canertinib, pelitinib, WZ4002, WZ8040, WZ3146, CO-1686 and AZD9291. In some embodiments, the adverse reaction is an activation of the oncogenic variant of an EGFR and wherein the oncogenic variant comprises a mutation in an extracellular domain of the receptor. In some embodiments, the adverse reaction is an activation of the oncogenic variant of a HER-2 Receptor and wherein the oncogenic variant comprises a mutation in an extracellular domain of the receptor.

[0725] In some embodiments, the method further comprises administering to the subject in need thereof a therapeutically effective amount of a non-Type I inhibitor. In some embodiments, the non-Type I inhibitor comprises a small molecule Type II inhibitor.

[0726] In some embodiments, the method further comprises administering to the subject in need thereof a therapeutically effective amount of a non-Type I inhibitor. In some embodiments, the non-Type I inhibitor comprises a small molecule Type II inhibitor.

[0727] In some embodiments, the compound is used in combination with a therapeutically effective amount of a non-Type I inhibitor. In some embodiments, the non-Type I inhibitor comprises a small molecule Type II inhibitor.

[0728] In some embodiments, the composition further comprises a non-Type I inhibitor. In some embodiments, the non-Type I inhibitor comprises a small molecule Type II inhibitor.

[0729] In some embodiments, the therapeutically effective amount reduces a severity of a sign or

symptom of the cancer.

[0730] In some embodiments, the sign of the cancer comprises a tumor grade and wherein a reduction of the severity of the sign comprises a decrease of the tumor grade.

[0731] In some embodiments, the sign of the cancer comprises a tumor metastasis and wherein a reduction of the severity of the sign comprises an elimination of the metastasis or a reduction in the rate or extent the metastasis.

[0732] In some embodiments, the sign of the cancer comprises a tumor volume and wherein a reduction of the severity of the sign comprises an elimination of the tumor or a reduction in the volume.

[0733] In some embodiments, the symptom of the cancer comprises pain and wherein a reduction of the severity of the sign comprises an elimination or a reduction in the pain.

[0734] In some embodiments, the therapeutically effective amount induces a period of remission.

[0735] In some embodiments, the therapeutically effective amount improves a prognosis of the subject.

[0736] Such a use (or method of prevention or treatment) of a subject comprises administering to a subject in need of such prevention or treatment a therapeutically effective amount of a compound of the disclosure or pharmaceutically acceptable salts thereof or a pharmaceutical composition thereof by targeting allosteric and/or oncogenic variants of EGFR and HER-2 receptor.

[0737] The present disclosure contemplates administration of a compound of the disclosure alone or in combination with one or more additional therapeutic agents, such as other Tyrosine kinase inhibitors: Erlotinib hydrochloride (e.g. Tarceva(R) by Genentech/Roche), Linifanib (or ABT 869, by Genentech), sunitinib malate (e.g. Sutent(R) by Pfizer), bosutinib (or SKI-606, described in US 6,780,996), dasatinib (e.g. Sprycel(R) by Bristol-Myers Squibb), armala (e.g. pazopanib, e.g. Votrient(R) by GlaxoSmithKline), imatinib and imatinib mesylate (e.g. Gilvec(R) and Gleevec(R) by Novartis); Vascular Endothelial Growth Factor (VEG) receptor inhibitors (Bevacizumab, or Avastin(R) by Genentech/Roche), axitinib, (or AG013736, described in WO 01/002369), Brivanib Alaninate (or BMS-582664), motesanib (or AMG-706, described in PCT WO 02/066470), pasireotide (e.g. SOM230, described in WO 02/010192), sorafenib (e.g. Nexavar(R)); HER2 receptor inhibitors: Trastuzumab (e.g. Herceptin(R) by Genentech/Roche), neratinib (or HKI-272, described WO 05/028443), lapatinib or lapatinib ditosylate (e.g. Tykerb(R) by GlaxoSmithKline); CD20 antibodies: Rituximab (e.g. Riuxan(R) and MabThera(R) by Genentech/Roche),

tositumomab (e.g. Bexxar(R) by GlaxoSmithKline), ofatumumab (e.g. Arzerra(R) by GlaxoSmithKline); Bcr/Abl kinase inhibitors: nilotinib hydrochloride (e.g. Tasigna(R) by Novartis); DNA Synthesis inhibitors: Capecitabine (e.g. Xeloda(R) by Roche), gemcitabine hydrochloride (e.g. Gemzar(R) by Eli Lilly and Company), nelarabine (or Arranon(R) and Atriance(R) by GlaxoSmithKline); Antineoplastic agents: oxaliplatin (e.g. Eloxatin(R) by Sanofi-Aventis described in US 4,169,846); Epidermal growth factor receptor (EGFR) inhibitors: Gefitinib (or Iressa(R)), Afatinib (or Tovok(R) by Boehringer Ingelheim), cetuximab (e.g. Erbitux(R) by Bristol-Myers Squibb), panitumumab (e.g. Vectibix(R) by Amgen); HER dimerization inhibitors: Pertuzumab (e.g. Omnitarg(R), by Genentech); Human Granulocyte colony-stimulating factor (G-CSF) modulators: Filgrastim (e.g. Neupogen(R) by Amgen); Immunomodulators: Aflibercept (by Roche(R)), pegfilgrastim (e.g. Neulasta(R) by Amgen), lenalidomide (e.g. CC-5013, e.g. Revlimid(R)), thalidomide (e.g. Thalomid(R)); (m) CD40 inhibitors: Dacetuzumab (e.g. SGN-40 or huS2C6, by Seattle Genetics, Inc); Pro-apoptotic receptor agonists (PARAs): Dulanermin (e.g. AMG-951, by Amgen/Genentech); Hedgehog antagonists: Vismodegib (or GDC-0449, described in WO 06/028958); PI3K inhibitors: Pictilisib (or GDC-0941 described in WO 09/036082 and WO 09/055730), Dactolisib (or BEZ 235 or NVP-BEZ 235, described in WO 06/122806); Phospholipase A2 inhibitors: Anagrelide (e.g. Agrylin(R)); BCL-2 inhibitors: Navitoclax (or ABT-263, described in WO 09/155386); Mitogen-activated protein kinase kinase (MEK) inhibitors: XL-518 (Cas No. 1029872-29-4, by ACC Corp.); Aromatase inhibitors: Exemestane (e.g. Aromasin(R) by Pfizer), letrozole (e.g. Femara(R) by Novartis), anastrozole (e.g. Arimidex(R)); Topoisomerase I inhibitors: Irinotecan (e.g. Camptosar(R) by Pfizer), topotecan hydrochloride (e.g. Hycamtin(R) by GlaxoSmithKline); Topoisomerase II inhibitors: etoposide (e.g. VP-16 and Etoposide phosphate, e.g. Toposar(R), VePesid(R) and Etopophos(R)), teniposide (e.g. VM-26, e.g. Vumon(R)); mTOR inhibitors: Temsirolimus (e.g. Torisel(R) by Pfizer), ridaforolimus (formally known as deferolimus, (or AP23573 and MK8669, described in WO 03/064383), everolimus (e.g. Afinitor(R) by Novartis); Osteoclastic bone resorption inhibitors: zoledronic acid (or Zometa(R) by Novartis); CD33 Antibody Drug Conjugates: Gemtuzumab ozogamicin (e.g. Mylotarg(R) by Pfizer/Wyeth); CD22 Antibody Drug Conjugates: Inotuzumab ozogamicin (also referred to as CMC-544 and WAY-207294, by Hangzhou Sage Chemical Co., Ltd.); CD20 Antibody Drug Conjugates: Ibritumomab tiuxetan (e.g. Zevalin(R)); Somatostatin analogs: octreotide (e.g. octreotide acetate, e.g.


Sandostatin(R) and Sandostatin LAR(R)); Synthetic Interleukin-11 (IL-11): oprelvekin (e.g. Neumega(R) by Pfizer/Wyeth); Synthetic erythropoietin: Darbepoetin alfa (e.g. Aranesp(R) by Amgen); Receptor Activator for Nuclear Factor kappa B (RANK) inhibitors: Denosumab (e.g. Prolia(R) by Amgen); Thrombopoietin mimetic peptibodies: Romiplostim (e.g. Nplate(R) by Amgen); Cell growth stimulators: Palifermin (e.g. Kepivance(R) by Amgen); Anti-Insulin-like Growth Factor-1 receptor (IGF-1R) antibodies: Figitumumab (e.g. CP-751,871, by ACC Corp), robatumumab (CAS No. 934235-44-6); Anti-CS1 antibodies: Elotuzumab (HuLuc63, CAS No. 915296-00-3); CD52 antibodies: Alemtuzumab (e.g. Campath(R)); CTLA-4 inhibitors: Tremelimumab (IgG2 monoclonal antibody by Pfizer, formerly known as ticilimumab, CP-675,206), ipilimumab (CTLA-4 antibody, e.g. MDX-010, CAS No. 477202-00-9); Histone deacetylase inhibitors (HDI): Voninostat (e.g. Zolinza(R) by Merck); Alkylating agents: Temozolomide (e.g. Temodar(R) and Temodal(R) by Schering-Plough/Merck), dactinomycin (e.g. actinomycin-D and e.g. Cosmegen(R)), melphalan (e.g. L-PAM, L-sarcolysin, and phenylalanine mustard, e.g. Alkeran(R)), altretamine (e.g. hexamethylmelamine (HMM), e.g. Hexalen(R)), carmustine (e.g. BiCNU(R)), bendamustine (e.g. Treanda(R)), busulfan (e.g. Busulfex(R) and Myleran(R)), carboplatin (e.g. Paraplatin(R)), lomustine (e.g. CCNU, e.g. CeeNU(R)), cisplatin (e.g. CDDP, e.g. Platinol(R) and Platinol(R)-AQ), chlorambucil (e.g. Leukeran(R)), cyclophosphamide (e.g. Cytosan(R) and Neosar(R)), dacarbazine (e.g. DTIC, DIC and imidazole carboxamide, e.g. DTIC-Dome(R)), altretamine (e.g. hexamethylmelamine (HMM) e.g. Hexalen(R)), ifosfamide (e.g. Ifex(R)), procarbazine (e.g. Matulane(R)), mechlorethamine (e.g. nitrogen mustard, mustine and mechlorethamine hydrochloride, e.g. Mustargen(R)), streptozocin (e.g. Zanosar(R)), thiotepa (e.g. thiophosphoamide, TESP and TSPA, e.g. Thioplex(R)); Biologic response modifiers: bacillus calmette-guerin (e.g. theraCys(R) and TICE(R) BCG), denileukin diftitox (e.g. Ontak(R)); Anti-tumor antibiotics: doxorubicin (e.g. Adriamycin(R) and Rubex(R)), bleomycin (e.g. lenoxane(R)), daunorubicin (e.g. daunorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, e.g. Cerubidine(R)), daunorubicin liposomal (daunorubicin citrate liposome, e.g. DaunoXome(R)), mitoxantrone (e.g. DHAD, e.g. Novantrone(R)), epirubicin (e.g. Ellence™), idarubicin (e.g. Idamycin(R), Idamycin PFS(R)), mitomycin C (e.g. Mutamycin(R)); Anti-microtubule agents: Estramustine (e.g. Emcyl(R)); Cathepsin K inhibitors: Odanacatib (or MK-0822, by Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, described in WO 03/075836); Epothilone B analogs: Ixabepilone (e.g. Lxemptra(R)

by Bristol-Myers Squibb); Heat Shock Protein (HSP) inhibitors: Tanespimycin (17-allylamino-17-demethoxygeldanamycin, e.g. KOS-953 and 17-AAG, by SIGMA, described in US 4,261,989); TpoR agonists: Eltrombopag (e.g. Promacta(R) and Revolade(R) by GlaxoSmithKline); Anti-mitotic agents: Docetaxel (e.g. Taxotere(R) by Sanofi-Aventis); Adrenal steroid inhibitors: aminoglutethimide (e.g. Cytadren(R)); Anti-androgens: Nilutamide (e.g. Nilandron(R) and Anandron(R)), bicalutamide (sold under tradename Casodex(R)), flutamide (e.g. Fulexin™); Androgens: Fluoxymesterone (e.g. halotestin(R)); Proteasome inhibitors: Bortezomib (e.g. Velcade(R)); CDK1 inhibitors: Alvocidib (e.g. flovopirdol or HMR-1275, described in US 5,621,002); Gonadotropin-releasing hormone (GnRH) receptor agonists: Leuprolide or leuprolide acetate (e.g. Viadure(R) by Bayer AG, Eligard(R) by Sanofi-Aventis and Lupron(R) by Abbott Lab); Taxane anti-neoplastic agents: Cabazitaxel, larotaxel; 5HT1a receptor agonists: Xaliproden (or SR57746, described in US 5,266,573); HPC vaccines: Cervarix(R) sold by GlaxoSmithKline, Gardasil(R) sold by Merck; Iron Chelating agents: Deferasinox (e.g. Exjade(R) by Novartis); Anti-metabolites: Claribine (2-chlorodeoxyadenosine, e.g. leustatin(R)), 5-fluorouracil (e.g. Adrucil(R)), 6-thioguanine (e.g. Purinethol(R)), pemetrexed (e.g. Alimta(R)), cytarabine (e.g. arabinosylcytosine (Ara-C), e.g. Cytosar-U(R)), cytarabine liposomal (e.g. Liposomal Ara-C, e.g. DepoCyt™), decitabine (e.g. Dacogen(R)), hydroxyurea (e.g. Hydrea(R), Droxia™ and Mylocel™), fludarabine (e.g. Fludara(R)), floxuridine (e.g. FUDR(R)), cladribine (e.g. 2-chlorodeoxyadenosine (2-CdA) e.g. Leustatin™), methotrexate (e.g. amethopterin, methotrexate sodim (MTX), e.g. Rheumatrex(R) and Trexall™), pentostatin (e.g. Nipent(R)); Bisphosphonates: Pamidronate (e.g. Aredia(R)), zoledronic acid (e.g. Zometa(R)); Demethylating agents: 5-azacitidine (e.g. Vidaza(R)), decitabine (e.g. Dacogen(R)); Plant Alkaloids: Paclitaxel protein-bound (e.g. Abraxane(R)), vinblastine (e.g. vinblastine sulfate, vincalkeboplastine and VLB, e.g. Alkaban-AQ(R) and Velban(R)), vincristine (e.g. vincristine sulfate, LCR, and VCR, e.g. Oncovin(R) and Vincasar Pfs(R)), vinorelbine (e.g. Navelbine(R)), paclitaxel (e.g. Taxol and Onxal™); Retinoids: Alitretinoin (e.g. Panretin(R)), tretinoin (all-trans retinoic acid, e.g. ATRA, e.g. Vesanoide(R)), Isotretinoin (13-cis-retinoic acid, e.g. Accutane(R), Amnesteem(R), Claravis(R), Clarus(R), Decutan(R), Isotane(R), Izotech(R), Oratane(R), Isotret(R), and Sotret(R)), bexarotene (e.g. Targretin(R)); Glucocorticosteroids: Hydrocortisone (e.g. cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and e.g. Ala-Cort(R), Hydrocortisone Phosphate, Solu-Cortef(R), Hydrocort Acetate(R) and Lanacort(R)),

dexamethasone, prednisolone (e.g. Delta-Cortel(R), Orapred(R), Pediapred(R) and Prelone(R)), prednisone (e.g. Deltasone(R), Liquid Red(R), Meticorten(R) and Orasone(R)), methylprednisolone (e.g. 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, e.g. Duralone(R), Medralone(R), Medrol(R), M-Prednisol(R) and Solu-Medrol(R)); Cytokines: interleukin-2 (e.g. aldesleukin and IL-2, e.g. Proleukin(R)), interleukin-11 (e.g. oprevelkin, e.g. Neumega(R)), alpha interferon alfa (e.g. IFN-alpha, e.g. Intron(R) A, and Roferon-A(R)); Luteinizing hormone releasing hormone (LHRH) agonists: Goserelin (e.g. Zoladex(R)); Progesterones: megestrol (e.g. megestrol acetate, e.g. Megace(R)); Miscellaneous cytotoxic agents: Arsenic trioxide (e.g. Trisenox(R)), asparaginase (e.g. L-asparaginase, Erwinia L-asparaginase, e.g. Elspar(R) and Kidrolase(R)); Anti-nausea drugs: NK-1 receptor antagonists: Casopitant (e.g. Rezonic(R) and Zunrisa(R) by GlaxoSmithKline); and Cytoprotective agents: Amifostine (e.g. Ethyol(R)), leucovorin (e.g. calcium leucovorin, citrovorum factor and folinic acid).

Exemplary Embodiments

Embodiment No. 1: A compound of Formula (I'):



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ;

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b} ; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂.

Embodiment No. 2: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3 or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl)C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;


Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -

NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂;



then Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

Embodiment No. 3: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3 or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};


each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl)C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more $\text{R}^{\text{A}1}$;

each $\text{R}^{\text{A}1}$ independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more $\text{R}^{\text{A}1\text{a}}$; and

each $\text{R}^{\text{A}1\text{a}}$ independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more $\text{R}^{\text{A}1\text{b}}$; and

each $\text{R}^{\text{A}1\text{b}}$ independently is halogen, CN, -OH, or -NH₂;



or more halogen.

Embodiment No. 4: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^{Z} ;

each R^{Z} independently is halogen, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{T} ;

each R^{T} independently is halogen, -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more $\text{R}^{\text{A}1}$;

each $\text{R}^{\text{A}1}$ independently is halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl) optionally substituted with one or more $\text{R}^{\text{A}1\text{a}}$; and

each R^{A1a} independently is C_6 - C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6 - C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

Embodiment No. 5: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C_1 - C_6 alkyl), C_1 - C_6 alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C_1 - C_6 alkyl), C_1 - C_6 alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is -O-(C_1 - C_6 alkyl), -NH-(C_1 - C_6 alkyl), C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl; wherein the C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C_1 - C_6 alkyl), -N(C_1 - C_6 alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C_1 - C_6 alkyl), -N(C_1 - C_6 alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6 - C_{10} aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C_1 - C_6 alkyl) optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C_6 - C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6 - C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

Embodiment No. 6: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C_1 - C_6 alkyl), or C_1 - C_6 alkyl; wherein the -O-(C_1 - C_6 alkyl) or C_1 - C_6 alkyl is optionally substituted with one or more halogen;


T is -O-(C_1 - C_6 alkyl), -NH-(C_1 - C_6 alkyl), C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl; wherein the C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;



or more halogen.

Embodiment No. 7: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;


T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C₆-C₁₀ aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;



or more halogen.

Embodiment No. 8: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

Embodiment No. 9: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

Embodiment No. 10: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C₁-C₆ alkyl;

T is C₂-C₆ alkenyl optionally substituted with one or more 6-membered heterocycloalkyl; and

Ar¹ is C₆ aryl optionally substituted with one or more halogen.

Embodiment No. 11: The compound of any one of the preceding Embodiments, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C₁-C₆ alkyl;

T is C₂-C₆ alkenyl optionally substituted with one or more 6-membered monocyclic heterocycloalkyl; and

Ar¹ is C₆ aryl optionally substituted with one or more halogen.

Embodiment No. 12: The compound of any one of the preceding Embodiments, wherein W is CH.

Embodiment No. 13: The compound of any one of the preceding Embodiments, wherein W is N.

Embodiment No. 14: The compound of any one of the preceding Embodiments, wherein Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z; and


each R^Z independently is halogen, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen.

Embodiment No. 15: The compound of any one of the preceding Embodiments, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-


azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .


Embodiment No. 16: The compound of any one of the preceding Embodiments, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .

Embodiment No. 17: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 18: The compound of any one of the preceding Embodiments, wherein





Embodiment No. 19: The compound of any one of the preceding Embodiments, wherein at least one R^Z is halogen.

Embodiment No. 20: The compound of any one of the preceding Embodiments, wherein at least one R^Z is F or Cl.

Embodiment No. 21: The compound of any one of the preceding Embodiments, wherein at least one R^Z is CN, -OH, or -NH₂.

Embodiment No. 22: The compound of any one of the preceding Embodiments, wherein at least one R^Z is -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za} .

Embodiment No. 23: The compound of any one of the preceding Embodiments, wherein at least one R^Z is -O-(C₁-C₆ alkyl) optionally substituted with one or more R^{Za} .

Embodiment No. 24: The compound of any one of the preceding Embodiments, wherein at least one R^Z is -OCH₃.

Embodiment No. 25: The compound of any one of the preceding Embodiments, wherein at least one R^Z is -O-(C₁-C₆ alkyl) substituted with one or more halogen.

Embodiment No. 26: The compound of any one of the preceding Embodiments, wherein at least one R^Z is C₁-C₆ alkyl.

Embodiment No. 27: The compound of any one of the preceding Embodiments, wherein at least one R^Z is methyl, ethyl, or propyl.

Embodiment No. 28: The compound of any one of the preceding Embodiments, wherein at least one R^Z is C₁-C₆ alkyl substituted with one or more halogen.

Embodiment No. 29: The compound of any one of the preceding Embodiments, wherein at least one R^Z is CF₃.

Embodiment No. 30: The compound of any one of the preceding Embodiments, wherein at least one R^Z is C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za} .

Embodiment No. 31: The compound of any one of the preceding Embodiments, wherein at least one R^Z is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Za} .

Embodiment No. 32: The compound of any one of the preceding Embodiments, wherein at least one R^Z is 4-membered heterocycloalkyl optionally substituted with one or more R^{Za} .

Embodiment No. 33: The compound of any one of the preceding Embodiments, wherein at least one R^Z is oxetanyl.

Embodiment No. 34: The compound of any one of the preceding Embodiments, wherein at least one R^{Za} is halogen.

Embodiment No. 35: The compound of any one of the preceding Embodiments, wherein at least one R^{Za} is F or Cl.

Embodiment No. 36: The compound of any one of the preceding Embodiments, wherein at least one R^{Za} is CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Embodiment No. 37: The compound of any one of the preceding Embodiments, wherein T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆

alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}; and

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Embodiment No. 38: The compound of any one of the preceding Embodiments, wherein T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 7-membered monocyclic heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}, and

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Embodiment No. 39: The compound of any one of the preceding Embodiments, wherein T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

Embodiment No. 40: The compound of any one of the preceding Embodiments, wherein T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

Embodiment No. 41: The compound of any one of the preceding Embodiments, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ; and each R^T independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$.

Embodiment No. 42: The compound of any one of the preceding Embodiments, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ; and each R^T independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered monocyclic heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered monocyclic heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$.

Embodiment No. 43: The compound of any one of the preceding Embodiments, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ optionally substituted with one or more R^T .

Embodiment No. 44: The compound of any one of the preceding Embodiments, wherein T is $-\text{OCH}_3$.

Embodiment No. 45: The compound of any one of the preceding Embodiments, wherein T is $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ optionally substituted with one or more R^T .

Embodiment No. 46: The compound of any one of the preceding Embodiments, wherein T is $-\text{NHCH}_3$.

Embodiment No. 47: The compound of any one of the preceding Embodiments, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$ optionally substituted with one or more R^T .

Embodiment No. 48: The compound of any one of the preceding Embodiments, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$.

Embodiment No. 49: The compound of any one of the preceding Embodiments, wherein T is methyl or ethyl.

Embodiment No. 50: The compound of any one of the preceding Embodiments, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$ substituted with one or more halogen.

Embodiment No. 51: The compound of any one of the preceding Embodiments, wherein T is $-\text{CHFCl}$.

Embodiment No. 52: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkenyl optionally substituted with one or more R^T.

Embodiment No. 53: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkenyl.

Embodiment No. 54: The compound of any one of the preceding Embodiments, wherein T is ethenyl.

Embodiment No. 55: The compound of any one of the preceding Embodiments, wherein T is propenyl.

Embodiment No. 56: The compound of any one of the preceding Embodiments, wherein T is pentenyl.

Embodiment No. 57: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkenyl substituted with one or more R^T.

Embodiment No. 58: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkenyl substituted with one or more -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

Embodiment No. 59: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkynyl.


Embodiment No. 60: The compound of any one of the preceding Embodiments, wherein T is propynyl.


Embodiment No. 61: The compound of any one of the preceding Embodiments, wherein T is C₂-C₆ alkynyl substituted with one or more R^T.

Embodiment No. 62: The compound of any one of the preceding Embodiments, wherein T is propynyl substituted with one or more R^T.


Embodiment No. 63: The compound of any one of the preceding Embodiments, wherein T is propynyl substituted with one or more 3- to 10-membered heterocycloalkyl.

Embodiment No. 64: The compound of any one of the preceding Embodiments, wherein





Embodiment No. 65: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 66: The compound of any one of the preceding Embodiments, wherein at least one R^T is halogen.

Embodiment No. 67: The compound of any one of the preceding Embodiments, wherein at least one R^T is CN, -OH, or -NH₂.

Embodiment No. 68: The compound of any one of the preceding Embodiments, wherein at least one R^T is -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), or -N(C₁-C₆ alkyl)₂; wherein the O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), or -N(C₁-C₆ alkyl)₂ is optionally substituted with one or more R^{Ta}.

Embodiment No. 69: The compound of any one of the preceding Embodiments, wherein at least one R^T is -O-(C₁-C₆ alkyl) or -N(C₁-C₆ alkyl)₂.

Embodiment No. 70: The compound of any one of the preceding Embodiments, wherein at least one R^T is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{Ta}.

Embodiment No. 71: The compound of any one of the preceding Embodiments, wherein at least one R^T is C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-

membered heteroaryl; wherein the C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}.

Embodiment No. 72: The compound of any one of the preceding Embodiments, wherein at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more C(=O)OH.

Embodiment No. 73: The compound of any one of the preceding Embodiments, wherein at least one R^{Ta} is C(=O)OH.

Embodiment No. 74: The compound of any one of the preceding Embodiments, wherein at least one R^{Ta} is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

Embodiment No. 75: The compound of any one of the preceding Embodiments, wherein Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a};

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂.

Embodiment No. 76: The compound of any one of the preceding Embodiments, wherein Ar¹ is C₆-C₁₀ aryl.

Embodiment No. 77: The compound of any one of the preceding Embodiments, wherein Ar¹ is C₆-C₁₀ aryl substituted with one or more R^{A1}.

Embodiment No. 78: The compound of any one of the preceding Embodiments, wherein Ar¹ is phenyl substituted with one or more halogen, -OR^{A1a}, or -O-(C₁-C₆ alkyl); wherein the -O-(C₁-C₆ alkyl) is optionally substituted with one or more R^{A1a}, and each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.


Embodiment No. 79: The compound of any one of the preceding Embodiments, wherein Ar¹ is phenyl substituted with one or more halogen

Embodiment No. 80: The compound of any one of the preceding Embodiments, wherein Ar¹ is phenyl substituted with one F and one Cl.


Embodiment No. 81: The compound of any one of the preceding Embodiments, wherein Ar¹ is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.

Embodiment No. 82: The compound of any one of the preceding Embodiments, wherein Ar¹ is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with -O-phenyl or -O-pyridinyl; wherein the -O-phenyl or -O-pyridinyl is optionally substituted with one or more halogen.


Embodiment No. 83: The compound of any one of the preceding Embodiments, wherein




Embodiment No. 84: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 85: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 86: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 87: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is halogen.

Embodiment No. 88: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is F, and at least one R^{A1} is Cl.

Embodiment No. 89: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is CN, -OH, or -NH₂.

Embodiment No. 90: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -OR^{A1a}.

Embodiment No. 91: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more R^{A1b} .

Embodiment No. 92: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.

Embodiment No. 93: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-phenyl or -O-pyridinyl; wherein the -O-phenyl or -O-pyridinyl is optionally substituted with one or more halogen.

Embodiment No. 94: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl, wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a} .

Embodiment No. 95: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-(C₁-C₆ alkyl) substituted with one or more C₆-C₁₀ aryl or 5- to 10-membered heteroaryl, wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

Embodiment No. 96: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-CH₂-(C₆-C₁₀ aryl) or -O-CH₂-(5- to 10-membered heteroaryl), wherein the -O-CH₂-(C₆-C₁₀ aryl) or -O-CH₂-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.

Embodiment No. 97: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is -O-CH₂-phenyl or -O-CH₂-pyridinyl, wherein the -O-CH₂-phenyl or -O-CH₂-pyridinyl is optionally substituted with one or more halogen.

Embodiment No. 98: The compound of any one of the preceding Embodiments, wherein at least one R^{A1} is C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a} .

Embodiment No. 99: The compound of any one of the preceding Embodiments, wherein at least one R^{A1a} is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl, wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b} .

Embodiment No. 100: The compound of any one of the preceding Embodiments, wherein at least one R^{A1a} is C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b} .

Embodiment No. 101: The compound of any one of the preceding Embodiments, wherein at least one R^{A1a} is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.


Embodiment No. 102: The compound of any one of the preceding Embodiments, wherein at least one R^{A1a} is phenyl or pyridinyl; wherein the phenyl or pyridinyl is optionally substituted with one or more halogen.

Embodiment No. 103: The compound of any one of the preceding Embodiments, wherein at least one R^{A1b} is halogen.

Embodiment No. 104: The compound of any one of the preceding Embodiments, wherein at least one R^{A1b} is F, and at least one R^{A1b} is Cl.

Embodiment No. 105: The compound of any one of the preceding Embodiments, wherein at least one R^{A1b} is CN, -OH, or -NH₂.

Embodiment No. 106: The compound of any one of the preceding Embodiments, wherein




T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{T} ; and wherein the $\text{C}_2\text{-C}_6 \text{ alkenyl}$ is substituted with one or more R^{T}


each R^{T} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ; and

each R^{Ta} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.


Embodiment No. 107: The compound of any one of the preceding Embodiments, wherein




Embodiment No. 108: The compound of any one of the preceding Embodiments, wherein




Embodiment No. 109: The compound of any one of the preceding Embodiments, wherein




Embodiment No. 110: The compound of any one of the preceding Embodiments, wherein



Embodiment No. 111: The compound of any one of the preceding Embodiments, wherein




Embodiment No. 112: The compound of any one of the preceding Embodiments, wherein the compound is of formula (II'):





or a pharmaceutically acceptable salt or stereoisomer thereof.

Embodiment No. 113: The compound of any one of the preceding Embodiments, wherein the compound is of formula (II'):





or a pharmaceutically acceptable salt or stereoisomer thereof.

Embodiment No. 114: The compound of any one of the preceding Embodiments, wherein the compound is of formula (III') or (III'-a):




or a pharmaceutically acceptable salt or stereoisomer thereof.

Embodiment No. 115: The compound of any one of the preceding Embodiments, wherein the compound is of formula (IV') or (IV'-a):



or a pharmaceutically acceptable salt or stereoisomer thereof.

Embodiment No. 116: The compound of any one of the preceding Embodiments, where in the compound is of formula I



Embodiment No. 120: The compound of any one of the preceding Embodiments, wherein X^1 is $-NR^3-$, and R^2 is C_{1-4} alkyl, or is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .

Embodiment No. 121: The compound of any one of the preceding Embodiments, wherein when n is 0, R^2 is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .

Embodiment No. 122: The compound of any one of the preceding Embodiments, wherein when n is 0, R^2 is $-(CH_2)_q-$ which forms a ring with R^3 .

Embodiment No. 123: The compound of any one of the preceding Embodiments, wherein n is 0, and R^2 is $-(CH_2)_q-$ which forms a ring with R^3 or with one of R^a .


Embodiment No. 124: The compound of any one of the preceding Embodiments, wherein n is 0, and R^2 is $-(CH_2)_q-$ which forms a ring with R^3 .

Embodiment No. 125: The compound of any one of the preceding Embodiments, wherein X^1 is NR^3 or O and wherein R^3 is methyl, ethyl, n-propyl or n-butyl.

Embodiment No. 126: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 127: The compound of any one of the preceding Embodiments, wherein R^2 is methyl, ethyl, n-propyl or n-butyl-, preferably methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

Embodiment No. 128: The compound of any one of the preceding Embodiments, wherein Ar^1 is of formula i or pharmaceutically acceptable salts or stereoisomers thereof



wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;


R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl.

Embodiment No. 129: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 130: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 131: The compound of any one of the preceding Embodiments, wherein R^2 is methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 , or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

Embodiment No. 132: The compound of any one of the preceding Embodiments, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe;

X^3 is CH or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;


R^7 is hydrogen or halogen, preferably F.

Embodiment No. 133: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 134: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 135: The compound of any one of the preceding Embodiments, wherein R^2 is methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

Embodiment No. 136: The compound of any one of the preceding Embodiments, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^3 is CH or N, preferably N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;


R^7 is hydrogen or halogen, preferably F.

Embodiment No. 137: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 138: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 139: The compound of any one of the preceding Embodiments, wherein R^2 is methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

Embodiment No. 140: The compound of any one of the preceding Embodiments, wherein Ar^1 is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^5' , R^6 , R^6' are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;



R^7 is hydrogen or halogen, preferably F.

Embodiment No. 141: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 142: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 143: The compound of any one of the preceding Embodiments, wherein R^2 is methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with one of R^a .

Embodiment No. 144: The compound of any one of the preceding Embodiments, being of formula IIa or IIb



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X^1 is $-O-$ or $-NR^3-$;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, preferably methyl or is $-(CH_2)_q-$ which forms a ring with R^3 ;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $-(CH_2)_p-$ which forms a ring with R^2 ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;


s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxy-carbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

Embodiment No. 145: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 146: The compound of any one of the preceding Embodiments, wherein R^2 is methyl or wherein R^2 is $-(CH_2)-$ or $-(CH_2)_2-$ which forms a ring with R^3 .

Embodiment No. 147: The compound of any one of the preceding Embodiments, being of formula III




or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

 R^1 is H or F;


Ar¹ is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, -CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, or C₆ aryl;

Z is selected from



Embodiment No. 148: The compound of any one of the preceding Embodiments, wherein R¹ is hydrogen.

Embodiment No. 149: The compound of any one of the preceding Embodiments, being of formula IV




or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl or C_6 aryl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;





Z is selected from



Embodiment No. 150: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 151: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 152: The compound of any one of the preceding Embodiments, being of formula V-1, V-2, V-3 or V-4

**V-1****V-2****V-3****V-4**

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;


Z is selected from




Embodiment No. 153: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 154: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.


Embodiment No. 155: The compound of any one of the preceding Embodiments, being of formula VI-1, VI-2, VI-3 or VI-4




VI-1



VI-2



VI-3



VI-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;







Z is selected from




Embodiment No. 156: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.


Embodiment No. 157: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 158: The compound of any one of the preceding Embodiments, being of formula VII-1, VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9






VII-7



VII-8



VII-9

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;


α is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



Embodiment No. 159: The compound of any one of the preceding Embodiments, wherein R^5 is F and/or wherein R^6 is F or Cl.

Embodiment No. 160: The compound of any one of the preceding Embodiments, wherein R^1 is hydrogen.

Embodiment No. 161: The compound of any one of the preceding Embodiments, being selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

Embodiment No. 162: The compound of any one of the preceding Embodiments, being selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

Embodiment No. 163: The compound of any one of the preceding Embodiments, being selected from the compounds described in Tables 1 and 2.

Embodiment No. 164: A composition comprising to the compound of any one of the preceding Embodiments, and a pharmaceutically acceptable carrier.

Embodiment No. 165: The composition of any one of the preceding Embodiments, further comprising a second therapeutically active agent.

Embodiment No. 166: A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding Embodiments.

Embodiment No. 167: A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering the subject in need thereof the composition of any one of the preceding Embodiments.

Embodiment No. 168: A method of preventing or treating cancer, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding Embodiments.

Embodiment No. 169: A method of preventing or treating cancer, comprising administering the subject in need thereof the composition of any one of the preceding Embodiments.

Embodiment No. 170: The compound of any one of the preceding Embodiments for use in the prevention or treatment of cancer.

Embodiment No. 171: The compound of any one of the preceding Embodiments for use in the inhibition of an oncogenic variant of an ErbB receptor.

Embodiment No. 172: The composition of any one of the preceding Embodiments for use in the inhibition of an oncogenic variant of an ErbB receptor.

Embodiment No. 173: The composition of any one of the preceding Embodiments for use in the prevention or treatment of cancer.

Embodiment No. 174: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer is a solid tumor.

Embodiment No. 175: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

Embodiment No. 176: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer is glioblastoma (GBM) or any subtype thereof.

Embodiment No. 177: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer is glioblastoma.

Embodiment No. 178: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an ErbB receptor.

Embodiment No. 179: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of the ErbB receptor comprises an allosteric mutation.

Embodiment No. 180: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of an ErbB receptor is an allosteric variant of the ErbB receptor.

Embodiment No. 181: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an epidermal growth factor receptor (EGFR).

Embodiment No. 182: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of EGFR is an allosteric variant of EGFR.

Embodiment No. 183: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of EGFR comprises an allosteric mutation.

Embodiment No. 184: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of a human epidermal growth factor receptor 2 (HER2) receptor.

Embodiment No. 185: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor.

Embodiment No. 186: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant of the HER2 receptor comprises an allosteric mutation.

Embodiment No. 187: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the oncogenic variant or the oncogenic mutation is detected by a Food and Drug Administration (FDA)-approved diagnosis.

Embodiment No. 188: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein prior to the treatment with the compound of the present disclosure, the subject is treated with a therapeutic agent different from the compound of any one of the preceding Embodiments.

Embodiment No. 189: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the cancer, or a tumor or a cell thereof, is insensitive or resistant to treatment with the therapeutic agent different from the compound of any one of the preceding Embodiments.

Embodiment No. 190: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the subject has an adverse reaction to treatment with a therapeutic agent different from the compound of any one of the preceding Embodiments.

Embodiment No. 191: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the therapeutically effective amount reduces a severity of a sign or symptom of the cancer.

Embodiment No. 192: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the sign of the cancer comprises a tumor grade and wherein a reduction of the severity of the sign comprises a decrease of the tumor grade.

Embodiment No. 193: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the sign of the cancer comprises a tumor metastasis

and wherein a reduction of the severity of the sign comprises an elimination of the metastasis or a reduction in the rate or extent the metastasis.

Embodiment No. 194: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the sign of the cancer comprises a tumor volume and wherein a reduction of the severity of the sign comprises an elimination of the tumor or a reduction in the volume.

Embodiment No. 195: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the symptom of the cancer comprises pain and wherein a reduction of the severity of the sign comprises an elimination or a reduction in the pain.

Embodiment No. 196: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the therapeutically effective amount induces a period of remission.

Embodiment No. 197: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the therapeutically effective amount improves a prognosis of the subject.

Embodiment No. 198: A method of preventing or treating glioblastoma, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding Embodiments.

Embodiment No. 199: A method of preventing or treating glioblastoma, comprising administering the subject in need thereof the composition of any one of the preceding Embodiments.

Embodiment No. 200: The compound of any one of the preceding Embodiments for use in the prevention or treatment of glioblastoma.

Embodiment No. 201: The composition of any one of the preceding Embodiments for use in the prevention or treatment of glioblastoma.


Embodiment No. 202: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the compound is selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

Embodiment No. 203: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the compound is selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

Embodiment No. 204: The method, the compound for use, or the composition for use of any one of the preceding Embodiments, wherein the compound is selected from the compounds described in Table 1 and 2.

EXAMPLES

Preparation of (*R*)-tert-butyl 2-ethynyl-2-methylpyrrolidine-1-carboxylate (**S5**)



[0738] **S2**: To a solution of (*R*)-2-methylpyrrolidine-2-carboxylic acid **S1** (3.00 g, 23.3 mmol, 1.00 eq) and triethylamine (7.05 g, 69.7 mmol, 9.70 mL, 3.00 eq) in a mixture solvent of water (20.0 mL) and acetonitrile (20.0 mL) was added di-tert-butyl dicarbonate (5.58 g, 25.6 mmol, 5.87 mL, 1.10 eq). The mixture was stirred at 25 °C for 10 h. The pH of the reaction mixture was adjusted to around 2.00 by progressively adding aqueous solution of hydrochloric acid (2.00 M, 15.0 ml). The mixture was filtered and concentrated to give (*R*)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid **S2** (4.20 g, crude) as a white solid. ¹H NMR (400MHz, CDCl₃) δ = 3.65 - 3.46 (m, 4H), 2.59 (*br d*, *J* = 5.1 Hz, 1H), 2.34 - 2.25 (m, 1H), 2.03 - 1.92 (m, 2H), 1.91 - 1.79 (m, 4H), 1.63 (s, 3H), 1.55 - 1.53 (m, 3H), 1.49 (s, 9H).


[0739] **S3**: To a solution of (*R*)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid **S2** (5.30 g, 23.1 mmol, 1.00 eq) in tetrahydrofuran (50.0 mL) was added borane dimethyl sulfide complex (10.0 M, 4.62 mL, 2.00 eq) dropwise at 0 °C. Then the mixture was stirred at 70 °C for 12 h. The reaction mixture was quenched by methanol (15.0 ml) and concentrated to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 3/1) to afford (*R*)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate **S3** (1.10 g, 5.11 mmol, 22% yield) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ = 3.72 - 3.64 (m, 1H), 3.63 -

3.50 (m, 2H), 3.38 - 3.27 (m, 1H), 2.03 - 1.70 (m, 4H), 1.47 (s, 9H), 1.38 (s, 3H).

[0740] **S4**: To a solution of (*R*)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate **S3** (1.10 g, 5.11 mmol, 1.00 eq) in dichloromethane (15.0 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (2.60 g, 6.13 mmol, 1.90 mL, 1.20 eq). The mixture was stirred at 25 °C for 10 h. The reaction mixture was filtered and the filtrate was poured into saturated aqueous solution of sodium carbonate (60.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 40.0 mL). The combined organic phase was washed with brine (2 × 30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to afford (*R*)-tert-butyl 2-formyl-2-methylpyrrolidine-1-carboxylate **S4** (0.900 g, 4.22 mmol, 83% yield) as a yellow oil. It was used for the next step directly. ¹H NMR (400 MHz, CDCl₃) δ = 9.26 (s, 1H), 3.50 - 3.36 (m, 2H), 1.89 (dd, *J* = 1.3, 5.8 Hz, 2H), 1.66 - 1.49 (m, 2H), 1.34 (s, 9H), 1.31 (s, 3H).

[0741] **S5**: To a solution of (*R*)-tert-butyl 2-formyl-2-methylpyrrolidine-1-carboxylate **S4** (0.900 g, 4.22 mmol, 1.00 eq) in methanol (8.00 mL) was added potassium carbonate (1.17 g, 8.44 mmol, 2.00 eq) and dimethyl (1-diazo-2-oxopropyl)phosphonate (1.22 g, 6.33 mmol, 1.50 eq) dropwise at 0 °C. Then the mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated in vacuum to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to afford (*R*)-tert-butyl 2-ethynyl-2-methylpyrrolidine-1-carboxylate **S5** (0.620 g, 2.96 mmol, 70% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 3.56 - 3.40 (m, 1H), 3.36 - 3.25 (m, 1H), 2.21 (*br s*, 2H), 1.94 - 1.81 (m, 2H), 1.78 - 1.67 (m, 1H), 1.55 (*br s*, 3H), 1.42 (s, 9H).

Example 1. Synthesis of Compound 1



[0742] **Synthesis of S6**: To a solution of 7-fluoro-6-nitro-quinazolin-4-ol (5.00 g, 23.9 mmol, 1.00

eq) in thionyl chloride (82.0 g, 689 mmol, 50.0 mL, 28.8 eq) was added dropwise dimethylformamide (175 mg, 2.39 mmol, 184 μ L, 0.100 eq) as catalyst. The mixture was heated to 80 °C and stirred for 12 h. The reaction mixture was concentrated to afford 4-chloro-7-fluoro-6-nitro-quinazoline (5.44 g, 23.9 mmol, 100% yield) as a white solid. The product was used in next step directly.

[0743] To a solution of 4-chloro-7-fluoro-6-nitro-quinazoline (5.44 g, 23.9 mmol, 1.00 eq) in isopropanol (100 mL) was added 3-chloro-2-fluoro-aniline (3.83 g, 26.3 mmol, 1.10 eq). The mixture was stirred at 90 °C for 2 hr. The mixture was concentrated to afford a yellow solid which was triturated with ethyl acetate (50.0 mL). After filtration, the filter cake was washed with ethyl acetate (20.0 mL), dried in vacuum to afford N-(3-chloro-2-fluoro-phenyl)-7-fluoro-6-nitro-quinazolin-4-amine (8.40 g, crude) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 12.5 (br s, 1 H), 9.7 - 10.0 (m, 1 H), 8.8 - 8.9 (m, 1 H), 7.9 - 8.1 (m, 1 H), 7.6 (td, J = 7.46, 1.47 Hz, 1 H), 7.5 (br t, J = 7.34 Hz, 1 H), 7.3 - 7.4 (m, 1 H). MS (ESI) m/z 336.9 $[\text{M}+\text{H}]^+$

[0744] To a solution of N-(3-chloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (8.40 g, 25.0 mmol, 1.00 eq) in dimethylformamide (100 mL) was added potassium acetate (12.2 g, 125 mmol, 5.00 eq) at 15 °C. The mixture was stirred at 100 °C for 1 h. The mixture was concentrated to afford a residue. The residue was diluted with water (100 mL). After filtration, the filter cake was washed with water (30.0 mL), dried in vacuum to afford 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol **S93** (9.00 g, crude) as a brown solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 9.0 (s, 1 H), 8.3 (s, 1 H), 7.4 - 7.5 (m, 2 H), 7.2 - 7.3 (m, 1 H), 7.0 - 7.1 (m, 1 H). MS (ESI) m/z 335.2 $[\text{M}+\text{H}]^+$

[0745] To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol **S93** (9.00 g, 26.9 mmol, 1.00 eq) and pyridine (10.6 g, 134 mmol, 10.9 mL, 5.00 eq) in dichloromethane (200 mL) was added trifluoromethanesulfonic anhydride (15.2 g, 53.8 mmol, 8.87 mL, 2.00 eq) at 0 °C. The mixture was stirred at 20 °C for 12 h. The mixture was concentrated to afford a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 1:1~0:1) to afford 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (4.00 g, 7.97 mmol, 30% yield, 93% purity) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.9 (br s, 1 H), 9.7 (br s, 1 H), 8.7 (br d, J = 9.41 Hz, 1 H), 8.1 (br s, 1 H), 7.5 - 7.6 (m, 2 H), 7.3 - 7.4 (m, 1 H). MS (ESI) m/z 467.2 $[\text{M}+\text{H}]^+$

[0746] **S7**: A mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl

trifluoromethanesulfonate **S6** (0.500 g, 1.07 mmol, 1.00 eq), tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (291 mg, 1.39 mmol, 1.30 eq), tetrakis(triphenylphosphine) palladium(0) (124 mg, 107 μ mol, 0.100 eq), cuprous iodide (40.8 mg, 214 μ mol, 0.200 eq) and triethylamine (325 mg, 3.21 mmol, 447 μ L, 3.00 eq) in tetrahydrofuran (10.0 mL) was stirred at 25 °C in nitrogen atmosphere for 10 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 1/1) to give tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methyl pyrrolidine-1-carboxylate **S7** (525 mg, 998 μ mol, 93% yield) as a yellow solid. ^1H NMR (400MHz, CDCl_3) δ = 8.88 (s, 1H), 8.79 (d, J = 3.4 Hz, 1H), 8.31 (t, J = 7.4 Hz, 1H), 8.11 (s, 1H), 8.02 - 7.94 (m, 1H), 7.44 - 7.34 (m, 1H), 7.25 - 7.19 (m, 1H), 3.83 - 3.70 (m, 1H), 3.68 - 3.49 (m, 2H), 3.38 - 3.30 (m, 1H), 2.36 - 2.27 (m, 1H), 2.02 - 1.92 (m, 1H), 1.55 - 1.47 (m, 12H).

[0747] **S8**: A mixture of *N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S7** (0.520 g, 998 μ mol, 1.00 eq) in hydrochloric acid / ethyl acetate (5.00 mL) was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to afford *N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S8** (0.500 g, crude, hydrochloric acid) as a yellow solid.


[0748] **S9**: To a solution of *N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S8** (0.500 g, 1.17 mmol, 1.00 eq) and paraformaldehyde (176 mg, 5.87 mmol, 162 μ L, 5.00 eq) in trifluoroethanol (8.00 mL) was added sodium borohydride (88.8 mg, 2.35 mmol, 2.00 eq). Then the mixture was stirred at 60 °C for 12 h. The reaction mixture was quenched by addition methanol (10.0 mL), and concentrated to obtain a residue. Then the mixture diluted with water (10.0 mL) and extracted with ethyl acetate (3×25.0 mL). The combined organic layers were washed with brine (15.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give *N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S9** (0.500 g, crude) as a yellow solid. ^1H NMR (400MHz, CDCl_3) δ = 8.91 - 8.78 (m, 1H), 8.16 - 8.05 (m, 1H), 7.63 (br dd, J = 8.0, 12.0 Hz, 1H), 7.59 - 7.53 (m, 1H), 7.49 - 7.44 (m, 1H), 7.17 (br t, J = 7.8 Hz, 1H), 4.02 - 3.87 (m, 1H), 2.95 (d, J = 9.2 Hz, 1H), 2.77 - 2.69 (m, 1H), 2.67 - 2.59 (m, 1H), 2.46 - 2.30 (m, 4H), 1.99 - 1.91 (m, 1H), 1.53 (s, 3H).

[0749] **S10**: A mixture of *N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-

6-nitroquinazolin-4-amine **S9** (0.500 g, 1.14 mmol, 1.00 eq), ammonium chloride (182 mg, 3.41 mmol, 3.00 eq) and iron powder (190 mg, 3.41 mmol, 3.00 eq) in water (8.00 mL) and methanol (8.00 mL) was stirred at 80 °C for 10 h. The reaction mixture was filtered and the filtration was concentrated under reduced pressure to give a residue. The residue was purified by reverse phase chromatography (column: C18, condition: H₂O-0.1% FA-acetonitrile) and lyophilized to give *N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl) ethynyl)quinazoline-4,6-diamine **S10** (over two steps 0.220 g, 444 μmol, 85% purity) as a yellow solid. ¹H NMR (400MHz, CD₃OD) δ = 8.27 (s, 1H), 7.98 (s, 1H), 7.74 (s, 1H), 7.64 - 7.58 (m, 1H), 7.45 - 7.38 (m, 2H), 7.24 (*br* dd, *J* = 1.2, 8.2 Hz, 1H), 3.87 (*br* d, *J* = 11.8 Hz, 1H), 3.82 - 3.72 (m, 1H), 3.66 - 3.54 (m, 1H), 3.38 (*br* d, *J* = 12.6 Hz, 1H), 2.86 (s, 3H), 2.66 - 2.56 (m, 1H), 2.39 - 2.27 (m, 1H), 1.71 - 1.62 (m, 3H).

[0750] **1**: A mixture of *N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S10** (0.250 g, 609 μmol, 1.00 eq), acrylic acid (57.1 mg, 792 μmol, 54.4 μL, 1.30 eq), pyridine (144 mg, 1.83 mmol, 147 μL, 3.00 eq) and 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (350 mg, 1.83 mmol, 3.00 eq) in dimethyl formamide (2.00 ml) was stirred at 25 °C for 2 hr. The reaction mixture was filtered and the filtration was purified by prep-HPLC (column: Xtimate C18 150 × 25mm×5μm; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 48%-78%,10min) and lyophilized to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **1** (35.3 mg, 74.5 μmol, 12% yield, 98% purity) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 9.13 (s, 1H), 8.69 - 8.63 (m, 1H), 8.60 - 8.54 (m, 1H), 8.28 (dt, *J* = 2.2, 7.4 Hz, 1H), 7.87 (s, 1H), 7.73 (*br* s, 1H), 7.16 - 7.05 (m, 2H), 6.52 - 6.43 (m, 1H), 6.40 - 6.29 (m, 1H), 5.80 (dd, *J* = 1.2, 10.0 Hz, 1H), 3.01 (d, *J* = 8.8 Hz, 1H), 2.92 (dt, *J* = 5.8, 8.8 Hz, 1H), 2.55 - 2.46 (m, 1H), 2.41 - 2.35 (m, 4H), 2.34 - 2.26 (m, 1H), 1.91 (ddd, *J* = 5.8, 8.8, 12.8 Hz, 1H), 1.47 (s, 3H). MS (ESI) *m/z* 464.2 [M+H]⁺.

Example 2. Synthesis of Compound 2



[0751] **S11:** To a mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (710 mg, 1.52 mmol, 1.00 eq), (*R*)-tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (350 mg, 1.67 mmol, 1.10 eq) and cuprous iodide (57.9 mg, 304 μ mol, 0.200 eq) in dimethyl formamide (2.00 mL) and triethylamine (2.00 mL) was added tetrakis(triphenylphosphine) palladium (0) (176 mg, 152 μ mol, 0.100 eq) under nitrogen atmosphere. The mixture was stirred at 15 °C for 1 h. The mixture was concentrated to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate = 5/1 - 2/1) to give (*R*)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S11** (800 mg, 1.52 mmol, 99% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.62 (*br s*, 1H), 9.41 (*br s*, 1H), 8.67 (*br s*, 1H), 7.99 (*br s*, 1H), 7.43 (*br s*, 1H), 7.39 - 7.26 (m, 2H), 3.61 (d, *J* = 10.4 Hz, 1H), 3.56 - 3.41 (m, 2H), 3.30 - 3.21 (m, 1H), 2.24 - 2.15 (m, 1H), 1.98 - 1.90 (m, 1H), 1.45 (s, 3H), 1.42 (s, 9H). MS (ESI) *m/z* 526.0 [M+H]⁺.

[0752] **S12:** To a mixture of (*R*)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S11** (700 mg, 1.33 mmol, 1.00 eq) in ethyl acetate (10.0 mL) was added hydrochloric acid/ethyl acetate (4.00 M, 12.0 mL), the mixture was stirred at 15 °C for 2 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (10.0 mL). After filtration, the filter cake was washed with ethyl acetate (5.00 mL), dried in vacuum to give (*R*)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S12** (600 mg, 1.30 mmol, 97% yield, hydrochloric acid) as a yellow solid. MS (ESI) *m/z* 426.0 [M+H]⁺.

[0753] **S13**: A mixture of (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S12** (500 mg, 1.17 mmol, 1.00 eq), paraformaldehyde (176 mg, 5.87


mmol, 5.00 eq) in trifluoroethanol (8.00 mL) was added sodium borohydride (88.8 mg, 2.35 mmol, 2.00 eq) at 15 °C. The mixture was stirred at 60 °C for 2 h. The mixture was quenched by methanol (5.00 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20.0 mL) and washed with water (20.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S13** (500 mg, 1.14 mmol, 97% yield) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ = 8.87 (*br s*, 1H), 8.73 (*s*, 1H), 8.32 (*br s*, 1H), 8.10 (*s*, 1H), 7.71 - 7.59 (*m*, 1H), 7.46 (*dt*, *J* = 3.2, 7.4 Hz, 1H), 7.22 - 7.15 (*m*, 1H), 2.96 (*d*, *J* = 9.2 Hz, 1H), 2.80 - 2.70 (*m*, 2H), 2.65 (*d*, *J* = 9.2 Hz, 1H), 2.46 - 2.38 (*m*, 4H), 1.96 (*td*, *J* = 7.2, 12.6 Hz, 1H), 1.54 (*s*, 3H). MS (ESI) *m/z* 439.8 [M+H]⁺.

[0754] **S14**: A mixture of (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S13** (450 mg, 1.02 mmol, 1.00 eq), iron powder (286 mg, 5.12 mmol, 5.00 eq) and ammonium chloride (274 mg, 5.12 mmol, 5.00 eq) in methanol (10.0 mL) and water (3.00 mL) was stirred at 80 °C for 3 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20.0 mL) and washed with saturated sodium bicarbonate solution (20.0 mL), brine (15.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give (*R*)-*N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S14** (260 mg, 634 μ mol, 62% yield) as a yellow solid. MS (ESI) *m/z* 410.1 [M+H]⁺.

[0755] **2**: To a mixture of (*R*)-*N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S14** (200 mg, 488 μ mol, 1.00 eq), acrylic acid (45.7 mg, 634 μ mol, 1.30 eq) and pyridine (154 mg, 1.95 mmol, 4.00 eq) in dimethyl formamide (3.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (374 mg, 1.95 mmol, 4.00 eq) at 15 °C. The mixture was stirred at 15 °C for 2 h and then filtered. The filtrate was purified by prep-HPLC (column: Xtimate C18 10 μ 250mm*80mm; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 47%-67%, 10min) and (column: Phenomenex Synergi C18 150*25*10 μ m; mobile phase: [water(0.225%FA)-ACN]; B%: 20%-50%, 9min) to give (*R*)-*N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **2** (60.0 mg, 129 μ mol, 27% yield) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ = 9.28 (*br s*, 1H), 9.12 (*s*, 1H), 8.75 (*s*, 1H), 8.44 (*br s*, 1H), 8.37 - 8.31 (*m*, 1H), 7.97 (*s*, 1H), 7.78 (*br s*, 1H), 7.25 - 7.14 (*m*, 2H), 6.67 - 6.56 (*m*, 2H), 5.87 (*dd*, *J* = 2.4, 9.2 Hz, 1H), 3.52 (*d*, *J* =

10.0 Hz, 1H), 3.50 - 3.41 (m, 1H), 2.94 - 2.84 (m, 1H), 2.73 - 2.67 (m, 4H), 2.50 (ddd, $J = 5.6, 7.8, 13.2$ Hz, 1H), 2.12 (ddd, $J = 7.0, 8.6, 13.1$ Hz, 1H), 1.62 (s, 3H). MS (ESI) m/z 464.0 $[M+H]^+$.

Example 3. Synthesis of Compound 3



[0756] **S15:** *N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S8** (23.0 g, 54.0 mmol, 1.00 eq) was separated by chiral resolution (column: Phenomenex-Cellulose-2(250mm*30mm, 10um); mobile phase: [0.1% NH₃H₂O MEOH]; B%: 70%-70%, 8.9 min; 1900 min/min) to give (*S*)-*N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S15** (8.40 g, 18.2 mmol, 34% yield, 92% purity, 99% *ee*) and (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S12** (8.30 g, 16.6 mmol, 31% yield, 85% purity, 95% *ee*) as a yellow solid. **S15:** MS (ESI) m/z 426.1 $[M+H]^+$; ¹H NMR (400 MHz, DMSO-*d*₆) δ = 11.02 - 10.60 (m, 1H), 9.50 (*br d*, $J = 1.4$ Hz, 1H), 8.80 - 8.59 (m, 1H), 8.25 - 8.04 (m, 1H), 7.63 - 7.47 (m, 2H), 7.32 (*br t*, $J = 7.4$ Hz, 1H), 4.12 (q, $J = 5.3$ Hz, 1H), 3.53 - 3.43 (m, 2H), 3.17 (d, $J = 4.9$ Hz, 2H), 2.34 - 2.25 (m, 1H), 2.14 - 2.00 (m, 1H), 1.53 (s, 3H); **S12:** MS (ESI) m/z 426.1 $[M+H]^+$; ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.40 (s, 1H), 8.61 (s, 1H), 8.05 (s, 1H), 7.51 (td, $J = 6.8, 13.8$ Hz, 2H), 7.36 - 7.27 (m, 1H), 3.69 - 3.59 (m, 2H), 3.17 (s, 2H), 2.30 - 2.17 (m, 1H), 2.02 - 1.87 (m, 1H), 1.49 (s, 3H).

[0757] **S16:** To a solution of (*S*)-*N*-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S15** (8.40 g, 19.7 mmol, 1.00 eq) in 2,2,2-trifluoroethanol (80.0 mL) was added paraformaldehyde (2.96 g, 98.6 mmol, 2.72 mL, 5.00 eq) in portions. The


mixture was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (1.49 g, 39.5 mmol, 2.00 eq) in portions at 60 °C. The mixture was stirred at 60 °C for 1 h. The mixture was added methanol (50.0 mL) and concentrated to give crude product. The crude product was diluted with water (100 mL) and extracted with ethyl acetate (3 × 70.0 mL). The combined organic layer was washed with brine (50.0 mL) and dried over sodium sulfate, filtered and concentrated to give (S)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S16** (7.50 g, crude) as a yellow solid. MS (ESI) m/z 440.1 [M+H]⁺.

[0758] **S17**: To a solution of (S)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S16** (7.50 g, 17.1 mmol, 1.00 eq) and ammonium chloride (4.56 g, 85.5 mmol, 5.00 eq) in methanol (80.0 mL) and water (20.0 mL) was added iron powder (4.76 g, 85.3 mmol, 5.00 eq) in portions. The mixture was stirred at 80 °C for 1 h. The mixture was added methanol (200 mL) and filtered. The filtrate was concentrated to give the residue. The residue was diluted with saturated sodium hydrogencarbonate solution (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layer was washed with brine (50.0 mL) and dried over sodium sulfate, filtered and concentrated to give (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S17** (6.10 g, crude) as a yellow solid. MS (ESI) m/z 410.1 [M+H]⁺.

[0759] **3**: To a solution of (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S17** (5.60 g, 13.7 mmol, 1.00 eq), acrylic acid (1.18 g, 16.4 mmol, 1.13 mL, 1.20 eq) and pyridine (4.32 g, 54.7 mmol, 4.41 mL, 4.00 eq) in dimethyl formamide (40.0 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.5 g, 54.7 mmol, 4.00 eq) in portions. The mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layer was washed with brine (50.0 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (ethyl acetate / methanol = 1/0 to 10/1) and further purified by prep-HPLC (column: Waters Xbridge C18 150*50mm* 10um; mobile phase: [water(10mM NH₄HCO₃)-ACN];B%: 38%-68%,11.5min) and lyophilized to give (S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **3** (1.76 g, 3.71 mmol, 27% yield, 98% purity) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 9.21 (s, 1H), 8.73 (s, 1H), 8.68 (s, 1H), 8.32 (dt, J = 1.9, 7.4 Hz, 1H), 7.95 (s, 1H), 7.91 (br s, 1H), 7.24 - 7.12 (m, 2H), 6.59 - 6.51 (m,

1H), 6.49 - 6.37 (m, 1H), 5.89 (dd, $J = 1.2, 10.1$ Hz, 1H), 3.09 (d, $J = 9.0$ Hz, 1H), 3.01 (dt, $J = 5.6, 8.8$ Hz, 1H), 2.58 (dt, $J = 6.1, 9.1$ Hz, 1H), 2.48 (s, 1H), 2.45 (s, 3H), 2.43 - 2.34 (m, 1H), 2.00 (ddd, $J = 5.6, 8.8, 12.9$ Hz, 1H), 1.56 (s, 3H). MS (ESI) m/z 464.2 $[M+H]^+$.

Example 4. Synthesis of Compound 4



[0760] **S18**: To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (600 mg, 1.29 mmol, 1.00 eq), tert-butyl 4-ethynyl-4-methylpiperidine-1-carboxylate (315 mg, 1.41 mmol, 1.10 eq), triethylamine (390 mg, 3.86 mmol, 3.00 eq) and copper(I) iodide (48.9 mg, 257 μmol , 0.200 eq) in dimethyl formamide (1.00 mL) was added tetrakis[triphenylphosphine]palladium(0) (148 mg, 128 μmol , 0.100 eq) at 25°C . The mixture was stirred at 25°C for 1 h. The reaction mixture was concentrated to remove dimethyl formamide. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate = 10/1 to 1/1) to give tert-butyl 4-((4-((3-chloro-2-fluorophenyl) amino)-6-nitroquinazolin-7-yl)ethynyl)-4-methylpiperidine-1-carboxylate **S18** (700 mg, crude) as a yellow solid. MS (ESI) m/z 540.2 $[M+H]^+$.


[0761] **S19**: A mixture of tert-butyl 4-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-4-methylpiperidine-1-carboxylate **S18** (700 mg, 1.30 mmol, 1.00 eq) in hydrogen chloride/ethyl acetate (4 M, 3.00 mL, 9.26 eq) was stirred at 25°C for 2 h. The reaction mixture was concentrated to give a residue. The residue was triturated with ethyl acetate (10.0 mL) to give *N*-(3-chloro-2-fluorophenyl)-7-((4-methylpiperidin-4-yl)ethynyl)-6-nitroquinazolin-4-amine **S19** (550 mg, 1.25 mmol, 96% yield) as a yellow solid. MS (ESI) m/z 440.2 $[M+H]^+$.

[0762] **S20**: To a solution of *N*-(3-chloro-2-fluorophenyl)-7-((4-methylpiperidin-4-yl)ethynyl)-6-nitroquinazolin-4-amine **S19** (450 mg, 1.02 mmol, 1.00 eq) and formaldehyde (415 mg, 5.12 mmol, 5.00 eq) in acetonitrile (5.00 mL) was added sodium triacetoxyborohydride (650 mg, 3.07 mmol, 3.00 eq). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (3 × 50.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give *N*-(3-chloro-2-fluorophenyl)-7-((1,4-dimethylpiperidin-4-yl)ethynyl)-6-nitroquinazolin-4-amine **S20** (500 mg, crude) as a yellow solid. MS (ESI) *m/z* 454.4 [M+H]⁺.

[0763] **S21**: A mixture of *N*-(3-chloro-2-fluorophenyl)-7-((1,4-dimethylpiperidin-4-yl)ethynyl)-6-nitroquinazolin-4-amine **S20** (400 mg, 881 μmol, 1.00 eq), iron powder (492 mg, 8.81 mmol, 10.0 eq) and ammonium chloride (471 mg, 8.81 mmol, 10.0 eq) in methanol (2.00 mL) and water (1.00 mL) was stirred at 80 °C for 0.5 h. The reaction mixture was concentrated to give a residue. The crude product was purified by reversed-phase HPLC (0.1% NH₃·H₂O) and lyophilized to give *N*-(3-chloro-2-fluorophenyl)-7-((1,4-dimethylpiperidin-4-yl)ethynyl)quinazoline-4,6-diamine **S21** (200 mg, crude) as a yellow solid. MS (ESI) *m/z* 424.2 [M+H]⁺.


[0764] **4**: To a solution of *N*-(3-chloro-2-fluorophenyl)-7-((1,4-dimethylpiperidin-4-yl)ethynyl)quinazoline-4,6-diamine **S21** (100 mg, 235 μmol, 1.00 eq) and triethylamine (47.7 mg, 471 μmol, 2.00 eq) in dimethyl formamide (1.00 mL) was added prop-2-enoyl chloride (23.5 mg, 259 μmol, 1.10 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water(10mM NH₄HCO₃)-ACN]; B%: 27%-57%, 10min) and further purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4μ; mobile phase: [water(0.225%FA)-ACN]; B%: 10%-40%, 10min) and lyophilized to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,4-dimethylpiperidin-4-yl)ethynyl)quinazolin-6-yl)acrylamide **4** (3.51 mg, 7.27 μmol, 3% yield, 99% purity) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.10 (*br s*, 1H), 9.82 (*br s*, 1H), 8.65 (*s*, 1H), 8.50 (*br s*, 1H), 8.25 (*s*, 1H), 7.84 (*br s*, 1H), 7.51 (*br s*, 2H), 7.30 (*br d*, *J* = 8.2 Hz, 1H), 6.56 (*dd*, *J* = 10.3, 17.2 Hz, 1H), 6.34 (*br d*, *J* = 17.0 Hz, 1H), 5.85 (*br d*, *J* = 10.0 Hz, 1H), 2.64 (*br d*, *J* = 11.4 Hz, 2H), 2.32 - 2.25 (*m*, 2H), 2.19 (*s*, 3H), 1.79 (*br d*, *J* = 12.5 Hz, 2H), 1.54 (*dt*, *J* = 3.7, 12.4 Hz, 2H), 1.34 (*s*, 3H). MS (ESI) *m/z* 478.3 [M+H]⁺.

Example 5. Synthesis of Compound 5



[0765] **5**: To a solution of *N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S10** (250 mg, 610 μ mol, 1.00 eq), 2-fluoroacrylic acid (82.4 mg, 915 μ mol, 1.50 eq) and triethylamine (494 mg, 4.88 mmol, 679 μ L, 8.00 eq) in ethyl acetate (3.00 mL) was added propylphosphonic anhydride (1.55 g, 2.44 mmol, 1.45 mL, 50% purity, 4.00 eq) dropwise at 0 °C. The mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (30.0 mL) and extracted with ethyl acetate (3 $\times$ 30.0 mL). The combined organic layer was washed with brine (20.0 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH₄HCO₃)-ACN (=MeCN)]; B%: 32%-62%, 10min) and lyophilized to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)-2-fluoroacrylamide **5** (35.22 mg, 67.9 μ mol, 11% yield, 93% purity) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 10.12 (*br s*, 1H), 10.04 (*br s*, 1H), 8.70 (*s*, 1H), 8.52 (*s*, 1H), 7.84 (*s*, 1H), 7.52 (*br t*, *J* = 7.3 Hz, 2H), 7.30 (*br t*, *J* = 8.0 Hz, 1H), 5.89 - 5.69 (*m*, 1H), 5.55 (*dd*, *J* = 3.7, 15.7 Hz, 1H), 2.73 (*d*, *J* = 8.8 Hz, 1H), 2.65 - 2.62 (*m*, 1H), 2.57 (*br s*, 2H), 2.27 (*s*, 3H), 2.24 - 2.16 (*m*, 1H), 1.86 (*td*, *J* = 7.3, 12.5 Hz, 1H), 1.43 (*s*, 3H). LC-MS (ESI) *m/z* 482.1 [*M*+H]⁺.

Example 6. Synthesis of Compound 6



[0766] **S22**: A mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (1.20 g, 2.57 mmol, 1.00 eq), (*R*)-tert-butyl 2-ethynyl-2-methylpyrrolidine-1-carboxylate **S5** (591 mg, 2.83 mmol, 1.10 eq), tetrakis(triphenylphosphine) palladium(0) (297 mg, 257 μmol , 0.100 eq), cuprous iodide (97.9 mg, 514 μmol , 0.200 eq) and triethylamine (780 mg, 7.71 mmol, 1.07 mL, 3.00 eq) in tetrahydrofuran (10.0 mL) was degassed and purged with nitrogen for three times. Then the mixture was stirred at 25 °C for 3 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=3/1) to afford (*R*)-tert-butyl 2-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-2-methylpyrrolidine-1-carboxylate **S22** (1.43 g, crude) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ = 8.92 - 8.69 (m, 2H), 8.14 - 7.99 (m, 1H), 7.67 - 7.41 (m, 1H), 7.40 - 7.33 (m, 1H), 7.22 - 7.16 (m, 1H), 3.72 - 3.64 (m, 1H), 3.45 (br d, J = 8.6 Hz, 1H), 2.54 - 2.42 (m, 1H), 2.20 - 2.05 (m, 2H), 1.95 - 1.84 (m, 1H), 1.74 (br s, 3H), 1.49 (br s, 9H).

[0767] **S23**: To a solution of (*R*)-tert-butyl 2-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-2-methylpyrrolidine-1-carboxylate **S22** (1.90 g, 3.61 mmol, 1.00 eq) in hydrochloric/ethyl acetate (4M, 18.0 mL). The mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give (*R*)-N-(3-chloro-2-fluorophenyl)-7-((2-methylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S23** (1.60 g, 3.46 mmol, 96% yield, hydrochloride) as a brown solid. It was used for the next step without purification. ^1H NMR (400 MHz, DMSO-d_6) δ = 10.28 - 10.05 (m, 2H), 9.70 (s, 1H), 8.80 (s, 1H), 8.26 (s, 1H), 7.66 - 7.59 (m, 2H), 7.59 - 7.49 (m, 2H), 7.35 (dt, J = 1.1, 8.1 Hz, 1H), 3.47 - 3.37

(m, 2H), 2.41 - 2.32 (m, 1H), 2.26 - 2.08 (m, 3H), 1.91 (s, 4H), 1.83 (s, 3H).


[0768] **S24**: To a solution of (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((2-methylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S23** (1.60 g, 3.46 mmol, 1.00 eq, hydrochloride) and paraformaldehyde (519 mg, 17.3 mmol, 476 uL, 5.00 eq) in trifluoroethanol (16.0 mL) was added sodium borohydride (654 mg, 17.3 mmol, 5.00 eq) slowly. The mixture was stirred at 60 °C for 10 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed phase chromatography (column: C18, 330 g; condition: CH₃CN - 0.1% NH₃·H₂O) to afford (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S24** (0.360 g, 0.818 mmol, 23% yield) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.89 (s, 1H), 8.74 (s, 1H), 8.35 (*br t*, *J* = 7.30 Hz, 1H), 8.15 (s, 1H), 7.32 - 7.26 (m, 2H), 7.25 - 7.18 (m, 1H), 3.19 - 3.06 (m, 1H), 2.77 - 2.61 (m, 1H), 2.45 (s, 3H), 2.36 - 2.26 (m, 1H), 1.96 - 1.89 (m, 3H), 1.54 (s, 3H).

[0769] **S25**: To a solution of (*R*)-*N*-(3-chloro-2-fluorophenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S24** (0.358 g, 813 umol, 1.00 eq) in methanol (8.00 mL) and water (5.00 mL) was added ammonium chloride (348 mg, 6.51 mmol, 8.00 eq) and iron powder (363 mg, 6.51 mmol, 8.00 eq). Then the mixture was stirred at 80 °C for 10 h. The reaction mixture was filtered and concentrated in vacuum to give a residue. The residue was poured into water (20.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 30.0 mL). The combined organic phase was washed with brine (3 × 30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by reversed phase chromatography (column: C18, 80 g; condition: CH₃CN-0.1% NH₃H₂O) to afford (*R*)-*N*⁴-(3-chloro-2-fluorophenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)quinazoline-4,6-diamine **S25** (0.160 g, 390 umol, 48% yield) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.59 - 8.52 (m, 2H), 7.83 (s, 1H), 7.29 (*br s*, 1H), 7.10 - 7.03 (m, 2H), 6.88 (s, 1H), 4.50 (*br s*, 2H), 3.08 - 2.98 (m, 1H), 2.57 - 2.48 (m, 1H), 2.34 (s, 3H), 2.22 - 2.16 (m, 1H), 1.86 - 1.79 (m, 3H), 1.45 (s, 3H).

[0770] **6**: To a solution of (*R*)-*N*⁴-(3-chloro-2-fluorophenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)quinazoline-4,6-diamine **S25** (0.076 g, 185 umol, 1.00 eq) and acrylic acid (26.7 mg, 370 umol, 25.5 uL, 2.00 eq) in dimethylformamide (3.00 mL) was added pyridine (44.0 mg, 556 umol, 44.9 uL, 3.00 eq) and 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (88.9 mg, 463 umol, 2.50 eq). The mixture was stirred at 25 °C for 2 h. The reaction mixture was filtered and concentrated in vacuum to give a residue. The residue was purified by Prep-HPLC

(column: Xtimate C18 150×25mm×5μm; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 38%-68%, 10min) and lyophilized to afford (*R*)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,2-dimethylpyrrolidin-2-yl)-ethynyl)quinazolin-6-yl)acrylamide **6** (18.09 mg, 38.60 μmol, 21% yield, 99% purity) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 9.23 (s, 1H), 8.76 (s, 1H), 8.45 - 8.28 (m, 2H), 8.03 (s, 1H), 7.82 (*br s*, 1H), 7.26 - 7.15 (m, 2H), 6.56 (dd, *J* = 0.7, 16.8 Hz, 1H), 6.32 (dd, *J* = 10.3, 16.8 Hz, 1H), 5.94 (d, *J* = 10.1 Hz, 1H), 3.21 - 3.13 (m, 1H), 2.67 - 2.59 (m, 1H), 2.46 (s, 3H), 2.36 - 2.27 (m, 1H), 2.07 - 1.89 (m, 3H), 1.58 (s, 3H), MS (ESI) *m/z* 464.2 [M+H]⁺.

Example 7. Synthesis of Compound 7



[0771] **S27**: A mixture of 4-chloro-7-fluoro-6-nitroquinazoline **S26** (3.00 g, 13.2 mmol, 1.00 eq) and 3,4-dichloro-2-fluoroaniline (2.37 g, 13.2 mmol, 1.00 eq) in acetonitrile (30.0 mL) was stirred at 25 °C for 12 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (20.0 mL) and filtered, the filter cake was washed with ethyl acetate (10.0 mL) and concentrated to dryness to give N-(3,4-dichloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine **S27** (4.00 g, 10.8 mmol, 82% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ = 9.87 - 9.72 (m, 1H), 8.90 - 8.79 (m, 1H), 8.35 (s, 1H), 8.05 - 7.96 (m, 1H), 7.81 (d, *J* = 12.2 Hz, 1H), 7.69 - 7.64 (m, 1H), 7.62 - 7.55 (m, 1H). MS (ESI) *m/z* 370.8

$[M+H]^+$.

[0772] **S28**: To a solution of N-(3,4-dichloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine **S27** (4.00 g, 10.8 mmol, 1.00 eq) in dimethyl formamide (40.0 mL) was added potassium acetate (5.29 g, 53.9 mmol, 5.00 eq) at 25 °C. The mixture was stirred at 100 °C for 5 h. The mixture was concentrated to afford a residue. The residue was triturated with water (50.0 mL). After filtration, the filter cake was washed with water (30.0 mL), dried in vacuum to give 4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol **S28** (3.50 g, 9.48 mmol, 88% yield) as a brown solid. MS (ESI) m/z 368.9 $[M+H]^+$.

[0773] **S29**: To a solution of 4-(3,4-dichloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol **S28** (3.50 g, 9.48 mmol, 1.00 eq) and pyridine (3.75 g, 47.4 mmol, 3.83 mL, 5.00 eq) in dichloromethane (40.0 mL) was added trifluoromethanesulfonic peroxyanhydride (5.35 g, 18.9 mmol, 3.13 mL, 2.00 eq) dropwise at 0 °C, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (300 mL) and the aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic phase was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 8/1) to afford 4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S29** (700 mg, 1.40 mmol, 14% yield) as a yellow oil. MS (ESI) m/z 500.9 $[M+H]^+$.

[0774] **S30**: To a solution of 4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S29** (600 mg, 1.20 mmol, 1.00 eq), tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (250 mg, 1.20 mmol, 1.00 eq) and triethylamine (4.36 g, 43.1 mmol, 6.00 mL, 36.0 eq) in dimethyl formamide (6.00 mL) was added cuprous iodid (45.6 mg, 239 μ mol, 0.200 eq) and tetrakis(triphenylphosphine) palladium(0) (138 mg, 119 μ mol, 0.100 eq) at 25 °C under nitrogen, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (120 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 × 60.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 6/1 to 3/1) to afford tert-butyl 3-((4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S30** (600 mg, 1.07 mmol, 89% yield) as a yellow oil. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.84 - 10.57 (m, 1H), 9.57 - 9.22 (m, 1H), 8.66 (br s, 1H), 8.03 - 7.86 (m, 2H), 7.49 - 7.36

(m, 1H), 3.61 (d, J = 10.2 Hz, 1H), 3.56 - 3.44 (m, 2H), 3.30 - 3.22 (m, 1H), 2.26 - 2.13 (m, 1H), 2.05 - 1.93 (m, 1H), 1.47 - 1.44 (m, 3H), 1.42 (s, 9H). MS (ESI) m/z 504.1 [M+H-56]⁺.

[0775] **S31**: To a solution of tert-butyl 3-((4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S30** (500 mg, 892 μ mol, 1.00 eq) in dichloromethane (5.00 mL) was added trifluoroacetic acid (1.54 g, 13.5 mmol, 1.00 mL, 15.1 eq) at 25 °C, the mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to give N-(3,4-dichloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl) ethynyl)-6-nitroquinazolin-4-amine (400 mg, 869 μ mol, 97% yield) **S31** as a yellow oil. MS (ESI) m/z 460.1 [M+H]⁺.


[0776] **S32**: To a solution of N-(3,4-dichloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S31** (400 mg, 869 μ mol, 1.00 eq) and paraformaldehyde (130 mg, 4.35 mmol, 119 μ L, 5.00 eq) in trifluoroethanol (4.00 mL) was added sodium borohydride (65.7 mg, 1.74 mmol, 2.00 eq) at 25 °C, the mixture was stirred at 60 °C for 2 h. The reaction was quenched with methanol slowly and then concentrated to give a residue which was poured into water (80.0 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 $\times$ 60.0 mL). The combined organic phase was washed with brine (50.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N-(3,4-dichloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S32** (400 mg, crude) as a yellow solid. MS (ESI) m/z 474.4 [M+H]⁺.

[0777] **S33**: A mixture of N-(3,4-dichloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S32** (400 mg, 843 μ mol, 1.00 eq), iron powder (141 mg, 2.53 mmol, 3.00 eq) and ammonium chloride (225 mg, 4.22 mmol, 5.00 eq) in methanol (4.00 mL) and water (2.00 mL) was stirred at 80 °C for 1 h. The reaction mixture was filtered and the filtrate was concentrated to give a residue, the residue was poured into water (80.0 mL), the aqueous phase was extracted with ethyl acetate (3 $\times$ 40.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by reversed-phase HPLC (0.1% ammonium hydroxide) to afford N⁴-(3,4-dichloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine **S33** (140 mg, 315 μ mol, 37% yield) as a yellow solid. MS (ESI) m/z 444.1 [M+H]⁺.

[0778] **7**: To a solution of N⁴-(3,4-dichloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S33** (100 mg, 225 μ mol, 1.00 eq), acrylic acid (16.2 mg, 225 μ mol, 15.4 μ L, 1.00 eq) and pyridine (89.0 mg, 1.13 mmol, 90.8 μ L, 5.00 eq) in dimethyl

formamide (1.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (172 mg, 900 μmol , 4.00 eq), the mixture was stirred at 25 °C for 2 h. The reaction mixture was filtered to give a filtrate. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 51%-70%, 10min) and prep-HPLC (column: UniSil 3-100 C18 Ultra (150*25mm*3 μm); mobile phase: [water(0.225%FA)-ACN]; B%: 14%-44%, 10min) to afford N-(4-((3,4-dichloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **7** (29.0 mg, 53.2 μmol , 23% yield, FA) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 9.07 (s, 1H), 8.82 (br s, 1H), 8.64 (s, 1H), 8.37 (s, 1H), 8.22 (t, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.77 (br s, 1H), 7.24 (dd, J = 2.0, 9.0 Hz, 1H), 6.51 - 6.35 (m, 2H), 5.83 - 5.76 (m, 1H), 3.17 (br d, J = 9.2 Hz, 1H), 3.14 - 3.05 (m, 1H), 2.60 (dt, J = 6.0, 9.4 Hz, 1H), 2.46 (s, 3H), 2.40 - 2.30 (m, 2H), 1.96 (ddd, J = 6.2, 8.8, 13.0 Hz, 1H), 1.50 (s, 3H). MS (ESI) m/z 498.1 $[\text{M}+\text{H}]^+$.

Example 8. Synthesis of Compound 8



[0779] **S34**: A mixture of 4-chloro-7-fluoro-6-nitroquinazoline **S26** (3.50 g, 15.4 mmol, 1.00 eq) and 3-chloro-2,4-difluoroaniline (2.52 g, 15.4 mmol, 1.00 eq) in acetonitrile (30.0 mL) was stirred at 25 °C for 12 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (20.0 mL) and filtered, the filter cake was washed with ethyl acetate

(10.0 mL) and concentrated to dryness to give N-(3-chloro-2,4-difluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine **S34** (4.20 g, 11.8 mmol, 77% yield) as an off-white solid. MS (ESI) m/z 354.9 $[M+H]^+$.

[0780] **S35**: To a solution of N-(3-chloro-2,4-difluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine **S34** (4.05 g, 11.4 mmol, 1.00 eq) in dimethyl formamide (40.0 mL) was added potassium acetate (5.60 g, 57.1 mmol, 5.00 eq) at 25 °C. The mixture was stirred at 100 °C for 5 h. The mixture was concentrated to afford a residue. The residue was triturated with water (50.0 mL). After filtration, the filter cake was washed with water (30.0 mL), dried in vacuum to give 4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-ol **S35** (3.50 g, 9.92 mmol, 87% yield) as a brown solid. MS (ESI) m/z 353.0 $[M+H]^+$.

[0781] **S36**: To a solution of 4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-ol **S35** (3.00 g, 8.51 mmol, 1.00 eq) and pyridine (3.36 g, 42.5 mmol, 3.43 mL, 5.00 eq) in dichloromethane (40.0 mL) was added trifluoromethanesulfonic peroxyanhydride (4.80 g, 17.0 mmol, 2.81 mL, 2.00 eq) dropwise at 0 °C, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (150 mL) and the aqueous phase was extracted with ethyl acetate (3 × 50.0 mL). The combined organic phase was washed with brine (50.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 8/1) to afford 4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S36** (1.20 g, 2.48 mmol, 29% yield) as a yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ = 9.02 - 8.96 (m, 1H), 8.90 (s, 1H), 8.07 (dt, J = 5.4, 8.8 Hz, 1H), 8.01 - 7.89 (m, 2H), 7.18 - 7.11 (m, 1H). MS (ESI) m/z 484.9 $[M+H]^+$.

[0782] **S37**: To a solution of 4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S36** (1.00 g, 2.06 mmol, 1.00 eq), tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (518 mg, 2.48 mmol, 1.20 eq) and triethylamine (2.18 g, 21.6 mmol, 3.00 mL, 10.5 eq) in dimethyl formamide (6.00 mL) was added cuprous iodide (78.6 mg, 413 μ mol, 0.200 eq) and tetrakis(triphenylphosphine) palladium(0) (238 mg, 206 μ mol, 0.100 eq) at 25 °C under nitrogen, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (120 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 × 60.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by

silica gel chromatography (Petroleum ether/Ethyl acetate = 6/1 to 3/1) to afford tert-butyl 3-((4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S37** (1.20 g, crude) as a yellow oil. ¹H NMR (400MHz, DMSO-d₆) δ = 10.63 (s, 1H), 9.39 (s, 1H), 8.67 (br s, 1H), 8.01 (br s, 1H), 7.41 (br s, 2H), 3.61 (d, J =10.4 Hz, 1H), 3.54 - 3.42 (m, 2H), 3.29 - 3.22 (m, 1H), 2.24 - 2.15 (m, 1H), 1.99 - 1.92 (m, 1H), 1.45 (s, 3H), 1.42 (s, 9H). MS (ESI) m/z 487.9 [M+H]⁺.

[0783] **S38**: To a solution of tert-butyl 3-((4-((3-chloro-2,4-difluorophenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methylpyrrolidine-1-carboxylate **S37** (900 mg, 1.65 mmol, 1.00 eq) in ethyl acetate (4.00 mL) was added 4 M hydrochloride/ethyl acetate (4.00 mL) at 25 °C, the mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give a residue. The residue was triturated with ethyl acetate (5.00 mL). After filtration, the filter cake was washed with ethyl acetate (2.00 mL), dried in vacuum to afford N-(3-chloro-2,4-difluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S38** (1.00 g, crude, hydrochloride) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 9.74 (br s, 1H), 9.61 (s, 2H), 8.80 (br s, 1H), 8.21 (br s, 1H), 7.46 (dt, J = 1.6, 8.8 Hz, 1H), 3.51 - 3.42 (m, 3H), 3.25 - 3.18 (m, 1H), 2.33 (td, J = 6.2, 12.6 Hz, 1H), 2.12 - 2.07 (m, 1H), 1.53 (s, 3H). MS (ESI) m/z 444.0 [M+H]⁺.


[0784] **S39**: To a solution of N-(3,4-dichloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S38** (600 mg, 1.35 mmol, 1.00 eq) and paraformaldehyde (203 mg, 6.76 mmol, 5.00 eq) in trifluoroethanol (4.00 mL) was added sodium borohydride (102 mg, 2.70 mmol, 2.00 eq) at 25 °C, the mixture was stirred at 60 °C for 2 h. The reaction was quenched with methanol slowly and then concentrated to give a residue which was poured into water (50.0 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 × 50.0 mL). The combined organic phase was washed with brine (50.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N-(3-chloro-2,4-difluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S39** (550 mg, crude) as a yellow solid. MS (ESI) m/z 458.1 [M+H]⁺.

[0785] **S40**: A mixture of N-(3-chloro-2,4-difluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S39** (700 mg, 1.53 mmol, 1.00 eq), iron powder (256 mg, 4.59 mmol, 3.00 eq) and ammonium chloride (409 mg, 4.64 mmol, 5.00 eq) in methanol (7.00 mL) and water (3.00 mL) was stirred at 80 °C for 1 h. The reaction mixture was filtered and the filtrate was concentrated to give a residue, the residue was poured into water (80.0 mL), the aqueous phase

was extracted with ethyl acetate (3×40.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2,4-difluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline -4,6-diamine **S40** (500 mg, 1.17 mmol, 76% yield) as a yellow solid. MS (ESI) m/z 428.2 $[M+H]^+$.

[0786] **8**: To a solution of N⁴-(3-chloro-2,4-difluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline -4,6-diamine **S40** (200 mg, 467 μ mol, 1.00 eq), acrylic acid (34.0 mg, 468 μ mol, 32.0 μ L, 1.00 eq) and pyridine (185.0 mg, 2.34 mmol, 189 μ L, 5.00 eq) in dimethyl formamide (1.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (358 mg, 1.87 mmol, 4.00 eq), the mixture was stirred at 25 °C for 2 h. The reaction mixture was filtered to give a filtrate. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH_4HCO_3)- ACN];B%: 37%-65%,10min) to afford N-(4-((3-chloro-2,4-difluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-quinazolin-6-yl)acrylamide **8** (40.6 mg, 1.84 μ mol, 18% yield, FA) as a yellow solid. ¹H NMR (400MHz, CDCl_3) δ = 9.10 (s, 1H), 8.60 (s, 2H), 8.04 (dt, J = 5.6, 8.8 Hz, 1H), 7.85 (s, 1H), 7.71 (br s, 1H), 7.02 - 6.93 (m, 1H), 6.52 - 6.42 (m, 1H), 6.39 - 6.29 (m, 1H), 5.80 (dd, J = 1.2, 10.0 Hz, 1H), 3.01 (d, J = 8.8 Hz, 1H), 2.97 - 2.87 (m, 1H), 2.55 - 2.45 (m, 1H), 2.40 - 2.34 (m, 4H), 2.34 - 2.27 (m, 1H). MS (ESI) m/z 482.2 $[M+H]^+$.

Example 9. Synthesis of Compound 10



[0787] **S51**: To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (1.00 g, 2.14 mmol, 1.00 eq), *tert*-butyl 1-ethynyl-7-


azabicyclo[2.2.1]heptane-7-carboxylate **S45** (616 mg, 2.79 mmol, 1.30 *eq*), triethylamine (2.17 g, 21.42 mmol, 2.98 mL, 10.0 *eq*) and copper iodide (81.6 mg, 428 μ mol, 0.200 *eq*) in dimethyl formamide (25.0 mL) was added tetrakis[triphenylphosphine]palladium(0) (128 mg, 107 μ mol, 0.0500 *eq*) at 25 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 $\times$ 20 mL). The combined organic layers were washed with brine (3 $\times$ 20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate = 1/0 to 1/1) to give *tert*-butyl 1-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate **S51** (700 mg, 1.30 mmol, 60% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.66 (s, 1H), 9.45 (s, 1H), 8.68 (s, 1H), 8.01 (s, 1H), 7.61 - 7.55 (m, 2H), 7.33 (dt, *J* = 1.0, 8.0 Hz, 1H), 4.22 (t, *J* = 5.0 Hz, 1H), 2.10 - 1.94 (m, 4H), 1.81 (td, *J* = 5.6, 10.8 Hz, 2H), 1.62 - 1.47 (m, 2H), 1.38 (s, 9H). MS (ESI) *m/z* 538.2 [M+H]⁺

[0788] **S52**: To a solution of *tert*-butyl 1-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-7- azabicyclo[2.2.1]heptane-7-carboxylate **S51** (650 mg, 1.21 mmol, 1.00 *eq*) in dichloromethane (25.0 mL) was added trifluoroacetic acid (5.51 g, 48.3 mmol, 3.58 mL, 40.0 *eq*) dropwise and the mixture was stirred at 25 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to remove solvent. To the residue was added saturated sodium dicarbonate solution till pH = 8. Then the mixture was filtered and the filter cake was dried to give 7-(7-azabicyclo[2.2.1]heptan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6- nitroquinazolin-4-amine **S52** (500 mg, crude) as a yellow solid. MS (ESI) *m/z* 438.2 [M+H]⁺

[0789] **S53**: A mixture of 7-(7-azabicyclo[2.2.1]heptan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin- 4-amine **S52** (450 mg, 1.03 mmol, 1.00 *eq*) and paraformaldehyde (154 mg, 5.14 mmol, 5.00 *eq*) in trifluoroethanol (25.0 mL) was stirred at 60 °C for 0.5 h under nitrogen atmosphere. Then to the mixture was added sodium borohydride (77.7 mg, 2.06 mmol, 2.00 *eq*) in portions at 60 °C and the mixture was refluxed for 4.5 h at 60 °C. The reaction mixture was concentrated under reduced pressure to remove solvent and diluted with water (20 mL), extracted with ethyl acetate (3 $\times$ 20 mL). The combined organic layers were washed with brine (3 $\times$ 20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Ethyl acetate) to give *N*-(3-chloro-2-fluorophenyl)-7-((7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)ethynyl)-6-

nitroquinazolin-4-amine **S53** (300 mg, 664 μmol , 64% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 8.88 (br s, 1H), 8.79 (s, 1H), 8.30 (br s, 1H), 8.15 (s, 1H), 8.06 - 7.90 (m, 1H), 7.32 - 7.29 (m, 1H), 7.25 - 7.17 (m, 1H), 3.48 - 3.38 (m, 1H), 2.49 (s, 3H), 2.14 (br d, J = 1.8 Hz, 2H), 2.02 (br d, J = 8.8 Hz, 2H), 1.92 - 1.84 (m, 2H), 1.49 (br s, 2H). MS (ESI) m/z 452.3 $[\text{M}+\text{H}]^+$ [0790] **S54**: A mixture of *N*-(3-chloro-2-fluorophenyl)-7-((7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)ethynyl)-6-nitroquinazolin-4-amine **S53** (300 mg, 664 μmol , 1.00 *eq*), iron powder (185 mg, 3.32 mmol, 5.00 *eq*), ammonium chloride (177 mg, 3.32 mmol, 5.00 *eq*) in water (10.0 mL) and methanol (15.0 mL) was degassed and purged with nitrogen for 3 times, and then the mixture was stirred at 80 °C for 4 h under nitrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Methanol/Ethyl acetate = 0/1 to 1/5) to give *N*⁴-(3-chloro-2-fluorophenyl)-7-((7-methyl-7-azabicyclo[2.2.1] heptan-1-yl)ethynyl)quinazoline-4,6-diamine **S54** (90.0 mg, 213 μmol , 32% yield) as a yellow solid. MS (ESI) m/z 422.3 $[\text{M}+\text{H}]^+$ [0791] **10**: To a stirring solution of *N*⁴-(3-chloro-2-fluorophenyl)-7-((7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)ethynyl) quinazoline-4,6-diamine **S54** (45.0 mg, 107 μmol , 1.00 *eq*), pyridine (16.8 mg, 213 μmol , 17.2 μL , 2.00 *eq*) and acrylic acid (15.4 mg, 213 μmol , 14.6 μL , 2.00 *eq*) in dimethyl formamide (1.50 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (81.8 mg, 427 μmol , 4.00 *eq*) in portions at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was filtered and the filtrate was purified by *prep*-HPLC (column: Xtimate C₁₈ 150*25mm*5 μm ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 43%-73%, 10min) to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)ethynyl)quinazolin-6-yl)acrylamide **10** (15.79 mg, 32.8 μmol , 30% yield, 99% purity) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 9.22 (s, 1H), 8.76 (s, 1H), 8.51 (br s, 1H), 8.35 (br t, J = 7.4 Hz, 1H), 8.05 (s, 1H), 7.87 (br s, 1H), 7.26 - 7.15 (m, 2H), 6.62 - 6.42 (m, 2H), 5.91 (br d, J = 8.8 Hz, 1H), 3.49 (br s, 1H), 2.50 (s, 3H), 2.17 (br d, J = 11.5 Hz, 2H), 2.11 - 2.02 (m, 2H), 1.94 (br d, J = 10.4 Hz, 2H), 1.57 (br s, 2H). MS (ESI) m/z 476.3 $[\text{M}+\text{H}]^+$

Example 10. Synthesis of Compound 11



[0792] **S56**: To a solution of 1-(*tert*-butoxycarbonyl)-3-methylazetidine-3-carboxylic acid **S55** (800 mg, 3.72 mmol, 1.00 *eq*) in tetrahydrofuran (10.0 mL) was added borane dimethyl sulfide complex (10.0 M, 558 μL , 1.50 *eq*) dropwise at 0 °C. The mixture was stirred at 20 °C for 1 h. The mixture was quenched with methanol (50.0 mL) and concentrated to give *tert*-butyl 3-(hydroxymethyl)-3-methylazetidine-1-carboxylate **S56** (750 mg, crude) as colorless oil. ^1H NMR (400MHz, CDCl_3) δ = 3.70 (d, J = 8.4 Hz, 2H), 3.63 (br t, J = 5.8 Hz, 1H), 3.54 (s, 2H), 3.48 (d, J = 8.4 Hz, 2H), 1.37 (s, 9H), 1.20 (s, 3H).

[0793] **S57**: To a solution of *tert*-butyl 3-(hydroxymethyl)-3-methylazetidine-1-carboxylate **S56** (750 mg, 3.73 mmol, 1.00 *eq*) in dichloromethane (10.0 mL) was added Dess-Martin Periodinane (3.16 g, 7.45 mmol, 2.31 mL, 2.00 *eq*) in portions at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10/1 to 3/1) to give *tert*-butyl 3-formyl-3-methylazetidine-1-carboxylate **S57** (740 mg, crude) as colorless oil.

[0794] **S58**: To a solution of *tert*-butyl 3-formyl-3-methylazetidine-1-carboxylate **S57** (740 mg, 3.71 mmol, 1.00 *eq*) and potassium carbonate (1.03 g, 7.43 mmol, 2.00 *eq*) in methanol (8.00 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (928 mg, 4.83 mmol, 1.30 *eq*) dropwise. The mixture was stirred at 25 °C for 12 h. The mixture was concentrated to give crude product.

The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate = 20/1 to 10/1) to give *tert*-butyl 3-ethynyl-3-methylazetidine-1-carboxylate **S58** (700 mg, 3.59 mmol, 97% yield) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 4.00 (d, J = 8.1 Hz, 2H), 3.66 (d, J = 8.2 Hz, 2H), 2.25 (s, 1H), 1.47 (s, 3H), 1.37 (s, 9H).

[0795] **S59**: To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S6** (900 mg, 1.93 mmol, 1.00 *eq*), *tert*-butyl 3-ethynyl-3-methylazetidine-1-carboxylate (414 mg, 2.12 mmol, 1.10 *eq*) and copper(I) iodide (73.5 mg, 386 μ mol, 0.200 *eq*) in dimethyl formamide (5.00 mL) and triethylamine (5.00 mL) was added tetrakis(triphenylphosphine)palladium(0) (223 mg, 193 μ mol, 0.100 *eq*) in one portion under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (2 $\times$ 40.0 mL). The combined organic layer was washed with brine (20.0 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10/1 to 3/1) to give *tert*-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylazetidine-1-carboxylate **S59** (650 mg, 1.27 mmol, 66% yield) as yellow oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.88 - 10.52 (m, 1H), 9.43 (br s, 1H), 8.67 (br s, 1H), 8.06 (br s, 1H), 7.67 - 7.45 (m, 2H), 7.37 - 7.28 (m, 1H), 4.11 (br d, J = 7.7 Hz, 2H), 3.88 (br d, J = 7.7 Hz, 2H), 1.62 (s, 3H), 1.41 (s, 9H). MS (ESI) m/z 512.0 [M+H]⁺

[0796] **S60**: To a solution of *tert*-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylazetidine-1-carboxylate **S59** (600 mg, 1.17 mmol, 1.00 *eq*) in methanol (5.00 mL) was added hydrochloric acid / ethyl acetate (4 M, 5.00 mL, 17.1 *eq*) dropwise. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give *N*-(3-chloro-2-fluorophenyl)-7-((3-methylazetidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S60** (480 mg, 1.17 mmol, 99% yield) as a yellow solid. MS (ESI) m/z 411.9 [M+H]⁺

[0797] **S61**: To a solution of *N*-(3-chloro-2-fluorophenyl)-7-((3-methylazetidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S60** (480 mg, 1.17 mmol, 1.00 *eq*) in 2,2,2-trifluoroethanol (10.0 mL) was added paraformaldehyde (175 mg, 5.83 mmol, 161 μ L, 5.00 *eq*) in portions at 60 °C. The mixture was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (88.2 mg, 2.33 mmol, 2.00 *eq*) in portions. The mixture was stirred at 60 °C for 1 h. The mixture was concentrated to give crude product. The residue was diluted with water (50.0 mL) and extracted with ethyl acetate (3 $\times$ 30.0 mL). The combined organic layer was washed with brine (20.0 mL)

and dried over sodium sulfate, filtered and concentrated to give *N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylazetidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S61** (500 mg, crude) as a yellow solid.


[0798] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.36 (s, 1H), 8.60 (br s, 1H), 7.95 (s, 1H), 7.71 - 7.42 (m, 3H), 7.31 (t, *J* = 7.7 Hz, 1H), 3.32 - 3.30 (m, 2H), 3.28 - 3.24 (m, 2H), 2.27 (s, 3H), 1.60 (s, 3H).

[0799] **S62**: To a solution of *N*-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylazetidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S61** (500 mg, 1.17 mmol, 1.00 *eq*) and ammonium chloride (314 mg, 5.87 mmol, 5.00 *eq*) in methanol (20.0 mL) and water (5.00 mL) was added iron powder (328 mg, 5.87 mmol, 5.00 *eq*) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was added methanol (200 mL) and filtered. The filtrate was concentrated to give crude product. The residue was diluted with saturated sodium hydrogencarbonate solution (50.0 mL) and extracted with ethyl acetate (3 × 40.0 mL). The combined organic layer was washed with brine (20.0 mL) and dried over sodium sulfate, filtered and concentrated to give *N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylazetidin-3-yl)ethynyl)quinazoline-4,6-diamine **S62** (450 mg, 1.14 mmol, 97% yield) as a yellow solid. MS (ESI) *m/z* 396.0 [M+H]⁺

[0800] **11**: To a solution of *N*⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylazetidin-3-yl)ethynyl)quinazoline-4,6-diamine **S62** (400 mg, 1.01 mmol, 1.00 *eq*), acrylic acid (87.4 mg, 1.21 mmol, 83.2 μ L, 1.20 *eq*) and pyridine (320 mg, 4.04 mmol, 326 μ L, 4.00 *eq*) in dimethyl formamide (6.00 mL) was added 1-(3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (775 mg, 4.04 mmol, 4.00 *eq*) in portions. The mixture was stirred at 25 °C for 1 h. The mixture was filtered and the filtrate was purified by *prep*-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH₄HCO₃)-ACN];B%: 37%-67%,10min) and lyophilized to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylazetidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **11** (14.08 mg, 30.7 μ mol, 3% yield, 98% purity) as a yellow solid.

[0801] ¹H NMR (400 MHz, CDCl₃) δ = 9.20 (s, 1H), 8.75 (s, 1H), 8.69 (br s, 1H), 8.35 (dt, *J* = 1.9, 7.4 Hz, 1H), 7.99 (s, 1H), 7.87 (br s, 1H), 7.24 - 7.15 (m, 2H), 6.60 - 6.44 (m, 2H), 5.94 - 5.88 (m, 1H), 3.66 (br d, *J* = 3.2 Hz, 2H), 3.36 (br d, *J* = 6.7 Hz, 2H), 2.48 (s, 3H), 1.70 (s, 3H). MS (ESI) *m/z* 449.9 [M+H]⁺

Example 11. Synthesis of Compound 12



[0802] **S64:** To a solution of 1-(*tert*-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid **S63** (1.50 g, 6.54 mmol, 1.00 *eq*) in THF (10.0 mL) was added borane dimethyl sulfide complex (10.0 M, 654 μ L, 1.00 *eq*) dropwise at 0°C. Then the mixture was stirred at 25 °C for 10 h. The reaction mixture was quenched by addition methanol (15.0 mL), and then diluted with water (30.0 mL) and extracted with ethyl acetate (3 $\times$ 60.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give *tert*-butyl 3-(hydroxymethyl)-3-methylpyrrolidine-1- carboxylate **S64** (1.65 g, crude) as yellow oil. ^1H NMR (400 MHz, Chloroform-*d*) δ = 3.48 - 3.27 (m, 4H), 3.27 - 3.14 (m, 1H), 3.05 - 2.90 (m, 1H), 1.86 - 1.70 (m, 1H), 1.56 - 1.46 (m, 1H), 1.46 - 1.34 (m, 9H), 1.03 (s, 3H).

[0803] **S65:** To a solution of *tert*-butyl 3-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate **S64** (1.83 g, 8.50 mmol, 1.00 *eq*) in dichloromethane (20.0 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (3.61 g, 8.50 mmol, 2.63 mL, 1.00 *eq*). Then the mixture was stirred at 25 °C for 10 h. The reaction mixture was concentrated under reduced pressure to remove dichloromethane. The residue was diluted with saturated sodium bicarbonate (40.0 mL) and extracted with ethyl acetate (3×80.0 mL). The combined organic layers were washed with brine

(45.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give *tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S65** (1.90 g, crude) as yellow oil. ¹H NMR (400 MHz, Chloroform-*d*) δ = 9.48 (s, 1H), 3.76 - 3.61 (m, 1H), 3.38 - 3.25 (m, 2H), 3.12 - 2.97 (m, 1H), 2.25 - 2.12 (m, 1H), 1.64 (br dd, J = 7.6, 12.9 Hz, 1H), 1.39 (s, 9H), 1.17 (s, 3H).

[0804] **S66**: To a solution of *tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S65** (1.90 g, 8.91 mmol, 1.00 *eq*) and potassium carbonate (2.46 g, 17.8 mmol, 2.00 *eq*) in methanol (20.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (2.05 g, 10.7 mmol, 1.20 *eq*) dropwise at 0 °C. Then the mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate=10/1) to afford *tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S66** (1.40 g, 6.69 mmol, 75% yield) as yellow oil. ¹H NMR (400 MHz, Chloroform-*d*) δ = 3.55 - 3.29 (m, 3H), 3.19 - 3.06 (m, 1H), 2.09 (s, 1H), 2.07 - 1.99 (m, 1H), 1.78 - 1.68 (m, 1H), 1.39 (s, 9H), 1.28 (s, 3H).

[0805] **S67**: A mixture of 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yltrifluoromethane sulfonate **S46** (1.00 g, 1.80 mmol, 1.00 *eq*), *tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S66** (489 mg, 2.34 mmol, 1.30 *eq*), tetrakis(triphenylphosphine) palladium(0) (208 mg, 180 μ mol, 0.100 *eq*), cuprous iodide (68.5 mg, 360 μ mol, 0.200 *eq*) and triethylamine (546 mg, 5.40 mmol, 751 μ L, 3.00 *eq*) in tetrahydrofuran (10.0 mL) was stirred at 25 °C in nitrogen atmosphere for 10 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate=1/1) to afford *tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S67** (0.862 g, 1.40 mmol, 78% yield) as a yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ = 9.03 (d, J = 14.2 Hz, 1H), 8.80 (s, 1H), 8.62 (d, J = 4.6 Hz, 1H), 8.02 (d, J = 4.2 Hz, 1H), 7.93 (s, 1H), 7.82 - 7.76 (m, 1H), 7.70 - 7.65 (m, 2H), 7.48 (dd, J = 3.2, 7.7 Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 5.32 (s, 2H), 3.83 - 3.74 (m, 1H), 3.71 - 3.62 (m, 1H), 3.61 - 3.52 (m, 1H), 3.31 (br d, J = 10.4 Hz, 1H), 2.36 - 2.22 (m, 1H), 1.99 - 1.88 (m, 1H), 1.53 - 1.48 (m, 12H).

[0806] **S68**: A mixture of *tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methylpyrrolidine-1-carboxylate **S67** (0.862 g, 1.40 mmol, 1.00 *eq*) in hydrochloric acid /ethyl acetate (2.00 mL) was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give *N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-

((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4- amine **S68** (0.800 g, crude, hydrochloric acid) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 9.61 (s, 1H), 9.57 - 9.42 (m, 2H), 8.85 - 8.81 (m, 1H), 8.67 (d, J = 5.0 Hz, 1H), 8.14 (s, 1H), 8.05 - 7.98 (m, 2H), 7.59 - 7.55 (m, 1H), 7.49 (dd, J = 5.0, 7.8 Hz, 1H), 7.35 (d, J = 9.0 Hz, 1H), 5.38 (s, 2H), 3.46 - 3.39 (m, 3H), 3.24 - 3.16 (m, 1H), 2.12 - 2.01 (m, 2H), 1.53 (s, 3H).


[0807] **S69**: A mixture of *N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6- nitroquinazolin-4-amine **S68** (0.800 g, 1.45 mmol, 1.00 *eq*, hydrochloric acid), paraformaldehyde (218 mg, 7.25 mmol, 200 μL , 5.00 *eq*) and sodium borohydride (110 mg, 2.90 mmol, 2.00 *eq*) in trifluoroethanol (10.0 mL) was stirred at 60 °C for 12 h. The reaction mixture was quenched by addition methanol (15.0 mL), and concentrated to obtained a residue. Then the mixture diluted with water (15.0 mL) and extracted with ethyl acetate (3 $\times$ 35.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give *N*-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S69** (0.800 g, crude) as a yellow solid. ^1H NMR (400 MHz, Chloroform- d) δ = 8.81 (s, 1H), 8.73 (s, 1H), 8.65 - 8.59 (m, 1H), 8.06 (s, 1H), 7.92 - 7.89 (m, 1H), 7.80 - 7.77 (m, 1H), 7.68 (s, 1H), 7.58 - 7.54 (m, 1H), 7.50 (d, J = 2.8 Hz, 1H), 7.09 - 7.04 (m, 1H), 5.36 - 5.29 (m, 2H), 4.02 - 3.94 (m, 1H), 2.99 - 2.88 (m, 1H), 2.78 - 2.71 (m, 1H), 2.68 - 2.63 (m, 1H), 2.50 - 2.33 (m, 4H), 2.00 - 1.92 (m, 1H), 1.55 - 1.52 (m, 3H).

[0808] **S70**: A mixture of *N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6- nitroquinazolin-4-amine **S69** (0.800 g, 1.51 mmol, 1.00 *eq*), ammonium chloride (243 mg, 4.54 mmol, 3.00 *eq*) and ferrous powder (253 mg, 4.54 mmol, 3.00 *eq*) in methanol (8.00 mL) and water (8.00 mL) was stirred at 80 °C for 10 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified was by reverse phase chromatography (column: C18, 80 g; condition: water-0.1% formic acid - acetonitrile) and lyophilized to afford *N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl) -7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S70** (160 mg, 317 μmol , 21% yield, 99% purity) as a yellow solid. ^1H NMR (400 MHz, Chloroform- d) δ = 8.56 - 8.48 (m, 1H), 8.44 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.73 - 7.65 (m, 2H), 7.58 (br d, J = 7.8 Hz, 1H), 7.47 - 7.39 (m, 1H), 7.17 (br d, J = 6.5 Hz, 1H), 6.98 - 6.87 (m, 2H), 5.25 - 5.14 (m, 2H), 3.19 (br d, J = 10.0 Hz, 1H), 3.13 - 3.02 (m, 1H), 2.92 - 2.84 (m, 1H), 2.72 (br d, J = 10.0 Hz, 1H), 2.51 (s, 3H), 2.34 (br

d, $J = 5.4$ Hz, 1H), 1.97 (td, $J = 7.7, 12.9$ Hz, 1H), 1.48 (s, 3H).

[0809] **12:** A mixture of *N*⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine **S70** (80.0 mg, 160 μ mol, 1.00 *eq*), acrylic acid (15.0 mg, 208 μ mol, 14.3 μ L, 1.30 *eq*), 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (92.2 mg, 481 μ mol, 3.00 *eq*) and pyridine (38.0 mg, 481 μ mol, 38.8 μ L, 3.00 *eq*) in dimethyl formamide (2.00 mL) was stirred at 25 °C for 10 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by *prep*-HPLC (column: Phenomenex Gemini 150×25mm×10 μ m; mobile phase: [water (10mM NH₄HCO₃)-ACN]; B%: 45%-69%, 10min) and lyophilized to afford *N*-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **12** (27.35 mg, 49.0 μ mol, 30% yield, 99% purity) as a yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ = 9.02 (s, 1H), 8.59 (s, 2H), 8.54 - 8.50 (m, 1H), 7.86 - 7.80 (m, 2H), 7.74 (s, 1H), 7.71 - 7.66 (m, 1H), 7.62 - 7.57 (m, 1H), 7.47 (dd, $J = 2.8, 8.8$ Hz, 1H), 7.18 - 7.15 (m, 1H), 6.94 (d, $J = 8.8$ Hz, 1H), 6.50 - 6.41 (m, 1H), 6.39 - 6.29 (m, 1H), 5.83 - 5.76 (m, 1H), 5.23 (s, 2H), 3.00 (d, $J = 9.0$ Hz, 1H), 2.91 (dt, $J = 5.6, 8.8$ Hz, 1H), 2.49 (dt, $J = 6.0, 9.2$ Hz, 1H), 2.40 - 2.35 (m, 4H), 2.34 - 2.25 (m, 1H), 1.90 (ddd, $J = 5.6, 8.8, 13.0$ Hz, 1H), 1.46 (s, 3H). MS (ESI) m/z 553.4 [M+H]⁺

Example 12. Synthesis of Compound 13



[0810] **S72**: To a solution of (*R*)-3-methylpyrrolidine-3-carboxylic acid **S71** (1.20 g, 9.29 mmol) in dichloromethane (40.0 mL) was added di-*tert* butyl dicarbonate (2.43 g, 11.2 mmol) and triethylamine (1.88 g, 18.6 mmol) at 0 °C. The mixture was stirred at 20 °C for 12 h. The mixture was concentrated under vacuum to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1, dichloromethane/methanol/formic acid = 10/1/0.001) to give (*R*)-1-(*tert*-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid **S72** (2.20 g, crude) as brown oil. ^1H NMR (400 MHz, CDCl_3) δ = 3.88 - 3.75 (m, 1H), 3.46 (br s, 2H), 3.29 - 3.17 (m, 1H), 2.45 - 2.23 (m, 1H), 1.90 - 1.67 (m, 1H), 1.47 (br s, 9H), 1.39 (br s, 3H).

[0811] **S73**: To a solution of (*R*)-1-(*tert*-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid **S72** (2.20 g, 9.60 mmol) in tetrahydrofuran (30.0 mL) was added borane dimethyl sulfide complex (10.0 M, 0.960 mL) drop-wise at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched by addition methanol (15.0 mL) and then concentrated under vacuum. The residue was diluted with ethyl acetate (60.0 mL), washed with brine (2 $\times$ 20.0 mL). The combined organic layer was dried over anhydrous sodium sulfate to give (*R*)-*tert*-butyl 3-

(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate **S73** (1.90 g, crude) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ = 3.49 (br d, J = 4.2 Hz, 2H), 3.45 - 3.35 (m, 2H), 3.33 - 3.23 (m, 1H), 3.11 - 2.98 (m, 1H), 1.91 - 1.81 (m, 1H), 1.53 - 1.49 (m, 1H), 1.47 (s, 9H), 1.11 (s, 3H).

[0812] **S74**: To a solution (*R*)-*tert*-butyl 3-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate **S73** (1.90 g, 8.83 mmol) in dichloromethane (100 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (3.74 g, 8.83 mmol) at 0 °C. The mixture was stirred at 20 °C for 12 h. The reaction mixture was concentrated under reduced pressure to remove dichloromethane to give a residue. The residue was diluted with saturated sodium bicarbonate (40.0 mL) and ethyl acetate (100 mL). The mixture was filtered and the filtrate was extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine (45.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give (*R*)-*tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S74** (1.70 g, crude) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ = 9.55 (s, 1H), 3.84 - 3.73 (m, 1H), 3.46 - 3.35 (m, 2H), 3.16 - 3.07 (m, 1H), 2.27 - 2.20 (m, 1H), 1.76 - 1.69 (m, 1H), 1.47 (s, 9H), 1.24 (s, 3H).

[0813] **S75**: To a suspension of (*R*)-*tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S74** (1.70 g, 7.97 mmol), dimethyl (1-diazo-2-oxopropyl)phosphonate (1.84 g, 9.57 mmol) in methanol (10.0 mL) was added potassium carbonate (2.20 g, 15.9 mmol) at 0 °C. The mixture was stirred at 20 °C for 2 h. The reaction mixture was filtered, and filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 10/1) to give (*S*)-*tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S75** (1.10 g, 5.26 mmol, 65% yield) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ = 3.62 - 3.40 (m, 3H), 3.26 - 3.15 (m, 1H), 2.16 (d, J = 3.0 Hz, 1H), 2.14 - 2.08 (m, 1H), 2.14 - 2.07 (m, 1H), 1.87 - 1.77 (m, 1H), 1.47 (s, 9H), 1.36 (s, 3H).

[0814] **S76**: To a suspension of 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S46** (2.78 g, 5.01 mmol), (*S*)-*tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S75** (1.10 g, 5.26 mmol), cuprous iodide (0.191 g, 1.00 mmol), triethylamine (1.52 g, 15.0 mmol) in tetrahydrofuran (30.0 mL) was added tetrakis(triphenylphosphine) palladium (0) (0.578 g, 0.501 mmol) at 20 °C. The mixture was degassed with nitrogen for 0.1 h, and stirred at 20 °C under nitrogen atmosphere for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate =

5/1 to 0/1) to afford (*S*)-*tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methylpyrrolidine-1-carboxylate **S76** (2.50 g, 4.06 mmol, 81% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.92 (s, 1H), 8.80 (s, 1H), 8.61 (td, *J* = 0.8, 4.1 Hz, 1H), 8.43 - 8.33 (m, 1H), 8.11 - 8.00 (m, 1H), 7.96 - 7.90 (m, 1H), 7.82 - 7.73 (m, 1H), 7.70 - 7.63 (m, 1H), 7.55 (dt, *J* = 2.8, 5.8 Hz, 1H), 7.07 - 6.98 (m, 1H), 5.32 (s, 2H), 3.77 (s, 1H), 3.69 - 3.61 (m, 1H), 3.59 - 3.48 (m, 1H), 3.19 (br dd, *J* = 3.6, 7.2 Hz, 1H), 2.35 - 2.23 (m, 1H), 1.99 - 1.88 (m, 1H), 1.50 (br s, 3H), 1.49 (s, 9H).

[0815] **S77**: A solution of (*S*)-*tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methylpyrrolidine-1-carboxylate **S76** (1.50 g, 2.44 mmol) in hydrochloric acid/ethyl acetate (4.00 M, 10.0 mL) was stirred at 20 °C for 1 h. The mixture was concentrated under vacuum to give a residue. The residue was triturated with ethyl acetate (20.0 mL) to give (*S*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S77** (hydrochloride, 1.30 g, 2.36 mmol, 96% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 11.74 - 11.47 (m, 1H), 9.74 (s, 2H), 9.69 - 9.58 (m, 1H), 8.90 (s, 1H), 8.72 (br d, *J* = 4.5 Hz, 1H), 8.21 - 8.17 (m, 1H), 8.15 - 8.09 (m, 1H), 8.01 - 7.98 (m, 1H), 7.80 - 7.74 (m, 1H), 7.72 (dd, *J* = 2.5, 8.9 Hz, 1H), 7.62 - 7.56 (m, 1H), 7.37 (d, *J* = 9.0 Hz, 1H), 5.43 (s, 2H), 3.51 - 3.37 (m, 3H), 3.26 - 3.16 (m, 1H), 2.36 - 2.25 (m, 1H), 2.07 (td, *J* = 8.2, 12.9 Hz, 1H), 1.52 (s, 3H). MS (ESI) *m/z* 515.3 [M+H]⁺

[0816] **S78**: To a solution of (*S*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)- 6-nitroquinazolin-4-amine **S77** (1.40 g, 2.54 mmol, hydrochloride) and paraformaldehyde (0.762 g, 25.4 mmol) in trifluoroethanol (60.0 mL) was added sodium borohydride (0.192 g, 5.08 mmol) at 20 °C. The mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched by addition methanol (15.0 mL), and concentrated to give a residue. Then the residue was diluted with water (15.0 mL) and extracted with ethyl acetate (3 × 35.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (5.00 mL) and ethyl acetate (1.00 mL) to give (*S*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S78** (1.10 g, 2.08 mmol, 81% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.90 (s, 1H), 8.76 (s, 1H), 8.61 (d, *J* = 4.5 Hz, 1H), 8.31 (br s, 1H), 8.00 (s, 1H), 7.89 (d, *J* = 2.4 Hz, 1H), 7.78 (br d, *J* = 1.6 Hz, 1H), 7.66 (d, *J* = 7.8 Hz, 1H), 7.52 (dd, *J* = 2.4, 8.7 Hz, 1H), 7.00


(d, $J = 8.9$ Hz, 1H), 5.30 (s, 2H), 3.08 (br d, $J = 9.8$ Hz, 1H), 2.95 (br s, 2H), 2.83 (br d, $J = 9.4$ Hz, 1H), 2.55 (s, 3H), 2.44 - 2.39 (m, 1H), 2.03 - 1.98 (m, 1H), 1.54 (s, 3H). MS (ESI) m/z 529.3 $[M+H]^+$

[0817] **S79**: To a suspension of (*S*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S78** (1.10 g, 2.08 mmol) in methanol (100 mL) and water (20.0 mL) was added iron powder (0.813 g, 14.6 mmol), ammonium chloride (0.779 mg, 14.6 mmol) at 20 °C. The mixture was stirred at 80 °C for 2 h. The mixture was added methanol (100 mL) and filter. The filtration was concentrated under vacuum. The residue was purified by reverse phase chromatography (column: C18, 80 g; condition: water-0.1% ammonium hydroxide - acetonitrile) and concentrated to give (*S*)-*N*⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S79** (0.900 g, 1.80 mmol, 87% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.60 (d, $J = 4.6$ Hz, 1H), 8.57 (s, 1H), 7.86 (d, $J = 2.6$ Hz, 1H), 7.82 (s, 1H), 7.79 - 7.74 (m, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 7.49 (dd, $J = 2.6, 8.9$ Hz, 1H), 7.26 - 7.22 (m, 1H), 7.01 (d, $J = 8.8$ Hz, 2H), 6.91 (s, 1H), 5.30 (s, 2H), 4.57 (br s, 2H), 2.94 (d, $J = 9.1$ Hz, 1H), 2.85 - 2.75 (m, 1H), 2.74 - 2.66 (m, 1H), 2.65 - 2.57 (m, 1H), 2.42 (s, 3H), 2.39 - 2.31 (m, 1H), 2.01 - 1.91 (m, 1H), 1.53 (s, 3H). MS (ESI) m/z 499.2 $[M+H]^+$

[0818] **13**: To a solution of (*S*)-*N*⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine **S79** (0.700 g, 1.40 mmol), 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (0.807 g, 4.21 mmol), pyridine (0.333 g, 4.21 mmol) in dimethyl formamide (5.00 mL) was added acrylic acid (0.131 g, 1.82 mmol) at 20 °C. The mixture was stirred at 20 °C for 2 h. The mixture was filtered, filtrate was purified by *prep*-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water(10mM NH₄HCO₃)-ACN]; B%: 38%-68%, min) and lyophilized to afford (*S*)-*N*-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide **13** (345.9 mg, 619.18 umol, 44% yield, 99% purity) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 9.13 (s, 1H), 8.68 (s, 1H), 8.65 - 8.58 (m, 2H), 7.90 (s, 2H), 7.81 - 7.73 (m, 1H), 7.67 (d, $J = 8.1$ Hz, 1H), 7.60 (s, 1H), 7.53 (dd, $J = 2.6, 8.8$ Hz, 1H), 7.24 (br d, $J = 7.2$ Hz, 1H), 7.03 (d, $J = 8.9$ Hz, 1H), 6.56 - 6.49 (m, 1H), 6.45 - 6.36 (m, 1H), 5.88 (d, $J = 10.4$ Hz, 1H), 5.31 (s, 2H), 3.07 (d, $J = 8.9$ Hz, 1H), 2.98 (dt, $J = 5.6, 8.7$ Hz, 1H), 2.57 (dt, $J = 6.0, 9.0$ Hz, 1H), 2.46 (d, $J = 9.0$ Hz, 1H), 2.44 (s, 3H), 2.41 - 2.33 (m, 1H), 2.03 - 1.94 (m, 1H), 1.54 (s, 3H). MS (ESI)

m/z 553.3 $[M+H]^+$

Example 13. Synthesis of Compound 14



[0819] **S81**: To a mixture of (S)-3-methylpyrrolidine-3-carboxylic acid **S80** (1.70 g, 13.2 mmol, 1.00 eq) and triethylamine (2.66 g, 26.3 mmol, 3.66 mL, 2.00 eq) in dichloromethane (30.0 mL) was added di-*tert* butyl dicarbonate (4.31 g, 19.7 mmol, 4.54 mL, 1.50 eq) at 0 °C. The mixture was stirred at 20 °C for 12 h. The mixture was concentrated to dryness to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol/formic acid = 10/1/0.001) to give (S)-1-(*tert*-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid **S81** (2.83 g, 12.3 mmol, 94% yield) as a brown oil. ^1H NMR (400MHz, CDCl_3) δ = 8.91 (br s, 1H), 3.81 - 3.71 (m, 1H), 3.46 - 3.34 (m, 2H), 3.23 - 3.12 (m, 1H), 2.39 - 2.25 (m, 1H), 1.71 (td, J = 6.4, 12.8 Hz, 1H), 1.45 (s, 9H), 1.31 (s, 3H).

[0820] **S82**: To a solution of (S)-1-(*tert*-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid **S81** (2.80 g, 12.2 mmol, 1.00 eq) in tetrahydrofuran (20.0 mL) was added borane dimethyl sulfide complex (10.0 M, 2.50 mL, 2.00 eq) at 0 °C. The mixture was stirred at 20 °C for 2 h. The reaction mixture was quenched by addition of methanol (20.0 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (60.0 mL) and washed with water (50.0 mL),

the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford (*S*)-*tert*-butyl 3-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate **S82** (2.10 g, crude) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ = 3.42 - 3.30 (m, 4H), 3.21 (br dd, *J* = 10.8, 18.8 Hz, 1H), 3.01 - 2.92 (m, 1H), 2.37 (br s, 1H), 1.83 - 1.72 (m, 1H), 1.51 (td, *J* = 6.0, 12.0 Hz, 1H), 1.38 (s, 9H), 1.03 (s, 3H).

[0821] **S83**: To a solution of (*S*)-*tert*-butyl 3-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate **S82** (2.10 g, 9.75 mmol, 1.00 *eq*) in dichloromethane (10.0 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (6.20 g, 14.6 mmol, 1.50 *eq*) at 0 °C. The mixture was stirred at 20 °C for 2 h. The mixture was diluted with water (5.00 mL) and saturated sodium carbonate (5.00 mL), extracted with dichloromethane (2 × 20.0 mL). The combined organic layers were washed with water (20.0 mL), dried over anhydrous sodium sulfate, filtered. The filtrate was concentrated to afford a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 5/1) to give (*S*)-*tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S83** (1.60 g, 7.50 mmol, 77% yield) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ = 9.48 (s, 1H), 3.74 - 3.62 (m, 1H), 3.41 - 3.24 (m, 2H), 3.11 - 2.98 (m, 1H), 2.23 - 2.11 (m, 1H), 1.68 - 1.59 (m, 1H), 1.39 (s, 9H), 1.17 (s, 3H).

[0822] **S84**: To a mixture of (*S*)-*tert*-butyl 3-formyl-3-methylpyrrolidine-1-carboxylate **S83** (1.50 g, 7.03 mmol, 1.00 *eq*) and potassium carbonate (1.94 g, 14.1 mmol, 2.00 *eq*) in methanol (20.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (1.76 g, 9.14 mmol, 1.30 *eq*) at 20 °C. The mixture was stirred at 20 °C for 5 h. The mixture was concentrated to dryness to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 10/1) to give (*R*)-*tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S84** (1.10 g, 5.26 mmol, 75% yield) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ = 3.54 - 3.31 (m, 3H), 3.18 - 3.07 (m, 1H), 2.09 (s, 1H), 2.06 - 1.99 (m, 1H), 1.77 - 1.68 (m, 1H), 1.39 (s, 9H), 1.28 (s, 3H).

[0823] **S85**: To a mixture of 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S46** (2.00 g, 3.60 mmol, 1.00 *eq*), (*R*)-*tert*-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate **S84** (753 mg, 3.60 mmol, 1.00 *eq*) and triethylamine (3.64 g, 35.9 mmol, 5.00 mL, 10.0 *eq*) in dimethyl formamide (5.00 mL) was added tetrakis(triphenylphosphine) palladium (0) (416 mg, 360 μ mol, 0.10 *eq*) and cuprous iodide (140 mg, 735.10 μ mol, 0.20 *eq*) at 25 °C. The mixture was stirred under nitrogen atmosphere at 20 °C for 2 h. The mixture was concentrated to give a residue. The residue was purified by silica gel

chromatography (Petroleum ether/Ethyl acetate = 2/1 - 1/2) to afford (*R*)-*tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-

methylpyrrolidine-1-carboxylate **S85** (2.00 g, 3.25 mmol, 90% yield) as a yellow solid. ¹H NMR (400MHz, DMSO-*d*₆) δ = 10.36 (s, 1H), 9.44 (s, 1H), 8.71 (s, 1H), 8.61 (d, *J* = 4.6 Hz, 1H), 8.02 (d, *J* = 2.6 Hz, 1H), 7.94 (s, 1H), 7.89 (dt, *J* = 1.8, 7.8 Hz, 1H), 7.72 (dd, *J* = 2.6, 8.8 Hz, 1H), 7.38 (dd, *J* = 5.2, 7.2 Hz, 1H), 7.31 (d, *J* = 9.0 Hz, 1H), 5.31 (s, 2H), 3.61 (d, *J* = 10.4 Hz, 1H), 3.55 - 3.41 (m, 2H), 3.28 - 3.22 (m, 1H), 2.19 (br d, *J* = 4.8 Hz, 1H), 1.99 - 1.91 (m, 1H), 1.44 (s, 3H), 1.42 (s, 9H). MS (ESI) *m/z* 615.1 [M+H]⁺

[0824] **S86**: To a mixture of (*R*)-*tert*-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate **S85** (2.00 g, 3.25 mmol, 1.00 *eq*) in ethyl acetate (20.0 mL) was added hydrochloric acid/ethyl acetate (4.00 M, 12.00 mL), the mixture was stirred at 20 °C for 3 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (20.0 mL). After filtration, the filter cake was washed with ethyl acetate (10.0 mL) dried in vacuum to give (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S86** (2.00 g, crude, HCl) as a yellow solid. ¹H NMR (400MHz, DMSO-*d*₆) δ = 9.83 (br s, 2H), 9.77 - 9.65 (m, 1H), 8.94 (s, 1H), 8.76 (br d, *J* = 4.4 Hz, 1H), 8.26 - 8.16 (m, 2H), 7.99 (d, *J* = 2.6 Hz, 1H), 7.83 (br d, *J* = 7.4 Hz, 1H), 7.73 (dd, *J* = 2.4, 8.8 Hz, 1H), 7.69 - 7.62 (m, 1H), 7.39 (d, *J* = 9.0 Hz, 1H), 5.48 (s, 2H), 3.52 - 3.35 (m, 3H), 3.26 - 3.17 (m, 1H), 2.37 - 2.27 (m, 1H), 2.13 - 2.06 (m, 1H), 1.53 (s, 3H). MS (ESI) *m/z* 515.0 [M+H]⁺


[0825] **S87**: A mixture of (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S86** (1.00 g, 1.94 mmol, 1.00 *eq*), paraformaldehyde (195 mg, 9.70 mmol, 5.00 *eq*) in trifluoroethanol (15.0 mL) was added sodium borohydride (148 mg, 3.91 mmol, 2.00 *eq*) at 20 °C. The mixture was stirred at 60 °C for 1 h. The mixture was quenched with methanol (5.00 mL) and concentrated to dryness to give a residue. The residue was purified by *prep*-HPLC (column: Phenomenex luna C18 150*25 10 μ ; mobile phase: [water(0.1%TFA)-ACN]; B%: 13%-43%, 10min) to give (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine **S87** (1.40 g, crude) as a yellow solid. ¹H NMR (400MHz, DMSO-*d*₆) δ = 10.31 (br s, 1H), 9.39 (s, 1H), 8.69 (s, 1H), 8.61 (br d, *J* = 4.4 Hz, 1H), 8.01 (d, *J* = 2.4 Hz, 1H), 7.93 - 7.85 (m, 2H), 7.71 (br dd, *J* = 2.4, 8.8 Hz, 1H), 7.59 (d, *J* = 7.8 Hz, 1H), 7.38 (dd, *J* = 5.2, 6.8 Hz, 1H), 7.29 (d, *J* = 9.2 Hz,

1H), 5.31 (s, 2H), 2.76 (d, $J = 9.0$ Hz, 1H), 2.65 (dt, $J = 5.4, 8.4$ Hz, 1H), 2.56 (br d, $J = 8.8$ Hz, 2H), 2.28 (s, 3H), 2.25 - 2.17 (m, 1H), 1.94 - 1.82 (m, 1H), 1.43 (s, 3H). MS (ESI) m/z 529.0 $[M+H]^+$

[0826] **S88**: A mixture of (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) -6-nitroquinazolin-4-amine **S87** (900 mg, 1.70 mmol, 1.00 *eq*), iron powder (383 mg, 6.86 mmol, 4.00 *eq*) and ammonium chloride (460 mg, 8.50 mmol, 5.00 *eq*) in methanol (15.0 mL) and water (7.00 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20.0 mL) and washed with saturated sodium bicarbonate solution (20.0 mL), brine (20.0 mL), dried under vacuum to afford (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl) -7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine **S88** (750 mg, 1.50 mmol, 88% yield) as a yellow solid. MS (ESI) m/z 499.4 $[M+H]^+$

[0827] **14**: To a mixture of (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine **S88** (600 mg, 1.20 mmol, 1.00 *eq*) and triethylamine (254 mg, 2.51 mmol, 350 μ L, 2.00 *eq*) in dimethyl formamide (6.00 mL) was added acrylic anhydride (200 mg, 1.59 mmol, 1.30 *eq*) at 20 °C. The mixture was stirred at 20 °C for 1 h and then filtered. The filtrate was purified by *prep*-HPLC (column: Phenomenex Gemini 150*25mm*10 μ m; mobile phase: [water(10mM NH_4HCO_3)-ACN]; B%: 39%-69%, min) to give (*R*)-*N*-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl) quinazolin-6-yl)acrylamide **14** (130 mg, 235.06 μ mol, 19.55% yield) as a yellow solid. ^1H NMR (400MHz, CDCl_3) δ = 9.11 (s, 1H), 8.71 - 8.59 (m, 3H), 7.93 - 7.88 (m, 2H), 7.84 (s, 1H), 7.81 - 7.74 (m, 1H), 7.68 (br d, $J = 7.8$ Hz, 1H), 7.55 (dd, $J = 2.4, 8.8$ Hz, 1H), 7.26 (br d, $J = 6.6$ Hz, 1H), 7.02 (d, $J = 8.8$ Hz, 1H), 6.56 - 6.38 (m, 2H), 5.88 (d, $J = 9.8$ Hz, 1H), 5.32 (s, 2H), 3.08 (d, $J = 8.8$ Hz, 1H), 3.03 - 2.96 (m, 1H), 2.61 - 2.53 (m, 1H), 2.49 - 2.42 (m, 4H), 2.42 - 2.36 (m, 1H), 2.03 - 1.95 (m, 1H), 1.55 (s, 3H). MS (ESI) m/z 553.6 $[M+H]^+$

Example 14. Synthesis of Compound 16



[0828] **S89**: A mixture of 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate **S46** (0.540 g, 971 μmol , 1.00 *eq*), *(R)*-*tert*-butyl 2-ethynyl-2-methylpyrrolidine-1-carboxylate (203 mg, 971 μmol , 1.00 *eq*), tetrakis(triphenylphosphine) palladium(0) (112 mg, 97.1 μmol , 0.10 *eq*), cuprous iodide (37.0 mg, 194 μmol , 0.20 *eq*) and triethylamine (197 mg, 1.94 mmol, 270 μL , 2.00 *eq*) in tetrahydrofuran (10.0 mL) was stirred at 25 °C for 10 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/1) to afford *(R)*-*tert*-butyl 2-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-2-methylpyrrolidine-1-carboxylate **S89** (0.6 g, crude) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 8.89 (s, 1H), 8.73 - 8.58 (m, 1H), 8.53 (br d, J = 4.4 Hz, 1H), 8.01 - 7.87 (m, 1H), 7.69 (dd, J = 1.7, 7.6 Hz, 1H), 7.62 - 7.54 (m, 3H), 7.46 (qd, J = 1.7, 7.6 Hz, 1H), 7.41 - 7.36 (m, 2H), 5.30 - 5.15 (m, 2H), 3.75 - 3.55 (m, 1H), 3.45 - 3.35 (m, 1H), 2.48 - 2.33 (m, 1H), 2.16 - 1.98 (m, 2H), 1.89 - 1.77 (m, 1H), 1.67 (s, 3H), 1.58 (s, 9H).

[0829] **S90**: A mixture of *(R)*-*tert*-butyl 2-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-2-methylpyrrolidine-1-carboxylate **S89** (0.600 g, 976 μmol , 1.00 *eq*) in hydrochloric acid/ethyl acetate (2.00 mL) was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to afford *(R)*-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((2-methylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S90** (0.55 g, crude, hydrochloride) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 11.52 - 11.28 (m,

1H), 10.07 (br s, 2H), 9.79 - 9.71 (m, 1H), 8.89 (s, 1H), 8.72 (d, $J = 4.5$ Hz, 1H), 8.24 (s, 1H), 8.10 (dt, $J = 1.6, 7.7$ Hz, 1H), 8.01 (d, $J = 2.6$ Hz, 1H), 7.78 - 7.71 (m, 2H), 7.62 - 7.61 (m, 1H), 7.56 (d, $J = 1.0$ Hz, 1H), 7.37 (d, $J = 9.0$ Hz, 1H), 5.43 (s, 2H), 3.47 - 3.36 (m, 2H), 2.27 - 2.07 (m, 4H), 1.82 (s, 3H).


[0830] **S91**: To a solution of (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((2-methylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S90** (0.55 g, 1.07 mmol, 1.00 *eq*) and paraformaldehyde (160 mg, 5.34 mmol, 147 μ L, 5.00 *eq*) in trifluoroethanol (10.0 mL) was added sodium borohydride (80.8 mg, 2.14 mmol, 2.00 *eq*) slowly. The mixture was stirred at 60 °C for 12 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 0/1) to afford (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S91** (130 mg, 246 μ mol, 23% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.82 (s, 1H), 8.77 (s, 1H), 8.62 (d, $J = 4.2$ Hz, 1H), 8.10 (s, 1H), 7.92 - 7.86 (m, 2H), 7.83 - 7.77 (m, 1H), 7.68 (d, $J = 7.8$ Hz, 1H), 7.51 (dd, $J = 2.7, 8.8$ Hz, 1H), 7.30 (s, 1H), 7.27 (br s, 1H), 7.05 (d, $J = 8.8$ Hz, 1H), 5.34 (s, 2H), 3.19 - 3.07 (m, 1H), 2.75 - 2.63 (m, 1H), 2.46 (s, 3H), 2.36 - 2.26 (m, 1H), 1.99 - 1.87 (m, 3H), 1.57 - 1.50 (m, 3H).

[0831] **S92**: A mixture of (*R*)-*N*-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)-6-nitroquinazolin-4-amine **S91** (130 mg, 246 μ mol, 1.00 *eq*), ammonium chloride (39.4 mg, 737 μ mol, 3.00 *eq*) and ferrous powder (41.2 mg, 737 μ mol, 3.00 *eq*) in a mixture solvent of methanol (3.00 mL) and water (3.00 mL) was stirred at 80 °C for 10 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase chromatography (column: C18, 80 g; condition: H₂O-0.1% NH₃•H₂O-CH₃CN) and lyophilized to afford (*R*)-*N*⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)quinazoline-4,6-diamine **S92** (60.0 mg, 120 μ mol, 49% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.62 (d, $J = 4.6$ Hz, 1H), 8.59 (s, 1H), 7.90 - 7.87 (m, 2H), 7.78 (dt, $J = 1.7, 7.7$ Hz, 1H), 7.68 (d, $J = 7.5$ Hz, 1H), 7.55 - 7.49 (m, 1H), 7.26 (br s, 1H), 7.06 - 7.02 (m, 1H), 7.00 (s, 1H), 6.95 (s, 1H), 5.35 - 5.30 (m, 2H), 3.18 - 3.07 (m, 1H), 2.66 - 2.56 (m, 1H), 2.43 (s, 3H), 2.33 - 2.24 (m, 1H), 1.98 - 1.85 (m, 3H), 1.54 (s, 3H).

[0832] **16**: A mixture of (*R*)-*N*⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)quinazoline-4,6-diamine **S92** (50.0 mg, 100 μ mol, 1.00 *eq*),

acrylic acid (10.8 mg, 150 μmol , 10.3 μL , 1.50 eq), 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (57.6 mg, 300 μmol , 3.00 eq) and pyridine (23.8 mg, 300 μmol , 24.3 μL , 3.00 eq) in dimethylformamide (1.00 mL) was stirred at 25 °C for 10 h. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Waters Xbridge 150 $\times$ 25 5 μ ; mobile phase: [water (10mM NH_4HCO_3)-ACN]; B%: 35%-65%, 10min) to afford (*R*)-*N*-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,2-dimethylpyrrolidin-2-yl)ethynyl)quinazolin-6-yl)acrylamide **16** (28.33 mg, 50.7 μmol , 51% yield, 99% purity, >99% ee) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 9.04 (s, 1H), 8.61 (s, 1H), 8.53 (d, J = 4.2 Hz, 1H), 8.25 (s, 1H), 7.89 (s, 1H), 7.83 (d, J = 2.7 Hz, 1H), 7.72 - 7.66 (m, 1H), 7.63 - 7.57 (m, 2H), 7.46 (dd, J = 2.6, 8.8 Hz, 1H), 7.18 - 7.15 (m, 1H), 6.95 (d, J = 8.9 Hz, 1H), 6.45 (dd, J = 0.7, 16.9 Hz, 1H), 6.28 - 6.16 (m, 1H), 5.89 - 5.78 (m, 1H), 5.23 (s, 2H), 3.08 (ddd, J = 3.7, 7.7, 9.5 Hz, 1H), 2.59 - 2.48 (m, 1H), 2.36 (s, 3H), 2.26 - 2.18 (m, 1H), 1.97 - 1.78 (m, 3H), 1.48 (s, 3H). MS (ESI) m/z 553.4 $[\text{M}+\text{H}]^+$

Example 15. Synthesis of Compound 17



[0833] **Synthesis of 4-ethynylquinuclidine:** To a solution of quinuclidine-4-carbonitrile (900 mg, 6.61 mmol, 1.00 eq) in toluene (10.0 mL) was added diisobutylaluminium Hydride (1 M in toluene, 13.2 mL, 2.00 eq) at -78 °C. Then the mixture was stirred at -78 °C for 1 h. The reaction mixture was quenched by addition sodium sulfate decahydrate (15.0 g), and then filtered and the filtrate was concentrated under reduced pressure to give quinuclidine-4-carbaldehyde (1 g, crude) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.34 (s, 1H), 2.77 - 2.75 (m, 6H), 1.48 (br d, J =

2.4 Hz, 6H).

[0834] To a solution of quinuclidine-4-carbaldehyde (540 mg, 3.88 mmol, 1.00 eq) and potassium carbonate (1.07 g, 7.76 mmol, 2.00 eq) in methanol (10.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (894 mg, 4.66 mmol, 1.20 eq) at 0 °C. Then the mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Silica, dichloromethane/methanol = 10/1) to afford 4-ethynylquinuclidine (600 mg, crude) as colorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ = 2.98 (s, 1H), 2.87 - 2.81 (m, 6H), 1.69 - 1.64 (m, 6H).


[0835] **S6**: To a mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol **S93** (2.00 g, 5.98 mmol, 1.00 eq) in dichloromethane (20.0 mL) was added pyridine (2.36 g, 29.9 mmol, 2.41 mL, 5.00 eq) at 20 °C. After cooling to 0 °C, trifluoromethanesulfonic anhydride (2.53 g, 8.96 mmol, 1.48 mL, 1.50 eq) was added dropwise and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated under vacuum at 20 °C to give a residue. The residue was poured into water (50.0 mL) and the aqueous solution was extracted with ethyl acetate (2 × 50.0 mL). All organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1 to 1/1) to give 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yltrifluoromethanesulfonate **S6** (1.40 g, 2.95 mmol, 49 % yield, 98% purity) as a yellow solid. MS (ESI) m/z 467.0 [M+H]⁺

[0836] **S94**: To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yltrifluoromethanesulfonate **S6** (600 mg, 1.29 mmol, 1.00 eq) and 4-ethynylquinuclidine (220 mg, 1.63 mmol, 1.27 eq) in dimethyl formamide (2.00 mL) was added copper(I) iodide (49.0 mg, 257 umol, 0.200 eq), Tetrakis(triphenylphosphine) palladium(0) (149 mg, 129 umol, 0.100 eq) and triethylamine (1.30 g, 12.9 mmol, 1.79 mL, 10.0 eq) at 10 °C under nitrogen atmosphere. Then the mixture was stirred at 10 °C for 32 h. The mixture was poured into ammonium hydroxide aqueous solution (100 mL) and extracted with ethyl acetate (3 × 100 mL). All organic phases were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography on silica gel (ethyl acetate/methanol = 1/0 to 1/1) to give *N*-(3-chloro-2-fluorophenyl) -6-nitro-7-(quinuclidin-4-ylethynyl)quinazolin-4-amine **S94** (150 mg, 279 umol, 21% yield, 84% purity) as a brown solid. MS (ESI) m/z 452.3 [M+H]⁺

[0837] **S95:** To a solution of *N*-(3-chloro-2-fluorophenyl)-6-nitro-7-(quinuclidin-4-ylethynyl)quinazolin-4-amine **S94** (150 mg, 332 μmol , 1.00 *eq*) in methanol (4.00 mL) was added a solution of ammonium chloride (88.8 mg, 1.66 mmol, 5.00 *eq*) in water (1.00 mL) and iron powder (92.7 mg, 1.66 mmol, 5.00 *eq*) at 10 °C. The mixture was stirred at 80 °C for 6 h. The mixture was filtered and the filtrate was concentrated to give a residue. The residue was diluted with water (2.00 mL) and extracted with ethyl acetate (5 $\times$ 10.0 mL). All organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give *N*⁴-(3-chloro-2-fluorophenyl)-7-(quinuclidin-4-ylethynyl)quinazoline-4,6-diamine **S95** (100 mg, 171 μmol , 51% yield, 72% purity) as a yellow solid was used into next step without further purification. MS (ESI) *m/z* 422.3 [*M*+*H*]⁺

[0838] **17:** To a solution of *N*⁴-(3-chloro-2-fluorophenyl)-7-(quinuclidin-4-ylethynyl)quinazoline-4,6-diamine **S95** (50.0 mg, 119 μmol , 1.00 *eq*) in dimethyl formamide (1.00 mL) was added a solution of triethylamine (36.0 mg, 356 μmol , 49.5 μL , 3.00 *eq*) in dimethyl formamide (0.100 mL), followed by a solution of acrylic anhydride (15.0 mg, 119 μmol , 1.00 *eq*) in dimethyl formamide (0.100 mL) at 0 °C and the mixture was stirred at 0 °C for 30 min. Then a solution of acrylic anhydride (4.48 mg, 35.6 μmol , 0.300 *eq*) in dimethyl formamide (30.0 μL) was added and the mixture was stirred at 10 °C for 30 min. The mixture was diluted with dimethyl formamide (1.00 mL) to give a solution. The solution was purified by *prep*-HPLC (column: Waters Xbridge 150*25 5 μ ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 30%-60%, 10min) and further purified by *prep*-HPLC (column: Phenomenex Synergi C18 150*30mm*4 μ ; mobile phase: [water(0.225%FA)-ACN]; B%: 8%-38%, 10min). The desired fraction was collected and lyophilized to give *N*-(4-((3-chloro-2-fluorophenyl)amino)-7-(quinuclidin-4-ylethynyl)-quinazolin-6-yl)acrylamide **17** (1.75 mg, 3.35 μmol , 2% yield, 100% purity, formic acid) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.09 (br s, 1H), 9.74 (br s, 1H), 8.68 (s, 1H), 8.57 - 8.41 (m, 1H), 8.34 (br s, 1H), 7.95 - 7.65 (m, 1H), 7.48 (br s, 2H), 7.33 - 7.19 (m, 1H), 6.57 (br dd, *J* = 10.4, 17.0 Hz, 1H), 6.33 (dd, *J* = 1.5, 16.9 Hz, 1H), 5.85 (dd, *J* = 1.5, 10.3 Hz, 1H), 2.82 (br s, 6H), 1.75 (br s, 6H). MS (ESI) *m/z* 476.2 [*M*+*H*]⁺.

Example 16. Synthesis of Compound No. 18 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-4-morpholinobut-2-ynamide)




[0839] **Step 1.** To a solution of 4-prop-2-ynylmorpholine (500 mg, 3.99 mmol) in tetrahydrofuran (2.0 mL) was added n-BuLi (2.5 M, 1.60 mL) dropwise at -78 °C. The mixture was stirred at -78 °C for 1 h. Then dry ice (175 mg, 3.99 mmol) was added. The mixture was stirred at 25 °C for 16 h. Upon completion, the resulting solution was poured into saturated aqueous NH₄Cl solution (50 mL) and washed with ethyl acetate (50 mL). The aqueous layer was evaporated under reduced pressure to give the crude product. The crude product was dissolved in methanol (20 mL) and then filtered to remove any insoluble salt. The filtrate was collected and dried in vacuo to give 4-morpholinobut-2-ynoic acid (500 mg, 90% purity) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ = 3.63 - 3.59 (m, 4H), 3.56 (s, 2H), 2.52 (s, 4H).

[0840] **Step 2.** To a solution of 4-morpholinobut-2-ynoic acid (31.1 mg, 183 μmol) in tetrahydrofuran (3.0 mL) was added 4-methylmorpholine (18.6 mg, 183 μmol) and isobutyl carbonochloridate (25.1 mg, 183 μmol) at 0 °C. The mixture was stirred at 0 °C for 30 min, then mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (25.0 mg, 61.2 μmol) in pyridine (0.6 mL) was added. The mixture was stirred at 0 °C for 2 h. Upon completion, the mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water(0.225% formic acid)-acetonitrile]; B%: 1%-30%, 7min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]-4-morpholino-but-2-ynamide (6.0 mg, 16.6% yield) as a yellow solid.

[0841] m/z ES+ [M+H]⁺ 559.4; ¹H NMR (400 MHz, DMSO-d₆) δ = 10.47 (d, J = 3.2 Hz, 1H), 10.06 (s, 1H), 8.50 (s, 2H), 8.30 - 8.18 (m, 1H), 7.80 (s, 1H), 7.55 - 7.50 (m, 2H), 7.29 (t, J = 7.2 Hz, 1H), 3.67 - 3.61 (m, 4H), 3.58 (s, 2H), 3.12 (d, J = 8.4 Hz, 2H), 2.94 (d, J = 9.2 Hz, 1H), 2.57 (d, J = 1.6 Hz, 2H), 2.41 (dd, J = 4.0, 9.2 Hz, 2H), 2.26 (s, 3H), 2.00 - 1.90 (m, 2H), 1.39 (t, J = 4.4 Hz, 1H), 1.07 - 1.02 (m, 1H).

Example 17. Synthesis of Compound No. 19 (1-((E)-4-((4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)amino)-4-oxobut-2-en-1-yl)piperidine-3-carboxylic acid)




[0842] **Step 1.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo [3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 245 μ mol) and triethylamine (74.4 mg, 735 μ mol) in dichloromethane (2 mL) was added a solution of (E)-4-bromobut-2-enoyl chloride (89.9 mg, crude) in dichloromethane (0.5 mL) dropwise at 0 °C and the mixture was stirred at 0 °C for 10 min. On completion, the reaction mixture was concentrated under vacuum to give (E)-4-bromo-N-[4-(3-chloro-2-fluorophenyl)amino]-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl]but-2-enamide (140 mg, crude) as a yellow solid, which was used in the next step directly. m/z ES+ $[M+H]^+$ 556.0.

[0843] **Step 2.** A mixture of (E)-4-bromo-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3- azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]but-2-enamide (134 mg, 242 μ mol), piperidine-3-carboxylic acid (46.8 mg, 362 μ mol) and triethylamine (48.9 mg, 483 μ mol) in dichloromethane (3.0 mL) was stirred at 25 °C for 12 h. On completion, the reaction mixture was concentrated in vacuo to give a residue. The residue was purified by reverse-phase flash chromatography [acetonitrile/(0.1% $NH_3 \cdot H_2O$ in water), 0% to 90%] and further purified by Prep-HPLC [column: Phenomenex luna C18 150*25mm* 10 μ m; mobile phase: [water(0.225% formic acid)-acetonitrile]; B%: 3%-33%, 10min] to give 1-[(E)-4-[[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]amino]-4-oxo-but-2-enyl]piperidine-3-carboxylic acid (8.01 mg, 5.5% yield) as a brown solid. m/z ES+ $[M+H]^+$ 603.4; ^1H NMR (400 MHz, DMSO- d_6) δ 10.29 - 9.87 (m, 1H), 9.79 (s, 1H), 8.66 (s, 1H), 8.51 - 8.39 (m, 1H), 8.33 - 8.22 (m, 2H), 7.78 (s, 1H), 7.48 (d, J = 6.8 Hz, 2H), 7.34 - 7.20 (m, 1H), 6.81 (td, J = 6.0, 15.6 Hz, 1H), 6.42 (d, J = 15.6 Hz, 1H), 3.18 (d, J = 3.2 Hz, 1H), 3.11 (d, J = 8.8 Hz, 1H), 2.95 - 2.88 (m, 2H), 2.74 - 2.67 (m, 1H), 2.45 (d, J = 8.6 Hz, 1H), 2.40 (dd, J = 3.6, 8.8 Hz, 1H), 2.25 (s, 3H), 2.17 - 2.01 (m, 2H), 1.93 (td, J = 3.9, 8.0 Hz, 1H), 1.84 (dd, J = 3.6, 12.4 Hz, 1H),

1.71 - 1.61 (m, 2H), 1.53 - 1.43 (m, 1H), 1.40 - 1.31 (m, 2H), 1.25 - 1.15 (m, 1H), 1.02 (dd, J = 4.0, 8.0 Hz, 1H).

Example 18. Synthesis of Compound No. 20 ((E)-4-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)but-2-enamide)




[0844] **Step 1.** To a solution of (E)-4-bromobut-2-enoic acid (500 mg, 3.03 mmol) in dichloromethane (5 mL) was added (COCl)₂ (385 mg, 3.03 mmol) and one drop of dimethylformamide at 0 °C under N₂. The mixture was slowly warmed to 25 °C then stirred at 25 °C for 4 h. On completion, the reaction mixture was concentrated in vacuo to give (E)-4-bromobut-2-enoyl chloride (560 mg, crude) as a yellow oil.

[0845] **Step 2.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 245 μmol) and triethylamine (74.4 mg, 736 μmol) in dichloromethane (2.0 mL) was added a solution of (E)-4-bromobut-2-enoyl chloride (89.9 mg, 490 μmol) in dichloromethane (0.5 mL) dropwise at 0 °C and the mixture was stirred at 0 °C for 10 min. On completion, the reaction mixture was concentrated under vacuum to give (E)-4-bromo-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)but-2-enamide (140 mg, crude) as a yellow solid, which was used in the next step directly. m/z ES⁺ [M+H]⁺ 556.1

[0846] **Step 3.** A mixture of (E)-4-bromo-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]but-2-enamide (100 mg, 180 μmol), 3-oxa-6-azabicyclo[3.1.1]heptane (48.9 mg, 360 μmol, HCl salt), triethylamine (36.5 mg, 360 μmol) in dichloromethane (2.0 mL) was stirred at 25 °C for 12 h. On completion, the reaction mixture was concentrated in vacuo to give a residue. The residue was purified by reverse-phase flash [acetonitrile/(0.1% NH₃·H₂O in water), 0% to 90%] and further purified by prep-HPLC [column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 27%-57%, 11.5 min] to give 30 mg crude product. The crude

product was then purified by prep-HPLC [column: Phenomenex luna C18 150*25mm*10um;mobile phase: [water(0.225% formic acid)-acetonitrile];B%: 2%-32%,10min] to give (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]-4-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)but-2-enamide (3.6 mg, 3% yield) as a white solid. m/z ES+ $[M+H]^+$ 573.4; ^1H NMR (400 MHz, DMSO- d_6) δ 10.31 - 9.97 (m, 1H), 9.74 (s, 1H), 8.66 (s, 1H), 8.46 (s, 1H), 8.36 (s, 1H), 7.86 - 7.69 (m, 1H), 7.49 (d, J = 1.2 Hz, 2H), 7.28 (t, J = 8.4 Hz, 1H), 6.83 (td, J = 5.2, 15.6 Hz, 1H), 6.47 (d, J = 15.6 Hz, 1H), 4.10 (d, J = 10.8 Hz, 2H), 3.65 (d, J = 10.8 Hz, 2H), 3.52 - 3.47 (m, 4H), 3.10 (d, J = 8.4 Hz, 1H), 2.93 (d, J = 9.2 Hz, 1H), 2.56 (d, J = 6.4 Hz, 1H), 2.46 - 2.39 (m, 2H), 2.25 (s, 3H), 1.98 - 1.90 (m, 1H), 1.77 (d, J = 8.0 Hz, 1H), 1.37 (t, J = 4.4 Hz, 1H), 1.02 (dd, J = 3.6, 8.0 Hz, 1H).


Example 19. Synthesis of Compound No. 21 ((E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-4-methoxybut-2-enamide)



[0847] To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 245 μ mol), (E)-4-methoxybut-2-enoic acid (42.7 mg, 367 μ mol) in pyridine (1.5 mL) and dichloromethane (1.5 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (141 mg, 735 μ mol) at 0 °C. The mixture was stirred at 25 °C for 16 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a crude product. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um;mobile phase: [water(10mM NH_4HCO_3)-acetonitrile];B%: 36%-66%,8 min) to give (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]-4-methoxy-but-2-enamide (10.0 mg, 8 % yield) as a yellow solid. m/z ES+ $[M+H]^+$ 506.1; ^1H NMR (400 MHz, DMSO- d_6) δ = 10.22 - 9.93 (m, 1H), 9.78 (s, 1H), 8.64 (s, 1H), 8.52 - 8.35 (m, 1H), 7.83 - 7.70 (m, 1H), 7.47 (d, J = 2.0 Hz, 2H), 7.33 - 7.18 (m, 1H), 6.87 (td, J = 4.4, 15.6 Hz, 1H), 6.46 (d, J = 15.6 Hz, 1H),

4.14 (dd, $J = 2.0, 4.4$ Hz, 2H), 3.28 (s, 3H), 3.10 (d, $J = 8.4$ Hz, 1H), 2.92 (d, $J = 8.8$ Hz, 1H), 2.43 (d, $J = 8.4$ Hz, 1H), 2.39 (dd, $J = 3.6, 9.2$ Hz, 1H), 2.25 (s, 3H), 1.93 (td, $J = 4.4, 8.0$ Hz, 1H), 1.37 (t, $J = 4.4$ Hz, 1H), 1.02 (dd, $J = 3.6, 8.0$ Hz, 1H).


Example 20. Synthesis of Compound No. 22 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)propionamide)



[0848] To a mixture of N^4 -(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (0.05 g, 122 μ mol) and pyridine (482.45 mg, 6.10 mmol) in tetrahydrofuran (1 mL) was added propanoyl chloride (33.86 mg, 365.96 μ mol) dropwise at 25 °C under N_2 . The mixture was stirred at 25 °C for 1 h. On completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μ m; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 45%-75%, 8 min) to give (R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)propionamide (3.4 mg, 6% yield) as a white solid.


[0849] m/z ES+ $[M+H]^+$ 466.1; ^1H NMR (400 MHz, DMSO- d_6) δ 10.06 (s, 1H), 9.37 (s, 1H), 8.66 (s, 1H), 8.45 (s, 1H), 7.76 (s, 1H), 7.49 (d, $J = 8.8$ Hz, 2H), 7.27 (t, $J = 8.4$ Hz, 1H), 2.82 (d, $J = 8.4$ Hz, 1H), 2.62 (dd, $J = 7.2, 2.0$ Hz, 2H), 2.55 – 2.50 (m, 1H), 2.46 - 2.40 (m, 2H), 2.28 (s, 3H), 2.26 - 2.20 (m, 1H), 1.90 - 1.85 (m, 1H), 1.45 (s, 3H), 1.15-1.18 (t, $J = 7.6$ Hz, 3H).

Example 21. Synthesis of Compound No. 23 (2-chloro-N-(4-((3-chloro-2-fluorophenyl)-amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-2-fluoroacetamide)



[0850] To a mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 245 μmol), ethyl 2-chloro-2-fluoroacetate (68.9 mg, 490 μmol) in toluene (1.0 mL) was added trimethylaluminum (2 M in toluene, 245 μL) and the mixture was stirred at 100 °C for 16 h. On completion, the mixture was quenched by 0.2 mL MeOH and filtered. The filtrate was concentrated under vacuum. The obtained residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 42%-72%, 8min) to give 2-chloro-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-quinazolin-6-yl]-2-fluoroacetamide (20.2 mg, 16% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 502.1; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.58 (s, 1H), 10.16 (s, 1H), 8.65 - 8.45 (m, 2H), 7.85 (s, 1H), 7.58 - 7.45 (m, 2H), 7.30 (t, $J = 7.6$ Hz, 1H), 7.08 (d, $J = 49.6$ Hz, 1H), 3.12 (d, $J = 8.8$ Hz, 1H), 2.94 (d, $J = 9.2$ Hz, 1H), 2.47 - 2.36 (m, 2H), 2.26 (s, 3H), 2.00 - 1.92 (m, 1H), 1.39 (t, $J = 4.4$ Hz, 1H), 1.04 (td, $J = 4.4, 8.0$ Hz, 1H).

Example 22. Synthesis of Compound No. 24 ((R,E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide)




[0851] **Step 1.** To a solution of 2-diethoxyphosphorylacetic acid (143 mg, 731 μmol) in tetrahydrofuran (2 mL) was added 1,1'-carbonyldiimidazole (122 mg, 756 μmol) at 20 °C. The mixture was stirred at 40 °C for 0.5 h. Then (R)-N4-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (100 mg, 243 μmol) was added and the mixture was stirred at 40 °C for 16 h. On completion, the reaction mixture was diluted with ethyl

acetate (10 mL), washed with saturated aqueous NaHCO_3 (5 mL), H_2O (5 mL) and brine (5 mL x 3). The organic layer was dried over Na_2SO_4 and concentrated to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-2-diethoxyphosphoryl-acetamide (143 mg, crude) as a brown oil, which was used in the next step directly. m/z ES+ $[\text{M}+\text{H}]^+$ 588.1.

[0852] **Step 2.** To a mixture of N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl] ethynyl]quinazolin-6-yl]-2-diethoxyphosphoryl-acetamide (143 mg, 243 μmol) in ethanol (1.2 mL) was added LiCl (41.2 mg, 972 μmol) in one portion at 20 °C under N_2 . Then KOH (181 mg, 1.46 mmol, 45% aqueous solution) was added and the mixture was stirred at 20 °C for 5 min. Then 2-(dimethylamino)acetaldehyde (82.3 mg, 486 μmol , H_2SO_3 salt) in H_2O (0.7 mL) was added and the mixture was stirred at 20 °C for 0.5 h. On completion, the mixture was quenched by H_2O (5 mL) and then filtered to give a solid. The solid was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 30%-50%, 6 min) to give (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl] quinazolin-6-yl]-4-(dimethylamino)but-2-enamide (16.9 mg, 13% yield) as a white solid. m/z ES+ $[\text{M}+\text{H}]^+$ 521.1; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.08 (br s, 1H), 9.68 (s, 1H), 8.69 (s, 1H), 8.47 (s, 1H), 7.79 (s, 1H), 7.55 – 7.45 (m, 2H), 7.28 (t, $J = 8.0$ Hz, 1H), 6.85 – 6.75 (m, 1H), 6.39 (d, $J = 15.6$ Hz, 1H), 3.08 (br d, $J = 5.6$ Hz, 2H), 2.79 (d, $J = 8.8$ Hz, 1H), 2.59 (t, $J = 7.2$ Hz, 2H), 2.53 - 2.52 (m, 1H), 2.27 (s, 3H), 2.23 (dd, $J = 6.4$, 12.8 Hz, 1H), 2.18 (s, 6H), 1.84 (td, $J = 7.2$, 12.8 Hz, 1H), 1.42 (s, 3H).


Example 23. Synthesis of Compound No. 25 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)methacrylamide)



[0853] To a mixture of (R)-N4-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (20.0 mg, 49 μmol) in pyridine (1.5 mL) was added 2-

methylprop-2-enoyl chloride (6.1 mg, 58.6 μmol) dropwise at 0 °C under N_2 . The mixture was stirred at 0 °C for 0.5 hour. Then the reaction mixture was warmed to 50 °C and stirred for 1.5 hour. On completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30mm*3 μm ; mobile phase: [water(0.2%formic acid)-acetonitrile]; B%: 15%-50%, 8min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]-quinazolin-6-yl]-2-methyl-prop-2-enamide (5.4 mg, 23% yield, formic acid salt) as a brown solid. m/z ES+ $[\text{M}+\text{H}]^+$ 478.1; ^1H NMR (400 MHz, CDCl_3) δ 10.08 (s, 1H), 9.45 (s, 1H), 8.73 (s, 1H), 8.48 (s, 1H), 7.81 (s, 1H), 7.50 (t, $J = 6.8$ Hz, 2H), 7.30 – 7.25 (m, 1H), 6.01 (s, 1H), 5.62 (s, 1H), 2.77 (d, $J = 8.8$ Hz, 1H), 2.62 - 2.55 (m, 2H), 2.55 – 2.50 (m, 1H), 2.24 (s, 3H), 2.22 - 2.15 (m, 1H), 2.04 (s, 3H), 1.87 - 1.80 (m, 1H), 1.43 (s, 3H).

Example 24. Synthesis of Compound No. 26 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-2-(hydroxymethyl)acrylamide)




[0854] **Step 1.** To a mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl]ethynyl]quinazoline-4,6-diamine (150 mg, 367 μmol) and acrylic acid (31.8 mg, 441 μmol) in pyridine (3.0 mL) and dichloromethane (3.0 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (211 mg, 1.10 mmol) in portions at 0 °C. The mixture was stirred at 0-20 °C for 1 h. On completion, the mixture was quenched by 0.1 mL water and concentrated. The obtained residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm*5 μm ;mobile phase: [water(10mM NH_4HCO_3)-acetonitrile];B%: 32%-62%,9min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2- [(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (40.0 mg, 23% yield) as an off white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.16 - 10.00 (m, 1H), 9.86 (s, 1H), 8.68 (s, 1H), 8.46 (d, $J = 2.4$ Hz, 1H), 7.79 (s, 1H), 7.50 (d, $J = 7.2$ Hz, 2H), 7.34 - 7.23 (m, 1H), 6.61 (dd, $J = 10.4, 17.2$ Hz, 1H), 6.34 (dd, $J = 2.0, 17.2$ Hz, 1H), 5.89 - 5.81 (m, 1H), 3.11 (d, $J = 8.4$ Hz, 1H), 2.93 (d, $J = 9.2$ Hz, 1H),

2.46 - 2.37 (m, 2H), 2.26 (s, 3H), 1.98 - 1.91 (m, 1H), 1.38 (t, J = 4.4 Hz, 1H), 1.03 (dd, J = 3.6, 8.0 Hz, 1H).

[0855] **Step 2.** To a solution of N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (40.0 mg, 86.6 μ mol) in dioxane (2.0 mL) and H₂O (1.0 mL) was added paraformaldehyde (20.0 mg, 432 μ mol) and DABCO (29.1 mg, 259 μ mol). The mixture was heated to 80 °C for 8 hours. On completion, the mixture was concentrated. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μ m; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 30%-60%, 7min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]-2-(hydroxymethyl)prop-2-enamide (30.0 mg, 70% yield) as white solid. m/z ES+ [M+H]⁺ 492.1; ¹H NMR (400 MHz, DMSO-d₆) δ 10.10 (s, 1H), 10.02 (s, 1H), 8.96 (s, 1H), 8.47 (s, 1H), 7.83 (s, 1H), 7.50 (dt, J = 2.0, 7.6 Hz, 2H), 7.32 - 7.24 (m, 1H), 6.14 (s, 1H), 5.76 (s, 1H), 5.70 (t, J = 5.6 Hz, 1H), 4.35 (d, J = 5.2 Hz, 2H), 3.13 (d, J = 8.0 Hz, 1H), 2.93 (d, J = 8.8 Hz, 1H), 2.48 - 2.37 (m, 2H), 2.27 (s, 3H), 1.98 (td, J = 4.0, 7.6 Hz, 1H), 1.37 (t, J = 4.4 Hz, 1H), 1.07 (dd, J = 3.6, 7.6 Hz, 1H).

Example 25. Synthesis of Compound No. 27 ((R,E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)but-2-enamide)



[0856] **Step 1.** To a solution of 2-diethoxyphosphorylacetic acid (143 mg, 731 μ mol) in tetrahydrofuran (2 mL) was added 1,1'-carbonyldiimidazole (122 mg, 756 μ mol) at 20 °C. The mixture was stirred at 40 °C for 0.5 h. Then N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 243 μ mol) was added and the mixture was stirred at 45 °C for 16 h. On completion, the reaction mixture was diluted in ethyl acetate (10 mL), washed with saturated aqueous NaHCO₃ (5 mL), H₂O (5 mL), and brine (5 mL x 3), then dried with Na₂SO₄ and concentrated to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-2-diethoxyphosphoryl-acetamide (143 mg, crude) as a brown oil which was used for next step directly. m/z ES+ [M+H]⁺ 588.3.

[0857] **Step 2.** To a mixture of N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-2-diethoxyphosphoryl-acetamide (143 mg, 243 μ mol) in ethanol (1.2 mL) was added LiCl (41.2 mg, 972 μ mol) in one portion at 20 °C under N₂. Then aqueous KOH (181 mg, 1.46 mmol, 45 wt%) was added and the mixture was stirred at 20 °C for 5 min. Then acetaldehyde (53.5 mg, 486 μ mol, 40% in water) in H₂O (0.7 mL) was added and the mixture was stirred at 20 °C for 1 h. On completion, the mixture was quenched by 5 mL H₂O and then filtered. The resulting precipitate was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*25mm*5 μ m; mobile phase: [water (10mM NH₄HCO₃)-acetonitrile]; B%: 35%-65%, 10 min) to give (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]but-2-enamide (20.5 mg, 17% yield) as a white solid. *m/z* ES+ [M+H]⁺ 478.2; ¹H NMR (400MHz, DMSO-*d*₆) δ 10.07 (br s, 1H), 9.48 (s, 1H), 8.72 (s, 1H), 8.47 (s, 1H), 7.78 (s, 1H), 7.55 – 7.40 (m, 2H), 7.28 (t, *J* = 7.6 Hz, 1H), 6.97 - 6.81 (m, 1H), 6.26 (d, *J* = 14.4 Hz, 1H), 2.81 (d, *J* = 8.8 Hz, 1H), 2.61 (t, *J* = 6.8 Hz, 2H), 2.55 – 2.50 (m, 1H), 2.28 (s, 3H), 2.27 - 2.20 (m, 1H), 1.91 (d, *J* = 6.8 Hz, 3H), 1.88 - 1.79 (m, 1H), 1.44 (s, 3H). SFC retention time: 1.31 min

Example 26. Synthesis of Compound No. 28 (N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)

[0858] **Step 1.** To a solution of 2-methyl-4-nitrophenol (9.00 g, 58.8 mmol) in N-methyl pyrrolidone (65 mL) was added diisopropylethylamine (22.8 g, 176 mmol) and 4-chloropyridin-2-amine (7.56 g, 58.8 mmol). The mixture was stirred at 135 °C for 48 hours. On completion, the reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (300 mL x 4). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography [petroleum ether/ethyl acetate = 20/1 to 0/1] to give 4-(2-methyl-4-nitrophenoxy)pyridin-2-amine (1.14 g, 8% yield) as a brown oil. ¹H NMR (400MHz, DMSO-*d*₆) δ = 8.29 (d, *J* = 2.4 Hz, 1H), 8.13 (dd, *J* = 2.8, 8.8 Hz, 1H), 7.87 (d, *J* = 5.6 Hz, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 6.19 (dd, *J* = 2.4, 5.6 Hz, 1H), 6.06 (s, 2H), 5.89 (d, *J* = 2.4 Hz, 1H), 2.28 (s, 3H).

[0859] **Step 2.** To a mixture of 4-(2-methyl-4-nitrophenoxy)pyridin-2-amine (1.14 g, 4.65 mmol) in ethyl alcohol (12 mL) was added dimethyl formamide dimethyl acetal (665 mg, 5.58 mmol),

and the mixture was stirred at 75 °C for 16 h. On completion, the mixture was concentrated under vacuum to give (E)-N,N-dimethyl-N'-(4-(2-methyl-4-nitrophenoxy)pyridin-2-yl)formimidamide (1.40 g, crude) as a brown oil, which was used for next step directly.

[0860] **Step 3.** To a mixture of (E)-N,N-dimethyl-N'-(4-(2-methyl-4-nitrophenoxy)pyridin-2-yl)formimidamide (1.40 g, 4.66 mmol) in ethyl alcohol (12 mL) was added hydroxylamine hydrochloride (389 mg, 5.59 mmol). The mixture was stirred at 50 °C for 3 h under nitrogen atmosphere. On completion, the mixture was cooled to 20 °C and the resulting precipitate was filtered. The filter cake was dried under reduced pressure to give (E)-N-hydroxy-N'-(4-(2-methyl-4-nitrophenoxy) pyridin-2-yl) formimidamide (800 mg, 60% yield) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 10.07 (s, 1H), 9.36 (d, J = 10.0 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.16 (dd, J = 2.8, 9.2 Hz, 1H), 8.09 (d, J = 5.6 Hz, 1H), 7.82 (d, J = 10.2 Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 6.54 (dd, J = 2.4, 5.6 Hz, 1H), 2.27 (s, 3H).

[0861] **Step 4.** A mixture of 7-(2-methyl-4-nitro-phenoxy)-[1,2,4]triazolo[1,5-a]pyridine (420 mg, 1.55 mmol) and palladium on carbon (200 mg, 1.55 mmol, 10% loading) in tetrahydrofuran (10 mL) was degassed and purged with hydrogen for 3 times, and then the mixture was stirred at 40 °C for 16 h under hydrogen atmosphere. On completion, the mixture was filtered and concentrated under reduced pressure to give 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylaniline (420 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 241.4; ¹H NMR (400MHz, DMSO-d₆) δ = 8.88 (d, J = 7.6 Hz, 1H), 8.35 (s, 1H), 6.96 (dd, J = 2.8, 7.6 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.62 (dd, J = 2.4, 9.6 Hz, 2H), 6.56 (dd, J = 2.8, 8.4 Hz, 1H), 2.00 (s, 3H).

[0862] **Step 5.** To a solution of 3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)aniline (485 mg, 2.02 mmol) in CH₃CN (10 mL) was added 4-chloro-7-fluoro-6-nitro-quinazoline (505 mg, 2.22 mmol). The mixture was stirred at 60 °C for 2 h. On completion, the mixture was concentrated. The residue was washed with CH₃CN (5 mL) and then dried in vacuum to give 7-fluoro-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-6-nitro-quinazolin-4-amine (1.00 g, 93% yield) as a yellow solid. m/z ES+ [M+H]⁺ 432.0

[0863] **Step 6.** To a solution of 7-fluoro-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-6-nitro-quinazolin-4-amine (1.00 mg, 2.32 mmol) in dimethylformamide (8 mL) was added KOAc (1.14 g, 11.6 mmol) at 15 °C. The mixture was stirred at 100 °C for 2 h. On completion, the mixture was concentrated to afford a yellow solid, which was triturated with H₂O (50 mL). After filtration, the filter cake was washed with H₂O (20 mL) and dried in vacuum to

give compound 4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-ol (400 mg, 38% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 430.0

[0864] **Step 7.** To a mixture of 4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-ol (400 mg, 931 μ mol) and pyridine (368 mg, 4.66 mmol) in CH_2Cl_2 (5 mL) was added Tf_2O (394 mg, 1.40 mmol) at 0 °C. The mixture was stirred at 20 °C for 3 h. On completion, the mixture was concentrated under vacuum to give a residue. The residue was purified by column chromatography [petroleum ether/ethyl acetate = 1/1 to 0/1] to give [4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (400 mg, 74% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 562.0

[0865] **Step 8.** To a solution of tert-butyl 1-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (310 mg, 1.50 mmol), [4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (700 mg, 1.25 mmol), CuI (47.5 mg, 249 μ mol) and triethylamine (4.16 g, 41.1 mmol) in dimethylformamide (7 mL) was added $Pd(PPh_3)_4$ (144 mg, 125 μ mol) at 20 °C. The mixture was stirred at 20 °C for 12 h under N_2 . On completion, the mixture was concentrated to give a residue. The residue was purified by column chromatography [petroleum ether/ethyl acetate = 1/1 to 0/1] to give tert-butyl 1-[2-[4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-yl]ethynyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (400 mg, 38% yield) as a yellow gum. m/z ES+ $[M+H]^+$ 619.2

[0866] **Step 9.** To a solution of tert-butyl 1-[2-[4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]-6-nitro-quinazolin-7-yl]ethynyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (400 mg, 647 μ mol) in CH_2Cl_2 (5 mL) was added HCl/ethyl acetate (4 M, 3.23 mL) and the mixture was stirred at 20 °C for 1 h. On completion, the mixture was concentrated to give a residue. The residue was neutralized with saturated sodium carbonate (15.0 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layers were washed with water (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give compound 7-[2-(3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-phenyl]-6-nitro-quinazolin-4-amine (270 mg, 69% yield) as a brown solid. m/z ES+ $[M+H]^+$ 519.1; ^1H NMR (400 MHz, $DMSO-d_6$) δ 9.87 (br s, 1H), 9.72 (s, 1H), 9.48 (br s, 1H), 8.99 (d, J = 7.6 Hz, 1H), 8.90 (s, 1H), 8.48 (s, 1H), 8.11 (s, 1H), 7.85 – 7.70 (m, 2H), 7.30 (d, J = 8.8 Hz, 1H), 7.09 (dd, J = 2.0, 7.6 Hz, 1H), 6.88 (s, 1H), 3.60 – 3.35 (m, 4H), 2.23 (s, 3H), 1.55 (t, J = 6.0 Hz, 1H),

1.41 (t, J = 7.6 Hz, 1H), 1.17 (t, J = 7.2 Hz, 1H).


[0867] **Step 10.** To a solution of 7-[2-(3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-6-nitro-quinazolin-4-amine (125 mg, 241 μ mol) in dimethylformamide (3 mL) was added formic acid (222 mg, 4.82 mmol) and (HCHO)_n (145 mg, 4.82 mmol). The mixture was stirred at 60 °C for 2 h. On completion, the reaction was quenched by 10% NaOH solution (10 mL), then extracted with ethyl acetate (15 mL x 2). The combined organic phases were washed with brine (10 mL), dried with anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give 7-[2-(3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-6-nitro-quinazolin-4-amine (120 mg, 79% yield) as a brown solid. m/z ES+[M+H]⁺ 533.2

[0868] **Step 11.** To a solution of 7-[2-(3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-6-nitro-quinazolin-4-amine (110 mg, 207 μ mol) and NH₄Cl (122 mg, 2.27 mmol) in MeOH (2 mL) and H₂O (2 mL) was added iron powder (101 mg, 1.81 mmol) at 20 °C. The mixture was stirred at 80 °C for 1 h. On completion, the reaction mixture was filtered and concentrated under vacuum to afford a residue. The residue was diluted with water (10 mL) and stirred for 30 min. After filtration, the filter cake was washed with water (15 mL) and collected. The filtrate was extracted with ethyl acetate (20 mL x 2) to recover additional product. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give compound 7-[2-(3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-phenyl]quinazoline-4,6-diamine (100 mg, 76% yield) as a brown solid. m/z ES+[M+H]⁺ 503.1

[0869] **Step 12.** To a mixture of 7-[2-(3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine (90.0 mg, 179 μ mol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (137 mg, 716 μ mol) and pyridine (42.5 mg, 537 μ mol) in dimethylformamide (2 mL) was added a solution of acrylic acid (15.5 mg, 215 μ mol) in dimethylformamide (2 mL) dropwise at 20 °C. The mixture was stirred at 20 °C for 2 h. On completion, the reaction mixture was quenched by H₂O (5 mL). The aqueous layer was extracted with ethyl acetate (10 mL x 2). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 26%-56%, 9min) and prep-HPLC (formic acid condition; column:

Unisil 3-100 C18 Ultra 150*50mm*3 μ m; mobile phase: [water(0.225% formic acid)-acetonitrile]; B%: 10%-30%, 10min) to give N-[7-[2-(3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]quinazolin-6-yl]prop-2-enamide (15.0 mg, 15% yield, formic acid salt) as a yellow solid. m/z ES+[M+H]⁺ 557.3; ¹H NMR (400 MHz, DMSO-d₆) δ 9.92 (s, 2H), 8.93 (d, J = 7.6 Hz, 1H), 8.74 (s, 1H), 8.58 (s, 1H), 8.38 (s, 1H), 8.35 (s, 1H), 7.88 – 8.80 (m, 2H), 7.79 (s, 1H), 7.21 (d, J = 8.8 Hz, 1H), 7.03 (dd, J = 2.4, 7.2 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 6.60 (dd, J = 10.4, 17.6 Hz, 1H), 6.34 (dd, J = 1.6, 16.8 Hz, 1H), 5.89 – 5.83 (m, 1H), 3.10 (d, J = 8.8 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.43 (d, J = 8.4 Hz, 1H), 2.39 (dd, J = 3.6, 9.2 Hz, 1H), 2.25 (s, 3H), 2.19 (s, 3H), 1.95 – 1.88 (m, 1H), 1.37 (t, J = 4.8 Hz, 1H), 1.01 (dd, J = 4.0, 8.0 Hz, 1H).

Example 27. Synthesis of Compound No. 29 (N-(4-((5-chloro-2-fluorophenyl)amino)-7-((3-methyloxetan-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0870] **Step 1.** To a solution of 7-iodo-6-nitroquinazolin-4-ol (300 mg, 946 μ mol) in SOCl₂ (3.0 mL) was added dimethylformamide (69.1 mg, 946 μ mol) at 20 °C. Then the mixture was stirred at 90 °C for 4 hours. The reaction mixture was concentrated under reduced pressure to give a residue. Then it was dissolved in dichloromethane (10 mL) and washed with saturated sodium bicarbonate (5 mL) at 0 °C. The organic phase was washed with brine (3 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 4-chloro-7-iodo-6-nitroquinazoline (240 mg, 75% yield) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (s, 1H), 8.44 (s, 1H), 8.35 (s, 1H).

[0871] **Step 2.** To a solution of 4-chloro-7-iodo-6-nitroquinazoline (240 mg, 715 μ mol) in i-PrOH (2.0 mL) and dichloromethane (2 mL) was added 5-chloro-2-fluoroaniline (124 mg, 858 μ mol) and Tformic acid (120 mg, 1.05 mmol) at 0 °C. Then the mixture was stirred at 20 °C for 0.5 hour.

The reaction mixture was poured into water (5 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 15/1 to 3/1) to give N-(5-chloro-2-fluoro-phenyl)-7-iodo-6-nitro-quinazolin-4-amine (120 mg, 37% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.45 (s, 1H), 9.22 (s, 1H), 8.66 (s, 1H), 8.52 (s, 1H), 7.72 (d, J = 6.8 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H).


[0872] **Step 3.** A mixture of N-(5-chloro-2-fluoro-phenyl)-7-iodo-6-nitro-quinazolin-4-amine (120 mg, 269 μmol), 3-ethynyl-3-methyl-oxetane (31.1 mg, 323 μmol), CuI (10.2 mg, 53.9 μmol), Et₃N (872 mg, 8.62 mmol) and Pd(PPh₃)₂Cl₂ (18.9 mg, 26.9 μmol) in dimethylformamide (1.2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20 °C for 1 hour under N₂. The reaction mixture was poured into water (5 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 15/1 to 2/1) to give N-(5-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (100 mg 89 % yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 9.44 (s, 1H), 8.69 (s, 1H), 8.07 (s, 1H), 7.73 (d, J = 6.0 Hz, 1H), 7.44 (d, J = 8.4 Hz, 2H), 4.83 (d, J = 5.6 Hz, 2H), 4.51 (d, J = 5.6 Hz, 2H), 1.70 (s, 3H).

[0873] **Step 4.** To a mixture of N-(5-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (90.0 mg, 218 μmol) in tetrahydrofuran (1.0 mL) and H₂O (1.0 mL) was added sodium hydrosulfite (303.67 mg, 1.74 mmol) at 20 °C. The mixture was stirred at 60 °C for 16 hours. The reaction mixture was poured into water (5 mL) and extracted with dichloromethane (10 mL x 3). The combined organic phase was washed with brine (5 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give N4-(5-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]quinazoline-4,6-diamine (50.0 mg, 60% yield) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 9.44 (s, 1H), 8.28 (s, 1H), 7.77 (d, J = 5.6 Hz, 1H), 7.68 - 7.61 (m, 1H), 7.39 (s, 1H), 7.34 (br s, 1H), 5.76 (s, 2H), 4.87 (d, J = 5.2 Hz, 2H), 4.46 (d, J = 5.2 Hz, 2H), 1.71 (s, 3H).

[0874] **Step 5.** To a mixture of N4-(5-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-

yl)ethynyl] quinazoline-4,6-diamine (45.0 mg, 117 μmol) and acrylic acid (8.47 mg, 118 μmol) in pyridine (1.0 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (22.5 mg, 118 μmol) at 20 °C. The mixture was stirred at 20 °C for 16 hours. The organic solvent was removed by nitrogen purge. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 μm ; mobile phase: [water (10m M NH_4HCO_3)-acetonitrile]; B%: 36%-56%, 6 min) to give N4-(5-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]quinazoline-4,6-diamine (20.4 mg, 45% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 437.1; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.93 (br s, 1H), 8.70 (s, 1H), 8.44 (br s, 1H), 7.83 (s, 1H), 7.63 (br d, $J = 5.6$ Hz, 1H), 7.41 - 7.29 (m, 2H), 6.62 (dd, $J = 10.4, 16.8$ Hz, 1H), 6.34 (dd, $J = 2.0, 16.8$ Hz, 1H), 5.86 (dd, $J = 1.6, 10.2$ Hz, 1H), 4.83 (d, $J = 5.2$ Hz, 2H), 4.45 (d, $J = 5.6$ Hz, 2H), 1.68 (s, 3H).

Example 28. Synthesis of Compound No. 30 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyloxetan-3-yl)ethynyl)quinazolin-6-yl)acrylamide)




[0875] **Step 1.** To a solution of [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (200 mg, 428 μmol) in dimethylformamide (2.0 mL) was added CuI (16.3 mg, 85.7 μmol), Et_3N (1.45 g, 14.3 mmol), 3-ethynyl-3-methyl-oxetane (45.3 mg, 471 μmol) and $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (30.0 mg, 42.8 μmol). The mixture was stirred at 20 °C for 1 h under N_2 . On completion, the reaction mixture was quenched by water (10 mL), and extracted with ethyl acetate (5 mL $\times$ 3). The combined organic phase was washed with saturated NH_4Cl solution (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (150 mg, 84% yield) as an orange solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.66 (s, 1H), 9.43 (s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.67 - 7.49 (m, 2H), 7.32 (t, $J = 8.4$ Hz, 1H), 4.82 (d, $J = 5.6$ Hz, 2H), 4.50 (d, $J = 5.6$ Hz, 2H), 1.69 (s, 3H).

[0876] **Step 2.** To a mixture of N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-methyloxetan-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (80.0 mg, 194 μmol) in tetrahydrofuran (1.0 mL) and H_2O (1.0 mL) was added sodium hydrosulfite (270 mg, 1.55 mmol) at 20 °C. The mixture was stirred at 60 °C

for 16 h. On completion, the reaction mixture was poured into water (5 mL) and extracted with dichloromethane (10 mL x 3). The combined organic phase was washed with brine (5 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyloxetan-3-yl)ethynyl)quinazoline-4,6-diamine (50.0 mg, 67% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.57 (s, 1H), 8.25 (s, 1H), 7.67 - 7.62 (m, 1H), 7.58 - 7.51 (m, 1H), 7.45 (t, J = 6.8 Hz, 1H), 7.39 (s, 1H), 7.26 (t, J = 8.0 Hz, 1H), 5.76 - 5.71 (m, 2H), 4.87 (d, J = 5.2 Hz, 2H), 4.45 (d, J = 5.2 Hz, 2H), 1.71 (s, 3H).

[0877] **Step 3.** To a mixture of N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyloxetan-3-yl)ethynyl)quinazoline-4,6-diamine (30.0 mg, 78.4 μmol) in pyridine (1.0 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (18.0 mg, 94.0 μmol) and acrylic acid (6.78 mg, 94.0 μmol) at 20 °C. The mixture was stirred at 20 °C for 16 h. On completion, the organic solvent was removed by nitrogen purge. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 μm; mobile phase: [water (10 mM NH₄HCO₃)-acetonitrile]; B%: 34%-54%, 6 min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyloxetan-3-yl)ethynyl)quinazolin-6-yl)acrylamide (12.8 mg, 37% yield) as a yellow solid. m/z ES+ [M+H]⁺ 437.1; ¹H NMR (400 MHz, DMSO-d₆) δ 10.13 (s, 1H), 9.96 (s, 1H), 8.73 (s, 1H), 8.50 (s, 1H), 7.88 (s, 1H), 7.51 (q, J = 7.2 Hz, 2H), 7.29 (t, J = 8.0 Hz, 1H), 6.63 (dd, J = 10.0, 16.8 Hz, 1H), 6.35 (br d, J = 17.2 Hz, 1H), 5.86 (br d, J = 10.4 Hz, 1H), 4.83 (d, J = 5.6 Hz, 2H), 4.46 (d, J = 5.6 Hz, 2H), 1.68 (s, 3H).

Example 29. Synthesis of Compound No. 31 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)-2-(hydroxymethyl)acrylamide)




[0878] **Step 1.** To a mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl] ethynyl]quinazoline-4,6-diamine (100 mg, 243.97 μmol) in tetrahydrofuran (1 mL) and H₂O (0.25 mL) was added NaHCO₃ (102.48 mg, 1.22 mmol) and prop-2-enoyl chloride (66.1 mg, 730 μmol) in tetrahydrofuran (1.5 mL) dropwise at 0 °C. Then the mixture was stirred at 20 °C for 12

h. On completion, the reaction was concentrated in vacuo. The residue was diluted with H₂O (2 mL) and extracted with ethyl acetate (3 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under vacuum to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (80 mg, 70.68% yield) as a yellow solid. m/z ES+ [M+H]⁺ 464.1

[0879] **Step 2.** To a mixture of N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (60 mg, 129.33 μ mol) in dioxane (4 mL) and H₂O (1 mL) was added 1,4-diazabicyclo[2.2.2]octane (43.52 mg, 387.99 μ mol) and (CH₂O)_n (18.11 mg, 646.64 μ mol) at 20 °C. Then the mixture was stirred at 80 °C for 12 h. On completion, the reaction was diluted in DMSO (1 mL). The mixture was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10 μ m; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 33%-53%, 8min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-2-(hydroxymethyl)prop-2-enamide (5 mg, 7.83% yield) as a yellow solid. m/z ES+ [M+H]⁺ 494.0; ¹H NMR (400 MHz, CDCl₃) δ 11.01 (br s, 1H), 9.36 (s, 1H), 8.73 (s, 1H), 8.45 - 8.31 (m, 1H), 7.95 (s, 1H), 7.73 (br s, 1H), 7.23 - 7.11 (m, 2H), 6.44 (s, 1H), 5.69 (s, 1H), 4.62 (d, J = 11.2 Hz, 1H), 4.54 (d, J = 10.8 Hz, 1H), 3.44 (d, J = 10.0 Hz, 1H), 3.26 (br t, J = 8.4 Hz, 1H), 2.55 - 2.42 (m, 4H), 2.34 (q, J = 9.2 Hz, 1H), 2.26 - 2.16 (m, 1H), 2.08 - 1.93 (m, 1H), 1.61 (s, 4H).

Example 30. Synthesis of Compound No. 32 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0880] **Step 1.** To a solution of 4-(tert-butyl) 2-ethyl morpholine-2,4-dicarboxylate (5 g, 19.3 mmol) in tetrahydrofuran (38 mL) was added LiHMDS (1 M, 38.6 mL) dropwise under N₂ at -65 °C over 1 h. Then the mixture was stirred at -65 °C for 1.5 h. And MeI (11.0 g, 77.1 mmol, 4.80 mL) was added dropwise at -65 °C. The mixture was slowly warmed to 20 °C and stirred at 20 °C for 12 h. On completion, the reaction mixture was quenched by saturated NH₄Cl solution (50 mL) at 15 °C, and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography [SiO₂, petroleum ether/ ethyl acetate = 50/ 1 to 3/ 1] to give 4-tert-butyl 2-ethyl morpholine-2,4-dicarboxylate (3.03 g, 57.49% yield) as a yellow oil. ¹HNMR (400 MHz, CDCl₃) δ 4.37 (d, J = 13.2 Hz, 1H), 4.23 (s, 2H), 3.89 - 3.75 (m, 3H), 3.02 (br s, 1H), 2.87 (d, J = 13.2 Hz, 1H), 1.47 (s, 9H), 1.39 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).

[0881] **Step 2.** To a mixture of 4-tert-butyl 2-ethyl morpholine-2,4-dicarboxylate (3 g, 11.0 mmol) in tetrahydrofuran (30 mL) was added LiBH₄ (960 mg, 44.1 mmol) at 0 °C under N₂. The mixture was stirred at 25 °C for 6 hours. On completion, the mixture was quenched by MeOH (30 mL) carefully and then concentrated in vacuum to give a residue. The residue was partitioned between HCl (0.5 N, 20 mL) and ethyl acetate (10 mL). The aqueous phase was extracted with ethyl acetate (20 mL x 2). The combined organic phase was washed with brine (50 mL x 2), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography [SiO₂, petroleum ether/ ethyl acetate = 1/ 0 to 0/ 1] to give tert-butyl 2-(hydroxymethyl)-2-methylmorpholine-4-carboxylate (1.8 g, 70.65% yield) as a yellow oil. m/z ES+ [M+H]⁺ 176.2

[0882] **Step 3.** To a mixture of tert-butyl 2-(hydroxymethyl)-2-methylmorpholine-4-carboxylate (1.4 g, 6.05 mmol) in dichloromethane (15 mL) was added DMP (3.34 g, 7.87 mmol) in one portion at 0 °C under N₂. The mixture was stirred at 0 °C for 1 hour. On completion, the mixture was poured into saturated aqueous Na₂CO₃ (20 mL) and dichloromethane (10 mL). The aqueous phase was extracted with dichloromethane (5 mL x 3). The combined organic phase was washed with brine (10 mL x 2), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give tert-butyl 2-formyl-2-methylmorpholine-4-carboxylate (2.2 g, crude) as a white solid.

[0883] **Step 4.** To a mixture of tert-butyl 2-formyl-2-methylmorpholine-4-carboxylate (2.2 g, 9.60 mmol) and 1-diazo-1-dimethoxyphosphoryl-propan-2-one (2.77 g, 14.4 mmol) in MeOH (30 mL)

was added K_2CO_3 (2.65 g, 19.2 mmol) in one portion at 0 °C under N_2 . The mixture was stirred at 25 °C for 2 hours. On completion, the mixture was filtered and the filter cake was washed with MeOH (4 mL x 2). Then the filtrate was concentrated in vacuum to give a residue. The residue was purified by column chromatography [SiO_2 , petroleum ether/ ethyl acetate = 1/ 0 to 0/ 1] to give tert-butyl 2-ethynyl-2-methylmorpholine-4-carboxylate (1.2 g, 55.51% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-d_6) δ 3.95 - 3.83 (m, 1H), 3.83 - 3.73 (m, 2H), 3.62 (dd, J = 11.2, 2.8 Hz, 1H), 3.47 (s, 1H), 2.83 (s, 1H), 2.90 – 2.70 (m, 2H), 1.40 (s, 9H), 1.35 (s, 3H).

[0884] **Step 5.** To a mixture of tert-butyl 2-ethynyl-2-methylmorpholine-4-carboxylate (265 mg, 1.18 mmol), CuI (40.8 mg, 214 μmol), Et_3N (3.63 g, 35.9 mmol, 4.99 mL) and [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (500 mg, 1.07 mmol) in dimethylformamide (5 mL) was added $\text{Pd}(\text{PPh}_3)_4$ (124 mg, 107 μmol) in one portion at 20 °C. The mixture was degassed and purged with N_2 for 3 times, and then stirred at 20 °C for 12 hours. On completion, the mixture was poured into H_2O (10 mL) and ethyl acetate (5 mL). The aqueous phase was extracted with ethyl acetate (5 mL x 2). The combined organic phase was washed with brine (5 mL x 2), dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography [SiO_2 , petroleum ether/ethyl acetate = 1/0 to 0/1] to give tert-butyl2-((4-((3-chloro-2-fluorophenyl) amino)-6-nitroquinazolin-7-yl)ethynyl)-2-methylmorpholine-4-carboxylate (0.65 g, crude) as a brown solid. ^1H NMR (400 MHz, DMSO-d_6) δ 9.46 (s, 1H), 8.68 (s, 1H), 8.02 (s, 1H), 7.95 (s, 1H), 7.60 – 7.45 (m, 2H), 7.37 - 7.27 (m, 1H), 4.15 – 4.05 (m, 1H), 4.05 – 3.95 (m, 1 H), 3.95 – 3.80 (m, 1H), 3.80 – 3.70 (m, 1H), 3.10 – 2.93 (m, 1H), 2.89 - 2.80 (m, 1H), 1.52 (s, 3H), 1.32 (s, 9H).

[0885] **Step 6.** A mixture of tert-butyl2-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-2-methylmorpholine-4-carboxylate (500 mg, 923 μmol) in HCl/ethyl acetate (6 mL) was stirred at 20 °C for 2 hours. On completion, the mixture was concentrated in vacuum to give a residue. The residue was poured into saturated aqueous NaHCO_3 solution (15 mL) and ethyl acetate (10 mL). The aqueous phase was extracted with ethyl acetate (8 mL x 3). The combined organic phase was washed with brine (10 mL x 2), dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give N-(3-chloro-2-fluorophenyl)-7-((2-methylmorpholin-2-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, crude) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 442.2


[0886] **Step 7.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((2-methylmorpholin-2-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, 1.13 mmol) in trifluoroethanol (5 mL) was added

(CH₂O)_n (170 mg, 5.66 mmol) at 60 °C. The mixture was stirred at 60 °C for 10 min. Then NaBH₄ (85.6 mg, 2.26 mmol) was added. The mixture was stirred at 60 °C for 12 hours. On completion, the mixture was quenched by saturated aqueous NH₄Cl (10 mL). The aqueous phase was extracted with ethyl acetate (5 mL x 3). The combined organic phase was washed with brine (5 mL x 2), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-TLC [SiO₂, dichloromethane/ MeOH = 10/ 1, R_f = 0.21] to give N-(3-chloro-2-fluorophenyl)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)-6-nitroquinazolin-4-amine (0.2 g, 38.77% yield) as a white solid.

[0887] **Step 8.** To a mixture of N-(3-chloro-2-fluorophenyl)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)-6-nitroquinazolin-4-amine (200 mg, 439 μmol) in tetrahydrofuran (1 mL) and H₂O (1 mL) was added sodium hydrosulfite (382 mg, 2.19 mmol) in one portion at 20 °C under N₂. The mixture was stirred at 20 °C for 2 hours. On completion, the mixture was poured into H₂O (5 mL) and dichloromethane (3 mL). The aqueous phase was extracted with dichloromethane (3 mL x 3). The combined organic phase was washed with brine (3 mL x 3), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-TLC [dichloromethane/ MeOH = 10/ 1, R_f = 0.24] to give N4-(3-chloro-2-fluorophenyl)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)quinazoline-4,6-diamine (0.1 g, 53.52% yield) as a white solid. m/z ES+ [M+H]⁺ 399.1

[0888] **Step 9.** To a mixture of N4-(3-chloro-2-fluorophenyl)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)quinazoline-4,6-diamine (0.06 g, 140 μmol) and acrylic acid (15.2 mg, 112 μmol) in dimethylformamide (1 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (108 mg, 564 μmol) and pyridine (89.16 mg, 1.13 mmol) in one portion at 25 °C under N₂. The mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 35%-60%, 8min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((2,4-dimethylmorpholin-2-yl)ethynyl)quinazolin-6-yl)acrylamide (2 mg, 2.79% yield) as a white solid. m/z ES+ [M+H]⁺ 480.0; ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (br s, 1H), 9.68 (br s, 1H), 8.83 (s, 1H), 8.50 (s, 1H), 7.88 (s, 1H), 7.55 – 7.45 (m, 2H), 7.29 (t, J = 7.6 Hz, 1H), 6.63 – 6.47 (m, 1H), 6.41 – 6.28 (m, 1H), 5.88 (d, J = 10.4 Hz, 1H), 4.00 (t, J = 10.4 Hz, 1H), 3.70 (d, J = 11.2 Hz, 1H), 2.98 (d, J = 11.2 Hz, 1H), 2.67 (d, J = 10.4 Hz, 1H), 2.21 (s, 3H), 2.05 – 1.93 (m, 2H), 1.49 (s, 3H).

Example 31. Synthesis of Compound No. 33 (N-(4-((3,4-dichloro-2-fluorophenyl)amino)-7-(((1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide) and Compound No. 34 (N-(4-((3,4-dichloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0889] **Step 1.** To a solution of [4-(3,4-dichloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (2.4 g, 4.79 mmol) and tert-butyl 1-ethynyl-3-azabicyclo[3.1.0] hexane-3-carboxylate (1.09 g, 5.27 mmol) in dimethylformamide (20 mL) and triethylamine (14.5 g, 144 mmol, 20 mL) was added CuI (182 mg, 958 μ mol) and Pd(PPh₃)₄ (277 mg, 239 μ mol) in one portion under nitrogen. The mixture was stirred at 25 °C for 2 h. On completion, the reaction mixture was diluted with H₂O (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Petroleum ether/Ethyl acetate=5/1 to 1/1) to give tert-butyl 1-((4-((3, 4-dichloro-2-fluorophenyl) amino)-6-nitroquinazolin-7-yl) ethynyl)-3-azabicyclo [3.1.0] hexane-3-carboxylate (2.60 g, 88% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 558.2; ¹H NMR (400 MHz,

CDCl₃) δ 8.93 - 8.78 (m, 2H), 8.62 - 8.36 (m, 1H), 8.05 (s, 2H), 7.57 (dd, J = 7.2, 11.6 Hz, 1H), 3.83 (d, J = 10.8 Hz, 1H), 3.63 - 3.48 (m, 2H), 2.99 (s, 1H), 2.89 (s, 1H), 1.45 (s, 9H)

[0890] **Step 2.** To a solution of tert-butyl 1-[2-[4-(3, 4-dichloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] ethynyl]-3-azabicyclo [3.1.0] hexane-3-carboxylate (2.40 g, 4.30 mmol) in ethyl acetate (20 mL) was added HCl/ethyl acetate (4 M, 7.68 mL), it was stirred at 20 °C for 2 hs. On completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C8 250*50mm*10um; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 5%-40%, 14.5 min) to give 7-(3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3,4-dichloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (780 mg, 36% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 458.1; ¹H NMR (400 MHz, DMSO-d₆) δ 9.90 (s, 1H), 8.74 (s, 1H), 8.08 (s, 1H), 7.67 - 7.63 (m, 1H), 7.57 (d, J = 7.6 Hz, 1H), 3.71 - 3.57 (m, 1H), 3.56 - 3.41 (m, 2H), 3.37 (dd, J = 6.0, 11.6 Hz, 1H), 2.42 - 2.33 (m, 1H), 1.56 (t, J = 5.6 Hz, 1H), 1.40 (t, J = 7.2 Hz, 1H).

[0891] **Step 3.** 7-[2-(3-azabicyclo [3.1.0] hexan-1-yl) ethynyl]-N-(3, 4-dichloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (780 mg, 1.53 mmol, 90% purity) was purified by SFC (column: Phenomenex-Cellulose-2 (250mm*30mm, 10um); mobile phase: [0.1% ammonium hydroxide methanol]; B%: 60%-60%, min) to give 7-((1R, 5S)-3-azabicyclo [3.1.0] hexan-1-ylethynyl)-N-(3,4-dichloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (300 mg, 40% yield) as a yellow solid and 7-((1S,5R)-3-azabicyclo[3.1.0] hexan-1-ylethynyl)-N-(3,4-dichloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (300 mg, 40% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 458.1; ¹H NMR (400 MHz, DMSO-d₆) δ 9.27 (s, 1H), 8.53 (s, 1H), 7.87 (s, 1H), 7.64 - 7.44 (m, 2H), 3.08 (d, J = 11.2 Hz, 1H), 2.91 - 2.80 (m, 3H), 1.93 (dd, J = 6.0, 7.2 Hz, 1H), 1.11 (t, J = 4.8 Hz, 1H), 1.07 - 1.03 (m, 1H). m/z ES+ $[M+H]^+$ 458.1; ¹H NMR (400 MHz, DMSO-d₆) δ 9.30 (s, 1H), 8.55 (s, 1H), 8.18 (s, 1H), 7.90 (s, 1H), 7.58 (d, J = 1.2 Hz, 2H), 3.12 (d, J = 11.2 Hz, 1H), 2.93 - 2.87 (m, 3H), 1.97 (dd, J = 5.2, 7.6 Hz, 1H), 1.14 (t, J = 4.8 Hz, 1H), 1.11 - 1.05 (m, 1H).

[0892] **Step 4.** To a solution of 7-[2-[(1R, 5S)-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]-N-(3, 4-dichloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (150 mg, 327 μ mol) in trifluoroethanol (3 mL) was added HCHO (49.1 mg, 1.64 mmol) and the mixture was stirred at 25 °C for 0.5 h. Then NaBH₄ (37.2 mg, 982 μ mol) was added, it was stirred at 60 °C for 3 hs. On completion, the mixture was quenched with methanol (8.0 mL) and concentrated to dryness to give a residue. The reaction mixture was diluted with H₂O (20 mL) and extracted with ethyl acetate (30 mL x 3). The combined

organic layers were washed with brine (25 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give N-(3,4-dichloro-2-fluorophenyl)-7-(((1R,5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl)ethynyl)-6-nitroquinazolin-4-amine (200 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 472.2

[0893] **Step 5.** To a solution of N-(3, 4-dichloro-2-fluoro-phenyl)-7-[2-[(1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (150 mg, 318 umol) in ethanol (3 mL) was added Fe (177 mg, 3.18 mmol) and HOAc (1.05 g, 17.48 mmol, 1.00 mL), it was stirred at 80 °C for 2 h. On completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with H₂O (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give N4-(3-chloro-2-fluorophenyl)-7-(6-methyl-2, 6-diazaspiro [3.4] octan-2-yl) quinazoline-4, 6-diamine (150 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 442.1

[0894] **Step 6.** To a solution of N4-(3, 4-dichloro-2-fluoro-phenyl)-7-[2-[(1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]quinazoline-4, 6-diamine (65.6 mg, 148 umol) in pyridine (1 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (142 mg, 741 umol) and acrylic acid (10.7 mg, 148 umol), it was stirred at 20 °C for 1 h. On completion, the reaction mixture was diluted with H₂O (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5um; mobile phase: [water (10mM NH₄HCO₃)-acetonitrile]; B%: 46%-76%, 10min) to give N-(4-((3, 4-dichloro-2-fluorophenyl) amino)-7-(((1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide (16.3 mg, 21% yield) as a yellow solid. m/z ES+ [M+H]⁺ 496.1; ¹H NMR (400 MHz, DMSO-d₆) δ 10.35 - 9.97 (m, 1H), 9.84 (s, 1H), 8.67 (s, 1H), 8.52 - 8.30 (m, 1H), 7.76 (s, 1H), 7.64 - 7.37 (m, 2H), 6.60 (dd, J = 10.4, 17.2 Hz, 1H), 6.33 (dd, J = 1.6, 17.2 Hz, 1H), 5.94 - 5.71 (m, 1H), 3.11 (d, J = 8.4 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.47 - 2.38 (m, 2H), 2.25 (s, 3H), 1.99 - 1.87 (m, 1H), 1.37 (t, J = 4.4 Hz, 1H), 1.03 (s, 1H).


[0895] **Step 7.** To a solution of 7-[2-[(1S, 5R)-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]-N-(3, 4-dichloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (150 mg, 327 umol) in trifluoroethanol (5 mL) was added HCHO (49.1 mg, 1.64 mmol) and the mixture was stirred at 25 °C for 0.5 h. Then NaBH₄ (37.2mg, 982 umol) was added and the mixture was stirred at 60 °C for 3 h. On completion,

the mixture was quenched with methanol (8 mL) and concentrated to dryness to give a residue. The reaction mixture was diluted with H₂O 20 mL and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (25 mL * 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give N-(3, 4-dichloro-2-fluorophenyl)-7-(((1S, 5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-6-nitroquinazolin-4-amine (130 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺472.1

[0896] **Step 8.** To a solution of N-(3, 4-dichloro-2-fluoro-phenyl)-7-[2-[(1S, 5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (65.0 mg, 138 μ mol) in MeOH (1 mL) and H₂O (1 mL) was added Fe (38.4 mg, 688 μ mol) and NH₄Cl (73.6 mg, 1.38 mmol), it was stirred at 80 °C for 2 h. On completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with H₂O (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give N4-(3, 4-dichloro-2-fluorophenyl)-7-(((1S, 5R)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl) ethynyl)quinazoline- 4, 6-diamine (60 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 442.2

[0897] **Step 9.** To a solution of N4-(3, 4-dichloro-2-fluoro-phenyl)-7-[2-[(1S, 5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (55.0 mg, 124 μ mol) in pyridine (1 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (119 mg, 622 μ mol) and acrylic acid (9.86 mg, 137 μ mol), it was stirred at 20 °C for 1 h. On completion, the reaction mixture was diluted with H₂O (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. It was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μ m; mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 15%-45%,9min) to give N-(4-((3, 4-dichloro-2-fluorophenyl) amino)-7-(((1S, 5R)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl) ethynyl) quinazolin-6-yl) acrylamide (14.4 mg, 21% yield, formic acid) as a yellow solid. m/z ES+ [M+H]⁺496.1; ¹H NMR (400 MHz, DMSO-d₆) δ 10.22 - 10.02 (m, 1H), 9.86 (s, 1H), 8.68 (s, 1H), 8.55 - 8.35 (m, 1H), 8.33 - 8.26 (m, 1H), 7.79 (d, J = 1.6 Hz, 1H), 7.55 (s, 2H), 6.60 (dd, J = 10.0, 16.8 Hz, 1H), 6.33 (dd, J = 1.6, 17.2 Hz, 1H), 5.85 (dd, J = 1.6, 10.2 Hz, 1H), 3.10 (d, J = 8.4 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.39 (dd, J = 3.6, 9.2 Hz, 2H), 2.25 (s, 3H), 1.94 (td, J = 4.4, 8.0 Hz, 1H), 1.37 (t, J = 4.4 Hz, 1H), 1.03 (dd, J = 3.6, 8.0 Hz, 1H).

Example 32. Synthesis of Compound No. 35 ((S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide) and Compound No. 36 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0898] **Step 1.** To a solution of 4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol (8.00 g, 23.9 mmol) in dichloromethane (120 mL) was added TiF_2O (20.2 g, 71.7 mmol) and pyridine (7.56 g, 95.6 mmol) at 0 °C. The mixture was stirred at 20 °C for 2 h. On completion, the organic solvent was removed under vacuum, the residue was diluted with ethyl acetate (150 mL), washed with water (50 mL x 3) and brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under vacuum to give [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (4.10 g, crude) as an orange solid. m/z ES^+ $[\text{M}+\text{H}]^+$ 466.9

[0899] **Step 2.** To a solution of [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (2.00 g, 4.28 mmol) and tert-butyl 3-ethynyl-3-methoxy-pyrrolidine-1-carboxylate (965 mg, 4.28 mmol) in dimethylformamide (20 mL) was added CuI (163 mg, 857 μmol), Et_3N (14.5 g, 144 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (495 mg, 428 μmol). The mixture was degassed and purged with N_2 for 3 times and then it was stirred at 20 °C for 12 h. On completion, the reaction was filtered and the filtered cake was washed with ethyl acetate (50 mL) to give tert-butyl 3-[2-[4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl]ethynyl]-3-methoxy-pyrrolidine-1-

carboxylate (2 g, crude) as a brown solid. m/z ES+ $[M+H]^+$ 542.1

[0900] **Step 3.** To a solution of tert-butyl 3-[2-[4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl]ethynyl]-3-methoxy-pyrrolidine-1-carboxylate (2.50 g, 4.61 mmol) in dichloromethane (20 mL) was added HCl/ethyl acetate (4 M, 5 mL). The mixture was stirred at 20 °C for 1 h. On completion, the organic solvent was removed under vacuum to afford N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-methoxypyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (2.00 g, crude) as a brown solid. m/z ES+ $[M+H]^+$ 442.0

[0901] **Step 4.** The N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-methoxypyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (1.50 g, 3.39 mmol) was purified by SFC (column: DAICEL CHIRALPAK AD-H(250mm*30mm,5um); mobile phase: [Neu-ETOH]; B%: 0%-0%,0min;0min) to afford N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxypyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.32 g, 724 umol, 21% yield, 100% purity) and N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxypyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, 659 umol, 19% yield, 97% purity) as red solids. SFC Retention time: 1.625 min, 2.566 min

[0902] **Step 5.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxypyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, 679 umol) in trifluoroethanol (6 mL) was added HCHO (102 mg, 3.4 mmol) and NaBH₄ (51.4 mg, 1.36 mmol). The mixture was stirred at 60 °C for 4 h. On completion, the reaction was diluted with water (100 mL), extracted with EA (30 mL x 3), washed with brine (40 mL), dried over Na₂SO₄, filtered and concentrated under vacuum to afford N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, crude) as a brown solid. m/z ES+ $[M+H]^+$ 456.0

[0903] **Step 6.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, 658 umol) in MeOH (3.0 mL) and H₂O (3.0 mL) was added NH₄Cl (422 mg, 7.9 mmol) and Fe (331 mg, 5.9 mmol). The mixture was stirred at 80 °C for 1 h. On completion, the reaction was filtered through a pad of celite while it was still hot, the filtered cake was washed with MeOH (10 mL), and the combined organic solvent was concentrated in vacuo to afford N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (0.22 g, crude) as a brown solid.

[0904] **Step 7.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-methoxy-1-methyl-

pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (200 mg, 470 μmol) in pyridine (4.00 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (360 mg, 1.88 mmol) and acrylic acid (50.8 mg, 704.4 μmol). The mixture was stirred at 0 °C for 2 h. On completion, the organic solvent was removed under vacuum and the crude was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 26%-56%,8min) and repurified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μm ; mobile phase: [water(0.225%formic acid)-acetonitrile]; B%: 15%-25%,9min) to afford N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (24 mg, 50 μmol , 10.7% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 480.2; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.36 - 9.90 (m, 2H), 8.64 (s, 1H), 8.55 - 8.42 (m, 1H), 8.26 (s, 2H), 7.91 (br s, 1H), 7.49 (br d, J = 6.4 Hz, 2H), 7.33 - 7.26 (m, 1H), 6.56 (dd, J = 10.2, 17.2 Hz, 1H), 6.33 (dd, J = 1.6, 17.2 Hz, 1H), 5.85 (dd, J = 1.6, 10.4 Hz, 1H), 3.34 (s, 3H), 2.94 - 2.83 (m, 2H), 2.68 - 2.57 (m, 2H), 2.34 - 2.27 (m, 4H), 2.21 - 2.13 (m, 1H).


[0905] **Step 8.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxypyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, 679 μmol) in trifluoroethanol (6.0 mL) was added HCHO (102 mg, 3.40 mmol) and NaBH_4 (51.4 mg, 1.36 mmol). The mixture was stirred at 60 °C for 4 h. On completion, the reaction was diluted with water (100 mL), extracted with ethyl acetate (30 mL x 3), washed with brine (40 mL), dried over Na_2SO_4 , filtered and concentrated under vacuum to afford N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, crude) as a brown solid. m/z ES+ $[\text{M}+\text{H}]^+$ 456.0

[0907] **Step 9.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.30 g, 658 μmol) in MeOH (3.0 mL) and H_2O (3.0 mL) was added NH_4Cl (422 mg, 7.90 mmol) and Fe (331 mg, 5.90 mmol). The mixture was stirred at 80 °C for 1 h. On completion, the reaction was filtered through a pad of celite while it was still hot and the filtered cake was washed with MeOH (10 mL), the combined organic solvent was concentrated in vacuo to afford N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (0.24 g, crude) as a brown solid. m/z ES+ $[\text{M}+\text{H}]^+$ 426.1

[0908] **Step 10.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (0.20 g, 470 μmol) in pyridine (4.0 mL) was

added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (360 mg, 1.88 mmol) and acrylic acid (33.8 mg, 470 μmol). The mixture was stirred at 0 °C for 2 h. On completion, the reaction was concentrated in vacuo and the crude was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 26%-56%, 8min) and repurified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3 μm ; mobile phase: [water(0.225%formic acid)-acetonitrile]; B%: 15%-25%, 9min) to afford N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3S)-3-methoxy-1-methyl-pyrrolidin-3-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (26.0 mg, 54.2 μmol , 11.5% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 480.2; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.33 - 9.88 (m, 2H), 8.64 (s, 1H), 8.50 (br d, $J = 1.2$ Hz, 1H), 8.23 (s, 1H), 7.91 (br s, 1H), 7.55 - 7.41 (m, 2H), 7.33 - 7.25 (m, 1H), 6.56 (dd, $J = 10.2, 16.8$ Hz, 1H), 6.33 (dd, $J = 1.6, 17.2$ Hz, 1H), 5.90 - 5.81 (m, 1H), 3.34 (s, 3H), 2.94 - 2.82 (m, 2H), 2.70 - 2.57 (m, 2H), 2.34 - 2.27 (m, 4H), 2.22 - 2.12 (m, 1H).

Example 33. Synthesis of Compound No. 37 ((E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-4-morpholinobut-2-enamide)




[0909] **Step 1.** To a solution of (E)-4-bromobut-2-enoic acid (5.00 g, 30.3 mmol) and dimethylformamide (22.2 mg, 303 μmol) in dichloromethane (20 mL) was added $(\text{COCl})_2$ (3.85 g, 30.3 mmol) dropwise at 0 °C under N_2 . The mixture was stirred at 0 ~ 25 °C for 4 h. On completion, the reaction mixture was concentrated in vacuo to give (E)-4-bromobut-2-enoyl chloride (5.8 g, crude) as a yellow oil.

[0910] **Step 2.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo [3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (4.00 g, 9.81 mmol) and triethylamine (2.98 g, 29.4 mmol) in dichloromethane (70 mL) was added a solution of (E)-4-bromobut-2-enoyl chloride (3.60 g, 19.6 mmol) in dichloromethane (15 mL) dropwise at 0 °C and the mixture was stirred at 0 °C for 10 min. On completion, the reaction mixture was concentrated under vacuum to give (E)-4-bromo-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-

methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]quinazolin-6-yl]but-2-enamide (5.44 g, crude) as a yellow solid, which was used for next step directly. m/z ES+ $[M+H]^+$ 556.0

[0911] **Step 3.** A mixture of (E)-4-bromo-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]but-2-enamide (5.44 g, 9.80 mmol), morpholine (1.71 g, 19.6 mmol), triethylamine (992 mg, 9.80 mmol) in dichloromethane (1.5 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 25 °C for 12 hs under N_2 atmosphere. On completion, the reaction mixture was concentrated in vacuo to give a residue. The residue was purified by reverse phase flash [acetonitrile/(0.1% formic acid in water), 0% to 90%] to give 2.8 g crude product. Then it was purified by Prep-HPLC [column: Waters Xbridge BEH C18 250*50mm*10um;mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile];B%: 35%-55%,22min] to give 2.2 g crude product. Then the crude product was triturated with EA/petroleum ether = 5/1 (200 mL) twice to give (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]-4-morpholino-but-2- enamide (1.84 g, 33% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 561.3; ^1H NMR (400 MHz, DMSO- d_6) δ 10.06 (s, 1H), 9.78 (s, 1H), 8.67 (s, 1H), 8.48 (s, 1H), 7.80 (s, 1H), 7.50 (s, 2H), 7.29 (t, J = 7.6 Hz, 1H), 6.81 (td, J = 5.6, 15.6 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 3.65 - 3.60 (m, 4H), 3.17 (d, J = 5.2 Hz, 2H), 3.11 (d, J = 8.4 Hz, 1H), 2.93 (d, J = 9.0 Hz, 1H), 2.46 - 2.38 (m, 6H), 2.26 (s, 3H), 1.98 - 1.90 (m, 1H), 1.38 (t, J = 4.4 Hz, 1H), 1.03 (dd, J = 4.0, 8.0 Hz, 1H).


Example 34. Synthesis of Compound No. 38 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)but-2-ynamide)



[0912] **Step 1.** To a solution of N4-(3-chloro-2-fluorophenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl]ethynyl]quinazoline-4,6-diamine (100 mg, 245 μ mol), but-2-ynoic acid (41.2 mg, 490 μ mol) in pyridine (1.0 mL) and dichloromethane (1.0 mL) was added 1-ethyl-


3-(3-dimethylaminopropyl)carbodiimide (188 mg, 980 μmol) at 0 °C. The mixture was stirred at 0 ~ 25 °C for 1 h. Upon completion, the mixture was concentrated in vacuo to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge C18 150*50mm* 10 μm ; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 42%-72%, 11 min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-quinazolin-6-yl]but-2-ynamide (38.0 mg, 31% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 474.2; ^1H NMR (400 MHz, DMSO- d_6) δ = 10.25 (s, 1H), 10.04 (s, 1H), 8.48 (s, 2H), 7.78 (s, 1H), 7.53 - 7.48 (m, 2H), 7.31 - 7.25 (m, 1H), 3.12 (d, J = 8.8 Hz, 1H), 2.93 (d, J = 9.2 Hz, 1H), 2.40 (dd, J = 3.6, 9.2 Hz, 1H), 2.26 (s, 3H), 2.07 (s, 3H), 1.96 - 1.93 (m, 1H), 1.39 (t, J = 4.4 Hz, 1H), 1.23 (s, 1H), 1.03 (dd, J = 4.0, 8.0 Hz, 1H).

Example 35. Synthesis of Compound No. 39 ((E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-4-methyl-pent-2-enamide)



[0913] **Step 1.** A solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (60.0 mg, 146 μmol), (E)-4-methylpent-2-enoic acid (21.7 mg, 190 μmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (112 mg, 586 μmol) in pyridine (0.6 mL) was stirred at 25 °C for 1 h. On completion, the reaction mixture was evaporated. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 56%-86%, 10 min) to afford (E)-N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-1,3-dimethylpyrrolidin-3-yl]ethynyl]quinazolin-6-yl]-4-methyl-pent-2-enamide (20.0 mg, 27% yield, 100% purity) as a yellow solid. m/z ES+ $[M+H]^+$ 506.3; ^1H NMR (400 MHz, DMSO- d_6) δ = 10.04 (br s, 1H), 9.56 (s, 1H), 8.67 (s, 1H), 8.47 (s, 1H), 7.78 (s, 1H), 7.50 (s, 2H), 7.31 - 7.23 (m, 1H), 6.87 (dd, J = 6.8, 15.6 Hz, 1H), 6.20 (d, J = 16.0 Hz, 1H), 2.78 (d, J = 8.8 Hz, 1H), 2.64 - 2.56 (m, 2H), 2.55 - 2.52 (m, 2H), 2.27 (s, 3H), 2.26 - 2.21 (m, 1H), 1.88 - 1.81 (m, 1H), 1.43 (s, 3H), 1.07 (d, J = 6.8 Hz, 6H).

Example 36. Synthesis of Compound No. 40 (N-(7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-4-((4-phenoxyphenyl)amino)quinazolin-6-yl)acrylamide) and Compound No. 41 (N-(7-(((1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-4-((4-phenoxyphenyl)amino)quinazolin-6-yl)acrylamide)



[0914] **Step 1.** To a solution of 7-fluoro-6-nitro-quinazolin-4-ol (5 g, 23.9 mmol) in SOCl_2 (50 mL) was added dimethylformamide (175 mg, 2.39 mmol). The mixture was stirred at 90 °C for 12 h. On completion, the reaction mixture was concentrated under reduced pressure to give 4-chloro-7-fluoro-6-nitroquinazoline (5.5 g, crude) as a yellow solid. m/z ES^+ $[\text{M}+\text{H}]^+$ 228.0

[0915] **Step 2.** To a solution of 4-chloro-7-fluoro-6-nitro-quinazoline (5 g, 22.0 mmol) in CH_3CN (60 mL) was added 4-phenoxyaniline (4.07 g, 22.0 mmol). The mixture was stirred at 20 °C for 12 h. On completion, the reaction mixture was concentrated under reduced pressure to give a

residue. The crude product was triturated with ethyl acetate (500 mL) at 25 °C for 30 min to give 7-fluoro-6-nitro-N-(4-phenoxyphenyl)quinazolin-4-amine (9 g, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 377.2

[0916] **Step 3.** To a solution of 7-fluoro-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (9 g, 23.9 mmol) in dimethylformamide (80 mL) was added KOAc (11.3 g, 115 mmol). The mixture was stirred at 100 °C for 3 h. On completion, the mixture was poured into water (150 mL). The resulting yellow precipitate was collected by filtration and dried in vacuo to give 6-nitro-4-((4-phenoxyphenyl) amino) quinazolin-7-ol (7 g, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 375.2; ^1H NMR (400 MHz, DMSO- d_6) δ = 12.11 - 11.77 (m, 1H), 10.14 (s, 1H), 9.24 (s, 1H), 8.52 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.46 - 7.36 (m, 2H), 7.18 - 6.98 (m, 6H).

[0917] **Step 4.** To a suspension of 6-nitro-4-(4-phenoxyanilino)quinazolin-7-ol (1.5 g, 4.01 mmol) in dichloromethane (20 mL) was added pyridine (1.58 g, 20.0 mmol) and Tf_2O (2.26 g, 8.01 mmol). The mixture was stirred at 15 °C for 12 h. On completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate = 5/1 to 1/1) to give 6-nitro-4-((4-phenoxyphenyl) amino) quinazolin-7-yl trifluoromethanesulfonate (1.1 g, 52.6% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 507.2

[0918] **Step 5.** To a solution of [6-nitro-4-(4-phenoxyanilino)quinazolin-7-yl] trifluoromethanesulfonate (1 g, 1.97 mmol) and tert-butyl 1-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (409 mg, 1.97 mmol) in dimethylformamide (12 mL) and triethylamine (600 mg, 5.92 mmol) was added $Pd(PPh_3)_4$ (228 mg, 197 μ mol) and CuI (75.2 mg, 395 μ mol) in one portion under nitrogen. The mixture was stirred at 20 °C for 2 h. On completion, the reaction mixture was diluted with H_2O (100 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate = 5/1 to 1/1) to give tert-butyl 1-((6-nitro-4-((4-phenoxyphenyl) amino) quinazolin-7-yl) ethynyl)-3-azabicyclo [3.1.0] hexane-3-carboxylate (1 g, 79.1% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 564.4

[0919] **Step 6.** To a solution of tert-butyl 1-[2-[6-nitro-4-(4-phenoxyanilino) quinazolin-7-yl] ethynyl]-3-azabicyclo [3.1.0] hexane-3-carboxylate (1 g, 1.58 mmol) in ethyl acetate (10 mL) was added HCl/ethyl acetate (4 mL). The mixture was stirred at 25 °C for 2 h. On completion, the

reaction mixture was concentrated under reduced pressure to give 7-(3-azabicyclo [3.1.0] hexan-1-ylethynyl)-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (1 g, crude, HCl) as a yellow solid. m/z ES+ [M+H]⁺ 464.2

[0920] **Step 7.** A mixture of 7-[2-(3-azabicyclo [3.1.0] hexan-1-yl) ethynyl]-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (1.2 g, 2.40 mmol, HCl), HCHO (360 mg, 12.0 mmol) in trifluoroethanol (20 mL) was added NaBH₄ (185 mg, 4.90 mmol) at 25 °C. The mixture was stirred at 60 °C for 2 h. On completion, the mixture was quenched by methanol (5.00 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (50.0 mL) and washed with water (50.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40mm* 15um; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 20%-50%, 11min) to give 7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-6-nitro-N-(4-phenoxyphenyl)quinazolin-4-amine (700 mg, 59.9% yield) as a white solid. m/z ES+ [M+H]⁺ 478.3

[0921] **Step 8.** 7-[2-(3-methyl-3-azabicyclo [3.1.0] hexan-1-yl) ethynyl]-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (620 mg, 1.30 mmol) was purified by SFC (column: DAICEL CHIRALPAK AS (250mm*30mm, 10um); mobile phase: [0.1% ammonium hydroxide methanol]; B%: 50%-50%, 4.8min; 580minmin) to give 7-(((1S, 5R)-3-methyl-3-azabicyclo [3.1.0]hexan-1-yl) ethynyl)-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (250 mg, 40.3% yield, >99% ee, SFC retention time: 2.186 min) as a yellow solid and 7-(((1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl) ethynyl)-6-nitro-N-(4-phenoxyphenyl) quinazolin-4-amine (260 mg, 41.9% yield, 98.4% ee, SFC retention time: 2.344 min) as a yellow solid.

[0922] **Step 9.** To a solution of 7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-N-(4-phenoxyphenyl)quinazolin-4-amine (220 mg, 460.72 umol) and NH₄Cl (246 mg, 4.61 mmol) in MeOH (2.2 mL) and H₂O (2.2 mL) was added Fe powder (129 mg, 2.30 mmol) and the mixture was stirred at 80 °C for 2 h. On completion, the reaction mixture was filtered and evaporated to afford 7-[2-[(1S, 5R)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]-N4-(4-phenoxyphenyl) quinazoline-4, 6-diamine (230 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 448.3

[0923] **Step 10.** A solution of 7-[2-[(1S, 5R)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl] ethynyl]-N4-(4-phenoxyphenyl) quinazoline-4,6-diamine (230 mg, 514 umol), acrylic acid (37.0 mg, 514


umol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (394 mg, 2.06 mmol) in pyridine (2.5 mL) was stirred at 15 °C for 1 h. On completion, the reaction mixture was diluted with water (6 mL) and extracted with ethyl acetate (8 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over Na₂SO₄ and evaporated. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5um; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 38%-71%, 10min) to afford N-[7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-4-(4-phenoxyanilino)quinazolin-6-yl]prop-2-enamide (40.0 mg, 16% yield) as a yellow solid. m/z ES+ [M+H]⁺ 502.3; ¹H NMR (400 MHz, DMSO-d₆) δ = 9.89 (s, 2H), 8.69 (s, 1H), 8.52 (s, 1H), 7.83 - 7.74 (m, 3H), 7.42 - 7.37 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 7.07 - 7.01 (m, 4H), 6.59 (dd, J = 10.4, 17.6 Hz, 1H), 6.33 (dd, J = 2.0, 17.2 Hz, 1H), 5.89 - 5.81 (m, 1H), 3.09 (d, J = 8.4 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.43 (d, J = 8.4 Hz, 1H), 2.39 (dd, J = 3.6, 9.2 Hz, 1H), 2.25 (s, 3H), 1.94 - 1.89 (m, 1H), 1.36 (t, J = 4.4 Hz, 1H), 1.00 (dd, J = 4.0, 8.0 Hz, 1H).

[0924] **Step 11.** To a solution of 7-[2-[(1R, 5S)-3-methyl-3-azabicyclo[3.1.0] hexan-1-yl] ethynyl]-6-nitro-N-(4-phenoxyphenyl)quinazolin-4-amine (260 mg, 544 umol) and NH₄Cl (291 mg, 5.44 mmol) in MeOH (2.2 mL) and H₂O (2.2 mL) was added Fe powder (152 mg, 2.72 mmol) and the mixture was stirred at 80 °C for 2 h. On completion, the reaction mixture was filtered and evaporated to afford 7-[2-[(1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]-N4-(4-phenoxyphenyl) quinazoline-4, 6-diamine (260 mg, crude) as a yellow solid.

[0925] **Step 12.** A solution of 7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N4-(4-phenoxyphenyl)quinazoline-4,6-diamine (260 mg, 581 umol), acrylic acid (41.9 mg, 581 umol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (445 mg, 2.32 mmol) in pyridine (2.5 mL) was stirred at 15 °C for 1 h. On completion, the reaction mixture was evaporated. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5um; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 42%-72%, 10min) to afford N-[7-[2-[(1R, 5S)-3-methyl-3-azabicyclo [3.1.0] hexan-1-yl] ethynyl]-4-(4-phenoxyanilino) quinazolin-6-yl] prop-2-enamide (70.0 mg, 24% yield, 100% purity) as a yellow solid. m/z ES+ [M+H]⁺ 502.3; ¹H NMR (400 MHz, DMSO-d₆) δ = 9.89 (d, J = 4.0 Hz, 2H), 8.69 (s, 1H), 8.52 (s, 1H), 7.86 - 7.73 (m, 3H), 7.44 - 7.35 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 7.08 - 7.00 (m, 4H), 6.59 (dd, J = 10.4, 17.2 Hz, 1H), 6.33 (dd, J = 2.0, 17.2 Hz, 1H), 5.85 (dd, J = 2.0, 10.4 Hz, 1H), 3.09 (d, J = 8.8 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.43 (d, J = 8.4 Hz, 1H), 2.39 (dd, J = 3.6, 9.2 Hz, 1H), 2.25 (s, 3H), 1.94

- 1.89 (m, 1H), 1.36 (t, J = 4.4 Hz, 1H), 1.00 (dd, J = 4.0, 8.0 Hz, 1H).

Example 37. Synthesis of Compound No. 42 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)




[0926] **Step 1.** To a solution of 7-[2-[(1S,5R)-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N-(3-chloro-2-fluorophenyl)-6-nitro-quinazolin-4-amine (500 mg, 1.18 mmol) in MeCN (5 mL) and acetone (5 mL) was added $\text{NaBH}(\text{OAc})_3$ (1.25 g, 5.90 mmol) and HOAc (212.53 mg, 3.54 mmol) at 0°C . The mixture was stirred 20°C for 16 h. On completion, the reaction was diluted with water (60 mL), and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated under vacuum. The crude product was purified by column chromatography (petroleum ether/ethyl acetate from 5/1 to 1/1) to give N-(3-chloro-2-fluorophenyl)-7-[2-[(1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (0.42 g, 68.77% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 466.2

[0927] **Step 2.** To a mixture of N-(3-chloro-2-fluorophenyl)-7-[2-[(1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitroquinazolin-4-amine (0.5 g, 1.07 mmol) in MeOH (6 mL) and H_2O (2 mL) was added Fe powder (299.66 mg, 5.37 mmol) and NH_4Cl (574.06 mg, 10.73 mmol) in one portion at 20°C . The mixture was then stirred at 80°C for 2 h. On completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with water (50 mL) and then extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give compound N4-(3-chloro-2-fluorophenyl)-7-[2-[(1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (0.4 g,

82.94% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 436.2

[0928] **Step 3.** To a mixture of N-4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (300 mg, 688.19 μ mol) and acrylic acid (99.19 mg, 1.38 mmol) in dimethylformamide (3 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (395.78 mg, 2.06 mmol) and pyridine (272.18 mg, 3.44 mmol) in one portion at 20 °C. The mixture was stirred at 20 °C for 2 h. On completion, the reaction mixture was quenched by water (10 mL) at 20 °C, and then extracted with dichloromethane (10 mL x 3). The combined organic layers were washed with water (10 mL x 2), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Shim-pack C18 150*25*10 μ m; mobile phase: [water(0.225% formic acid)-acetonitrile]; B%: 10%-40%, 10min) and further purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 56%-86%, 5min) to give compound N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1S,5R)-3-isopropyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (21 mg, 6.23% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 490.3; ^1H NMR (400 MHz, $DMSO-d_6$) δ 10.07 (s, 1H), 9.87 (s, 1H), 8.68 (s, 1H), 8.48 (s, 1H), 7.81 (s, 1H), 7.50 - 7.48 (m, 2H), 7.30 - 7.27 (m, 1H), 6.64 - 6.57 (m, 1H), 6.36 (dd, J = 1.2, 15.6 Hz, 1H), 5.84 (d, J = 11.6 Hz, 1H), 3.16 (d, J = 8.4 Hz, 1H), 2.98 (d, J = 8.4 Hz, 1H), 2.54 - 2.45 (m, 2H), 1.96 - 1.90 (m, 1H), 1.32 (t, J = 4.4 Hz, 1H), 1.33 - 0.97 (m, 8H).

Example 38. Synthesis of Compound No. 43 (Methyl (4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)carbamate)



[0929] **Step 1.** A mixture of [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (550 mg, 1.18 mmol), tert-butyl 3-ethynyl-3-methyl-pyrrolidine-1-

carboxylate (271.27 mg, 1.30 mmol), Pd(PPh₃)₄ (136.17 mg, 117.84 μ mol), CuI (22.44 mg, 117.84 μ mol) in dimethylformamide (6 mL) and triethylamine (6 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 50 °C for 1 h under N₂ atmosphere. On completion, the reaction mixture was diluted with H₂O (70 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate = 3/1 to 1/1) to give tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (300 mg, 39 % yield) as an orange solid. m/z ES+ [M+H]⁺ 526.3

[0930] **Step 2.** A solution of tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (470 mg, 893.61 μ mol) in HCl/ethyl acetate (4 M, 5 mL) was stirred at 25 °C for 1 h. On completion, the reaction mixture was concentrated under reduced pressure to give N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (410 mg, crude, HCl) as a yellow solid. m/z ES+ [M+H]⁺ 426.2


[0931] **Step 3.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (410 mg, 962.80 μ mol, HCl) in trifluoroethanol (5 mL) was added triethylamine to adjust the mixture to pH = 8. Then (HCHO)_n (144.54 mg, 4.81 mmol) was added. The mixture was stirred at 60 °C for 30 min. Then NaBH₄ (72.85 mg, 1.93 mmol) was added and the mixture was stirred at 60 °C for 1 h. On completion, the reaction mixture was quenched by MeOH (12 mL), and concentrated under reduced pressure to give a residue. The crude product was purified by reverse-phase flash column (0.1% NH₃•H₂O) to give N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (210 mg, 44.6% yield) as a yellow solid. m/z ES+ [M+H]⁺ 440.1

[0932] **Step 4.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-(1,3-dimethylpyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (180 mg, 409 μ mol) and NH₄Cl (219 mg, 4.09 mmol) in MeOH (2 mL) and H₂O (2 mL) was added Fe powder (114 mg, 2.05 mmol) and the mixture was stirred at 80 °C for 2 h. On completion, the reaction mixture was filtered and evaporated. The crude product was purified by reversed-phase HPLC (acetonitrile/0.1% NH₃.H₂O=80%) to afford N4-(3-chloro-2-fluoro-phenyl)-7-[2-(1,3-dimethylpyrrolidin-3-yl)ethynyl]quinazoline-4,6-diamine (90.0 mg, 54% yield) as a yellow solid. m/z ES+ [M+H]⁺ 410.1

[0933] **Step 5.** To a solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-(1,3-dimethylpyrrolidin-3-

yl)ethynyl]quinazoline-4,6-diamine (90 mg, 138 μ mol, 63% purity) in pyridine (1 mL) was added methyl carbonochloridate (26.1 mg, 277 μ mol) at 0 °C and the mixture was stirred at 15 °C for 1 h. On completion, the mixture was poured into water (0.5 mL) and filtered. The filter cake was washed with water (2 mL $\times$ 3) and dried under vacuum to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 45%-75%, 10min) to afford methyl N-[4-(3-chloro-2-fluoro-anilino)-7-[2-(1,3-dimethylpyrrolidin-3-yl)ethynyl]quinazolin-6-yl]carbamate (25.0 mg, 36% yield, 94% purity) as an off-white solid. *m/z* ES+ [M+H]⁺ 468.3; ¹H NMR (400 MHz, DMSO-d₆) δ = 10.03 (s, 1H), 9.02 (s, 1H), 8.57 - 8.41 (m, 2H), 7.76 (s, 1H), 7.49 (s, 2H), 7.27 (t, *J* = 7.2 Hz, 1H), 3.72 (s, 3H), 2.78 (d, *J* = 9.2 Hz, 1H), 2.64 - 2.60 (m, 2H), 2.53 (d, *J* = 3.2 Hz, 1H), 2.29 (s, 3H), 2.25 - 2.19 (m, 1H), 1.90 - 1.80 (m, 1H), 1.43 (s, 3H).

Example 39. Synthesis of Compound No. 44 ((E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide)



[0934] **Step 1.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (600 mg, 1.29 mmol), 3-ethynyl-3-methyltetrahydrofuran (170 mg, 1.54 mmol) in dimethylformamide (9.00 mL) and triethylamine (9.00 mL) was added CuI (48.9 mg, 257 μ mol) and tetrakis(triphenylphosphine)palladium(0) (149 mg, 129 μ mol) in one portion under nitrogen. The mixture was stirred at 20 °C for 2 h. The mixture was diluted with water (60.0 mL) and extracted with ethyl acetate (3 $\times$ 40.0 mL). The combined organic layer was washed with brine (20.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 2/1) to give N-(3-chloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (320 mg,

58% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.62 (s, 1H), 9.40 (s, 1H), 7.99 (s, 1H), 7.57 - 7.52 (m, 3H), 7.35 - 7.25 (m, 1H), 3.94 - 3.86 (m, 3H), 3.62 (d, J = 8.1 Hz, 1H), 2.34 - 2.24 (m, 1H), 2.05 - 1.95 (m, 1H), 1.44 (s, 3H).


[0935] **Step 2.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (320 mg, 750 μmol), ammonium chloride (281 mg, 5.25 mmol) in methanol (8.00 mL) and water (2.00 mL) was added iron powder (209 mg, 3.75 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with water (50.0 mL) and extracted with ethyl acetate (3×40.0 mL). The combined organic layer was washed with brine (30.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by reverse-phase chromatography (0.1% formic acid), then purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazoline-4,6-diamine (150 mg, 50% yield) as a yellow solid.

[0936] **Step 3.** A mixture of 1,1'-carbonyldiimidazole (24.5 mg, 151 μmol) and 2-diethoxyphosphorylactic acid (29.7 mg, 151 μmol) in tetrahydrofuran (1 mL) were stirred at 40 °C for 30 min. Then a solution of N⁴-(3-chloro-2-fluoro-phenyl)-7-[2-(3-methyltetrahydrofuran-3-yl) ethynyl] quinazoline-4, 6-diamine (50 mg, 126 μmol) in tetrahydrofuran (0.5 mL) was added and the mixture was stirred at 40 °C for 12 h. On completion, the reaction mixture was diluted with H₂O (20 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give diethyl (2-((4-((3-chloro-2-fluorophenyl) amino)-7-((3-methyltetrahydrofuran-3-yl) ethynyl) quinazolin-6-yl) amino)-2-oxoethyl) phosphonate (60 mg, crude) as a yellow oil. m/z ES+ $[\text{M}+\text{H}]^+$ 575.4

[0937] **Step 4.** To a solution of diethyl (2-((4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazolin-6-yl)amino)-2-oxoethyl)phosphonate (60 mg, 104 μmol) in ethanol (1 mL) was added LiCl (8.85 mg, 209 μmol) and aqueous KOH solution (26.0 mg, 209 μmol , 45wt%) at 20 °C. After 5 min, a solution of 2-(dimethylamino)acetaldehyde sulfate (35.1 mg, 209 μmol) in H₂O (0.5 mL) was added, and the mixture was stirred at 20 °C for 2 h. On completion, the reaction mixture was diluted with H₂O (10 mL), and then adjusted to pH = 7 by aqueous HCl solution (1 M). The mixture was extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure

to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%formic acid)-acetonitrile]; B%: 13%-43%, 8.5min) to give N-(7-cyano-4-((4-phenoxyphenyl) amino) quinazolin-6-yl) acrylamide (15 mg, 25.4% yield, 100% purity, formic acid) as a yellow solid. m/z ES+ $[M+H]^+$ 508.3; ^1H NMR (400 MHz, DMSO- d_6) δ = 10.07 (br s, 1H), 9.72 (s, 1H), 8.67 (s, 1H), 8.55 - 8.41 (m, 1H), 7.81 (s, 1H), 7.49 (s, 2H), 7.31 - 7.25 (m, 1H), 6.82 (td, J = 6.0, 15.2 Hz, 1H), 6.40 (d, J = 16.0 Hz, 1H), 3.92 - 3.87 (m, 3H), 3.59 (d, J = 8.0 Hz, 1H), 3.09 (d, J = 5.2 Hz, 2H), 2.32 - 2.25 (m, 1H), 2.18 (s, 6H), 1.97 (td, J = 7.2, 12.0 Hz, 1H), 1.42 (s, 3H).

Example 40. Synthesis of Compound No. 45 (N-{4-[(3-chloro-2-fluorophenyl)amino]-7-{2-[(3S)-3-fluoro-1-methylpyrrolidin-3-yl]ethynyl}quinazolin-6-yl}prop-2-enamide) and Compound No. 46 (N-{4-[(3-chloro-2-fluorophenyl)amino]-7-{2-[(3R)-3-fluoro-1-methylpyrrolidin-3-yl]ethynyl}quinazolin-6-yl}prop-2-enamide)



[0938] **Step 1.** To a solution of 7-fluoro-6-nitro-quinazolin-4-ol (100 g, 478 mmol) in $SOCl_2$ (400 mL) was added dimethylformamide (3.50 g, 47.8 mmol) dropwise. The mixture was stirred at 80 °C for 14 h. On completion, the reaction mixture was concentrated under vacuum to afford 4-chloro-7-fluoro-6-nitro-quinazoline (108 g, crude) as a yellow solid, which was used in the next step directly. ^1H NMR (400 MHz, DMSO- d_6) δ 8.73 - 8.70 (m, 1H), 8.33 (s, 1H), 7.79 - 7.75 (m,

1H).

[0939] **Step 2.** A solution of 4-chloro-7-fluoro-6-nitro-quinazoline (108 g, 475 mmol) and 3-chloro-2-fluoro-aniline (69 g, 475 mmol) in MeCN (1.5 L) was stirred at 80 °C for 2 h. On completion, the reaction mixture was concentrated to give N-(3-chloro-2-fluoro-phenyl)-7-fluoro-6-nitro-quinazolin-4-amine (180 g, crude) as a yellow solid, which was used for the next step without purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.67 (d, J = 8.0 Hz, 1H), 8.75 (s, 1H), 7.93 (d, J = 12.0 Hz, 1H), 7.61 - 7.50 (m, 2H), 7.35 (t, J = 8.0 Hz, 1H).

[0940] **Step 3.** A solution of N-(3-chloro-2-fluoro-phenyl)-7-fluoro-6-nitro-quinazolin-4-amine (140 g, 416 mmol) and KOAc (204 g, 2.08 mol) in dimethylformamide (1.4 L) was stirred at 80 °C for 14 h. On completion, the mixture was diluted with ethanol (500 mL) and then filtered. The filtrate was concentrated under vacuum to give a residue. The residue was poured into the water (1.5 L), and then extracted with ethyl acetate (1.5 L x 2). The combined organic layers were collected, dried over Na₂SO₄, filtered and concentrated under vacuum to give a residue. The residue was triturated with petroleum ether/ethyl acetate (10/1 v/v, 1.1 L) to give 4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol (140 g, crude) as a red solid, which was used for the next step without purification. m/z ES+[M+H]⁺ 335.2; ¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 9.16 (s, 1H), 8.48 (s, 1H), 7.60 - 7.40 (m, 2H), 7.40 - 7.10 (m, 3H).

[0941] **Step 4.** To a solution of 4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol (70 g, 142 mmol) and pyridine (56 g, 711 mmol) in dichloromethane (700 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (60.2 g, 213 mmol) dropwise at 0 °C under N₂. The mixture was stirred at 20 °C for 2 h. On completion, the mixture was concentrated under vacuum. The residue was diluted with water (200 mL) and extracted with dichloromethane (200 mL x 2). The combined organic layers were collected, dried over Na₂SO₄, filtered and concentrated to afford a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 5:1~2:1) to afford a crude product. Then the crude product was triturated in petroleum ether (100 mL) to give [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (40 g, 57% yield) as a yellow solid. m/z ES+[M+H]⁺ 466.9; ¹H NMR (400 MHz, DMSO-d₆) δ 9.03 (s, 1H), 8.90 (s, 1H), 8.15 - 8.10 (m, 1H), 7.95 (s, 1H), 7.33 (dd, J = 5.6, 7.2 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H).

[0942] **Step 5.** To a solution of tert-butyl 3-fluoro-3-(hydroxymethyl)pyrrolidine-1-carboxylate (54 g, 246 mmol) in dichloromethane (600 mL) was added DMP (157 g, 369 mmol) in portions at

0 °C. The mixture was stirred at 20 °C for 1 h. On completion, the mixture was concentrated at room temperature to give a residue. The residue was diluted with ethyl acetate (200 mL) and then filtered. The filtrate was concentrated under vacuum to give a crude product. The crude product was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate = 5/1 to 1/2) to give tert-butyl 3-fluoro-3-formyl-pyrrolidine-1-carboxylate (50 g, crude) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 9.87 (s, 1H), 3.80 - 3.40 (m, 4H), 2.33 - 2.20 (m, 2H), 1.46 (s, 9H).

[0943] **Step 6.** To a solution of tert-butyl 3-fluoro-3-formyl-pyrrolidine-1-carboxylate (50 g, 230 mmol) and K₂CO₃ (95.4 g, 690 mmol) in MeOH (500 mL) was added 1-diazo-1-dimethoxyphosphoryl-propan-2-one (57 g, 299 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 2 h until the color of the reaction solution turned from yellow to green. On completion, the mixture was diluted with water (1 L) and concentrated at room temperature to give a residue. The residue was then extracted with ethyl acetate (500 mL × 3). The combined organic layers were collected, dried over Na₂SO₄ and concentrated under vacuum. The crude product was purified by column chromatography (petroleum ether/ethyl acetate = 10/1) to give tert-butyl 3-ethynyl-3-fluoro-pyrrolidine-1-carboxylate (25 g, 51% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 3.84 - 3.46 (m, 4H), 2.77 (d, J = 4.8 Hz, 1H), 2.45 - 2.21 (m, 2H), 1.47 (s, 9H).

[0944] **Step 7.** To a solution of [4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl] trifluoromethanesulfonate (22 g, 47.1 mmol) and tert-butyl 3-ethynyl-3-fluoro-pyrrolidine-1-carboxylate (10.1 g, 47.1 mmol) in dimethylformamide (200 mL) was added Pd(PPh₃)₄ (5.45 g, 4.71 mmol), CuI (1.80 g, 9.43 mmol) and triethylamine (145 g, 1.44 mol). The mixture was degassed and purged with N₂ for 3 times and then it was stirred at 20 °C for 2 h. Upon completion, the mixture was diluted with water (1 L) and extracted with ethyl acetate (3 × 300 mL). The combined organic layer was washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give tert-butyl 3-[2-[4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl]ethynyl]-3-fluoro-pyrrolidine-1-carboxylate (24 g, 88% yield) as a brown oil. m/z ES+[M+H-56]⁺ 474.1

[0945] **Step 8.** To a solution of tert-butyl 3-[2-[4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl]ethynyl]-3-fluoro-pyrrolidine-1-carboxylate (27 g, 51 mmol) in ethyl acetate (50 mL) was added HCl/ethyl acetate (4 M, 306.82 mL). The mixture was stirred at 20 °C for 14 h. On completion, the mixture was filtered and the filter cake was washed with ethyl acetate (20 mL) to

give a crude product. The crude product was purified by reverse-phase flash column (HCl conditions) to give N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoropyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (12 g, 44% yield) as a brown solid. m/z ES+[M+H]⁺ 430.0

[0946] **Step 9.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoropyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (10 g, 18.6 mmol) in MeOH (100 mL) was added AcOH (2.24 g, 37.2 mmol) and (HCHO)_n (7.55 g, 93 mmol). The mixture was stirred at 20 °C for 0.2 h. Then NaBH₃CN (5.00 g, 79.6 mmol) was added in portions. The mixture was stirred at 20 °C for 0.8 h. On completion, the reaction mixture was added dropwise to a stirred solution of ice water (800 mL) and ethyl acetate (100 mL), and then extracted with ethyl acetate (200 mL x 3). The combined organic layers were collected, dried over Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by Prep-HPLC (Neu: column: Phenomenex luna C₁₈ 250 mm * 100 mm * 10 μm; mobile phase: [water(10 mM NH₄HCO₃)-acetonitrile]; B%: 40%-70%, 25 min) and Prep-HPLC (Base: column: Waters Xbridge C₁₈ 150 * 50 mm * 10 μm; mobile phase: [water (0.05% ammonium hydroxide v/v) - acetonitrile]; B%: 38% - 68%, 11 min) to give N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoro-1-methyl-pyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (5 g, 54% yield) as a brown oil. m/z ES+[M+H]⁺ 444.1; ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 8.80 (s, 1H), 8.32 (t, J = 7.6 Hz, 1H), 8.18 (s, 1H), 7.84 (s, 1H), 7.31 - 7.29 (m, 1H), 7.23 - 7.19 (m, 1H), 3.31 - 3.23 (m, 1H), 3.05 - 2.96 (m, 2H), 2.61 - 2.50 (m, 3H), 2.46 (s, 3H).

[0947] **Step 10.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoro-1-methyl-pyrrolidin-3-yl)ethynyl]-6-nitro-quinazolin-4-amine (3.4 g, 6.82 mmol) in MeOH (60 mL) was added a solution of NH₄Cl (3.65 g, 68.2 mmol) in H₂O (12 mL). Then Fe (1.90 g, 34.1 mmol) was added in portions and the mixture was stirred at 80 °C for 1 h. Upon completion, the reaction mixture was added methanol (300 mL) and then filtered through Celite. The filtrate was concentrated to give a residue. The residue was diluted with saturated NaHCO₃ solution (500 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic layer was washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated to give a crude product. The crude was triturated with a solution of petroleum ether/EA (10/1 v/v, 110 mL) at 20 °C for 30 min to give N4-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoro-1-methyl-pyrrolidin-3-yl)ethynyl]-quinazoline-4,6-diamine (2.7 g, 86% yield) as a yellow solid. m/z ES+[M+H]⁺ 414.1

[0948] **Step 11.** N4-(3-chloro-2-fluoro-phenyl)-7-[2-(3-fluoro-1-methyl-pyrrolidin-3-yl)ethynyl]-quinazoline-4,6-diamine (3.1 g, 6.74 mmol) was purified by chiral HPLC (column: Daicel ChiralPak


IG (250 * 30mm, 10 um); mobile phase: [0.1% ammonium hydroxide MeOH]; B%: 50% - 50%, 5.1 min; 410 min) to give N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-fluoro-1-methyl-pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (1.3 g, 46% yield, >99% ee, SFC rt: 0.939 min) as a yellow solid and N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-fluoro-1-methyl-pyrrolidin-3-yl] ethynyl] quinazoline-4,6-diamine (1.1 g, 39% yield, >99% ee, SFC rt: 1.384 min) as a yellow solid. m/z ES+[M+H]⁺ 414.1

[0949] **Step 12.** To a mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3R)-3-fluoro-1-methyl -pyrrolidin-3-yl]ethynyl]quinazoline-4,6-diamine (1 g, 2.42 mmol) and pyridine (764 mg, 9.67 mmol) was added a solution of acrylic acid (200 mg, 2.78 mmol) in dimethylformamide (6 mL). Then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.85 g, 9.67 mmol) was added and the mixture was stirred at 25°C for 1 h. On completion, the reaction mixture was diluted with ethyl acetate (50 mL) and water (60 mL), then extracted with ethyl acetate (30 mL x 2). The combined organic layers were collected, dried over Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by Prep-HPLC (Neu:column: Waters Xbridge C₁₈ 150 * 50 mm * 10 um; mobile phase: [water(10 mM NH₄HCO₃) - acetonitrile]; B%: 32% - 62%, 11 min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3R)-3-fluoro-1-methyl-pyrrolidin-3-yl] ethynyl]quinazolin-6-yl]prop-2-enamide (451 mg, 38% yield, >99% ee) as a yellow solid. m/z ES+[M+H]⁺ 468.2; ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (s, 1H), 10.08 (s, 1H), 8.66 (s, 1H), 8.51 (s, 1H), 7.95 (s, 1H), 7.50 (s, 2H), 7.28 (t, J = 8.0 Hz, 1H), 6.58 (dd, J = 17.2, 10.0 Hz, 1H), 6.36 - 6.31 (m, 1H), 5.86 (d, J = 10.4 Hz, 1H), 3.13 (dd, J = 21.2, 11.6 Hz, 1H), 2.91 - 2.82 (m, 2H), 2.47 - 2.35 (m, 3H), 2.30 (s, 3H).

[0950] **Step 13.** To a mixture of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(3S)-3-fluoro-1-methyl-pyrrolidin -3-yl]ethynyl]quinazoline-4,6-diamine (1 g, 2.42 mmol) and pyridine (765 mg, 9.67 mmol) was added a solution of acrylic acid (200 mg, 2.78 mmol) in dimethylformamide (8 mL). Then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.85 g, 9.67 mmol) was added and the mixture was stirred at 25 °C for 1 h. On completion, the reaction mixture was diluted with ethyl acetate (50 mL) and water (60 mL), then extracted with ethyl acetate (30 mL x 2). The combined organic layers were collected, dried over Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by Prep-HPLC (Neu: column: Waters Xbridge C₁₈ 150 * 50 mm * 10 um; mobile phase: [water(10 mM NH₄HCO₃) - acetonitrile]; B%: 32% - 62%, 11 min) to give N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(3S)-3-fluoro-1-methyl-pyrrolidin-3-yl]ethynyl]quinazolin-6-

yl]prop-2-enamide (554 mg, 47% yield, 99% ee) as a yellow solid. m/z ES+[M+H]⁺ 468.2; ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (s, 1H), 10.09 (s, 1H), 8.66 (s, 1H), 8.51 (s, 1H), 7.96 (s, 1H), 7.50 (s, 2H), 7.28 (t, J = 8.0 Hz, 1H), 6.58 (dd, J = 17.2, 10.0 Hz, 1H), 6.36 - 6.32 (m, 1H), 5.86 (d, J = 10.4 Hz, 1H), 3.13 (dd, J = 21.2, 11.6 Hz, 1H), 2.91 - 2.82 (m, 2H), 2.47 - 2.45 (m, 3H), 2.30 (s, 3H).

Example 41. Synthesis of Compound No. 47 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((5,7-dimethyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0951] **Step 1.** To a mixture of N-benzyl-1-(trimethylsilyl)methanamine (80.5 g, 416 mmol) and oxetan-3-one (15.0 g, 208 mmol) in acetic acid (250 mL) was added TMSCN (22.7 g, 228 mmol, 28.6 mL) dropwise at 0 °C. The mixture was stirred at 25 °C for 72 h. On completion, the mixture was poured into water (1.00 L) and extracted with ethyl acetate (2 × 300 mL). The combined organic phase was washed with acetic acid (5% in water, 500 mL) and brine (500 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 10/1) to give 3-(benzyl((trimethylsilyl)methyl)amino)oxetane-3-carbonitrile (30.0 g, 52% yield) as a colorless oil. m/z ES+[M+H]⁺ 275.1

[0952] **Step 2.** A mixture of 3-(benzyl((trimethylsilyl)methyl)amino)oxetane-3-carbonitrile (12.0 g, 43.7 mmol), methyl methacrylate (21.8 g, 218 mmol) and AgF (16.6 g, 131 mmol) in acetonitrile

(120 mL) was stirred at 25 °C in darkness for 72 h. On completion, the mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 20/1 to 10/1) to give methyl 5-benzyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-7-carboxylate (4.00 g, 33% yield) as a yellow oil. The structure was confirmed by 2D NMR.

[0953] **Step 3.** To a solution of methyl 5-benzyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-7-carboxylate (500 mg, 1.82 mmol) in tetrahydrofuran (20.0 mL) was added lithium aluminum hydride (140 mg, 3.69 mmol). The mixture was stirred at 0 °C for 1 h. The mixture was quenched with sodium sulfate decahydrate (100 mg) and then filtered. The filtrate was concentrated under reduced pressure to give (5-benzyl-7-methyl-2-oxa-5-azaspiro[3.4]octan-7-yl)methanol (450 mg, crude) as a colorless oil.

[0954] **Step 4.** To a solution of (5-benzyl-7-methyl-2-oxa-5-azaspiro[3.4]octan-7-yl)methanol (450 mg, 1.82 mmol) in tetrahydrofuran (50.0 mL) was added di-tert-butyl dicarbonate (840 mg, 3.85 mmol, 884 μ L) and palladium on activated carbon (100 mg, 10% loading). The mixture was stirred at 20 °C for 12 h under H₂ (15 Psi). The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1/1) to give tert-butyl 7-(hydroxymethyl)-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (410 mg, 87% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 5.45 (br s, 1H), 5.24 (br dd, J = 5.2, 11.2 Hz, 1H), 4.59 - 4.44 (m, 2H), 3.47 - 3.29 (m, 3H), 3.22 - 3.07 (m, 1H), 2.49 - 2.31 (m, 1H), 2.17 - 2.07 (m, 1H), 1.66 - 1.47 (m, 9H), 1.05 (s, 3H).

[0955] **Step 5.** To a solution of tert-butyl 7-(hydroxymethyl)-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (410 mg, 1.59 mmol) in dichloromethane (20.0 mL) was added DMP (1.64 g, 3.87 mmol) portionwise. The mixture was stirred at 20 °C for 1 h. The mixture was carefully concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1/1) to give tert-butyl 7-formyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (400 mg, 98% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 9.52 (s, 1H), 5.55 - 5.27 (m, 1H), 5.27 - 5.07 (m, 1H), 4.57 - 4.44 (m, 2H), 3.93 - 3.73 (m, 1H), 3.28 - 3.12 (m, 1H), 2.93 - 2.72 (m, 1H), 1.61 - 1.52 (m, 9H), 1.23 (s, 3H).

[0956] **Step 6.** To a solution of tert-butyl 7-formyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (520 mg, 2.04 mmol) in methanol (20.0 mL) was added potassium carbonate (1.13 g,

8.15 mmol) and dimethyl (1-diazo-2-oxopropyl)phosphonate (800 mg, 4.16 mmol). The mixture was stirred at 20 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 1/1) to give tert-butyl 7-ethynyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (420 mg, 82% yield) as a yellow oil.

[0957] **Step 7.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (500 mg, 1.07 mmol) and tert-butyl 7-ethynyl-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (300 mg, 1.19 mmol) in dimethyl formamide (5.00 mL) and triethylamine (5.00 mL) was added copper(I) iodide (50.0 mg, 263 μ mol) and tetrakis(triphenylphosphine)palladium (130 mg, 113 μ mol). The mixture was stirred at 20 °C for 1 h under nitrogen. The mixture was added ethyl acetate (40.0 mL) and saturated sodium bicarbonate solution (20.0 mL). The organic phase was separated, washed with brine (2 $\times$ 20.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate = 3/1) to give tert-butyl 7-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-7-methyl-2-oxa-5-

azaspiro[3.4]octane-5-carboxylate (500 mg, 82% yield) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ = 9.39 - 9.31 (m, 1H), 8.83 - 8.66 (m, 1H), 8.09 - 7.90 (m, 2H), 7.75 - 7.60 (m, 3H), 7.58 - 7.51 (m, 1H), 7.50 - 7.41 (m, 2H), 7.24 - 7.08 (m, 1H), 5.62 - 5.38 (m, 1H), 5.37 - 5.21 (m, 1H), 4.79 - 4.61 (m, 1H), 4.57 - 4.44 (m, 1H), 4.16 - 4.08 (m, 1H), 3.93 - 3.74 (m, 1H), 3.40 - 3.23 (m, 1H), 2.99 - 2.92 (m, 3H), 2.91 - 2.84 (m, 4H), 2.56 (br d, J = 1.9 Hz, 1H), 2.36 - 2.27 (m, 1H), 1.64 - 1.41 (m, 14H), 1.31 - 1.18 (m, 4H), 0.92 - 0.77 (m, 2H).

[0958] **Step 8.** To a solution of tert-butyl 7-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-7-methyl-2-oxa-5-azaspiro[3.4]octane-5-carboxylate (360 mg, 633 μ mol) in dichloromethane (1.50 mL) was added trifluoroacetic acid (13.9 g, 122 mmol). The mixture was stirred at 20 °C for 1 h. On completion, the mixture was concentrated under reduced pressure to give N-(3-chloro-2-fluorophenyl)-7-((7-methyl-2-oxa-5-azaspiro [3.4]octan-7-yl)ethynyl)-6-nitroquinazolin-4-amine (350 mg, 94% yield, trifluoroacetic acid) as a brown solid. m/z ES+[M+H]⁺ 468.1

[0959] **Step 9.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((7-methyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl)-6-nitroquinazolin-4-amine (350 mg, 601 μ mol, trifluoroacetic acid) in trifluoroethanol (5.00 mL) was added paraformaldehyde (54.5 mg, 1.82 mmol). The mixture was stirred at 60 °C for 1 h. Then sodium borohydride (22.8 mg, 601 μ mol) was added


and the mixture was stirred at 60 °C for another 1 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was dissolved in dimethyl formamide (2.00 mL) and purified by prep-HPLC (column: Shim-pack C18 150*25*10 μ m; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 23%-43%, 10 min) to give N-(3-chloro-2-fluorophenyl)-7-((5,7-dimethyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl)-6-nitroquinazolin-4-amine (240 mg, 75% yield, formate) as a yellow solid. m/z ES+[M+H]⁺ 482.1; ¹H NMR (400 MHz, DMSO- d_6) δ = 9.33 (br s, 1H), 8.60 (br s, 1H), 7.91 (s, 1H), 7.56 - 7.46 (m, 2H), 7.33 - 7.27 (m, 1H), 4.83 (d, J = 6.8 Hz, 1H), 4.76 (d, J = 6.8 Hz, 1H), 4.50 (d, J = 6.8 Hz, 1H), 4.46 (d, J = 6.8 Hz, 1H), 2.99 (d, J = 9.2 Hz, 1H), 2.79 (d, J = 9.2 Hz, 1H), 2.63 (d, J = 13.2 Hz, 1H), 2.55 (s, 3H), 2.28 - 2.22 (m, 1H), 1.41 (s, 3H).

[0960] **Step 10.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((5,7-dimethyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl)-6-nitroquinazolin-4-amine (240 mg, 454 μ mol, formate) in methanol (6.00 mL) and water (2.00 mL) was added iron powder (128 mg, 2.29 mmol) and ammonium chloride (197 mg, 3.67 mmol). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The mixture was diluted with ethyl acetate (40.0 mL) and water (20.0 mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated to give N⁴-(3-chloro-2-fluorophenyl)-7-((5,7-dimethyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl)quinazoline-4,6-diamine (110 mg, 53% yield) as a brown solid. m/z ES+[M+H]⁺ 452.2

[0961] **Step 11.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((5,7-dimethyl-2-oxa-5-azaspiro[3.4]octan-7-yl)ethynyl) quinazoline-4,6-diamine (110 mg, 243 μ mol) in dimethyl formamide (2.00 mL) was added acrylic acid (35.7 mg, 495 μ mol), pyridine (76.4 mg, 966 μ mol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (94.0 mg, 490 μ mol). The mixture was stirred at 15 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with dimethyl formamide (2.00 mL) and purified by prep-HPLC (column: Shim-pack C18 150*25*10 μ m; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 18%-38%, 10 min), which was further purified by prep-HPLC (column: Waters Xbridge 150*25 mm* 5 μ m; mobile phase: [water (10 mM NH₄HCO₃)-acetonitrile]; B%: 30%-60%, 9 min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((5,7-dimethyl-2-oxa-5-azaspiro [3.4]octan-7-yl)ethynyl)quinazolin-6-yl)acrylamide (9.98 mg, 8% yield, 99% purity) as a yellow solid. m/z ES+[M+H]⁺ 506.2; ¹H NMR (400 MHz, DMSO- d_6) δ =

10.15 (br s, 1H), 9.75 (br s, 1H), 8.64 (s, 1H), 8.39 (s, 1H), 7.73 (br s, 1H), 7.44 (br d, $J = 5.6$ Hz, 2H), 7.29 - 7.21 (m, 1H), 6.57 (dd, $J = 10.2, 17.2$ Hz, 1H), 6.33 (dd, $J = 1.6, 17.2$ Hz, 1H), 5.86 (dd, $J = 1.6, 10.4$ Hz, 1H), 4.80 (d, $J = 6.8$ Hz, 1H), 4.74 (d, $J = 6.8$ Hz, 1H), 4.46 (d, $J = 6.8$ Hz, 1H), 4.43 (d, $J = 6.7$ Hz, 1H), 2.99 (d, $J = 9.2$ Hz, 1H), 2.74 (d, $J = 9.2$ Hz, 1H), 2.64 (d, $J = 13.2$ Hz, 1H), 2.53 (s, 3H), 2.22 (d, $J = 13.2$ Hz, 1H), 1.39 (s, 3H).

Example 42. Synthesis of Compound No. 48 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)




[0962] **Step 1.** To a solution of 7-((1S,5R)-3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (1.20 g, 2.83 mmol) in dichloromethane (10.0 mL) was added oxetan-3-one (1.02 g, 14.2 mmol) dropwise. The mixture was stirred at 25 °C for 0.5 h. Then the mixture was added sodium triacetoxyborohydride (1.20 g, 5.66 mmol) in portions and stirred at 25 °C for 1 h. The mixture was diluted with water (30.0 mL) and extracted with ethyl acetate (3×30.0 mL). The combined organic layer was washed with brine (10.0 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 2/1 to 0/1) to give N-(3-chloro-2-fluorophenyl)-6-nitro-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-4-amine (1.00 g, 74% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 480.0;

[0963] **Step 2.** To a solution of N-(3-chloro-2-fluorophenyl)-6-nitro-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-4-amine (1.00 g, 2.08 mmol), ammonium chloride (780 mg, 14.6 mmol) in methanol (12.0 mL) and water (3.00 mL) was added iron powder (582 mg, 10.4 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with water (100 mL) and extracted with ethyl acetate (3×80.0 mL). The combined organic layer was washed with brine

(40.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazoline-4,6-diamine (650 mg, crude) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 9.70 - 9.43 (m, 1H), 8.34 - 8.15 (m, 1H), 7.78 - 7.46 (m, 3H), 7.46 - 7.33 (m, 2H), 7.28 - 7.20 (m, 1H), 5.65 (br s, 1H), 4.59 - 4.50 (m, 2H), 4.45 (q, J = 6.0 Hz, 2H), 3.76 (br t, J = 6.0 Hz, 1H), 3.32 - 3.25 (m, 1H), 3.17 (d, J = 8.4 Hz, 1H), 2.95 (d, J = 8.8 Hz, 1H), 2.57 (br d, J = 8.4 Hz, 1H), 2.02 (td, J = 4.0, 7.8 Hz, 1H), 1.37 (br t, J = 4.0 Hz, 1H), 1.12 (br dd, J = 4.0, 8.0 Hz, 1H).

[0964] **Step 3.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl) ethynyl)quinazoline-4,6-diamine (550 mg, 1.22 mmol), acrylic acid (106 mg, 1.47 mmol, 101 uL) and pyridine (387 mg, 4.89 mmol, 395 uL) in dimethyl formamide (6.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (937 mg, 4.89 mmol) in portions. The mixture was stirred at 25 °C for 1 h. The mixture was diluted with water (30.0 mL) and extracted with ethyl acetate (3 × 30.0 mL). The combined organic layer was washed with brine (10.0 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by prep-HPLC (column: Waters Xbridge C18 150*50mm* 10um;mobile phase: [water(10mM NH₄HCO₃)-acetonitrile];B%: 33%-63%,11.5min) and lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide (176.2 mg, 28% yield) as a yellow solid. m/z ES+ [M+H]⁺ 504.3; ¹H NMR (400MHz, CDCl₃) δ = 9.21 (s, 1H), 8.75 (s, 1H), 8.39 (dt, J = 2.4, 7.3 Hz, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.69 (br d, J = 2.4 Hz, 1H), 7.26 - 7.14 (m, 2H), 6.57 - 6.47 (m, 1H), 6.39 - 6.25 (m, 1H), 6.00 - 5.87 (m, 1H), 4.78 - 4.68 (m, 2H), 4.63 (dt, J = 4.0, 6.4 Hz, 2H), 3.85 (quin, J = 6.4 Hz, 1H), 3.27 (d, J = 8.4 Hz, 1H), 3.07 (d, J = 8.8 Hz, 1H), 2.69 - 2.58 (m, 2H), 2.05 - 1.97 (m, 1H), 1.66 (t, J = 4.8 Hz, 1H), 1.14 (dd, J = 4.8, 8.0 Hz, 1H).

Example 43. Synthesis of Compound No. 49 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0965] **Step 1.** To a solution of ethyl propiolate (43.4 g, 442 mmol, 43.4 mL) and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)ethanamine (100 g, 421 mmol) in dichloromethane (1.00 L) was added trifluoroacetic acid (7.68 g, 67.4 mmol, 4.99 mL) dropwise at 0 °C. The mixture was stirred at 25 °C for 2 h. The mixture was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 20/1 to 5/1) to give ethyl 1-benzyl-2,5-dihydro-1H-pyrrole-3-carboxylate (40.0 g, 41% yield) as yellow oil. ¹H NMR (400MHz, CDCl₃) δ = 7.33 - 7.24 (m, 5H), 6.71 - 6.66 (m, 1H), 4.17 - 4.10 (m, 2H), 3.76 (s, 2H), 3.65 - 3.56 (m, 4H), 1.23 - 1.20 (m, 3H).

[0966] **Step 2.** To a solution of sodium hydride (13.5 g, 337 mmol, 60% purity) in dimethylsulfoxide (400 mL) was added trimethylsulfoxonium iodide (74.2 g, 337 mmol) in portions at 20 °C. The mixture was added ethyl 1-benzyl-2,5-dihydro-1H-pyrrole-3-carboxylate (60.0 g, 259 mmol) dissolved in dimethylsulfoxide (200 mL) dropwise. The mixture was stirred at 20 °C for 1 h. The mixture was quenched with saturated ammonium chloride solution (500 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layer was washed with brine (100 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude

product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 20/1 to 10/1) to give ethyl 3-benzyl-3-azabicyclo[3.1.0]hexane-1-carboxylate (32.0 g, 130 mmol) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 7.33 - 7.27 (m, 5H), 4.14 (q, J = 7.2 Hz, 2H), 3.64 (d, J = 2.0 Hz, 2H), 3.08 (d, J = 8.8 Hz, 1H), 2.96 (d, J = 8.8 Hz, 1H), 2.74 (d, J = 8.8 Hz, 1H), 2.45 (dd, J = 3.6, 8.8 Hz, 1H), 1.93 (ddd, J = 3.6, 4.8, 8.3 Hz, 1H), 1.50 (t, J = 4.4 Hz, 1H), 1.31 (dd, J = 3.6, 8.8 Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H).

[0967] **Step 3.** To a solution of ethyl 3-benzyl-3-azabicyclo[3.1.0]hexane-1-carboxylate (32.0 g, 130 mmol) in tetrahydrofuran (300 mL) was added lithium aluminum hydride (9.90 g, 261 mmol) in portions at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was quenched with sodium sulfate decahydrate (20.0 g) and filtered. The filtrate was concentrated to give (3-benzyl-3-azabicyclo [3.1.0]hexan-1-yl)methanol (27.5 g, crude) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ = 7.34 - 7.29 (m, 4H), 7.27 - 7.21 (m, 1H), 3.78 - 3.73 (m, 1H), 3.69 - 3.58 (m, 3H), 3.05 (d, J = 8.4 Hz, 1H), 2.97 (d, J = 8.8 Hz, 1H), 2.44 (br d, J = 8.4 Hz, 2H), 1.28 (br d, J = 3.6 Hz, 1H), 1.14 (t, J = 4.0 Hz, 1H), 0.48 (dd, J = 4.0, 8.0 Hz, 1H).

[0968] **Step 4.** To a solution of (3-benzyl-3-azabicyclo [3.1.0]hexan-1-yl)methanol (27.5 g, 135 mmol) and di-tert-butylidicarbonate (59.1 g, 271 mmol, 62.2 mL) in tetrahydrofuran (300 mL) was added palladium/carbon (4.00 g, 10% purity) in one portion under hydrogen. The mixture was stirred at 25 °C under hydrogen (15 Psi) for 12 h. The mixture was filtered and the filtrate was concentrated to give crude product. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 3/1) to give tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (17.8 g, 62% yield) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 3.69 - 3.40 (m, 4H), 3.37 - 3.28 (m, 2H), 1.37 (s, 9H), 1.34 - 1.31 (m, 1H), 0.71 (dd, J = 5.2, 8.0 Hz, 1H), 0.47 - 0.37 (m, 1H).

[0969] **Step 5.** To a solution of tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (19.8 g, 92.8 mmol) in dichloromethane (200 mL) was added Dess-Martin periodinane (59.1 g, 139 mmol, 43.1 mL) in portions at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was quenched with saturated sodium sulfite solution (100 mL) and saturated sodium hydrogencarbonate solution (200 mL), and extracted with dichloromethane (3 × 200 mL). The combined organic layer was washed with brine (100 mL) and dried over sodium sulfate, filtered and concentrated to give tert-butyl 1-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (18.0 g, crude) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ = 9.23 - 8.89 (m, 1H), 3.86 (br d, J = 11.2

Hz, 1H), 3.78 - 3.56 (m, 2H), 3.53 - 3.41 (m, 1H), 2.30 - 2.11 (m, 1H), 1.73 - 1.60 (m, 1H), 1.47 (s, 9H), 1.21 - 1.10 (m, 1H).

[0970] **Step 6.** To a solution of tert-butyl 1-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (18.0 g, 85.2 mmol) and potassium carbonate (35.3 g, 256 mmol) in methanol (180 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (21.3 g, 111 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 5/1) to give tert-butyl 1-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (13.0 g, 74% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ = 3.86 - 3.68 (m, 1H), 3.66 - 3.50 (m, 1H), 3.48 - 3.36 (m, 2H), 2.02 (s, 1H), 1.82 (br dd, J = 4.0, 7.8 Hz, 1H), 1.46 (s, 9H), 1.17 (dd, J = 5.2, 8.0 Hz, 1H), 0.74 (t, J = 4.8 Hz, 1H).

[0971] **Step 7.** To a solution of 7-fluoro-6-nitroquinazolin-4-ol (50.0 g, 239 mmol) in thionyl chloride (820 g, 6.89 mol, 500 mL) was added dimethyl formamide (1.75 g, 23.9 mmol, 1.84 mL) dropwise. The mixture was stirred at 90 °C for 12 h. The mixture was concentrated to give 4-chloro-7-fluoro-6-nitroquinazoline (54.0 g, crude) as a yellow solid.

[0972] **Step 8.** To a solution of 4-chloro-7-fluoro-6-nitroquinazoline (54.0 g, 237 mmol) in acetonitrile (500 mL) was added 3-chloro-2-fluoroaniline (34.5 g, 237 mmol) dropwise. The mixture was stirred at 20 °C for 12 h. The mixture was concentrated to give crude product. The crude product was washed with ethyl acetate (800 mL) and filtered. The filter cake was dried to give N-(3-chloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (105 g, crude) as a yellow solid. m/z ES+ [M+H]⁺ 337.0

[0973] **Step 9.** To a solution of N-(3-chloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (100 g, 297 mmol) in dimethyl formamide (500 mL) was added potassium acetate (140 g, 1.43 mol). The mixture was stirred at 100 °C for 3 h. After being cooled to room temperature, the mixture was poured into water (4.00 L). Yellow solid was precipitated from the mixture. The solid was collected by filtration and dried in vacuo to give 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol (75.0 g, crude) as a yellow solid. m/z ES+ [M+H]⁺ 335.0

[0974] **Step 10.** To a suspension of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol (30.0 g, 89.6 mmol) in dichloromethane (500 mL) was added pyridine (35.3 g, 446 mmol, 36.0 mL) and trifluoro methanesulfonic anhydride (51.3 g, 182 mmol, 30.0 mL). The mixture was stirred at 15 °C for 2 h. The mixture was diluted with dichloromethane (200 mL) and water (300

mL). The organic layer was separated and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1) to give 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (14.0 g, 33% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 466.9

[0975] **Step 11.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (15.5 g, 33.2 mmol) and tert-butyl 1-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (7.23 g, 34.9 mmol) in dimethyl formamide (70.0 mL) and triethylamine (70.0 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.92 g, 1.66 mmol) and copper(I) iodide (1.26 g, 6.64 mmol) in one portion under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (300 mL) and extracted with ethyl acetate (3 × 80 mL). The combined organic layer was washed with brine (40 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 3/1) to give tert-butyl 1-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (11.0 g, 63% yield) as a yellow solid. ^1H NMR (400 MHz, $CDCl_3$) δ = 8.89 (s, 1H), 8.74 (s, 1H), 8.41 - 8.28 (m, 1H), 8.10 (s, 1H), 7.84 (br s, 1H), 7.33 - 7.29 (m, 1H), 7.25 - 7.18 (m, 1H), 3.98 - 3.80 (m, 1H), 3.76 - 3.61 (m, 1H), 3.60 (s, 1H), 3.55 (dd, J = 4.0, 10.8 Hz, 1H), 2.11 - 2.07 (m, 1H), 1.48 (s, 9H), 1.43 (dd, J = 5.2, 8.0 Hz, 1H), 1.00 (t, J = 5.2 Hz, 1H).

[0976] **Step 12.** To a solution of tert-butyl 1-[2-[4-(3-chloro-2-fluoro-anilino)-6-nitro-quinazolin-7-yl]ethynyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (19.8 g, 37.8 mmol) in ethyl acetate (10 mL) was added HCl/ethyl acetate (4 M, 44 mL). The mixture was stirred at 20 °C for 2 h. On completion, the reaction was concentrated in vacuo to give a crude which was triturated with ethyl acetate (50 mL) at 25 °C for 30 min to afford 7-[2-(3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (15 g, 84% yield) as a purple solid. m/z ES+ $[M+H]^+$ 424.2

[0977] **Step 13.** 7-[2-(3-azabicyclo[3.1.0]hexan-1-yl)ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (15 g, 31.9 mmol, 90% purity) was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%ammonium hydroxide ETOH]; B%: 45%-45%,3.2 min;3200 minmin) to afford 7-[2-[(1S,5R)-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (6.5 g, 41.5% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 424.2; ^1H NMR (400 MHz, $DMSO-d_6$) δ = 9.65 - 9.36 (m, 1H),

8.07 (br s, 1H), 7.63 - 7.53 (m, 2H), 7.37 (br t, $J = 8.0$ Hz, 2H), 3.64 (d, $J = 11.2$ Hz, 1H), 3.53 - 3.47 (m, 3H), 2.43 - 2.36 (m, 1H), 1.61 (t, $J = 5.6$ Hz, 1H), 1.46 - 1.39 (m, 1H), 0.07 - 0.09 (m, 2H).

[0978] And 7-[2-[(1R,5S)-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (8.0 g, 49% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 424.2; ^1H NMR (400 MHz, DMSO- d_6) $\delta = 9.38$ (s, 1H), 8.63 (s, 1H), 7.96 (s, 1H), 7.56 (td, $J = 6.8, 13.2$ Hz, 2H), 7.39 - 7.32 (m, 1H), 3.49 (q, $J = 7.2$ Hz, 1H), 3.13 (d, $J = 11.2$ Hz, 1H), 2.94 - 2.87 (m, 3H), 1.98 (br dd, $J = 5.6, 7.2$ Hz, 1H), 1.18 (t, $J = 4.8$ Hz, 1H), 1.11 (t, $J = 6.8$ Hz, 2H).


[0979] **Step 14.** To a solution of 7-[2-[(1S,5R)-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (6.5 g, 15.34 mmol) in trifluoroethanol (65 mL) was added HCHO (921 mg, 30.7 mmol). The mixture was stirred at 20 °C for 30 min. Then HCHO (1.34 g, 46 mmol) was added and the mixture was stirred at 20 °C for another 30 min. Then NaBH₄ (580 mg, 15.3 mmol) was added, and the mixture was stirred at 60 °C for 30 min, followed by the addition of NaBH₄ (580 mg, 15.3 mmol). The mixture was stirred at 60 °C for 1 h. On completion, the reaction was quenched with MeOH (200 mL) and then concentrated in vacuum. The residue was diluted with water (300 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated under vacuum to afford N-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (6.60 g, 78% yield) as a brown solid. m/z ES+ $[M+H]^+$ 438.2

[0980] **Step 15.** To a solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (6.00 g, 13.7 mmol) in MeOH (120 mL) and H₂O (30 mL) were added Fe (3.80 g, 68.5 mmol) and NH₄Cl (3.7 g, 68.5 mmol). The mixture was stirred at 80 °C for 2 h. On completion, the reaction was filtered through celite and washed with MeOH (20 mL x 3). The filtrate was concentrated in vacuum to give a crude product, which was purified by reversed-phase HPLC (0.1% formic acid condition) to afford N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-quinazoline-4,6-diamine (4.7 g, 75% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 408.3; ^1H NMR (400 MHz, DMSO- d_6) $\delta = 9.55$ (s, 1H), 8.25 (s, 1H), 7.60 (s, 1H), 7.57 - 7.51 (m, 1H), 7.48 - 7.42 (m, 1H), 7.39 (s, 1H), 7.29 - 7.23 (m, 1H), 5.64 (s, 2H), 3.14 (d, $J = 8.4$ Hz, 1H), 2.95 - 2.89 (m, 1H), 2.47 (s, 1H), 2.42 (dd, $J = 3.6, 8.8$ Hz, 1H), 2.27 (s, 3H), 2.01 - 1.95 (m, 1H), 1.36 (t, $J = 4.2$

Hz, 1H), 1.11 - 1.02 (m, 1H).

[0981] **Step 16.** To a solution of N-4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (3.7 g, 9.1 mmol) and acrylic acid (850 mg, 11.8 mmol) in pyridine (50 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (7.0 g, 36.3 mmol). The mixture was stirred at 25 °C for 1 h. On completion, the reaction was diluted with ethyl acetate (300 mL), then washed with water (100 mL x 3) and brine (100 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under vacuum to give a crude product, which was purified by prep-HPLC (column: Phenomenex luna C18 150*40mm* 15um;mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 5%-35%,11min) to afford N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1S,5R)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazolin-6-yl]prop-2-enamide (2.50 g, 51% yield) as a brown solid. m/z ES+ [M+H]⁺ 462.2; ¹H NMR (400MHz, DMSO-d₆) δ 10.09 (s, 1H), 9.87 (s, 1H), 8.69 (s, 1H), 8.47 (s, 1H), 7.80 (s, 1H), 7.49 (br s, 2H), 7.28 (t, J = 8.0 Hz, 1H), 6.61 (dd, J = 16.8, 10.0 Hz, 1H), 6.37 – 6.30 (m, 1H), 5.86 (dd, J = 10.4, 1.6 Hz, 1H), 3.11 (d, J = 8.4 Hz, 1H), 2.93 (d, J = 9.2 Hz, 1H), 2.45 – 2.35 (m, 2H), 2.26 (s, 3H), 1.96 – 1.90 (m, 1H), 1.38 (t, J = 4.4 Hz, 1H), 1.03 (dd, J = 8.0, 4.0 Hz, 1H).

Example 44. Synthesis of Compound No. 50 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0982] **Step 1.** A mixture of 7-((1R,5S)-3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (1.35 g, 3.19 mmol), oxetan-3-one (1.38 g, 19.1 mmol) and acetic acid (105 mg, 1.75 mmol, 0.100 mL) in dichloromethane (10.0 mL) was added sodium triacetoxyhydroborate (4.05 g, 19.1 mmol) in portions at 25 °C. The mixture was stirred at 25 °C


for 2 h. The mixture was diluted with water (100 mL) and extracted with dichloromethane (3×80.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 0/1) to give N-(3-chloro-2-fluorophenyl)-6-nitro-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0] hexan-1-yl)ethynyl)quinazolin-4-amine (500 mg, 33% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.60 (br s, 1H), 9.39 (br s, 1H), 8.64 (br s, 1H), 7.96 (br s, 1H), 7.54 (br d, J = 7.2 Hz, 2H), 7.31 (br t, J = 7.6 Hz, 1H), 4.55 (dt, J = 2.8, 6.8 Hz, 2H), 4.47 - 4.43 (m, 2H), 4.09 (q, J = 5.2 Hz, 1H), 3.76 (t, J = 6.4 Hz, 1H), 3.17 (d, J = 5.2 Hz, 2H), 2.97 (d, J = 8.8 Hz, 1H), 2.09 - 2.00 (m, 1H), 1.45 (t, J = 4.4 Hz, 1H), 1.09 (dd, J = 4.0, 8.0 Hz, 1H).

[0983] **Step 2.** To a solution of N-(3-chloro-2-fluorophenyl)-6-nitro-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0] hexan-1-yl)ethynyl)quinazolin-4-amine (500 mg, 1.04 mmol), ammonium chloride (390 mg, 7.29 mmol) in methanol (8.00 mL) and water (2.00 mL) was added iron powder (291 mg, 5.21 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with water (80.0 mL) and extracted with ethyl acetate (3×80.0 mL). The combined organic layer was washed with brine (30.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-quinazoline-4,6-diamine (480 mg, crude) as a yellow solid. m/z ES⁺ [M+H]⁺ 424.2

[0984] **Step 3.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl) ethynyl)quinazoline-4,6-diamine (430 mg, 956 μmol), acrylic acid (82.6 mg, 1.15 mmol, 78.7 μL), pyridine (302 mg, 3.82 mmol, 309 μL) in dimethylformamide (4.00 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (733 mg, 3.82 mmol) in portions. The mixture was stirred at 15 °C for 1 h. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge C18 150*50mm* 10 μm ; mobile phase: [water(10mM NH_4HCO_3)-acetonitrile]; B%: 33%-63%, 11.5min) and lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide (88.7 mg, 18% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 504.3; ^1H NMR (400 MHz, CDCl_3) δ = 9.17 (s, 1H), 8.72 (s, 1H), 8.44 - 8.15 (m, 2H), 7.93 (s, 1H), 7.82 (br s, 1H), 7.25 - 7.07 (m, 2H), 6.55 - 6.41 (m, 1H), 6.39 - 6.25 (m, 1H), 5.99 - 5.84 (m, 1H), 4.70 (td, J = 3.2, 6.8 Hz, 2H), 4.62 (dt, J = 4.0, 6.4 Hz, 2H), 3.83 (t, J = 6.4 Hz, 1H), 3.41 (s,

1H), 3.25 (d, J = 8.0 Hz, 1H), 3.05 (d, J = 8.8 Hz, 1H), 2.66 - 2.54 (m, 2H), 2.00 (dd, J = 4.0, 8.0 Hz, 1H), 1.64 (t, J = 4.4 Hz, 1H), 1.12 (dd, J = 4.4, 8.0 Hz, 1H).

Example 45. Synthesis of Compound No. 51 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)




[0985] **Step 1.** To a solution of 7-[2-[(1R,5S)-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-N-(3-chloro-2-fluoro-phenyl)-6-nitro-quinazolin-4-amine (6.60 g, 15.6 mmol) in trifluoroethanol (65 mL) was added HCHO (2.34 g, 77.9 mmol) in portions. The mixture was stirred at 60 °C for 0.5 h. Then the mixture was added NaBH₄ (1.18 g, 31.1 mmol) in portions at 60 °C and stirred at 60 °C for 13.5 h. On completion, the mixture was added methanol (100 mL) and concentrated to give a residue. The residue was diluted with water (300 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layer was washed with brine (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give the N-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (6.20 g, crude) as a brown solid which was used for the next step without purification. m/z ES+[M+H]⁺ 438.2

[0986] **Step 2.** A solution of N-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-6-nitro-quinazolin-4-amine (5.7 g, 11.2 mmol) and Fe (3.13 g, 56 mmol), NH₄Cl (4.79 g, 90 mmol) in ethanol (100 mL) and H₂O (25 mL) was stirred at 80 °C for 1 h. The mixture was quenched with methanol (50 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (200 mL) and washed with water (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give the crude. The crude was purified by reverse-phase flash (0.1% trifluoroacetic acid) to give N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (3.20 g, 68% yield) as a yellow solid. m/z ES+[M+H]⁺ 408.3; ¹H NMR (400 MHz, DMSO-d₆) δ 9.52 (s, 1H), 8.23 (s, 1H), 7.59 (s, 1H), 7.53 - 7.51 (m, 1H), 7.46 - 7.42 (m, 1H), 7.37 (s, 1H), 7.27 - 7.25 (m, 1H), 5.62 (s, 2H), 3.12 (d, J = 8.4 Hz, 1H), 2.92 (d, J = 9.2 Hz, 1H), 2.46 - 2.39 (m, 2H), 2.25 (s, 3H), 1.98 - 1.97 (m, 1H), 1.35 - 1.33 (m, 1H), 1.07 - 1.05 (m, 1H).

[0987] **Step 3.** A solution of N4-(3-chloro-2-fluoro-phenyl)-7-[2-[(1R,5S)-3-methyl-3-

azabicyclo[3.1.0]hexan-1-yl]ethynyl]quinazoline-4,6-diamine (3.00 g, 7.36 mmol), acrylic acid (689 mg, 9.56 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (5.64 g, 29.4 mmol) in pyridine (40 mL) was stirred at 10 °C for 0.5 h and then stirred at 25 °C for another 1 h. On completion, the reaction mixture was quenched with water (500 mL) and then extracted with ethyl acetate (500 mL x 2). The organic layers were collected and then dried, filtered and concentrated to give the crude. The crude was purified by Prep-HPLC (formic acid: column: Phenomenex luna C₁₈ 150 * 40 mm * 15 um; mobile phase: [water(0.225% formic acid) - acetonitrile]; B%: 5% - 35%, 11 min) to give the first batch of product and another batch of product. Then the two batch of product were combined, and recrystallized with ethyl acetate (150 mL) to give the N-[4-(3-chloro-2-fluoro-anilino)-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl]ethynyl]-quinazolin-6-yl]prop-2-enamide (1.34 g, 39% yield) as a yellow solid. m/z ES+[M+H]⁺ 462.1; ¹H NMR (400 MHz, DMSO-d₆) δ 9.20 (s, 1H), 8.74 (s, 1H), 8.42 - 8.32(m, 2H), 7.95 (s, 1H), 7.65 (s, 1H), 7.20 - 7.16 (m, 2H), 6.53 - 6.49 (m, 1H), 6.35 - 6.28 (m, 1H), 5.93 - 5.91 (m, 1H), 3.27 (d, J = 8.4 Hz, 1H), 3.06 (d, J = 8.8 Hz, 1H), 2.58 - 2.53 (m, 2H), 2.38 (s, 3H), 1.96 - 1.94 (m, 1H), 1.60 - 1.57 (m, 1H), 1.10 - 1.07 (m, 1H).

Example 46. Synthesis of Compound No. 52 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[0988] **Step 1.** To a solution of ethynyltrimethylsilane (1.59 g, 16.2 mmol, 2.24 mL) in tetrahydrofuran (70.0 mL) was added *n*-butyllithium (2.50 M, 6.48 mL). The mixture was stirred at -78 °C for 30 min. A solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (2.50 g, 13.5 mmol) in tetrahydrofuran (10.0 mL) was added to the reaction through an addition funnel over 10 min. The mixture was stirred at 20 °C for 40 min. The reaction was quenched by addition of saturated ammonium chloride (15.0 mL), then extracted with ethyl acetate (3 × 50.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~4% Methanol/Dichloromethane @ 50 mL/min) to give tert-butyl 3-hydroxy-3-((trimethylsilyl)ethynyl) pyrrolidine-1-carboxylate (3.70 g, 97% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ = 5.31 (s, 1H), 3.64 - 3.54 (m, 2H), 3.53 - 3.39 (m, 2H), 2.24 - 2.09 (m, 2H), 1.48 - 1.41 (m, 9H), 0.26 - 0.07 (m, 9H).

[0989] **Step 2.** The tert-butyl 3-hydroxy-3-((trimethylsilyl)ethynyl)pyrrolidine-1-carboxylate (2.70 g, 9.53 mmol) was dissolved in tetrahydrofuran (50.0 mL) under an atmosphere of nitrogen and cooled to 0 °C in an ice bath. The sodium hydride (572 mg, 14.3 mmol, 60.0% purity) was added and the resulting suspension was stirred at 0 °C for 30 min. Iodomethane (4.06 g, 28.6 mmol, 1.78 mL) was then added and the reaction was allowed to slowly warm to 25 °C. The mixture was

stirred at 25 °C for 3 h. The reaction was quenched by addition of saturated ammonium chloride (50.0 mL), then extracted with ethyl acetate (3 × 50.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~4% methanol/dichloromethane gradient @ 30 mL/min) to give tert-butyl 3-methoxy-3-((trimethylsilyl)ethynyl) pyrrolidine-1-carboxylate (1.90 g, 67% yield) as a light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ = 3.71 - 3.57 (m, 1H), 3.51 - 3.40 (m, 3H), 3.35 (s, 3H), 2.24 - 2.03 (m, 2H), 1.45 (s, 9H), 0.17 (s, 9H).

[0990] **Step 3.** To a solution of tert-butyl 3-methoxy-3-((trimethylsilyl)ethynyl)pyrrolidine-1-carboxylate (2.18 g, 7.33 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride (1.00 M, 14.7 mL). The mixture was stirred at 0 °C for 1 h. The reaction mixture was extracted with water (20.0 mL) and ethyl acetate (2 × 30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~4% Methanol/Dichloromethane gradient @ 30 mL/min) to give tert-butyl 3-ethynyl-3-methoxypyrrolidine-1-carboxylate (1.30 g, 79% yield) as a light yellow solid. ¹H NMR (400 MHz, CD₃OD) δ = 3.62 (dd, J = 8.4, 10.4 Hz, 1H), 3.50 - 3.40 (m, 2H), 3.37 (s, 3H), 3.35 (br d, J = 3.6 Hz, 1H), 3.10 (s, 1H), 2.33 - 2.05 (m, 2H), 1.46 (s, 9H).

[0991] **Step 4.** To a solution of 7-fluoro-6-nitroquinazolin-4-ol (10.0 g, 47.8 mmol) in thionyl chloride (100 mL) was added dropwise dimethyl formamide (350 mg, 4.78 mmol, 368 uL) as catalyst. The mixture was heated to 80 °C and stirred for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove thionyl chloride to give the crude product 4-chloro-7-fluoro-6-nitroquinazoline (12.5 g, crude) as a white solid and used for next step directly without purification.

[0992] **Step 5.** To a solution of 4-chloro-7-fluoro-6-nitroquinazoline (12.5 g, 54.9 mmol) in isopropanol (150 mL) was added 3-chloro-2-fluoroaniline (8.79 g, 60.4 mmol). The mixture was stirred at 90 °C for 2 h. The mixture was concentrated to afford a yellow solid which was triturated with ethyl acetate (100 mL). After filtration, the filter cake was washed with ethyl acetate (40.0 mL), dried in vacuum to afford N-(3-chloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (18.8 g, crude) as a yellow solid.

[0993] **Step 6.** To a solution of N-(3-chloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine

(18.8 g, 55.8 mmol) in dimethyl formamide (200 mL) was added potassium acetate (27.4 g, 279 mmol) at 15 °C. The mixture was stirred at 100 °C for 1 h. The mixture was concentrated to afford a residue. The residue was triturated with water (20.0 mL). After filtration, the filter cake was washed with water (50.0 mL), dried in vacuum to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0~4% Methanol/Dichloromethane gradient @ 100 mL/min) to give 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol (3.80 g, 13% yield) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ = 10.46 (br s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.30 (br t, J = 7.2 Hz, 1H), 8.03 (s, 1H), 7.58 (s, 1H), 7.24 - 7.17 (m, 1H).

[0994] **Step 7.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-ol (2.00 g, 5.98 mmol) and 2,6-dimethylpyridine (2.56 g, 23.9 mmol, 2.78 mL) in dichloromethane (40.0 mL) was added trifluoromethanesulfonic anhydride (3.37 g, 12.0 mmol, 1.97 mL) at 0 °C. The mixture was stirred at 20 °C for 1 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (590 mg, 21% yield) as a yellow solid. ¹H NMR (400 MHz, MeOD) δ = 9.51 (s, 1H), 8.66 (br s, 1H), 7.91 (s, 1H), 7.58 - 7.52 (m, 1H), 7.46 (br t, J = 7.2 Hz, 1H), 7.26 (dt, J = 1.2, 8.0 Hz, 1H).

[0995] **Step 8.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (590 mg, 1.26 mmol), tert-butyl 3-ethynyl-3-methoxypyrrolidine-1-carboxylate (313 mg, 1.39 mmol), copper iodide (48.2 mg, 253 μmol) and triethylamine (4.28 g, 42.4 mmol, 5.89 mL) in dimethyl formamide (5.00 mL) was added tetrakis(triphenylphosphine)palladium(0) (146 mg, 126 μmol). The mixture was degassed and purged with nitrogen for 3 times, and then the mixture was stirred at 20 °C for 12 h under nitrogen atmosphere. Upon completion, the reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ether gradient @ 30 mL/min) to give tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methoxypyrrolidine-1-carboxylate (480 mg, 58% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ = 8.90 (s, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.35 - 8.24 (m, 1H), 8.17 (d, J = 4.0

Hz, 1H), 7.98 - 7.85 (m, 1H), 7.25 - 7.17 (m, 1H), 3.87 - 3.56 (m, 3H), 3.53 (s, 3H), 3.52 (br s, 1H), 2.46 - 2.23 (m, 2H), 1.49 (s, 9H).

[0996] **Step 9.** To a solution of tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methoxypyrrolidine-1-carboxylate (480 mg, 886 μ mol) in hydrochloric acid/ethyl acetate (4.00 M, 5.00 mL) was stirred at 15 °C for 0.5 h. The reaction mixture was concentrated to afford product as a hydrochloride which was freed with saturated sodium carbonate (5.00 mL) and extracted with ethyl acetate (30.0 mL). The organic layer was washed with water (10.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford N-(3-chloro-2-fluorophenyl)-7-((3-methoxypyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, crude) as a yellow solid.


[0997] **Step 10.** To a solution of paraformaldehyde (125 mg, 4.18 mmol) and N-(3-chloro-2-fluorophenyl)-7-((3-methoxypyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, 836 μ mol) in 2,2,2-trifluoroethanol (10.0 mL) was added sodium borohydride (63.3 mg, 1.67 mmol) at 60 °C. The mixture was stirred at 60 °C for 12 h. The mixture was concentrated to afford a residue. The residue was diluted with saturated sodium carbonate (20.0 mL) and water (20.0 mL), extracted with ethyl acetate (3 $\times$ 20.0 mL). The combined organic layers were washed with water (20.0 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure to afford N-(3-chloro-2-fluorophenyl)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, crude) as a brown solid.

[0998] **Step 11.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, 877 μ mol) and ammonium chloride (530 mg, 9.92 mmol) in methanol (5.00 mL) and water (5.00 mL) was added iron powder (429 mg, 7.68 mmol) at 20 °C. The mixture was stirred at 80 °C for 1 h. The mixture was diluted with saturated sodium carbonate (10.0 mL) and water (20.0 mL), extracted with ethyl acetate (3 $\times$ 20.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure to afford N⁴-(3-chloro-2-fluorophenyl)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (330 mg, 88% yield) as a brown solid.

[0999] **Step 12.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (310 mg, 728 μ mol) and pyridine (230 mg, 2.91 mmol, 235 μ L) in dimethyl formamide (4.00 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (279 mg, 1.46 mmol) and acrylic acid (78.7 mg, 1.09 mmol,

74.9 μL) at 0 $^{\circ}\text{C}$. The mixture was stirred at 25 $^{\circ}\text{C}$ for 5 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (Xtimate C18 100*30 mm*3 μm ; water (0.04% ammonium hydroxide+10 mM NH_4HCO_3)-acetonitrile; B: 38%~68%) and further purified by prep-HPLC (column: Shim-pack C18 150*25*10 μm ; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 15%-35%, 10 min). The eluent was concentrated to remove organic solvent and the residual aqueous solution was lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methoxy-1-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl) acrylamide (5.42 mg, 2% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 480.0; ^1H NMR (400 MHz, MeOD) δ = 8.67 (s, 1H), 8.50 (br s, 2H), 7.98 (s, 1H), 7.57 (br t, J = 6.4 Hz, 1H), 7.44 (br t, J = 6.8 Hz, 1H), 7.25 (dt, J = 1.6, 8.0 Hz, 1H), 6.67 - 6.56 (m, 1H), 6.53 - 6.46 (m, 1H), 5.92 (dd, J = 2.0, 10.0 Hz, 1H), 3.50 (s, 3H), 3.48 - 3.43 (m, 1H), 3.40 - 3.35 (m, 1H), 3.29 - 3.16 (m, 2H), 2.75 (s, 3H), 2.57 - 2.49 (m, 2H).

Example 47. Synthesis of Compound No. 53 ((S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)




[1000] **Step 1.** To a solution of (S)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (650 mg, 1.48 mmol) in 2,2,2-trifluoroethanol (6.00 mL) was added paraformaldehyde (222 mg, 7.39 mmol, 204 μL) in portions and the mixture was stirred at 60 $^{\circ}\text{C}$ for 0.5 h. Then the mixture was added sodium borohydride (112 mg, 2.96 mmol) in portions at 60 $^{\circ}\text{C}$. The mixture was stirred at 60 $^{\circ}\text{C}$ for 1 h. The mixture was quenched with methanol (50.0 mL) and concentrated in vacuum. The residue was diluted with water (100 mL) and extracted with ethyl acetate (3×60.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give (S)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (720 mg, crude) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.82 - 10.51 (m, 1H), 9.33 (br s, 1H), 8.60 (br s, 1H), 7.89 (s, 1H), 7.55 - 7.47 (m, 2H), 7.30 (t, J = 8.0 Hz, 1H), 2.76 - 2.64 (m, 1H), 2.56 (br s, 1H), 2.17 (s, 3H), 1.99 (s, 2H), 1.86 - 1.76 (m, 2H), 1.60 (dt, J = 4.4, 7.6 Hz, 1H),

1.39 - 1.32 (m, 1H), 1.31 (s, 3H).

[1001] **Step 2.** To a solution of (S)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (720 mg, 1.59 mmol), ammonium chloride (594 mg, 11.1 mmol) in methanol (8.00 mL) and water (2.00 mL) was added iron powder (443 mg, 7.93 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with water (80.0 mL) and extracted with ethyl acetate (3 × 60.0 mL). The combined organic layer was washed with brine (30.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl) quinazoline-4,6-diamine (550 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 424.2

[1002] **Step 3.** To a solution of (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6- diamine (500 mg, 1.18 mmol), acrylic acid (93.5 mg, 1.30 mmol, 89.0 uL), pyridine (373 mg, 4.72 mmol, 381 uL) in dimethylformamide (3.00 mL) was added 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (904 mg, 4.72 mmol) in portions. The mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 80.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by prep-HPLC(column: Waters Xbridge C18 150*50mm* 10um;mobile phase: [water(10mM NH₄HCO₃)-acetonitrile];B%: 45%-75%,11.5min) to give crude product which purified by prep-HPLC (column: Shim-pack C18 150*25*10um;mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 16%-36%,9min) and lyophilized to give (S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (102.46 mg, 18% yield) as a yellow solid. m/z ES+[M+H]⁺ 478.3; ¹H NMR (400 MHz, CDCl₃) δ = 9.72 (br s, 1H), 9.11 (s, 1H), 8.70 (s, 1H), 8.39 (s, 1H), 8.19 (br d, J = 7.2 Hz, 1H), 8.11 - 7.95 (m, 1H), 7.92 (s, 1H), 7.93 - 7.86 (m, 1H), 7.21 - 7.08 (m, 2H), 6.54 (d, J = 6.0 Hz, 2H), 5.85 - 5.79 (m, 1H), 3.25 (br d, J = 7.2 Hz, 1H), 3.18 (br d, J = 11.6 Hz, 1H), 2.53 (s, 3H), 2.19 - 2.08 (m, 3H), 2.03 (br d, J = 14.8 Hz, 1H), 1.83 - 1.75 (m, 1H), 1.42 (s, 3H), 1.39 - 1.30 (m, 1H).

Example 48. Synthesis of Compound No. 54 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)




[1003] **Step 1.** The N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (1.70 g, 3.86 mmol) was separated by SFC separation (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [0.1% ammonium hydroxide in methanol]) and further separated by SFC separation (column: DAICEL CHIRALPAK AD-H(250mm*30mm,5um); mobile phase: [0.1% ammonium hydroxide IPA]; B%: 30%-30%, 7.5min; 160min) to give (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, 47% yield, 94% ee) as a yellow solid and (S)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (700 mg, 41% yield, 98% ee) as a yellow solid. ^1H NMR (400MHz, $\text{DMSO}-d_6$) δ = 10.81 (br s, 1H), 9.65 - 9.32 (m, 1H), 8.67 (br s, 1H), 8.28 (br s, 1H), 7.61 - 7.48 (m, 2H), 7.35 - 7.17 (m, 2H), 3.36 (br s, 1H), 3.22 (br d, J = 12.4 Hz, 1H), 2.98 (br d, J = 12.4 Hz, 1H), 2.83 (br t, J = 11.2 Hz, 1H), 2.06 - 1.88 (m, 2H), 1.82 (br d, J = 14.4 Hz, 1H), 1.71 - 1.60 (m, 1H), 1.38 (s, 3H).

[1004] **Step 2.** To a solution of (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, 1.82 mmol) in trifluoroethanol (10.0 mL) was added paraformaldehyde (273 mg, 9.09 mmol, 251 μL) in portions. The mixture was stirred at 60°C for 0.5 h. Then the mixture was added sodium borohydride (138 mg, 3.64 mmol) in portions at 60°C , and stirred at 60°C for 1 h. The mixture was added methanol (20.0 mL) and concentrated to give residue. The residue was diluted with water (30.0 mL) and extracted with ethyl acetate (3×20.0 mL). The combined organic layer was washed with brine (10.0 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give (R)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (770 mg, crude) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 454.0.

[1005] **Step 3.** To a solution of (R)-N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (770 mg, 1.70 mmol) and ammonium chloride (454 mg, 8.48 mmol) in methanol (20.0 mL) and water (5.00 mL) was added iron powder (474 mg, 8.48 mmol) in portions. The mixture was stirred at 80 °C for 1 h. The mixture was added methanol (30.0 mL) and filtered. The filtrate was concentrated to give residue. The residue was diluted with saturated sodium bicarbonate solution (30.0 mL) and extracted with ethyl acetate (3 × 30.0 mL). The combined organic layer was washed with brine (10.0 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give (R)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (700 mg, crude) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 9.57 (br s, 1H), 8.24 (br s, 1H), 7.62 (br d, J = 6.7 Hz, 1H), 7.59 - 7.54 (m, 2H), 7.33 - 7.21 (m, 2H), 5.96 (br s, 2H), 2.84 - 2.70 (m, 2H), 2.23 (s, 3H), 1.91 - 1.87 (m, 2H), 1.80 (br d, J = 13.6 Hz, 2H), 1.61 (br d, J = 9.6 Hz, 2H), 1.29 (s, 3H).

[1006] **Step 4.** To a solution of (R)-N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (600 mg, 1.42 mmol), acrylic acid (112 mg, 1.56 mmol, 107 uL) and pyridine (448 mg, 5.66 mmol, 457 uL) in dimethyl formamide (5.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (1.09 g, 5.66 mmol) in portions at 20 °C. The mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (40.0 mL) and extracted with ethyl acetate (3 × 30.0 mL). The combined organic layer was washed with brine (10.0 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to give crude product. The residue was purified by prep-HPLC (column: Waters Xbridge C18 150*50mm* 10um;mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 48%-78%,11.5min) and prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 7%-37%,10min) and lyophilized to give (R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (89.95 mg, 12% yield) as a yellow solid. m/z ES+[M+H]⁺ 478.1; ¹H NMR (400MHz, CDCl₃) δ = 9.56 (br s, 1H), 9.17 (s, 1H), 8.74 (s, 1H), 8.40 (s, 1H), 8.35 - 8.26 (m, 1H), 7.95 (s, 1H), 7.84 (br s, 1H), 7.24 - 7.12 (m, 2H), 6.63 - 6.49 (m, 2H), 5.87 - 5.81 (m, 1H), 3.27 - 3.11 (m, 2H), 2.51 (s, 3H), 2.18 - 1.97 (m, 4H), 1.85 - 1.72 (m, 1H), 1.43 (s, 3H), 1.40 - 1.29 (m, 1H).

Example 49. Synthesis of Compound No. 55 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1007] **Step 1.** To a solution of 1-tert-butyl 3-ethyl 4-oxopyrrolidine-1,3-dicarboxylate (20.0 g, 77.7 mmol) in acetone (100 mL) was added potassium carbonate (32.0 g, 231 mmol) and methyl iodide (31.9 g, 225 mmol, 14.0 mL). The mixture was stirred at 25 °C for 4 h. The mixture was diluted with water / ethyl acetate (1 L / 1 L). The organic layer was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 1/0 to 10/1) to give 1-tert-butyl 3-ethyl 3-methyl-4-oxopyrrolidine-1,3-dicarboxylate (19.7 g, 93% yield) as a colorless oil.

[1008] **Step 2.** A solution of 1-tert-butyl 3-ethyl 3-methyl-4-oxopyrrolidine-1,3-dicarboxylate (2.00 g, 7.37 mmol) in 1,2-dichloroethane (40.0 mL) was added bis-(2-methoxyethyl)aminosulfur trifluoride (2.42 g, 10.9 mmol, 2.40 mL). The mixture was stirred at 80 °C for 12 h. The mixture was added dropwise to sodium bicarbonate (10%, 100 mL). The organic layer was separated and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 20/1) to give 1-tert-butyl 3-ethyl 4,4-difluoro-3-methylpyrrolidine-1,3-dicarboxylate (530 mg, 24% yield) as a colorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ = 4.30 - 4.22 (m, 2H), 3.95 (br t, J = 10.4 Hz, 1H), 3.91 - 3.71 (m, 2H), 3.46 (br dd, J = 11.2, 17.9 Hz, 1H), 1.49 (s, 9H), 1.45 (s, 3H), 1.34 - 1.29 (m, 3H).

[1009] **Step 3.** To a solution of 1-tert-butyl 3-ethyl 4,4-difluoro-3-methylpyrrolidine-1,3-dicarboxylate (450 mg, 1.53 mmol) in tetrahydrofuran (10.0 mL) was added lithium aluminum hydride (80.0 mg, 2.11 mmol) at -60 °C. The mixture was stirred at -60 °C for 1 h. Sodium sulfate decahydrate (100 mg) was added to the mixture at -60 °C. The mixture was stirred at this temperature for 10 min. Then the mixture was filtered and the filtrate was concentrated under

reduced pressure to give tert-butyl 3,3-difluoro-4-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate (350 mg, crude) as a colorless oil. ^1H NMR (400 MHz, DMSO- d_6) δ = 3.78 - 3.66 (m, 4H), 3.62 - 3.55 (m, 1H), 3.34 - 3.26 (m, 1H), 1.48 (s, 9H), 1.22 (d, J = 2.0 Hz, 3H).

[1010] **Step 4.** To a solution of tert-butyl 3,3-difluoro-4-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate (350 mg, 1.39 mmol) in dichloromethane (10.0 mL) was added Dess-Martin periodinane (1.18 g, 2.79 mmol). The mixture was stirred at 20 °C for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 10/1) to give tert-butyl 3,3-difluoro-4-formyl-4-methylpyrrolidine-1-carboxylate (310 mg, 89% yield) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ = 9.71 (s, 1H), 4.02 - 3.93 (m, 1H), 3.89 - 3.68 (m, 2H), 3.31 (br dd, J = 12.0, 16.0 Hz, 1H), 1.49 (s, 9H), 1.37 (s, 3H).

[1011] **Step 5.** To a solution of tert-butyl 3,3-difluoro-4-formyl-4-methylpyrrolidine-1-carboxylate (310 mg, 1.24 mmol) in methanol (10.0 mL) was added potassium carbonate (520 mg, 3.76 mmol) and dimethyl (1-diazo-2-oxopropyl)phosphonate (360 mg, 1.87 mmol). The mixture was stirred at 20 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 30/1) to give tert-butyl 3-ethynyl-4,4-difluoro-3-methylpyrrolidine-1-carboxylate (180 mg, 59% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ = 3.90 - 3.63 (m, 3H), 3.46 - 3.37 (m, 1H), 2.32 (d, J = 1.6 Hz, 1H), 1.48 (s, 9H), 1.42 (d, J = 1.6 Hz, 3H).

[1012] **Step 6.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (300 mg, 643 μmol) in dimethyl formamide (3.00 mL) and triethylamine (2.18 g, 21.6 mmol, 3.00 mL) was added tert-butyl 3-ethynyl-4,4-difluoro-3-methylpyrrolidine-1-carboxylate (160 mg, 652 μmol), copper(I)iodide (25.0 mg, 131 μmol) and tetrakis-(triphenylphosphine)palladium (75.0 mg, 64.9 μmol). The mixture was stirred at 20 °C for 1 h. The mixture was diluted with ethyl acetate (100 mL) and water (100 mL). The organic layer was separated and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 10/1 to 3/1) to give tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-4,4-difluoro-3-methylpyrrolidine-1-carboxylate (300 mg, 83% yield) as a colorless oil. ^1H NMR (400 MHz, DMSO- d_6) δ = 10.69 (br s, 1H), 9.47 (br s, 1H), 8.69 (br s, 1H), 8.08 (br s, 1H), 7.47 - 7.40 (m, 1H), 7.33 (br t, J = 6.4 Hz, 1H), 3.94 - 3.79 (m, 3H), 3.56 (br d, J = 5.2 Hz, 1H), 1.53 (s, 3H), 1.44 (s, 9H).

[1013] **Step 7.** A solution of tert-butyl 3-(((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-4,4-difluoro-3-methylpyrrolidine-1-carboxylate (300 mg, 534 μmol) in ethyl acetate (10.0 mL) was added hydrogen chloride / ethyl acetate (4 M, 2.00 mL). The mixture was stirred at 20 °C for 1 h. The mixture was concentrated under reduced pressure to give N-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (260 mg, crude, hydrogen chloride) as a yellow solid.


[1014] **Step 8.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (260 mg, 521 μmol , hydrogen chloride) in trifluoroethanol (10.0 mL) was added paraformaldehyde (60.0 mg, 2.00 mmol). The mixture was stirred at 60 °C for 1 h. Then sodium borohydride (40.0 mg, 1.06 mmol) was added to and the mixture was stirred at 60 °C for another 1 h. After being cooled to 20 °C, the mixture was quenched with methanol (2.00 mL) and concentrated under reduced pressure to give N-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (250 mg, crude) as a brown solid. m/z ES+ $[M+H]^+$ 476.0

[1015] **Step 9.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (250 mg, 525 μmol) in methanol (10.0 mL) and water (2.00 mL) was added iron powder (150 mg, 2.69 mmol) and ammonium chloride (230 mg, 4.30 mmol). The mixture was stirred at 80 °C for 1 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 1/1 to 0/1) to give N⁴-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (160 mg, 68% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 446.0

[1016] **Step 10.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (160 mg, 358 μmol) in dimethyl formamide (1.00 mL) was added pyridine (157 mg, 1.98 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (240 mg, 1.25 mmol) and acrylic acid (80.0 mg, 1.11 mmol). The mixture was stirred at 20 °C for 10 min. The mixture was filtered to give a solution. The solution was purified by prep-HPLC (column: Shim-pack C18 150*25*10 μm ; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 15%-45%, 10 min). Further purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 40%-70%, 8 min) to give crude product. Further purified by prep-HPLC

(column: Shim-pack C18 150*25*10um; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 26%-46%, 9 min). The desired fraction was collected and lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((4,4-difluoro-1,3-dimethylpyrrolidin-3-yl)ethynyl)-quinazolin-6-yl)acrylamide (4.10 mg, 2% yield, formate) as a yellow solid. m/z ES+[M+H]⁺ 500.0; ¹H NMR (400 MHz, DMSO-d₆) δ = 10.16 (br s, 1H), 9.79 (br s, 1H), 8.72 (s, 1H), 8.46 (br dd, J = 5.6, 7.2 Hz, 1H), 7.83 (br s, 1H), 7.49 (br s, 2H), 7.34 - 7.23 (m, 1H), 6.55 (dd, J = 10.0, 17.2 Hz, 1H), 6.40 - 6.28 (m, 1H), 5.86 (dd, J = 1.6, 10.0 Hz, 1H), 3.13 - 3.02 (m, 3H), 2.84 (dd, J = 1.2, 9.2 Hz, 1H), 2.31 (s, 3H), 1.49 (d, J = 3.6 Hz, 3H).

Example 50. Synthesis of Compound No. 56 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)




[1017] **Step 1.** To a mixture of (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, 865 μ mol), potassium carbonate (478 mg, 3.46 mmol) in N,N-dimethylformamide (4.00 mL) was added 1-bromo-2-fluoroethane (165 mg, 1.30 mmol) at 25 °C. The mixture was stirred at 60 °C for 12 h. The mixture was poured into water (50.0 mL) and extracted with ethyl acetate (3 $\times$ 20.0 mL). The combined organic phase was washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 3/1 to 1/1) to afford N-(3-chloro-2-fluorophenyl)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (300 mg, 73%) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ = 8.88 (s, 1H), 8.76 (s, 1H), 8.35 - 8.28 (m, 1H), 8.11 (s, 1H), 7.31 (br d, J = 1.6 Hz, 1H), 7.26 - 7.17 (m, 1H), 4.66 (t, J = 5.2 Hz, 1H), 4.55 (t, J = 5.2 Hz, 1H), 3.05 (d, J = 9.2 Hz, 1H), 2.96 - 2.91 (m, 2H), 2.88 - 2.79 (m, 3H), 2.43 - 2.33 (m, 1H), 1.96 (td, J = 7.2, 12.8 Hz, 1H), 1.55 (s, 3H).

[1018] **Step 2.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (300 mg, 635 μ mol), iron powder (177 mg, 3.18 mmol) and ammonium chloride (170 mg, 3.18 mmol) in methanol (5.00 mL) and water (3.00 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20.0 mL) and washed with

saturated sodium bicarbonate solution (20.0 mL) and brine (15.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (210 mg, 75% yield) as a yellow solid. m/z ES+ [M+H]⁺ 442.2

[1019] **Step 3.** To a mixture of N⁴-(3-chloro-2-fluorophenyl)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine (150 mg, 339 μ mol), acrylic acid (29.4 mg, 407 μ mol) and pyridine (107 mg, 1.36 mmol) in dimethyl formamide (3.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (260 mg, 1.36 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 h and then filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 37%-67%, 9min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)ethynyl) quinazolin-6-yl)acrylamide (25.4 mg, 15% yield) as a yellow solid. m/z ES+[M+H]⁺ 496.1; ¹H NMR (400 MHz, CDCl₃) δ = 9.22 (s, 1H), 8.76 (s, 1H), 8.52 (br s, 1H), 8.40 (dt, J = 2.4, 7.2 Hz, 1H), 7.98 (s, 1H), 7.74 (br s, 1H), 7.25 - 7.13 (m, 2H), 6.60 - 6.50 (m, 1H), 6.44 - 6.33 (m, 1H), 5.90 (d, J = 11.2 Hz, 1H), 4.69 (br t, J = 4.8 Hz, 1H), 4.57 (br t, J = 4.8 Hz, 1H), 3.20 (br d, J = 7.6 Hz, 1H), 3.06 (br s, 1H), 2.95 (br s, 1H), 2.88 (br s, 1H), 2.80 (br d, J = 5.2 Hz, 1H), 2.69 (br d, J = 8.8 Hz, 1H), 2.45 - 2.35 (m, 1H), 2.07 - 1.97 (m, 1H), 1.59 (s, 3H).

Example 51. Synthesis of Compound No. 57 (1-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)-3-methylurea)



Step 1. To a solution of tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-

yl)ethynyl)-3- methylpyrrolidine-1-carboxylate (430 mg, 817 μmol) in ethyl acetate (2.00 mL) was added hydrochloric acid/ethyl acetate (2.00 mL). The mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated in vacuum to give N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6- nitroquinazolin-4-amine (340 mg, 97% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 426.1


[1020] **Step 2.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (290 mg, 681 μmol) and formaldehyde (102 mg, 3.41 mmol, 93.8 μL) in tetrafluoroethylene (3.00 mL) was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (51.5 mg, 1.36 mmol) in portions at 60 °C. The mixture was stirred at 60 °C for 1.5 h. The mixture was quenched with methanol (10.0 mL) and concentrated to dryness to give a residue. The mixture was added ethyl acetate (20.0 mL) and saturated sodium bicarbonate solution (20.0 mL). The organic phase was separated, washed with brine (2×20.0 mL), dried over sodium sulfate, filtered and concentrated to give N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (360 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 440.0

[1021] **Step 3.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4- amine (360 mg, 818 μmol), iron powder (228 mg, 4.09 mmol) and ammonium chloride (218 mg, 4.09 mmol) in methanol (5.00 mL) and water (1.00 mL) was stirred at 80 °C for 2 h. The reaction mixture was added methanol (50.0 mL) and filtered, filtrate was concentrated on a rotary evaporator. Ethyl acetate (40.0 mL) and saturated sodium bicarbonate solution (40.0 mL) were added and organic layers were separated. The aqueous phase was extracted with ethyl acetate (2×20.0 mL). Combined organic phase was washed with brine (2×20.0 mL), dried over sodium sulfate, filtered, and concentrated to dryness to give N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (300 mg, 89% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 410.1

[1022] **Step 4.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)quinazoline-4,6- diamine (220 mg, 536 μmol) in dimethyl formamide (2.00 mL) and triethylamine (162 mg, 1.61 mmol, 224 μL) was added methylcarbamic chloride (151 mg, 1.61 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was filtered to give filtrate. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μm ; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 32%-62%, 10min) to give 1-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpyrrolidin-3-yl)ethynyl)-quinazolin-6-yl)-3-

methylurea (34.57 mg, 14% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 467.4; ^1H NMR (400 MHz, $CDCl_3$) δ = 8.96 - 8.89 (m, 1H), 8.73 - 8.66 (m, 1H), 8.41 - 8.33 (m, 1H), 8.09 - 8.02 (m, 1H), 7.86 (s, 1H), 7.76 - 7.67 (m, 1H), 7.22 - 7.18 (m, 1H), 7.18 - 7.13 (m, 1H), 5.97 - 5.87 (m, 1H), 3.36 (d, J = 9.2 Hz, 1H), 3.31 - 3.24 (m, 1H), 2.94 (d, J = 4.8 Hz, 3H), 2.50 (s, 3H), 2.47 - 2.36 (m, 2H), 2.30 (d, J = 9.2 Hz, 1H), 2.06 - 1.97 (m, 1H), 1.53 (s, 3H).

Example 52. Synthesis of Compound No. 58 ((S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



Step 1. To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (1.82 g, 3.91 mmol), (S)-tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (900 mg, 4.30 mmol) and triethylamine (2.65 g, 26.2 mmol, 3.65 mL) in dimethyl formamide (2.00 mL) was added tetrakis(triphenylphosphine) palladium(0) (451 mg, 390 μ mol) and cuprous iodide (148 mg, 781 μ mol) under nitrogen, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (120 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 $\times$ 60.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 8/1 to 2/1) to afford (S)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (1.50 g, 73% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 526.1

[1023] Step 2. To a solution of (S)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (1.50 g, 2.85 mmol) in ethyl acetate (10.0 mL) was added hydrochloric acid / ethyl acetate (4 M, 15.0 mL) at 25 °C, the mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to give a residue. The crude product was triturated with ethyl acetate (30.0 mL) at 25 °C for 30 min to afford (S)-N-(3-chloro-

2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (1.30 g, 98% yield, HCl) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 9.94 - 9.78 (m, 1H), 9.67 (s, 2H), 8.79 (s, 1H), 8.16 (s, 1H), 7.54 (br t, J = 6.8 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.33 - 7.25 (m, 1H), 3.45 - 3.29 (m, 3H), 3.19 - 3.07 (m, 1H), 2.31 - 2.17 (m, 1H), 2.00 (td, J = 8.0, 12.8 Hz, 1H), 1.45 (s, 3H). m/z ES+ $[\text{M}+\text{H}]^+$ 426.0


[1024] **Step 3.** A mixture of (S)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (1.00 g, 2.35 mmol) and oxetan-3-one (846 mg, 11.7 mmol) in dichloromethane (10.0 mL) was stirred at 25 °C for 0.5 h, then sodium triacetoxy borohydride (995 mg, 4.70 mmol) was added, the mixture was stirred at 25 °C for 1.5 h. The reaction mixture was poured into water (100 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 $\times$ 40.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by reversed-phase HPLC (0.1% formic acid condition) to afford (S)-N-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, 40% yield, formic acid) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 8.87 (s, 1H), 8.75 (br s, 1H), 8.05 (br s, 1H), 7.99 (s, 1H), 7.23 - 7.20 (m, 1H), 7.14 - 7.07 (m, 1H), 4.80 - 4.68 (m, 4H), 4.15 - 3.95 (m, 1H), 3.25 - 3.14 (m, 1H), 3.14 - 3.07 (m, 1H), 3.06 - 2.89 (m, 2H), 2.35 (ddd, J = 3.6, 6.8, 12.8 Hz, 1H), 2.02 (td, J = 8.4, 12.8 Hz, 1H), 1.52 (s, 3H). m/z ES+ $[\text{M}+\text{H}]^+$ 482.1

[1025] **Step 4.** A mixture of (S)-N-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, 947 μmol , formic acid), iron powder (158 mg, 2.84 mmol) and ammonium chloride (253 mg, 4.74 mmol) in methanol (5.00 mL) and water (2.00 mL) was stirred at 80 °C for 1 h. The reaction mixture was filtered to give a filtrate, the filtrate was concentrated to give a residue. The residue was poured into water (100 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3 $\times$ 40.0 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (400 mg, 93% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 452.2

[1026] **Step 5.** To a solution of (S)-N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (350 mg, 774 μmol), acrylic acid (61.4 mg,

852 μmol , 58.5 μL) and pyridine (306 mg, 3.87 mmol, 312 μL) in dimethyl formamide (4.00 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (594 mg, 3.10 mmol) at 25 °C, the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (100 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (3×40.0 mL). The combined organic phase was washed with brine (90.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm*5 μm ; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 40%-60%, 10min) and prep-HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3 μm ; mobile phase: [water(0.225% formic acid)-acetonitrile]; B%: 15%-35%, 10min) to afford (S)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (99.6 mg, 25% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 506.2; ^1H NMR (400 MHz, DMSO- d_6) δ = 10.26 - 10.00 (m, 1H), 9.81 (br s, 1H), 8.70 (s, 1H), 8.49 (br s, 1H), 8.21 (s, 1H), 7.81 (br s, 1H), 7.50 (br s, 2H), 7.36 - 7.22 (m, 1H), 6.59 (dd, J = 10.0, 16.9 Hz, 1H), 6.34 (dd, J = 1.2, 17.2 Hz, 1H), 5.86 (dd, J = 1.2, 10.0 Hz, 1H), 4.58 (t, J = 6.4 Hz, 2H), 4.48 (dt, J = 1.2, 5.6 Hz, 2H), 3.71 - 3.67 (m, 1H), 2.85 (d, J = 8.8 Hz, 1H), 2.73 - 2.64 (m, 2H), 2.59 (d, J = 8.8 Hz, 1H), 2.25 (ddd, J = 5.6, 7.2, 12.8 Hz, 1H), 1.87 (td, J = 7.2, 12.4 Hz, 1H), 1.45 (s, 3H).

Example 53. Synthesis of Compound No. 59 ((R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1027] **Step 1.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (3.30 g, 7.07 mmol), (R)-tert-butyl 3-ethynyl-3-methylpyrrolidine-1-carboxylate (1.48 g, 7.07 mmol) in dimethylformamide (10.0 mL) and triethylamine (10.0 mL) was

added copper iodide (269 mg, 1.41 mmol) and tetrakis(triphenylphosphine)palladium(0) (817 mg, 707 μ mol) in one portion under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 $\times$ 150 mL). The combined organic layer was washed with brine (60.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 3/1) to give (R)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl) amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (3.00 g, 80% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ = 9.09 (s, 1H), 8.77 (br s, 1H), 8.03 (s, 1H), 7.85 (br s, 1H), 7.34 (br t, J = 7.2 Hz, 1H), 7.27 - 7.23 (m, 1H), 7.14 (dt, J = 0.8, 8.0 Hz, 1H), 3.77 - 3.68 (m, 1H), 3.61 (dt, J = 3.6, 7.1 Hz, 1H), 3.56 - 3.48 (m, 1H), 3.29 (d, J = 10.8 Hz, 1H), 2.32 - 2.19 (m, 1H), 1.98 - 1.83 (m, 1H), 1.47 (br d, J = 4.0 Hz, 3H), 1.45 (s, 9H).

[1028] **Step 2.** To a solution of (R)-tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpyrrolidine-1-carboxylate (3.50 g, 6.65 mmol) in methanol (20.0 mL) was added hydrochloric acid/ethyl acetate (4 M, 5.00 mL) dropwise. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated in vacuum to give (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (2.90 g, crude) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.86 (br d, J = 4.0 Hz, 1H), 9.74 (s, 2H), 8.87 (s, 1H), 8.24 (s, 1H), 7.64 - 7.61 (m, 1H), 7.55 - 7.51 (m, 1H), 7.40 - 7.33 (m, 1H), 3.50 - 3.37 (m, 3H), 3.27 - 3.17 (m, 1H), 2.32 (td, J = 6.4, 12.8 Hz, 1H), 2.08 (td, J = 8.0, 12.8 Hz, 1H), 1.52 (s, 3H).

[1029] **Step 3.** To a solution of (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (1.20 g, 2.82 mmol) in dichloromethane (12.0 mL) was added oxetan-3-one (1.02 g, 14.1 mmol) in one portion for 0.5 h. Then the mixture was added sodium triacetoxyhydroborate (1.19 g, 5.64 mmol) and the mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (150 mL) and extracted with ethyl acetate (3 $\times$ 80.0 mL). The combined organic layer was washed with brine (60.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by reverse phase chromatography (0.1% formic acid) to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 1/4) to give (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (300 mg, 21% yield) as yellow oil. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 10.78 - 10.53 (m, 1H), 9.35 (br s, 1H), 8.61 (br s, 1H),


7.93 (s, 1H), 7.64 - 7.41 (m, 2H), 7.37 - 7.14 (m, 1H), 4.58 (t, J = 6.4 Hz, 2H), 4.48 (t, J = 6.0 Hz, 2H), 3.70 (d, J = 6.4 Hz, 1H), 2.83 (d, J = 9.2 Hz, 1H), 2.74 - 2.60 (m, 3H), 2.23 (ddd, J = 5.2, 7.6, 12.4 Hz, 1H), 1.89 (td, J = 7.2, 12.4 Hz, 1H), 1.45 (s, 3H).

[1030] **Step 4.** To a solution of (R)-N-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (300 mg, 623 μ mol), ammonium chloride (167 mg, 3.11 mmol) in methanol (8.00 mL) and water (4.00 mL) was added iron powder (139 mg, 2.49 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with water (80.0 mL) and extracted with ethyl acetate (3 $\times$ 60.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give (R)-N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (270 mg, crude) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ = 9.83 - 9.38 (m, 1H), 7.67 - 7.47 (m, 3H), 7.42 (br s, 2H), 7.27 - 7.19 (m, 1H), 5.64 (br s, 2H), 4.58 (br t, J = 6.4 Hz, 2H), 4.53 - 4.45 (m, 2H), 3.70 (td, J = 6.0, 12.0 Hz, 1H), 2.88 (br d, J = 8.8 Hz, 1H), 2.73 - 2.65 (m, 2H), 2.57 (br d, J = 8.8 Hz, 1H), 2.32 - 2.22 (m, 1H), 1.94 - 1.81 (m, 1H), 1.46 (s, 3H).

[1031] **Step 5.** To a solution of (R)-N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (240 mg, 531 μ mol), acrylic acid (45.9 mg, 637 μ mol, 43.7 μ L), pyridine (210 mg, 2.66 mmol, 214 μ L) in dimethylformamide (2.00 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (407 mg, 2.12 mmol) in portions. The mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (40.0 mL) and extracted with ethyl acetate (3 $\times$ 30.0 mL). The combined organic layer was washed with brine (20.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm* 5 μ m; mobile phase: [water (10mM NH₄HCO₃)-acetonitrile]; B%: 31%-61%, 9min) to give a residue which was further purified by prep-HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3 μ m; mobile phase: [water(0.225%formic acid)-acetonitrile]; B%: 8%-38%, 10min) and lyophilized to give (R)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)ethynyl)-quinazolin-6-yl)acrylamide (46.28 mg, 17% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 506.2; ¹H NMR (400 MHz, DMSO-d₆) δ = 10.21 - 9.97 (m, 1H), 9.79 (br s, 1H), 8.77 - 8.60 (m, 1H), 8.48 (br s, 1H), 8.21 (s, 1H), 7.80 (br s, 1H), 7.49 (br s, 2H), 7.36 - 7.17 (m, 1H), 6.59 (dd, J = 10.2, 17.2 Hz, 1H), 6.34 (d, J = 17.2 Hz, 1H), 5.85 (d, J = 10.4 Hz, 1H), 4.62 - 4.54 (m, 2H), 4.52 - 4.41

(m, 2H), 3.68 (br t, $J = 6.0$ Hz, 1H), 2.85 (d, $J = 9.2$ Hz, 1H), 2.74 - 2.62 (m, 2H), 2.59 (d, $J = 8.8$ Hz, 1H), 2.28 - 2.19 (m, 1H), 1.92 - 1.80 (m, 1H), 1.45 (s, 3H).

Example 54. Synthesis of Compound No. 60 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-fluoro-1-methylpyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1032] **Step 1.** To a solution of tert-butyl 3-fluoro-3-(hydroxymethyl)pyrrolidine-1-carboxylate (2.00 g, 9.12 mmol) in dichloromethane (25.0 mL) was added dess-martin periodinane (5.80 g, 13.7 mmol, 4.24 mL) in portions at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was filtered. The filtrate was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 5/1 to 1/1) to give tert-butyl 3-fluoro-3-formylpyrrolidine-1-carboxylate (2.50 g, crude) as colorless oil.

[1033] **Step 2.** To a solution of tert-butyl 3-fluoro-3-formylpyrrolidine-1-carboxylate (2.50 g, 11.5 mmol) and potassium carbonate (4.77 g, 34.5 mmol) in methanol (15.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (2.87 g, 15.0 mmol) dropwise. The mixture was stirred at 25 °C for 2 h. The mixture was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1) to give tert-butyl 3-ethynyl-3-fluoropyrrolidine-1-carboxylate (980 mg, 40% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) $\delta = 3.97 - 3.79$ (m, 1H), 3.73 - 3.44 (m, 3H), 2.78 (d, $J = 5.2$ Hz, 1H), 2.45 (ttdd, $J = 1.6, 6.8, 13.6, 15.2$ Hz, 1H), 2.34 - 2.13 (m, 1H), 1.48 (s, 9H).

[1034] **Step 3.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (1.90 g, 4.07 mmol) and tert-butyl 3-ethynyl-3-fluoropyrrolidine-1-carboxylate (955 mg, 4.48 mmol) in triethylamine (5.00 mL) and dimethyl formamide (5.00 mL)

was added tetrakis [triphenylphosphine]palladium(0) (470 mg, 407 μmol) and copper(I) iodide (77.5 mg, 407 μmol) in one portion under nitrogen. The mixture was stirred at 50 °C for 1 h. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 $\times$ 30.0 mL). The combined organic layer was washed with brine (20 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 3/1) to give tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-fluoropyrrolidine-1-carboxylate (900 mg, 42% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ = 11.03 - 10.47 (m, 1H), 9.49 (br s, 1H), 8.68 (s, 1H), 8.16 (br s, 1H), 7.67 - 7.57 (m, 2H), 7.33 (t, J = 7.6 Hz, 1H), 3.94 - 3.74 (m, 2H), 3.65 - 3.59 (m, 1H), 3.39 - 3.36 (m, 1H), 2.61 - 2.53 (m, 2H), 1.44 (s, 9H).

[1035] **Step 4.** A solution of tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-fluoropyrrolidine-1-carboxylate (900 mg, 1.70 mmol) in hydrochloric acid/ethyl acetate (4 M, 5.00 mL) was stirred at 25 °C for 0.5 h. The mixture was concentrated to give N-(3-chloro-2-fluorophenyl)-7-((3-fluoropyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, crude) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 430.0


[1036] **Step 5.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((3-fluoropyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, 1.86 mmol) in 2,2,2-trifluoroethanol (5.00 mL) was added paraformaldehyde (279 mg, 9.31 mmol, 256 μL) in one portion. The mixture was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (141 mg, 3.72 mmol) in portions at 60 °C. The mixture was stirred at 60 °C for 1 h. The reaction mixture was added methanol (10 mL) and concentrated to give residue. The residue was diluted with water (30 mL) and extracted with ethyl acetate (3 $\times$ 20.0 mL). The combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered and concentrated to give N-(3-chloro-2-fluorophenyl)-7-((3-fluoro-1-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, crude) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 444.0

[1037] **Step 6.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((3-fluoro-1-methylpyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (800 mg, 1.80 mmol) in methanol (12.0 mL) and water (3.00 mL) was added iron powder (503 mg, 9.01 mmol) and ammonium chloride (482 mg, 9.01 mmol) in portions. The mixture was stirred at 80 °C for 1 h. The mixture was added methanol (30 mL) and filtered. The filtrate was concentrated to give residue. The residue was diluted saturated sodium hydrogencarbonate solution (20 mL) and extracted with ethyl acetate (3 $\times$ 30 mL). The

combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by prep-HPLC (column: Phenomenex luna C18 150*40mm* 15um; mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 2%-32%,11min) and lyophilized to give N⁴-(3-chloro-2-fluorophenyl)-7-((3-fluoro-1-methylpyrrolidin-3-yl)ethynyl)quinazoline-4,6-diamine (120 mg, 16% yield) as a yellow solid. ¹H NMR (400 MHz, CD₃OD) δ = 8.58 (s, 1H), 7.89 (s, 1H), 7.64 (s, 1H), 7.58 - 7.51 (m, 2H), 7.31 (dt, J = 1.2, 8.0 Hz, 1H), 4.49 - 4.22 (m, 1H), 4.07 - 3.83 (m, 2H), 3.64 - 3.44 (m, 1H), 3.10 (s, 3H), 3.04 - 2.74 (m, 2H).

[1038] **Step 7.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((3-fluoro-1-methylpyrrolidin-3-yl)ethynyl)quinazoline- 4,6-diamine (100 mg, 242 umol), acrylic acid (26.1 mg, 362 umol, 24.9 uL) and pyridine (76.5 mg, 967 umol, 78.0 uL) in dimethyl formamide (2.00 mL) was added 1-(3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (185 mg, 967 umol) in portions. The mixture was stirred at 25 °C for 0.5 h. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3 um; mobile phase: [water(0.225%formic acid)-acetonitrile];B%: 12%-32%,10min) and lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-fluoro-1-methylpyrrolidin-3-yl) ethynyl)quinazolin-6-yl)acrylamide (40.07 mg, 35% yield) as a yellow solid. m/z ES+ [M+H]⁺ 468.3; ¹H NMR (400 MHz, DMSO-d₆) δ = 10.29 - 10.01 (m, 2H), 8.67 (s, 1H), 8.59 - 8.39 (m, 1H), 8.29 (s, 1H), 7.96 (br s, 1H), 7.51 (br s, 2H), 7.35 - 7.23 (m, 1H), 6.59 (dd, J = 10.4, 17.2 Hz, 1H), 6.35 (dd, J = 1.6, 17.2 Hz, 1H), 5.87 (dd, J = 1.6, 10.4 Hz, 1H), 3.22 - 3.09 (m, 2H), 2.93 - 2.83 (m, 2H), 2.45 - 2.33 (m, 2H), 2.31 (s, 3H).

Example 55. Synthesis of Compound No. 61 (N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)-phenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1039] **Step 1.** To a solution of 7-fluoro-6-nitroquinazolin-4-ol (5.00 g, 23.9 mmol) in thionyl chloride (30 mL) was added dimethylformamide (190 mg, 2.60 mmol) dropwise. The mixture was stirred at 90 °C for 12 h. The mixture was concentrated in vacuum to give 4-chloro-7-fluoro-6-nitroquinazoline (5.40 g, crude) as a white solid.

[1040] **Step 2.** To a solution of 4-chloro-7-fluoro-6-nitroquinazoline (5.40 g, 23.7 mmol) in acetonitrile (50 mL) was added 3-chloro-4-((3-fluorobenzyl)oxy)aniline (5.97 g, 23.7 mmol) in portions. The mixture was stirred at 25 °C for 12 h. The mixture was concentrated in vacuum to give N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-fluoro-6-nitroquinazolin-4-amine (12.3 g, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 443.1; ^1H NMR (400 MHz, DMSO- d_6) δ 11.99 - 11.47 (m, 1H), 9.85 (d, J = 7.5 Hz, 1H), 8.91 (s, 1H), 8.01 - 7.88 (m, 2H), 7.69 (dd, J = 2.6, 8.9 Hz, 1H), 7.48 (dt, J = 6.1, 8.0 Hz, 1H), 7.38 - 7.28 (m, 3H), 7.24 - 7.14 (m, 1H), 5.29 (s, 2H).

[1041] **Step 3.** To a solution of N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-fluoro-6-nitroquinazolin-4-amine (12.3 g, 27.8 mmol) in dimethylformamide (150 mL) was added potassium acetate (13.6 g, 139 mmol) in portions. The mixture was stirred at 100 °C for 2 h. The mixture was added water (500 mL) and filtered. The filter cake was dried in vacuum to give 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-nitroquinazolin-7-ol (13.0 g, crude) as a red solid. m/z ES+ $[M+H]^+$ 441.0; ^1H NMR (400 MHz, DMSO- d_6) δ 9.16 (s, 1H), 8.58 - 8.32 (m, 1H), 7.99 - 7.94 (m, 2H), 7.69 (br d, J = 9.0 Hz, 1H), 7.48 - 7.43 (m, 1H), 7.33 - 7.24 (m, 3H), 7.20 - 7.12 (m, 2H), 5.24 (s, 2H).

[1042] **Step 4.** To a solution of 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-nitroquinazolin-7-ol (2.00 g, 4.54 mmol), pyridine (1.79 g, 22.7 mmol) in dichloromethane (30 mL) was added trifluoromethanesulfonic anhydride (2.56 g, 9.07 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (150 mL) and extracted with dichloromethane (3 × 80 mL). The combined organic layer was washed with brine (60 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 3/1) to give 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (650 mg, 25% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.58 (s, 1H), 9.71 (s, 1H), 8.77 (s, 1H), 8.03 (s, 1H), 7.99 - 7.96 (m, 1H), 7.71 - 7.68 (m, 1H), 7.50 - 7.45 (m, 1H), 7.35 - 7.29 (m, 4H), 7.21 - 7.17 (m, 1H), 5.27 (s, 2H).


[1043] **Step 5.** To a solution of 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (600 mg, 1.05 mmol), 3-ethynyl-3-methyltetrahydrofuran (138 mg, 1.26 mmol) in dimethylformamide (9.00 mL) and triethylamine (9.00 mL) was added copper iodide (39.9 mg, 209 μmol) and tetrakis(triphenylphosphine)palladium(0) (121 mg, 105 μmol) in one portion. The mixture was stirred at 20 °C for 2 h. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 80.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 3/1) to give N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (290 mg, 52% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.42 (s, 1H), 8.70 (s, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.94 (s, 1H), 7.71 (dd, J = 2.6, 9.0 Hz, 1H), 7.47 (dt, J = 6.0, 8.0 Hz, 1H), 7.35 - 7.28 (m, 3H), 7.18 (dt, J = 2.3, 8.6 Hz, 1H), 5.27 (s, 2H), 4.11 (q, J = 4.9 Hz, 2H), 3.94 - 3.88 (m, 3H), 2.31 - 2.21 (m, 1H), 2.00 (td, J = 7.3, 12.2 Hz, 1H), 1.43 (s, 3H).

[1044] **Step 6.** To a solution of N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (280 mg, 525 μmol), ammonium chloride (197 mg, 3.68 mmol) in methanol (4.00 mL) and water (1.00 mL) was added iron powder (147 mg, 2.63 mmol) in portions. The mixture was stirred at 80 °C for 2 h. The mixture was filtered. The filtrate was concentrated in vacuum. The residue was diluted with saturated sodium bicarbonate solution (100 mL) and extracted with ethyl acetate (3 × 60.0 mL). The combined

organic layer was washed with brine (40.0 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazoline-4,6-diamine (250 mg, 95% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 503.2; ¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (s, 1H), 8.33 (s, 1H), 8.03 (d, J = 2.5 Hz, 1H), 7.71 (dd, J = 2.5, 8.9 Hz, 1H), 7.59 (s, 1H), 7.47 (br t, J = 2.9 Hz, 2H), 7.34 - 7.29 (m, 2H), 7.23 (d, J = 9.0 Hz, 1H), 7.18 (dt, J = 2.3, 8.7 Hz, 1H), 5.55 (s, 2H), 5.24 (s, 2H), 3.94 - 3.87 (m, 1H), 3.94 - 3.87 (m, 2H), 3.61 (d, J = 7.9 Hz, 1H), 2.36 - 2.29 (m, 1H), 2.02 - 1.98 (m, 1H), 1.45 (s, 3H).

[1045] **Step 7.** To a mixture of N⁴-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl) quinazoline-4,6-diamine (220 mg, 437 μmol), acrylic acid (37.8 mg, 525 μmol) and pyridine (138 mg, 1.75 mmol) in dimethylformamide (2.00 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (335 mg, 1.75 mmol) in portions. The mixture was stirred at 20 °C for 1 h. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge C18 150*50 mm* 10 μm; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 58%-78%, 10min) and lyophilized to give N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-quinazolin-6-yl)acrylamide (88.5 mg, 35% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 557.4; ¹H NMR (400 MHz, DMSO-d₆) δ 9.87 (s, 2H), 8.68 (s, 1H), 8.56 (s, 1H), 8.01 (d, J = 2.4 Hz, 1H), 7.80 (s, 1H), 7.72 (dd, J = 2.5, 9.0 Hz, 1H), 7.47 (dt, J = 6.1, 8.0 Hz, 1H), 7.36 - 7.29 (m, 2H), 7.26 (d, J = 9.2 Hz, 1H), 7.18 (dt, J = 1.9, 8.6 Hz, 1H), 6.58 (br dd, J = 10.2, 17.1 Hz, 1H), 6.34 (dd, J = 1.8, 17.1 Hz, 1H), 5.85 (dd, J = 1.8, 10.2 Hz, 1H), 5.25 (s, 2H), 3.93 - 3.82 (m, 3H), 3.59 (d, J = 8.1 Hz, 1H), 2.33 - 2.23 (m, 1H), 1.96 (td, J = 7.3, 12.2 Hz, 1H), 1.41 (s, 3H).

Example 56. Synthesis of Compound No. 62 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1046] **Step 1.** To a solution of 2-(trifluoromethyl)acrylic acid (6.00 g, 42.8 mmol) in dichloromethane (100 mL) was slowly added N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)ethanamine (10.0 g, 42.1 mmol) and trifluoroacetic acid (770 mg, 6.75 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 h under nitrogen. The mixture was concentrated under reduced pressure to give a 1-benzyl-3-(trifluoromethyl)pyrrolidine-3-carboxylic acid (11.5 g, crude) as a white solid. m/z ES+ $[M+H]^+$ 274.0;

[1047] **Step 2.** To a solution of 1-benzyl-3-(trifluoromethyl)pyrrolidine-3-carboxylic acid (5.50 g, 20.1 mmol) in tetrahydrofuran (30 mL) was added borane dimethyl sulfide complex (10.0 M in tetrahydrofuran, 4.08 mL) at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched with methanol (50 mL). Then the mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 20/1 to 4/1 to ethyl acetate/methanol = 4/1). The desired fraction was collected and concentrated under reduced pressure to give (1-benzyl-3-(trifluoromethyl)pyrrolidin-3-yl)methanol (2.67 g, crude) as colorless oil. m/z ES+ $[M+H]^+$ 260.1;

[1048] **Step 3.** To a solution of (1-benzyl-3-(trifluoromethyl)pyrrolidin-3-yl)methanol (2.67 g, 10.3 mmol) in dichloromethane (100 mL) was added Dess-Martin (6.68 g, 15.7 mmol). The mixture was stirred at 25 °C for 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 20/1 to 0/1). The desired fraction was collected and concentrated under reduced pressure to give 1-benzyl-3-(trifluoromethyl)pyrrolidine-3-carbaldehyde (2.60 g, crude) as yellow oil.

[1049] **Step 4.** To a solution of 1-benzyl-3-(trifluoromethyl)pyrrolidine-3-carbaldehyde (2.60 g, 10.1 mmol) in methanol (30.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (2.90 g, 15.1 mmol) and potassium carbonate (4.20 g, 30.3 mmol). The mixture was stirred at 25 °C for 12 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 0/1). The desired fraction was collected and concentrated under reduced pressure to give 1-benzyl-3-ethynyl-3-(trifluoromethyl)pyrrolidine (1.05 g, 41% yield) as colorless oil. m/z ES+ $[M+H]^+$ 254.2; ^1H NMR (400 MHz, DMSO- d_6) δ 7.36 - 7.24 (m, 5H), 3.68 - 3.59 (m, 2H), 2.90 (d, J = 9.9 Hz, 1H), 2.81 - 2.76 (m, 1H), 2.73 - 2.66 (m, 1H), 2.66 - 2.58 (m, 1H), 2.51 - 2.50 (m, 1H), 2.25 (td, J = 6.8, 13.2 Hz, 1H), 2.17 - 2.09 (m, 1H).

[1050] **Step 5.** To a solution of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (1.80 g, 3.86 mmol) in dimethyl formamide (10 mL) was added 1-benzyl-3-ethynyl-3-(trifluoromethyl) pyrrolidine (950 mg, 3.75 mmol), triethylamine (7.27 g, 71.8 mmol), cuprous iodide (150 mg, 787 μ mol) and tetrakis(triphenylphosphine)palladium(0) (45.0 mg, 38.9 μ mol). The mixture was stirred at 25 °C for 2 h under nitrogen. The mixture was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1 to 4/1). The desired fraction was collected and concentrated under reduced pressure to give 7-((1-benzyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (1.67 g, 75% yield) as a yellow oil. m/z ES+ $[M+H]^+$ 570.2; ^1H NMR (400 MHz, DMSO- d_6) δ 10.69 (br s, 1H), 9.48 (br s, 1H), 8.69 (br s, 1H), 8.07 (br s, 1H), 7.55 (br s, 2H), 7.37 - 7.32 (m, 5H), 7.29 (br dd, J = 4.8, 8.2 Hz, 1H), 3.75 - 3.67 (m, 2H), 3.08 - 2.99 (m, 2H), 2.84 - 2.78 (m, 1H), 2.77 - 2.70 (m, 1H), 2.42 - 2.35 (m, 2H).

[1051] **Step 6.** To a solution of 7-((1-benzyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (1.30 g, 2.28 mmol) in dichloromethane (6.0 mL) was added 2-chloroethyl carbonochloridate (8.34 g, 58.3 mmol). The mixture was stirred at 80 °C for 6 h under nitrogen. The mixture was concentrated under reduced pressure to give a residue. The residue was added methanol (20 mL) and stirred at 80 °C for 2 h. Then the mixture was concentrated under reduced pressure to give a residue. The residue was purified by reverse phase HPLC (0.1% formic acid condition). The desired fraction was concentrated and lyophilized to give a residue. The residue was purified by column chromatography on silica gel (ethyl acetate/methanol = 1/0 to 20/1). The desired fraction was collected and concentrated to give N-(3-

chloro-2-fluorophenyl)-6-nitro-7-((3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)quinazolin-4-amine (700 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 480.1;


[1052] **Step 7.** To a solution of N-(3-chloro-2-fluorophenyl)-6-nitro-7-((3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl) quinazolin-4-amine (700 mg, 1.46 mmol) in acetonitrile (20 mL) was added sodium triacetoxy borohydride (800 mg, 3.77 mmol) and paraformaldehyde (900 mg, 28.1 mmol). The mixture was stirred at 25 °C for 3 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 1/1 to 0/1). The desired fraction was collected and concentrated to give N-(3-chloro-2-fluorophenyl)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (360 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 494.1; ^1H NMR (400 MHz, DMSO- d_6) δ 10.88 - 10.58 (m, 1H), 9.54 - 9.38 (m, 1H), 8.68 (br s, 1H), 8.06 (br s, 1H), 7.55 (br dd, J = 5.7, 7.2 Hz, 2H), 7.32 (br s, 1H), 3.04 - 2.96 (m, 3H), 2.81 - 2.71 (m, 2H), 2.70 - 2.59 (m, 2H), 2.36 (br d, J = 6.5 Hz, 2H).

[1053] **Step 8.** To a solution of N-(3-chloro-2-fluorophenyl)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (360 mg, 729 μ mol) in methanol (20 mL) and water (3.0 mL) was added iron powder (400 mg, 7.16 mmol) and ammonium chloride (600 mg, 11.2 mmol). The mixture was stirred at 80 °C for 4 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by *prep*-HPLC (column: Phenomenex Synergi C18 150*25*10 μ m; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 10%-40%, 8 min). The desired fraction was collected and lyophilized to give N⁴-(3-chloro-2-fluorophenyl)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine (150 mg, 44% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 464.1; ^1H NMR (400 MHz, DMSO- d_6) δ 9.79 - 9.47 (m, 1H), 8.27 (br s, 1H), 8.16 (s, 1H), 7.67 (br s, 1H), 7.53 (br d, J = 2.9 Hz, 1H), 7.47 (br s, 1H), 7.26 (br t, J = 7.9 Hz, 1H), 5.64 (br s, 2H), 3.08 - 3.03 (m, 1H), 2.99 - 2.94 (m, 1H), 2.82 - 2.75 (m, 1H), 2.65 - 2.55 (m, 1H), 2.45 - 2.35 (m, 2H), 2.33 (s, 3H).

[1054] **Step 9.** To a solution of N⁴-(3-chloro-2-fluorophenyl)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl) quinazoline-4,6-diamine (120 mg, 258 μ mol) in dimethyl formamide (2.0 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (72.0 mg, 375 μ mol), pyridine (70.5 mg, 892 μ mol) and acrylic acid (20.0 mg, 277 μ mol). The mixture was stirred at 25 °C for 1 h. The mixture was filtered to give a solution. The solution was purified by *prep*-HPLC (column: Phenomenex Synergi C18 150*25*10 μ m; mobile

phase: [water (0.225% formic acid)-acetonitrile]; B%: 12%-42%, 10 min). The desired fraction was concentrated and lyophilized to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-methyl-3-(trifluoromethyl)pyrrolidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (49.1 mg, 33% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 518.1; ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (s, 1H), 10.02 (s, 1H), 8.64 (s, 1H), 8.53 (s, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.52 (br t, J = 7.3 Hz, 2H), 7.30 (br t, J = 8.0 Hz, 1H), 6.59 - 6.50 (m, 1H), 6.34 (dd, J = 1.7, 17.1 Hz, 1H), 5.86 (dd, J = 1.6, 10.2 Hz, 1H), 3.07 (br s, 2H), 2.79 - 2.70 (m, 2H), 2.37 (br s, 3H), 2.37 - 2.34 (m, 2H).

Example 57. Synthesis of Compound No. 63 (N-(4-((3,4-dichloro-2-fluorophenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1055] **Step 1.** To a solution of triethyl ethane-1,1,2-tricarboxylate (40.0 g, 162 mmol) in dimethyl formamide (300 mL) was added sodium hydride (9.10 g, 227 mmol, 60% purity) in portions at 0 °C. The mixture was stirred at 0 °C for 0.5 h. Then the mixture was added iodomethane (30.0 g, 211 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was quenched with saturated ammonium chloride solution (300 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layer was washed with brine (100 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel

chromatography (petroleum ether/ethyl acetate = 20/1 to 10/1) to give triethyl propane-1,2,2-tricarboxylate (45.0 g, crude) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 4.18 - 4.10 (m, 6H), 2.87 - 2.85 (m, 2H), 1.47 (s, 3H), 1.20 - 1.17 (m, 9H).

[1056] **Step 2.** Refluxing solution of triethyl propane-1,2,2-tricarboxylate (40.0 g, 154 mmol) and sodium borohydride (15.4 g, 407 mmol) in tert-butyl alcohol (400 mL) was added methanol (30.0 mL) dropwise over 0.5 h. The solution was boiled at 90 °C for a further 0.5 h and allowed to cool. 5 M hydrochloric acid was carefully added to neutralise the solution, which was then filtered. The residue was washed with ethanol (3 × 100 mL) and filtered. The solvent evaporated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 10/1 to 1/1) to give 2-(hydroxymethyl)-2-methylbutane-1,4-diol (10.0 g, 49% yield) as light yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 4.47 - 4.43 (m, 1H), 4.39 (t, J = 5.4 Hz, 2H), 3.46 (dt, J = 4.9, 7.1 Hz, 2H), 3.18 (d, J = 5.3 Hz, 4H), 1.40 - 1.35 (m, 2H), 0.74 (s, 3H).

[1057] **Step 3.** To a solution of 2-(hydroxymethyl)-2-methylbutane-1,4-diol (10.0 g, 74.5 mmol) in toluene (200 mL) was added 4-toluenesulfonic acid (1.28 g, 7.45 mmol) in portions. The mixture was stirred at 130 °C under Dean-Stark trap for 5 h. The mixture was concentrated to give residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 2/1) to give (3-methyltetrahydrofuran-3-yl)methanol (6.00 g, 69% yield) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 3.85 - 3.76 (m, 2H), 3.66 (d, J = 8.4 Hz, 1H), 3.44 (s, 2H), 3.32 (d, J = 8.4 Hz, 1H), 1.82 - 1.75 (m, 1H), 1.61 - 1.57 (m, 1H), 1.06 (s, 3H).

[1058] **Step 4.** To a solution of (3-methyltetrahydrofuran-3-yl)methanol (600 mg, 5.17 mmol) in dichloromethane (8.0 mL) was added Dess-Martin periodinane (3.29 g, 7.75 mmol) in portions at 0 °C. The mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 10/1 to 2/1) to give 3-methyltetrahydrofuran-3-carbaldehyde (500 mg, crude) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 9.51 (s, 1H), 3.90 - 3.86 (m, 1H), 3.85 - 3.79 (m, 2H), 3.41 (d, J = 9.1 Hz, 1H), 2.26 (ddd, J = 6.8, 8.0, 12.7 Hz, 1H), 1.66 (ddd, J = 5.6, 7.2, 12.8 Hz, 1H), 1.19 (s, 3H).

[1059] **Step 5.** To a solution of 3-methyltetrahydrofuran-3-carbaldehyde (500 mg, 4.38 mmol) and potassium carbonate (1.82 g, 13.1 mmol) in methanol (5.0 mL) was added dimethyl(1-diazo-2-oxopropyl) phosphonate (1.09 g, 5.69 mmol) dropwise. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (40 mL) and extracted with petroleum ether (3 × 20 mL). The combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered.

The organic layer was diluted with dimethyl formamide (10 mL) and concentrated to remove petroleum ether to give 3-ethynyl-3-methyl-tetrahydrofuran (~500 mg, crude) dissolved in dimethyl formamide (10 mL).

[1060] **Step 6.** To a solution of 7-fluoro-6-nitroquinazolin-4-ol (5.00 g, 23.9 mmol) in thionyl chloride (82.0 g, 689 mmol) was added dimethyl formamide (175 mg, 2.39 mmol) dropwise. The mixture was stirred at 90 °C for 12 h. The mixture was concentrated to give 4-chloro-7-fluoro-6-nitroquinazoline (5.40 g, crude) as a yellow solid.

[1061] **Step 7.** To a solution of 4-chloro-7-fluoro-6-nitroquinazoline (5.40 g, 23.7 mmol) in acetonitrile (50 mL) was added 3,4-dichloro-2-fluoroaniline (4.27 g, 23.7 mmol) in portions. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give crude product. The crude product was washed with ethyl acetate (200 mL) and filtered, the filter cake was dried to give N-(3,4-dichloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (9.00 g, crude) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.65 (br d, J = 7.6 Hz, 1H), 8.74 (s, 1H), 7.93 (d, J = 12.0 Hz, 1H), 7.68 - 7.62 (m, 1H), 7.61 - 7.54 (m, 1H)

[1062] **Step 8.** To a solution of N-(3,4-dichloro-2-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (9.00 g, 24.3 mmol) in dimethyl formamide (100 mL) was added potassium acetate (11.9 g, 121 mmol) in portions. The mixture was stirred at 100 °C for 2 h. The mixture was poured into water (500 mL) and filtered. The filter cake was dried to give 4-(3,4-dichloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol (8.00 g, crude) as a yellow solid. m/z ES+ [M+H]⁺ 368.9;

[1063] **Step 9.** To a solution of 4-(3,4-dichloro-2-fluoro-anilino)-6-nitro-quinazolin-7-ol (5.00 g, 13.6 mmol) and pyridine (5.36 g, 67.7 mmol, 5.47 mL) in dichloromethane (40 mL) was added trifluoromethanesulfonic anhydride (7.64 g, 27.1 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was diluted with water (30 mL) and extracted with dichloromethane (2 × 30 mL). The combined organic layer was washed with brine (20 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 20/1 to 10/1) to give 4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (3.50 g, 49% yield) as a yellow solid. m/z ES+ [M+H]⁺ 500.9;

[1064] **Step 10.** To a solution of 4-((3,4-dichloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (400 mg, 798 umol) and 3-ethynyl-3-methyltetrahydrofuran (16.5 mg, 150 umol) in dimethyl formamide (5.0 mL) and triethylamine (5.0 mL) was added


tetrakis[triphenylphosphine] palladium(0) (92.2 mg, 79.8 μmol) and copper(I)iodide (15.2 mg, 79.8 μmol) in one portion under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (40 mL) and extracted with ethyl acetate (3 $\times$ 30 mL). The combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 20/1 to 3/1) to give N-(3,4-dichloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (350 mg, 95% yield) as yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.89 (s, 1H), 8.75 (s, 1H), 8.34 (dd, J = 8.0, 9.2 Hz, 1H), 8.13 (s, 1H), 7.88 (br s, 1H), 7.40 (dd, J = 2.0, 9.2 Hz, 1H), 4.14 - 4.01 (m, 3H), 3.73 (d, J = 8.4 Hz, 1H), 2.49 - 2.37 (m, 1H), 2.10 - 1.99 (m, 1H), 1.54 (s, 3H).

[1065] **Step 11.** To a solution of N-(3,4-dichloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)-6-nitroquinazolin-4-amine (310 mg, 672 μmol) and ammonium chloride (180 mg, 3.36 mmol) in methanol (8.0 mL) and water (2.0 mL) was added iron powder (188 mg, 3.36 mmol) in portions. The mixture was stirred at 80 °C for 1.5 h. The mixture was added methanol (50 mL) and filtered. The filtrate was concentrated to give crude product. The residue was diluted with saturated sodium hydrogencarbonate solution (30 mL) and extracted with ethyl acetate (3 $\times$ 30 mL). The combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered and concentrated to give N⁴-(3,4-dichloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazoline-4,6-diamine (270 mg, crude) as a yellow solid. m/z ES⁺ [M+H]⁺ 431.0;

[1066] **Step 11.** To a solution of N⁴-(3,4-dichloro-2-fluorophenyl)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazoline-4,6-diamine (240 mg, 556 μmol), acrylic acid (52.1 mg, 723 μmol) and pyridine (176 mg, 2.23 mmol) in dimethyl formamide (3.0 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (427 mg, 2.23 mmol) in portions. The mixture was stirred at 25 °C for 1 h. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 $\times$ 20 mL). The combined organic layer was washed with brine (10 mL) and dried over sodium sulfate, filtered and concentrated to give crude product. The crude product was purified by prep-HPLC (column: Waters Xbridge C18 150*50 mm* 10 μm ; mobile phase: [water (10mM NH_4HCO_3)-acetonitrile]; B%: 53%-73%, 10 min) and lyophilized to give N-(4-((3,4-dichloro-2-fluorophenyl)amino)-7-((3-methyltetrahydrofuran-3-yl)ethynyl)quinazolin-6-yl)acrylamide (67.7 mg, 25% yield) as a yellow solid. m/z ES⁺ [M+H]⁺ 485.2; ^1H NMR (400 MHz, CDCl_3) δ 9.23 (s, 1H), 8.74 (s, 1H), 8.42 (s, 1H), 8.35 (dd, J = 8.0, 9.2 Hz, 1H), 7.97 (s, 1H),

7.81 (br s, 1H), 7.34 (dd, $J = 2.0, 9.2$ Hz, 1H), 6.61 - 6.52 (m, 1H), 6.49 - 6.37 (m, 1H), 5.92 (dd, $J = 1.2, 10.4$ Hz, 1H), 4.19 - 4.06 (m, 3H), 3.69 (d, $J = 8.4$ Hz, 1H), 2.51 - 2.37 (m, 1H), 2.15 - 2.03 (m, 1H), 1.59 (s, 3H).

Example 58. Synthesis of Compound No. 64 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)




[1067] **Step 1.** A mixture of 7-(3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (400 mg, 869 μmol), oxetan-3-one (376 mg, 5.21 mmol) and acetic acid (0.10 mL) in dichloromethane (10 mL) was added sodium borohydride acetate (1.11 g, 5.21 mmol) in portions at 25 °C. The mixture was stirred at 25 °C for 2 h. The mixture was quenched with methanol (20 mL) and concentrated to dryness to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 0/1) to give N-(3-chloro-2-fluorophenyl)-6-nitro-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-4-amine (350 mg, 84% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 480.4; ^1H NMR (400MHz, CDCl_3) δ 8.77 (s, 1H), 8.65 (s, 1H), 8.19 (br t, $J = 7.2$ Hz, 1H), 7.98 (s, 1H), 7.22 (br s, 1H), 7.15 - 7.08 (m, 1H), 4.65 - 4.60 (m, 2H), 4.56 - 4.52 (m, 2H), 3.78 - 3.72 (m, 1H), 3.15 (d, $J = 8.4$ Hz, 1H), 2.95 (d, $J = 8.8$ Hz, 1H), 2.55 (d, $J = 8.4$ Hz, 1H), 2.50 (dd, $J = 3.6, 8.8$ Hz, 1H), 2.02 (s, 1H), 1.95 - 1.90 (m, 1H), 1.51 (t, $J = 4.8$ Hz, 1H).

[1068] **Step 2.** A mixture of N-(3-chloro-2-fluorophenyl)-6-nitro-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-4-amine (350 mg, 729 μmol), iron powder (204 mg, 3.65 mmol) and ammonium chloride (195 mg, 3.65 mmol) in methanol (5.0 mL) and water (2.0 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (20 mL), brine (15 mL), dried with anhydrous sodium

sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazoline-4,6-diamine (210 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 450.1;

[1069] **Step 3.** To a mixture of N⁴-(3-chloro-2-fluorophenyl)-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazoline-4,6-diamine (150 mg, 333 μ mol), acrylic acid (26.4 mg, 367 μ mol) and pyridine (105 mg, 1.33 mmol) in dimethyl formamide (2.0 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (256 mg, 1.33 mmol) in portions at 25 °C. The mixture was stirred at 25 °C for 2 h and then filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25 mm* 5 μ m; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 35%-65%, 10 min) and prep-HPLC (column: Unisil 3-100 C18 Ultra 150*50 mm*3 μ m; mobile phase: [water (0.225%formic acid)-acetonitrile]; B%: 10%-40%, 10min) to give N-(4-((3-chloro-2-fluorophenyl) amino)-7-((3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide (14.6 mg, 8% yield) as a yellow solid. m/z ES+ [M+H]⁺ 504.4; ¹H NMR (400MHz, CDCl₃) δ = 9.19 (s, 1H), 8.74 (s, 1H), 8.36 - 8.27 (m, 2H), 7.96 (s, 1H), 7.86 (br s, 1H), 7.24 - 7.14 (m, 2H), 6.55 - 6.49 (m, 1H), 6.37 - 6.28 (m, 1H), 5.94 (d, J = 10.4 Hz, 1H), 4.72 (dt, J = 2.4, 6.4 Hz, 2H), 4.63 (dt, J = 3.6, 6.0 Hz, 2H), 3.85 (quin, J = 6.4 Hz, 1H), 3.27 (d, J = 8.4 Hz, 1H), 3.07 (d, J = 8.8 Hz, 1H), 2.67 - 2.60 (m, 2H), 2.01 (td, J = 4.0, 8.0 Hz, 1H), 1.66 (t, J = 4.4 Hz, 1H), 1.14 (dd, J = 4.4, 8.4 Hz, 1H).

Example 59. Synthesis of Compound No. 65 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)acrylamide)



Step 1. To a mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (1.80 g, 3.86 mmol), tert-butyl 1-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (802 mg, 3.87 mmol) and cuprous iodide (147 mg, 772 μ mol) in dimethyl formamide

(5.0 mL) and triethylamine (4.0 mL) was added tetrakis(triphenylphosphine) palladium (0) (446 mg, 386 μmol) under nitrogen atmosphere. The mixture was stirred at 25 °C for 2 h. The mixture was concentrated to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 5/1 - 2/1) to give tert-butyl 1-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (2.00 g, 99% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 524.0; ^1H NMR (400MHz, CDCl_3) δ = 8.87 - 8.79 (m, 2H), 8.23 (br t, J = 6.8 Hz, 1H), 8.16 (br s, 1H), 8.06 (br d, J = 14.3 Hz, 1H), 7.33 - 7.29 (m, 1H), 7.24 - 7.18 (m, 1H), 3.96 - 3.82 (m, 1H), 3.63 - 3.52 (m, 2H), 3.01 - 2.96 (m, 2H), 2.93 - 2.88 (m, 2H), 1.48 (s, 9H)

[1070] **Step 2.** To a mixture of tert-butyl 1-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.80 g, 3.44 mmol) in ethyl acetate (10 mL) was added hydrochloric acid/ethyl acetate (4.00 M, 4.00 mL), the mixture was stirred at 25 °C for 2 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (10 mL). After filtration, the filter cake was washed with ethyl acetate (5.0 mL), dried in vacuum to give 7-(3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (1.40 g, 96 % yield) as a yellow solid. m/z ES+ $[M+H]^+$ 424.1; ^1H NMR (400MHz, $\text{DMSO}-d_6$) δ 9.86 (br s, 1H), 9.60 - 9.40 (m, 2H), 8.74 (br s, 1H), 8.08 (br s, 1H), 7.61 - 7.57 (m, 1H), 7.52 (br t, J = 7.2 Hz, 1H), 7.38 - 7.31 (m, 1H), 3.63 (dd, J = 6.0, 11.2 Hz, 1H), 3.56 - 3.44 (m, 2H), 3.38 (dd, J = 6.0, 11.6 Hz, 1H), 2.41 - 2.35 (m, 1H), 1.60 - 1.51 (m, 1H), 1.47 - 1.39 (m, 1H).


[1071] **Step 3.** A mixture of 7-(3-azabicyclo[3.1.0]hexan-1-ylethynyl)-N-(3-chloro-2-fluorophenyl)-6-nitroquinazolin-4-amine (400 mg, 869 μmol), paraformaldehyde (130 mg, 4.35 mmol) in trifluoroethanol (5.0 mL) was added sodium borohydride (65.8 mg, 1.74 mmol) at 25 °C. The mixture was stirred at 60 °C for 1 h. The mixture was quenched with methanol (5.0 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with water (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N-(3-chloro-2-fluorophenyl)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-6-nitroquinazolin-4-amine (350 mg, 92% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 438.0;

[1072] **Step 4.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)-6-nitroquinazolin-4-amine (350 mg, 799 μmol), iron powder (223 mg, 4.00 mmol)

and ammonium chloride (214 mg, 4.00 mmol) in methanol (5.0 mL) and water (2.0 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (20 mL), brine (15 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazoline-4,6-diamine (300 mg, crude) as a yellow solid. m/z ES+ [M+H]⁺ 408.1.

[1073] **Step 5.** To a mixture of N⁴-(3-chloro-2-fluorophenyl)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl) quinazoline-4,6-diamine (250 mg, 613 μmol), acrylic acid (57.4 mg, 796 μmol) and pyridine (194 mg, 2.45 mmol) in dimethyl formamide (3.0 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (470 mg, 2.45 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 h and then filtered. The filtrate was purified by prep-HPLC (column: Welch Xtimate C18 150*30 mm* 5 μm; mobile phase: [water (0.05% ammonium hydroxide v/v) -acetonitrile]; B%: 40%-70%, 10min) and pre-HPLC (column: Unisil 3-100 C18 Ultra 150*50 mm*3 μm; mobile phase: [water (0.225% formic acid) -acetonitrile]; B%: 8%-38%, 10 min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl) quinazolin-6-yl) acrylamide (36.7 mg, 13% yield) as a yellow solid. m/z ES+ [M+H]⁺ 462.4; ¹H NMR (400MHz, CDCl₃) δ 9.18 (s, 1H), 8.72 (s, 1H), 8.38 - 8.30 (m, 2H), 7.94 (s, 1H), 7.78 (br s, 1H), 7.23 - 7.12 (m, 2H), 6.55 - 6.46 (m, 1H), 6.38 - 6.23 (m, 1H), 5.92 (d, J = 10.4 Hz, 1H), 3.28 (br d, J = 8.8 Hz, 1H), 3.08 (br d, J = 9.2 Hz, 1H), 2.59 (br d, J = 8.4 Hz, 2H), 2.39 (s, 3H), 1.96 (td, J = 4.0, 8.4 Hz, 1H), 1.25 (s, 1H), 1.09 (br dd, J = 4.0, 8.4 Hz, 1H).

Example 60. Synthesis of Compound No. 66 (N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1074] **Step 1.** To a mixture of 4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl trifluoromethanesulfonate (1.50 g, 3.21 mmol), tert-butyl 3-ethynyl-3-methylpiperidine-1-carboxylate (789 mg, 3.54 mmol) and triethylamine (3.27 g, 32.3 mmol) in dimethyl formamide (3.0 mL) was added tetrakis(triphenylphosphine) palladium (0) (371 mg, 321 μ mol) and cuprous iodide (122 mg, 643 μ mol) at 25 °C. The mixture was stirred under nitrogen atmosphere at 25 °C for 2 h. The mixture was concentrated to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 5/1 - 2/1) to afford tert-butyl 3-((4-((3-chloro-2-fluorophenyl) amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpiperidine-1-carboxylate (1.5 g, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 540.1; ^1H NMR (400MHz, $CDCl_3$) δ 8.86 (s, 1H), 8.78 (br s, 1H), 8.29 - 8.22 (m, 1H), 8.09 (s, 2H), 7.46 - 7.35 (m, 1H), 7.23 - 7.18 (m, 1H), 3.91 (br d, J = 13.2 Hz, 1H), 3.77 (br t, J = 6.4 Hz, 1H), 2.99 (s, 2H), 1.97 - 1.85 (m, 2H), 1.73 (s, 3H), 1.67 (br s, 1H), 1.57 (br d, J = 14.8 Hz, 1H), 1.44 (s, 9H), 1.37 (s, 3H).

[1075] **Step 2.** To a solution of tert-butyl 3-((4-((3-chloro-2-fluorophenyl)amino)-6-nitroquinazolin-7-yl)ethynyl)-3-methylpiperidine-1-carboxylate (1.00 g, 1.85 mmol) in ethyl acetate (5.0 mL) was added hydrochloric acid/ethyl acetate (4.00 M, 5.00 mL), the mixture was stirred at 25 °C for 1 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (10 mL). After filtration, the filter cake was washed with ethyl acetate (5.0 mL), dried in vacuum to give N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (850 mg, 96% yield, HCl) as a yellow solid. m/z ES+ $[M+H]^+$ 440.1; ^1H NMR (400MHz, $DMSO-d_6$) δ 9.70 - 9.47 (m, 2H), 8.74 (br s, 1H), 8.37 (br s, 1H), 8.29 (br s, 1H), 7.59 (br d, J = 6.4 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.36 - 7.32 (m, 1H), 3.37 (br d, J = 12.4 Hz, 1H), 3.24 (br d, J = 12.0 Hz, 1H), 3.01 (br t, J = 10.4 Hz, 1H), 2.91 - 2.81 (m, 1H), 1.98 - 1.90 (m, 2H), 1.84 (br d, J = 14.4 Hz, 1H), 1.74 - 1.62 (m, 1H), 1.40 (s, 3H).



[1076] **Step 3.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (550 mg, 1.15 mmol, HCl) and paraformaldehyde (173 mg, 5.77 mmol, 159 μ L) in trifluoroethanol (5.0 mL) was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (87.3 mg, 2.31 mmol) in portions at 60 °C. The mixture was stirred at 60 °C for 1.5 h. The mixture was quenched with methanol (5.0 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with water (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 454.4; ^1H NMR (400MHz, $CDCl_3$) δ 8.84 (br s, 1H), 8.74 (s, 1H), 8.28 (br s, 1H), 8.11 (s, 1H), 7.50 - 7.43 (m, 1H), 7.30 (br s, 1H), 7.21 (dd, $J = 1.2$, 8.2 Hz, 1H), 2.88 (br d, $J = 11.2$ Hz, 1H), 2.74 (br s, 1H), 2.31 (s, 3H), 2.01 (br s, 2H), 1.96 (br s, 2H), 1.75 - 1.68 (m, 2H), 1.39 (s, 3H).

[1077] **Step 4.** A mixture of N-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, 1.10 mmol), iron powder (308 mg, 5.51 mmol) and ammonium chloride (294 mg, 5.51 mmol) in methanol (8.0 mL) and water (3.0 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (400 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 424.1;

[1078] **Step 5.** To a mixture of N⁴-(3-chloro-2-fluorophenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (300 mg, 708 μ mol), acrylic acid (61.2 mg, 849 μ mol, 58.3 μ L) and pyridine (224 mg, 2.83 mmol) in dimethyl formamide (4.0 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (543 mg, 2.83 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 h. The mixture was purified by pre-HPLC (column: Phenomenex Gemini NX-C18(75*30 mm*3 μ m); mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B%: 50%-80%, 7min) and (column: Unisil 3-100 C18 Ultra 150*50 mm*3 μ m; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 10%-40%, 10min) to give N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (55.4 mg, 15% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 478.1; ^1H NMR (400MHz, $CDCl_3$) δ 9.52 (br s, 1H), 9.19 (s, 1H), 8.75 (s, 1H), 8.38 - 8.34 (m, 1H), 7.96 (s, 1H), 7.80 (br s,

1H), 7.25 - 7.15 (m, 2H), 6.63 - 6.49 (m, 2H), 5.89 - 5.83 (m, 1H), 3.14 (br d, J = 11.6 Hz, 2H), 2.50 (s, 3H), 2.14 - 2.01 (m, 4H), 1.79 (br dd, J = 3.2, 10.8 Hz, 1H), 1.43 (s, 3H), 1.36 (br dd, J = 3.6, 12.4 Hz, 1H).

Example 61. Synthesis of Compound No. 67 (N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide)



[1079] **Step 1.** To a solution of tert-butyl 3-(hydroxymethyl)-3-methylpiperidine-1-carboxylate (3.90 g, 17.0 mmol) in dichloromethane (20 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (10.1 g, 23.8 mmol) at 0 °C in portions. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to afford a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 10/1) to give tert-butyl 3-formyl-3-methylpiperidine-1-carboxylate (3.10 g, 80% yield) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ 3.80 (d, J = 13.2 Hz, 1H), 3.46 - 3.37 (m, 1H), 3.17 (td, J = 6.4, 12.8 Hz, 1H), 3.06 (d, J = 13.2 Hz, 1H), 1.58 - 1.47 (m, 3H), 1.42 (s, 1H), 1.38 (s, 9H), 1.14 (s, 3H).

[1080] **Step 2.** To a mixture of tert-butyl 3-formyl-3-methylpiperidine-1-carboxylate (3.00 g, 13.2 mmol) and potassium carbonate (3.65 g, 26.4 mmol) in methanol (20 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (3.30 g, 17.2 mmol) at 20 °C. The mixture was stirred at 20 °C for 2 h. The mixture was concentrated to dryness to give a residue. The residue was purified by

silica gel chromatography (Petroleum ether/Ethyl acetate = 10/1) to give tert-butyl 3-ethynyl-3-methylpiperidine-1-carboxylate (2.60 g, 88% yield) as a colorless oil. ^1H NMR (400MHz, CDCl_3) δ 3.91 - 3.67 (m, 2H), 2.86 (ddd, J = 3.6, 9.6, 13.2 Hz, 1H), 2.78 (br d, J = 12.4 Hz, 1H), 2.01 (s, 1H), 1.80 - 1.71 (m, 2H), 1.51 - 1.44 (m, 1H), 1.39 (s, 9H), 1.13 (s, 3H), 0.84 - 0.77 (m, 1H).

[1081] **Step 3.** To a mixture of 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl trifluoromethane sulfonate (1.00 g, 1.80 mmol), tert-butyl 3-ethynyl-3-methylpiperidine-1-carboxylate (442 mg, 1.98 mmol) and triethylamine (1.09 g, 10.9 mmol) in dimethyl formamide (1.50 mL) was added tetrakis(triphenylphosphine) palladium (0) (208 mg, 180 μmol) and cuprous iodide (68.5 mg, 360 μmol) at 25 $^\circ\text{C}$. The mixture was stirred under nitrogen atmosphere at 25 $^\circ\text{C}$ for 2 h. The mixture was concentrated to give a residue. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 5/1 - 2/1) to afford tert-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl)-ethynyl)-3-methylpiperidine-1-carboxylate (1.10 g, 97% yield) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 629.2; ^1H NMR (400MHz, CDCl_3) δ 9.20 (br s, 1H), 9.02 (br s, 1H), 8.68 (s, 1H), 8.52 (dd, J = 0.8, 4.8 Hz, 1H), 7.90 (s, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.74 - 7.68 (m, 1H), 7.39 - 7.33 (m, 2H), 7.20 - 7.18 (m, 1H), 6.85 (d, J = 8.8 Hz, 1H), 5.20 (s, 2H), 3.93 - 3.79 (m, 1H), 2.90 (s, 2H), 2.82 (s, 1H), 1.93 (br dd, J = 4.4, 13.6 Hz, 1H), 1.82 (br d, J = 6.4 Hz, 1H), 1.61 - 1.51 (m, 1H), 1.44 (br s, 1H), 1.34 (s, 9H), 1.26 (s, 3H).

[1082] **Step 4.** To a solution of tert-butyl 3-((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-nitroquinazolin-7-yl) ethynyl)-3-methylpiperidine-1-carboxylate (1.40 g, 2.23 mmol) in ethyl acetate (10 mL) was added hydrochloric acid/ethyl acetate (4.00 M, 10.0 mL), the mixture was stirred at 25 $^\circ\text{C}$ for 1 h. The mixture was concentrated to dryness to give a residue. The residue was triturated with ethyl acetate (20 mL). After filtration, the filter cake was washed with ethyl acetate (5.0 mL), dried in vacuum to give N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (1.10 g, 87% yield, HCl) as a yellow solid. m/z ES+ $[\text{M}+\text{H}]^+$ 529.2; ^1H NMR (400MHz, MeOD) δ 9.58 (s, 1H), 8.98 - 8.91 (m, 2H), 8.72 (t, J = 8.0 Hz, 1H), 8.34 - 8.27 (m, 2H), 8.12 (t, J = 6.8 Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.78 (dd, J = 2.4, 8.8 Hz, 1H), 7.46 (d, J = 9.2 Hz, 1H), 5.68 (s, 2H), 3.56 (br d, J = 12.4 Hz, 1H), 3.46 (br d, J = 12.4 Hz, 1H), 3.37 (s, 1H), 3.12 (d, J = 12.8 Hz, 1H), 3.05 (dt, J = 3.2, 12.8 Hz, 1H), 2.32 - 2.20 (m, 1H), 2.15 (br d, J = 13.6 Hz, 1H), 2.05 - 1.97 (m, 1H), 1.78 (dt, J = 3.6, 13.12 Hz, 1H), 1.52 (s, 3H).

[1083] **Step 5.** A mixture of N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((3-methylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (500 mg, 884 μmol , HCl) and paraformaldehyde (133 mg, 4.42 mmol) in trifluoroethanol (5.0 mL) was stirred at 60 °C for 0.5 h. Then the mixture was added sodium borohydride (56.1 mg, 1.48 mmol) in portions at 60 °C. The mixture was stirred at 60 °C for 1.5 h. The mixture was quenched with methanol (5.0 mL) and concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20.0 mL) and washed with water (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 543.4; ^1H NMR (400MHz, CDCl_3) δ 8.84 (s, 1H), 8.74 (s, 1H), 8.60 (br d, $J = 4.8$ Hz, 1H), 8.02 (s, 1H), 7.89 - 7.82 (m, 1H), 7.78 (dd, $J = 1.6, 7.6$ Hz, 1H), 7.67 (d, $J = 7.6$ Hz, 1H), 7.51 - 7.46 (m, 1H), 7.26 (br s, 1H), 7.00 - 6.96 (m, 1H), 5.30 (s, 2H), 2.93 - 2.81 (m, 1H), 2.73 (br s, 1H), 2.29 (s, 3H), 2.02 - 1.90 (m, 4H), 1.73 - 1.64 (m, 1H), 1.37 (s, 3H), 1.32 (br s, 1H).

[1084] **Step 6.** A mixture of N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)-6-nitroquinazolin-4-amine (400 mg, 737 μmol), iron powder (206 mg, 3.68 mmol) and ammonium chloride (197 mg, 3.68 mmol) in methanol (5.0 mL) and water (2.0 mL) was stirred at 80 °C for 2 h. The mixture was filtered and the filtrate was concentrated to dryness to give a residue. The residue was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (300 mg, crude) as a yellow solid. m/z ES+ $[M+H]^+$ 513.3.

[1085] **Step 7.** To a mixture of N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazoline-4,6-diamine (300 mg, 585 μmol), acrylic acid (59.0 mg, 818 μmol) and pyridine (185 mg, 2.34 mmol) in dimethyl formamide (3.0 mL) was added 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide hydrochloride (448 mg, 2.34 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 h. The mixture was purified by pre-HPLC (column: Waters Xbridge 150*25 mm* 5 μm ; mobile phase: [water (10mM NH_4HCO_3)-acetonitrile]; B%: 42%-72%, 10 min) to give N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-((1,3-dimethylpiperidin-3-yl)ethynyl)quinazolin-6-yl)acrylamide (101 mg, 30% yield) as a yellow solid. m/z ES+ $[M+H]^+$ 567.2; ^1H NMR (400MHz, CDCl_3) δ 9.70 - 9.47 (m, 2H), 8.74 (br s, 1H), 8.37

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 338

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 338


NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHIER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

CLAIMS

1. A compound of Formula (I'):



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};

each R^{Ta} independently is halogen, CN, -OH, -NH₂, -C(=O)OH, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^l is C₆-C₁₀ aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or -NH₂.

2. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3 or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₆-C₁₀ aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{T} ;

each R^{T} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ;


each R^{Ta} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, $\text{C}_2\text{-C}_6 \text{ alkynyl}$, $\text{C}_3\text{-C}_{10} \text{ cycloalkyl}$, $\text{C}_6\text{-C}_{10} \text{ aryl}$, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is $\text{C}_6\text{-C}_{10} \text{ aryl}$ optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{OR}^{\text{A1a}}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is halogen, CN, $-\text{OH}$, $-\text{NH}_2$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^{A1b} ; and

each R^{A1b} independently is halogen, CN, $-\text{OH}$, or $-\text{NH}_2$;

provided that when Z is , then Ar^1 is $\text{C}_6\text{-C}_{10} \text{ aryl}$ optionally substituted with one or more halogen.

3. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^{Z} ;

each R^Z independently is halogen, $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$; wherein the $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ;

each R^T independently is halogen, $-OH$, $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-C(=O)OH$;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, $-OR^{A1a}$, or $-O-(C_1-C_6 \text{ alkyl})$ optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

4. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, $-O-(C_1-C_6 \text{ alkyl})$, or $C_1-C_6 \text{ alkyl}$; wherein the $-O-(C_1-C_6 \text{ alkyl})$ or $C_1-C_6 \text{ alkyl}$ is optionally substituted with one or more halogen;


T is $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$; wherein the $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ;

each R^T independently is halogen, $-OH$, $-O-(C_1-C_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-C(=O)OH$;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1} ;

each R^{A1} independently is halogen, $-OR^{A1a}$, or $-O-(C_1-C_6 \text{ alkyl})$ optionally substituted with one or more R^{A1a} ; and

each R^{A1a} independently is C₆-C₁₀ aryl or 5- to 10-membered heteroaryl; wherein the C₆-C₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;

provided that when Z is , then Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

5. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ;

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), or C₁-C₆ alkyl; wherein the -O-(C₁-C₆ alkyl) or C₁-C₆ alkyl is optionally substituted with one or more halogen;

T is -O-(C₁-C₆ alkyl), -NH-(C₁-C₆ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^T ;

each R^T independently is halogen, -OH, -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more halogen.

6. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C₁-C₆ alkyl;

T is C₂-C₆ alkenyl optionally substituted with one or more 6-membered heterocycloalkyl; and

Ar¹ is C₆ aryl optionally substituted with one or more halogen.


7. The compound of any one of the preceding claims, wherein W is CH.



8. The compound of any one of the preceding claims, wherein Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z ; and

each R^Z independently is halogen, -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C₁-C₆ alkyl), C₁-C₆ alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen.

9. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .

10. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z .





13. The compound of any one of the preceding claims, wherein at least one R^Z is halogen.

14. The compound of any one of the preceding claims, wherein at least one R^Z is F or Cl.

15. The compound of any one of the preceding claims, wherein at least one R^Z is $-O-(C_1-C_6 \text{ alkyl})$ optionally substituted with one or more R^{Za} .

16. The compound of any one of the preceding claims, wherein at least one R^Z is $-OCH_3$.
17. The compound of any one of the preceding claims, wherein at least one R^Z is C_1 - C_6 alkyl.
18. The compound of any one of the preceding claims, wherein at least one R^Z is methyl, ethyl, or propyl.
19. The compound of any one of the preceding claims, wherein at least one R^Z is C_1 - C_6 alkyl substituted with one or more halogen.
20. The compound of any one of the preceding claims, wherein at least one R^Z is CF_3 .
21. The compound of any one of the preceding claims, wherein at least one R^Z is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Za} .
22. The compound of any one of the preceding claims, wherein at least one R^Z is oxetanyl.
23. The compound of any one of the preceding claims, wherein T is $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $-NH-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, or $C_2-C_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ;
 each R^T independently is halogen, CN, $-OH$, $-NH_2$, $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, $C_2-C_6 \text{ alkynyl}$, $C_3-C_{10} \text{ cycloalkyl}$, $C_6-C_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, $C_2-C_6 \text{ alkynyl}$, $C_3-C_{10} \text{ cycloalkyl}$, $C_6-C_{10} \text{ aryl}$, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta} ; and
 each R^{Ta} independently is halogen, CN, $-OH$, $-NH_2$, $-C(=O)OH$, $-O-(C_1-C_6 \text{ alkyl})$, $C_1-C_6 \text{ alkyl}$, $C_2-C_6 \text{ alkenyl}$, $C_2-C_6 \text{ alkynyl}$, $C_3-C_{10} \text{ cycloalkyl}$, $C_6-C_{10} \text{ aryl}$, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.


24. The compound of any one of the preceding claims, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ; and
each R^T independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$.
25. The compound of any one of the preceding claims, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$; wherein the $\text{C}_1\text{-C}_6 \text{ alkyl}$, $\text{C}_2\text{-C}_6 \text{ alkenyl}$, or $\text{C}_2\text{-C}_6 \text{ alkynyl}$ is optionally substituted with one or more R^T ; and
each R^T independently is halogen, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl; wherein the $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more $-\text{C}(=\text{O})\text{OH}$.
26. The compound of any one of the preceding claims, wherein T is $-\text{O}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ optionally substituted with one or more R^T .
27. The compound of any one of the preceding claims, wherein T is $-\text{NH}-(\text{C}_1\text{-C}_6 \text{ alkyl})$ optionally substituted with one or more R^T .
28. The compound of any one of the preceding claims, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$ optionally substituted with one or more R^T .
29. The compound of any one of the preceding claims, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$.
30. The compound of any one of the preceding claims, wherein T is $\text{C}_1\text{-C}_6 \text{ alkyl}$ substituted with one or more halogen.
31. The compound of any one of the preceding claims, wherein T is $-\text{CHFCl}$.
32. The compound of any one of the preceding claims, wherein T is $\text{C}_2\text{-C}_6 \text{ alkenyl}$.


33. The compound of any one of the preceding claims, wherein T is C₂-C₆ alkenyl substituted with one or more -OH, -O-(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, or 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.


34. The compound of any one of the preceding claims, wherein T is C₂-C₆ alkynyl.

35. The compound of any one of the preceding claims, wherein T is propynyl.

36. The compound of any one of the preceding claims, wherein T is propynyl substituted with one or more 3- to 10-membered heterocycloalkyl.

37. The compound of any one of the preceding claims, wherein T is 



38. The compound of any one of the preceding claims, wherein T is 





39. The compound of any one of the preceding claims, wherein at least one R^T is halogen.
40. The compound of any one of the preceding claims, wherein at least one R^T is CN, -OH, or -NH₂.
41. The compound of any one of the preceding claims, wherein at least one R^T is -O-(C₁-C₆ alkyl) or -N(C₁-C₆ alkyl)₂.
42. The compound of any one of the preceding claims, wherein at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more C(=O)OH.
43. The compound of any one of the preceding claims, wherein at least one R^{Ta} is C(=O)OH.
44. The compound of any one of the preceding claims, wherein Ar¹ is C₆-C₁₀ aryl optionally substituted with one or more R^{A1};
 each R^{A1} independently is halogen, CN, -OH, -NH₂, -OR^{A1a}, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1a};
 each R^{A1a} independently is halogen, CN, -OH, -NH₂, -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; wherein the -O-(C₁-C₆ alkyl), -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl is optionally substituted with one or more R^{A1b}; and
 each R^{A1b} independently is halogen, CN, -OH, or -NH₂.


45. The compound of any one of the preceding claims, wherein Ar¹ is C₆-C₁₀ aryl substituted with one or more R^{A1}.
46. The compound of any one of the preceding claims, wherein Ar¹ is phenyl substituted with one or more halogen.
47. The compound of any one of the preceding claims, wherein Ar¹ is phenyl substituted with one F and one Cl.
48. The compound of any one of the preceding claims, wherein Ar¹ is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl); wherein the -O-(C₆-C₁₀ aryl) or -O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.
49. The compound of any one of the preceding claims, wherein Ar¹ is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with -O-phenyl or -O-pyridinyl; wherein the -O-phenyl or -O-pyridinyl is optionally substituted with one or more halogen.


50. The compound of any one of the preceding claims, wherein Ar¹ is




51. The compound of any one of the preceding claims, wherein Ar¹ is ,



52. The compound of any one of the preceding claims, wherein Ar¹ is ,



53. The compound of any one of the preceding claims, wherein Ar¹ is



54. The compound of any one of the preceding claims, wherein at least one R^{A1} is halogen.
55. The compound of any one of the preceding claims, wherein at least one R^{A1} is F, and at least one R^{A1} is Cl.
56. The compound of any one of the preceding claims, wherein at least one R^{A1} is -O-phenyl or -O-pyridinyl; wherein the -O-phenyl or -O-pyridinyl is optionally substituted with one or more halogen.


57. The compound of any one of the preceding claims, wherein at least one R^{A1} is -O-CH₂-phenyl or -O-CH₂-pyridinyl, wherein the -O-CH₂-phenyl or -O-CH₂-pyridinyl is optionally substituted with one or more halogen.

58. The compound of any one of the preceding claims, wherein at least one R^{A1a} is phenyl or pyridinyl; wherein the phenyl or pyridinyl is optionally substituted with one or more halogen.

59. The compound of any one of the preceding claims, wherein at least one R^{A1b} is halogen.


60. The compound of any one of the preceding claims, wherein at least one R^{A1b} is F, and at least one R^{A1b} is Cl.

61. The compound of any one of the preceding claims, wherein the compound is of formula (II'):





or a pharmaceutically acceptable salt or stereoisomer thereof.

62. The compound of any one of the preceding claims, wherein the compound is of formula (II'):





or a pharmaceutically acceptable salt or stereoisomer thereof.

63. The compound of any one of the preceding claims, wherein the compound is of formula (III') or (III'-a):




or a pharmaceutically acceptable salt or stereoisomer thereof.

64. The compound of any one of the preceding claims, wherein the compound is of formula (IV') or (IV'-a):



or a pharmaceutically acceptable salt or stereoisomer thereof.

65. The compound of any one of the preceding claims, wherein the compound is of formula I



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

W is CH or N;

X¹ is -O-, -S-, -NR³-;

R^a, R^b are independently of each other hydrogen, C₁₋₄ alkyl or one of R^a is -(CH₂)_p- which forms a ring with X¹ if X¹ is NR³ or one of R^a is -(CH₂)_p- which forms a ring with R²

R^c, R^d are independently of each other hydrogen or C₁₋₄ alkyl;

R¹ is H or F;

R² is hydrogen or C₁₋₄ alkyl, or is -(CH₂)_q- which forms a ring with R³ or with one of R^a;

R³ is hydrogen or C₁₋₄ alkyl, preferably hydrogen or methyl, or is -(CH₂)_p- which forms a ring with R²;

m is 1, 2 or 3;


n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2 and

Ar¹ is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, -CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₇ cycloalkyl, hydroxy C₁₋₅ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy-C₆ aryl, C₁₋₆ alkoxy-C₅₋₆ heteroaryl, amino, amino C₁₋₄ alkyl, C₁₋₆ alkylamino, C₁₋₆ aminoalkyl-C₆ aryl, C₁₋₆ aminoalkyl-C₅₋₆ heteroaryl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxyaminocarbonyl, aryl C₁₋₆ alkoxy, or C₆ aryl.

66. The compound of any one of the preceding claims, wherein Ar¹ is of formula i or pharmaceutically acceptable salts or stereoisomers thereof




wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl.

67. The compound of any one of the preceding claims, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X^2 is O, NH or NMe;

X^3 is CH or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

68. The compound of any one of the preceding claims, wherein Ar¹ is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



wherein

X³ is CH or N, preferably N;


o is 0 or 1;

R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F.

69. The compound of any one of the preceding claims, wherein Ar¹ is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9 or pharmaceutically acceptable salts or stereoisomers thereof



wherein


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5 , R^5 , R^6 , R^6 are independently of each other hydrogen, $-\text{CF}_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

70. The compound of any one of the preceding claims, being of formula IIa or IIb



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X^1 is $-\text{O}-$ or $-\text{NR}^3-$;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, preferably methyl or is $-(\text{CH}_2)_q-$ which forms a ring with R^3 ;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $-(CH_2)_p-$ which forms a ring with R^2 ;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;


q is 0, 1 or 2;

r is 0 or 1;

s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

71. The compound of any one of the preceding claims, being of formula III




III

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein


R^1 is H or F;

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, or C_6 aryl;

Z is selected from



72. The compound of any one of the preceding claims, being of formula IV



IV


or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;


R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy- C_6 aryl, C_{1-6} alkoxy- C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl- C_6 aryl, C_{1-6} aminoalkyl- C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl or C_6 aryl;

R^5 , R^6 , R^5' , R^6' are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;


Z is selected from




73. The compound of any one of the preceding claims, being of formula V-1, V-2, V-3 or V-4




V-1



V-2



V-3



V-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5 , $R^{5'}$, R^6 , $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;


Z is selected from




74. The compound of any one of the preceding claims, being of formula VI-1, VI-2, VI-3 or VI-4




VI-1



VI-2



VI-3



VI-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5 , R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F:


Z is selected from




75. The compound of any one of the preceding claims, being of formula VII-1, VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9




VII-1




VII-2




VII-3




VII-4




VII-5




VII-6



VII-7



VII-8



VII-9

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R¹ is H or F;


o is 0 or 1;

R⁴ is hydrogen or halogen, preferably F or Cl;

R⁵, R⁶ are independently of each other hydrogen, -CF₃ or halogen, preferably F or Cl;

R⁷ is hydrogen or halogen, preferably F;

Z is selected from



76. The compound of any one of the preceding claims, being selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

77. A composition comprising to the compound of any one of the preceding claims, and a pharmaceutically acceptable carrier.

78. A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims.


79. A method of preventing or treating cancer, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims.

80. The compound of any one of the preceding claims for use in the prevention or treatment of cancer.

81. The compound of any one of the preceding claims for use in the inhibition of an oncogenic variant of an ErbB receptor.

82. The method or the compound of any one of the preceding claims, wherein the cancer is a solid tumor.
83. The method or the compound of any one of the preceding claims, wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.
84. The method or the compound of any one of the preceding claims, wherein the cancer is glioblastoma (GBM) or any subtype thereof.
85. The method or the compound of any one of the preceding claims, wherein the cancer is glioblastoma.
86. The method or the compound of any one of the preceding claims, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an ErbB receptor.
87. The method or the compound of any one of the preceding claims, wherein the oncogenic variant of the ErbB receptor comprises an allosteric mutation.
88. The method or the compound of any one of the preceding claims, wherein the oncogenic variant of an ErbB receptor is an allosteric variant of the ErbB receptor.
89. The method or the compound of any one of the preceding claims, wherein the oncogenic variant or the oncogenic mutation is detected by a Food and Drug Administration (FDA)-approved diagnosis.
90. A method of preventing or treating glioblastoma, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims.

91. The compound of any one of the preceding claims for use in the prevention or treatment of glioblastoma.
92. The method or the compound of any one of the preceding claims, wherein the compound is selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.
93. The method or the compound of any one of the preceding claims, wherein the compound is selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.
94. The method or the compound of any one of the preceding claims, wherein the compound is selected from the compounds described in Table 1 and 2.



(I')